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Abstract 
The maintenance of correct genome sequence is an essential cellular process in which 
the small ubiquitin-like modifier SUMO plays an important role, probably because its 
post-translational conjugation to certain proteins can regulate DNA metabolism. The 
identities of these proteins remain largely unknown, as do how their sumoylation is 
controlled or what effects their modification has. I was therefore interested in identifying 
such factors and studying the upstream signals and downstream consequences of their 
sumoylation, with a particular focus on how DNA may be involved in these processes.  
To address this problem, I initially used Xenopus laevis egg extracts to isolate and 
identify SUMO conjugates from replicating chromatin, as it should be enriched for 
proteins involved in DNA metabolism. I found that progression through S phase, but not 
genotoxic stress, altered the abundance of chromatin-associated SUMO conjugates. A 
proteomic analysis of these species during unperturbed and disrupted S phase 
identified several proteins with a role in DNA metabolism as putative sumoylation 
substrates. Some of these modification events were confirmed by western blotting and 
were also shown to be conserved in the budding yeast Saccharomyces cerevisiae.  
By further investigating the modification of one of the candidates I discovered, i.e. 
ORC1, the largest subunit of the six-membered origin recognition complex (ORC), I 
found that all of the ORC subunits were sumoylated. I, however, also observed that 
manipulating the general levels of sumoylation in either egg extracts or budding yeast 
did not affect the recognized functions of ORC in DNA replication, thus indicating that 
sumoylation does not play a significant role in such a process.  
I therefore focused on the sumoylation of another candidate I found in my screen, the 
DNA-break sensor poly(ADP-Ribose) polymerase 1, PARP-1. In vitro, I found that 
sumoylation of both the full-length protein and its DNA-binding domain alone depended 
on the presence of intact DNA and was strongly inhibited by nicks in the double helix. 
In vivo, two main sites of sumoylation in PARP-1 were identified. By mutating them and 
creating a linear PARP-1-SUMO fusion, to mimic a constitutively sumoylated 
polymerase, I investigated the functions of PARP-1 sumoylation in human cells. I found 
that the sumoylation of PARP-1 did not affect the protein’s catalytic activity, localization 
or binding to intact chromatin or nicked DNA. Instead, sumoylation appeared to 
accelerate PARP-1’s ubiquitylation and subsequent degradation.  
These observations exemplify how DNA and sumoylation can interplay with each other 
to control the properties of chromatin-associated proteins. They also suggest that when 
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PARP-1 is associated to single-stranded DNA breaks, and is therefore engaged in 
DNA repair, it becomes refractory to sumoylation and subsequent degradation. Thus, 
sumoylation may help cells to distinguish between two functionally distinct sub-
populations of PARP-1: one that is not sumoylated because it is bound to, and in the 
process of repairing, DNA nicks, and one that is sumoylated because it is bound to 
intact DNA, which could be involved in other processes in which the polymerase plays 
a role, such as transcription regulation. 
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ARH3 ADP-ribosylhydrolase 3 
ARS Autonomously replicating sequence 
ASC2 Activating signal co-integrator 2 
AT-rich Adenine- and thymine-rich 
ATCC American Type Culture Collection 
ATG Autophagy-related protein 
ATP Adenosine 5’-triphosphate 
ATR Ataxia-telangiectasia mutated- and Rad3-related 
BCL B-cell lymphoma 
BD Gal4 DNA-binding domain 
BER Base excision repair 
bp   Base pair 
BRCA Breast cancer 
BRCT Breast cancer susceptibility protein (BRCA1) C-terminus 
BSA Bovine serum albumin 
CAT for PARP-1 Catalytic domain 
CAT1 Cationic amino acid transporter 1 
CBP Calcium-binding protein 
CD Catalytic domain 
CDC Cell division cycle 
CDK Cyclin-dependent kinase 
CDT1 Cdc10-dependent transcript 1  
CENP Centromeric protein 
CHD Chromodomain-helicase-DNA-binding protein 
ChIP Chromatin immunoprecipitation 
CHX Cycloheximide 
CR-UK Cancer Research UK 
CTBP C-terminal-binding protein 
CTCF CCCTC-binding factor 
CTP Cytosine 5’ triphosphate 
CXCL1 CXC chemokine 1 
Da Dalton 
dATP Deoxyadenosine 5’-triphosphate 
DAPI 4,6-diamidino-2-phenylindole 
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DAXX Death domain-associated protein 6 
DBD DNA-binding domain 
DBF4 Dumbbell former 4 
dCTP Deoxycytidine 5’-triphosphate 
DDK Dbf-dependent kinase 
DMEM Dulbecco’s modified Eagle medium 
DMSO Dimethyl sulfoxide 
DN Dominant negative 
DNA Deoxy-ribonucleic acid 
DNA-PK    DNA-dependent protein kinase 
DNA-PKcs DNA protein kinase catalytic subunit 
DNMT1 DNA (cytosine-5)-methyltransferase 1 
DOX Doxycycline 
ds Double-stranded 
DSB Double-stranded break 
DTT Dithiothreitol 
EB Egg buffer 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced GFP 
EGTA Ethylene glycol tetraacetic acid 
ELB Egg lysis buffer 
ELG1 Enhanced levels of genome instability protein 1 
EMSA Electrophoretic mobility shift assay 
FAT10 Leukocyte antigen F-associated transcript 10 
FEN1 FLAP-endonuclease 1 
FSC Forward scatter  
FUB1 Fau ubiquitin-like protein 1 
g Gravity of Earth 
GAL Galactose 
GFP Green fluorescent protein 
GG Di-glycine 
GINS Go, Ichi, Nii, and San; five, one, two, and three in Japanese 
GMP1 GAP-modifying protein 1 
GST Glutathione S-transferase 
GTP Guanosine 5’-triphosphate 
HAT Histone acetyl transferase 
HDAC Histone deacetylase 
HECT Homologous to the E6-AP Carboxyl Terminus 
HES1 Hairy and enhancer of split 1 
HIC1 Hypermethylated in cancer 1 
HIPK2 Homeodomain-interacting protein kinase 2 
HML Mating type cassette - left 
HMR Mating type cassette - right 
HP1 Heterochromatin protein 1 
HPS  Homopolymeric runs of histidine 
HRP Horse radish peroxidase 
HSF Heat shock factor 
HSP Heat shock protein 
HT Herring testis  
HTLV Human T-lymphotropic virus 
HU Hydroxyurea 
IgG Immunoglobulin isotype G 
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IL  Interleukin 
IPTG Isopropyl-1-thio-β-D-galactopyranoside 
IR Internal repeat 
ISG15 Interferon-induced 15 kDa protein 
IUR Immediate upstream region 
IκBα Nuclear factor of κ light polypeptide gene enhancer in B-cells 
inhibitor α 
JAK STAT Janus kinase signal transducer and transcription activator 
KO Knock out 
LB Luria broth 
LC Liquid chromatography 
m/z Mass to charge ratio 
MBR Major breakpoint region 
MCM Mini-chromosome maintenance 
MEC1 Mitosis entry checkpoint 1 
MEF2  Myocyte-specific enhancer factor 2 
MHC Major histocompatibility complex 
Miz Myc-interacting zinc 
MLS Mitochondrial localization signal 
MMS Methyl methanesulfonate 
MNNG 1-Methyl-3-nitro-1-nitrosoguanidine 
MNSFα Monoclonal nonspecific suppressor factor α 
MNU N-Nitroso-N-methylurea 
MOI Multiplicity of infection 
MOPS 3-(N-Morpholino)propanesulfonic acid 
MRC LMB Medical Research Council - Laboratory of Molecular Biology 
mRNA Messenger RNA 
MS Mass spectrometry 
MVP-BD Major vault protein binding site 
MWCO Molecular weight cut-off 
NAD Nicotinamide adenine dinucleotide 
NCoR Nuclear receptor co-repressor 
NDSM Negatively charged residue-dependent sumoylation motif 
NEDD8 Neural precursor cell expressed developmentally down-regulated 
protein 8 
NES Nuclear export signal 
NFAT Nuclear factor of activated T-cells 
NFκB Nuclear factor κ-light-chain-enhancer of activated B cells 
NLS Nuclear localization signal 
NMR Nuclear magnetic resonance 
NoLS Nucleolar localization signal 
Nt Nucleotide 
NTA Nitrilotriacetic acid 
NuMA Nuclear mitotic apparatus protein 1 
OAc Acetate 
OCT1 Octamer-binding protein 1 
OD600 Optical density at 600 nm 
ORC Origin recognition complex 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PAR Poly(ADP-ribose) 
PARG Poly(ADP-ribose) glycohydrolase 
PARP Poly(ADP-ribose) polymerase 
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PBS Phosphate buffered saline 
PBS-T PBS with Tween 20 
PBS-Tx PBS with Triton X-100 
PBZ PAR-binding Zn finger 
PC Polycomb 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PDSM Phosphorylation-dependent sumoylation motif 
PEG Polyethylene glycol 
PES Polyethersulfone 
Pfu Pyrococcus furiosus 
pfu Plaque forming unit 
PGC1α Peroxisome proliferator-activated receptor gamma 1α 
PGK 3-phosphoglycerate kinase 
Pi Phosphate group 
PIAS Protein inhibitor of activated STAT protein 
PIC1 PML-interacting clone 1 
PLK1 Polo-like kinase protein 1 
PML Promyelocytic leukemia  
PMSF Phenylmethanesulfonyl fluoride 
POL Polymerase 
PPi Pyrophosphate group 
ppm Part per million 
Pre-RC Pre-replication complex 
PrSc Prescission protease (Human Rhinovirus 3C protease) 
PVDF Polyvinylidene Fluoride 
RAD Radiation sensitive 
RANBP2 Ran-binding protein 2 
RANGAP1 Ran GTPase-activating protein 1 
RBBP7 Retinoblastoma-binding protein 
REC Recombination 
REG Regenerating protein 1 
REP Replication 
RFC Replication factor C 
RFP Ring finger protein 
RING Really interesting new gene 
RIPA Radio-immunoprecipitation assay 
RNA Ribonucleic acid 
RNF4 RING finger protein 4 
RPA Replication protein A 
RRM RNA-recognition motif 
RSUME RWD-containing sumoylation enhancer 
RTEL1 Regulator of telomere elongation helicase 1 
SALL1 Sal-like protein 1 
SAM Sterile α-motif 
SAP SAF-A/B, Acinus and PIAS 
SAXS Small-angle X-ray scattering 
SC Synthetic complete 
SCID Severe combined immunodeficiency 
SDS Sodium dodecyl sulfate 
SENP Sentrin-specific protease 
SFC Skp1-Cul1-F-box 
SILAC Stable isotope labelling with amino acids in cell culture 
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SIM SUMO-interacting motif 
SIN3A SWI-independent protein 3A 
SIP1 Smad-interacting protein 1 
SIZ SAP and Miz-finger domain-containing protein 
SLD Synthetically lethal with Dpb11 
SLX Synthetic lethal of unknown function 
SML1 Suppressor of mec1 lethality 
SMT3 Suppressor of mif-two 3 
SP Specificity protein 
SP-RING SIZ/PIAS RING 
SREBP-2 Sterol regulatory element-binding protein 2 
SRS2 Suppressor of rad-six 2 
ss Single-stranded 
SSB Single-stranded break 
SSC Side scatter 
STAT Signal transducer and transcription activator 
STE Saline/Tris/EDTA 
Su-DBD Sumoylated PARP-1’s DBD 
Su-PARP-1 Sumoylated PARP-1 
SUMO Small ubiquitin-like modifier 
SuNaSp Sucrose sodium spermidine 
TAB2 TGF-beta-activated 
TAE Tris acetate EDTA 
Taq Thermus aquaticus 
TAT1 Trypanosome tubulin 1 
TBE Tris borate EDTA 
TCA Trichloroacetic acid 
TDG Thymine DNA glycosylase 
TE Tris EDTA 
TEF1 Transcriptional enhancer factor 1 
TEP1 Telomerase protein component 1 
tiPARP 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible PARP 
TLE1 Transducin-like enhancer protein 1 
TNF Tumour necrosis factor 
TOPBP1 DNA topoisomerase II binding protein 1 
TOPORS Topoisomerase I-binding RING finger protein 
TOR Target of rapamycin 
TRF Telomeric repeat-binding factor 
TRRAP Transformation/transcription domain-associated protein 
TXRE Tax-responsive element 
U Unit 
UBA Ubiquitin activating 
UBC Ubiquitin conjugating 
UBE1l Ubiquitin-activating enzyme E1-like 
UBL Ubiquitin-like 
UIM Ubiquitin-interacting motif 
ULP Ubiquitin-like-specific protease 
UPLC High performance liquid chromatography 
URM Ubiquitin-related modifier 
UTR Untranslated region 
UV Ultra-violet 
v/v Volume by volume 
VIT Vault inter-α-trypsin 
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vPARP Vault PARP 
vWA  Von Willebrand factor type A 
w/v Weight by volume 
WDHD1 WD repeat and HMG-box DNA-binding protein 1 
WGR Tryptophan, glycine and arginine 
WRN Werner’s 
WT Wild type 
WWE Tryptophan, tryptophan and glutamate 
Xcorr Cross-correlation 
XP Xeroderma pigmentosum 
XRCC1 X-ray repair cross-complementing 
YP Yeast peptone 
YPD Yeast peptone dextrose (glucose) 
YY1 Ying-yang protein 1 
β-ME β-mercaptoethanol 
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Recent estimates suggest that humans (~25,000 genes) have slightly more genes than 
the puffer fish Fugu rubripens (~26,000 genes) and the mustard weed Arabidopsis 
thaliana (~25,500 genes), and only about twice as many as the fruit fly Drosophila 
Melanogaster (~13,600 genes) and the worm Caenorhabditis elegans (~17,000 genes). 
This does not however mean that we are twice as complicated as a worm or a plant. In 
fact, it is not the number of genes that determines the complexity of an organism but 
rather the size and regulation of its proteome, which cannot be easily predicted on the 
basis of genomic sequence only. Eukaryotes can expand and control the complexity of 
their proteomes through a variety of mechanisms, including alternative splicing of 
messenger RNAs (mRNAs) and the post-translational modification of proteins with 
small chemical groups, such as phosphate, acetyl, methyl and ADP-ribose groups, 
and/or polypeptides, such as ubiquitin.  
Post-translational modifiers usually change, in a controlled manner, the biological 
properties of their targets. They can do so very quickly because their actions do not 
require the re-synthesis of substrate proteins or the production of additional factors, 
which allows cells to rapidly respond to specific cues. The first and best-characterized 
example of a polypeptide modifier is ubiquitin, which is well known for targeting 
proteins for degradation by the proteasome but it also plays non-degradative functions. 
Since the discovery of ubiquitin, several ubiquitin-like proteins have been found and 
demonstrated to also act as post-translational modifiers. One of these factors is the 
small ubiquitin-like modifier SUMO, which has been the main focus of my research. 
1.1 Ubiquitin and ubiquitin-like proteins as post-translation 
modifiers 
1.1.1 Ubiquitin  
Ubiquitin is a protein of 76 amino acids that is very well conserved in all eukaryotes. It 
adopts a particular structure, known as β-grasp fold, which consists of a four-stranded 
anti-parallel β-sheet holding onto an α-helix (Figure 1.1B). Ubiquitin is produced as a 
longer inactive precursors (e.g. head-to-tail tetra-ubiquitin chains) that needs to be 
processed by specific peptidases to expose a C-terminal di-glycine motif to become 
competent for conjugation (Jentsch and Pyrowolakis, 2000).   
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Figure 1.1 - Similarities between ubiquitin and SUMO. (A) Alignment of the primary 
sequences of the human ubiquitin, the S. cerevisiae protein Smt3 and the human SUMO1-4 
proteins (ClustalW2, Larkin et al., 2007). The alignment is coloured according to the chemical 
properties of amino acids, as follows: purple, basic; blue, acidic; red, hydrophobic; green, polar 
or small. The secondary structure of the presented sequences is indicated above the alignment 
itself (α = α-helix, β = β-strand). The consensus motif used to form poly-SUMO chains is boxed 
in blue. The C-terminal di-glycine motif is boxed in black. (B) Cartoon representations of the 
tertiary structures of the human ubiquitin and SUMO1 proteins. Secondary structure elements 
are colour in red, for α-helices, and green, for β-strands. The images were created with PyMOL 
(http://pymol.sourceforge.net/). 
 
 
Once ubiquitin has been processed, it is attached to its substrates by covalently linking 
the carboxyl group of its C-terminal most glycine with the ε-amino group of a lysine 
found within a specific target protein. This process is brought about by the successive 
actions of three classes of enzymes: an E1 or ubiquitin-activating enzyme, an E2 or 
ubiquitin-conjugating enzyme and E3 or ubiquitin protein ligase. There exist one main 
ubiquitin E1 enzyme in all eukaryotes, but many E2s and even more E3s. The latter 
two enzymes, and in particular the E3s, are responsible for defining the target 
specificity of a particular ubiquitylation event. Ubiquitin can modify its substrates as a 
single moiety and also as polymeric chains because it is itself a substrate of 
SUMO1 Ubiquitin 
COOH 
HOOC
A 
B 
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ubiquitylation, through any of the seven lysines it contains (Jentsch and Pyrowolakis, 
2000).  
Ubiquitylation is involved in many processes in a cell; its specific functions depend on 
the nature of a particular modification event. For instance, mono-ubiquitylation is 
involved in controlling protein trafficking throughout the cell (Hicke and Dunn, 2003). 
K48- and K11-linked ubiquitin chains target proteins for degradation by the 26S 
proteasome, while those linked through K63 act as signalling molecules in various 
pathways, such as DNA repair and cell signalling (Bergink and Jentsch, 2009; Jentsch 
and Pyrowolakis, 2000). 
1.1.2 The ubiquitin-like modifiers 
Ubiquitin is the founding member of a class of polypeptides known as ubiquitin-like 
proteins (UBLs). They share a similar β-grasp structure with ubiquitin but show little 
sequence identity with it. Like ubiquitin, these factors need to be processed to yield a 
C-terminal di-glycine motif. Such residues are ligated to lysines in certain target 
proteins through enzymatic cascades that are analogous, but usually distinct, from that 
of ubiquitin (Welchman et al., 2005). Nine different UBLs have been identified so far, 
however, more are likely to exist. Their salient features will be briefly highlighted below.  
NEDD8 is a 9-kDa protein that shares considerable sequence (60%) and structural 
identity with ubiquitin. It is conjugated to its substrates through its own E1 (NAE1-
UBA3), E2 (UBC12 and UBE2F) and E3 (DCN1) enzymes (Huang et al., 2009; 
Welchman et al., 2005). NEDD8 targets p53, inhibiting its transcriptional activity 
(Xirodimas et al., 2004), and almost all the members of the cullin family of proteins. 
These proteins act as scaffolding subunits for SFC-type ubiquitin ligases and their 
neddylation regulates the activity of such enzymes (Hori et al., 1999). 
FAT10 is an 18-kDa protein that consists of two ubiquitin-like domains 30% identical 
to ubiquitin. It is encoded by a gene located within the MHC I locus and is expressed in 
mature B cells, dendritic cells and other cell types upon exposure to specific 
immunological signals (Raasi et al., 1999). Under these conditions, FAT10 becomes 
conjugated to certain proteins, including a 35-kDa species that is targeted to the 26S 
proteasome and thereby degraded (Raasi et al., 2001). 
Like FAT10, ISG15 is an 18-kDa protein that contains two ubiquitin-like domains. It is 
activated by a dedicated E1 (UBE1L) but then it is attached to its substrates through 
the ubiquitin E2 enzyme UBCH8 (Welchman et al., 2005). ISG15 is also induced by 
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specific cellular signals, thus leading to the modification of several proteins, and it plays 
an important role in the regulation of interferon-related immune responses (D'Cunha et 
al., 1996).  
ATG8 and ATG12 are 15-kDa proteins that share 10-15% identity with ubiquitin and 
have a single C-terminal glycine residue. The E1-like enzyme ATG7 activates them 
both. The E2-like enzymes ATG10 and ATG3 then catalyze the transfer of ATG12 to 
ATG5 and that of ATG8 to phosphatidylethanolamine, respectively. ATG8 and ATG12 
play a critical role in autophagy, the process by which cell degrade their own 
cytoplasmic materials (Ichimura et al., 2000; Mizushima et al., 1998). 
URM1 is 11 kDa in size and although it shares only 12% identity with ubiquitin it 
contain a β-grasp fold. In budding yeast, it is activated by the E1-like enzyme Uba4 and 
it is believed to be conjugated to proteins; the fact that a double knockout mutant of 
URM1 and UBA4 is sensitive to rapamycin indicates that Urm1 must be involved in the 
TOR (target of rapamycin) pathway, which is activated in response to nutrient 
starvation (Mizushima et al., 1998). Interestingly, URM1 has also been shown to act as 
a sulphur carrier in thiolation of eukaryotic transfer RNA (Leidel et al., 2009). 
FUB1 is 8 kDa in size and shares 37% identity with ubiquitin. It targets the T-cell-
receptor-α-like protein MNSFα, which probably acts as a stabilization factor for FUB1 
itself given that it appears to be rather prone to aggregation in vivo (Nagata et al., 
1998). FUB1 also modifies the B-cell lymphoma-G, a pro-apoptotic factor of the BCL2 
family of proteins (Nakamura and Tanigawa, 2003). 
UBL5 is an 8-kDa protein that shares 22% identity with ubiquitin. It folds into a 
ubiquitin-type β-grasp fold but it bears a tyrosine, instead of a glycine, at its C-terminus. 
In addition, unlike ubiquitin’s unstructured C-terminal domain, UBL5’s one forms a β-
sheet, thus suggesting that it may not be conjugatable (Ramelot et al., 2003). Yet, in 
budding yeast Ubl5 has been reported to modify Sph1, a protein that plays a role in 
bud site selection and cellular morphogenesis during mating (Dittmar et al., 2002). 
1.1.3 The small ubiquitin-like modifier SUMO 
SUMO, also known as Smt3 in budding yeast and PIC1, sentrin, GMP1 and UBL1 in 
mammalian cells, is a well-conserved post-translational modifier of about 90 
aminoacids and 11 kDa. A single SUMO gene exists in lower eukaryotes, but four 
paralogues, SUMO1-4, have been reported in higher organisms. SUMO2/3 seem to 
constitute a greater percentage of total cellular sumoylation than does SUMO1 (Saitoh 
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and Hinchey, 2000). Although SUMO folds into a β-grasp structure very similar to that 
of ubiquitin, it shares only 18% sequence identity with this protein (Figure 1.1). It also 
contains a unique N-terminal extension of about 20 amino acid, which is involved in the 
formation of SUMO chains (see 1.2.6).  
Amongst the SUMO genes, SUMO4 remains somewhat of enigma for two reasons. 
Firstly, although it was initially thought to be a pseudo-gene given that it is located 
within an intron of the TAB2 gene, it has been found to be expressed, particularly in 
immune tissues, such as the kidneys and the pancreas (Bohren et al., 2004; Guo et al., 
2005; Su and Li, 2002). Secondly, ectopically producing a mature form of SUMO4 in 
cells leads to its incorporation into high molecular weight species, thus indicating that it 
must be competent for conjugation (Guo et al., 2005; Owerbach et al., 2005). Yet, the 
presence of a proline residue at position 90 of SUMO4, instead of the glutamine 
normally found in the other SUMO paralogues, has been shown to prevent the 
processing of the immature form of such protein, both in vivo and in vitro (Owerbach et 
al., 2005). Thus, it would appear that although SUMO4 can potentially be conjugated to 
proteins, it may not normally do so in vivo because it cannot be converted into its 
mature form. SUMO4 may nevertheless still have certain biological functions, which 
could be mediated through non-covalent protein-protein interactions (Owerbach et al., 
2005). SUMO4 has in fact been proposed to play a role in immune responses because 
a spontaneously occurring point mutation within this gene, which exchanges M55 for a 
valine residue in the corresponding protein, has been associated with an increased 
susceptibility to the auto-immune, type I, diabetes (Bohren et al., 2004; Guo et al., 
2004; Park et al., 2005; Qu et al., 2005; Smyth et al., 2005). 
1.2 The SUMO conjugation pathway 
SUMO is conjugated to its substrates through an enzymatic pathway that is analogous 
to, but distinct from, that of ubiquitylation: it involves the successive activities of a 
SUMO E1 (AOS1/UBA2), a SUMO E2 (UBC9) and one of several SUMO E3s (Figure 
1.2). In vitro, sumoylation of many, but not all substrates, can be achieved in the 
presence of the E1 and E2 enzymes only, but in vivo an E3 is usually required. 
Sumoylation is a reversible mode of post-translational modification: desumoylation is 
achieved by specific SUMO isopeptidases known as ULPs, which are also involved in 
process of SUMO maturation. 
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Figure 1.2 - The mechanism of reversible sumoylation. SUMO is produced as a longer, 
inactive, precursor that is proteolytically cleaved to reveal a C-terminal GG motif by SUMO 
proteases called sentrin-specific proteases, or SENPs. The mature SUMO is initially activated 
by the hetero-dimeric E1 enzyme AOS1/UBA2 in an ATP-dependent manner and then 
transferred to the E2 SUMO conjugating enzyme UBC9. Aided by one of several SUMO E3 
ligases, UBC9 transfers SUMO to specific lysines (K) within a target protein. UBC9 can 
sumoylate SUMO itself, thus leading to the formation of poly-SUMO chains.  SUMO-conjugated 
proteins can be de-sumoylated by SENPs. C = cysteine, PPi = pyrophosphate. Adapted from 
Geiss-Friedlander and Melchior (2007). 
 
1.2.1 The SUMO E1 (AOS1/UBA2) 
A single SUMO-activating enzyme has been found in both lower and higher 
eukaryotes, where it is mainly localized within the nucleus. It exists as a hetero-dimer 
of AOS1 and UBA2, which share sequence similarity to the N- and C-terminal domains 
of the ubiquitin activating enzyme, respectively (Desterro et al., 1999; Johnson et al., 
1997). In budding yeast, AOS1 and UBA2 are essential genes for viability, thus 
indicating that sumoylation must play vital functions in this organism (Johnson et al., 
1997).  
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Like the E1s for ubiquitin and other UBLs, the SUMO-activating enzyme performs two 
functions: 1) it activates SUMO through adeylation and thiolation, and subsequently 2) 
it transfers the modifier to UBC9. Initially, AOS1/UBA2 binds to ATP and SUMO 
exclusively through its UBA2 subunit, which contains a typical G-X-G-X-X-G ATP-
binding motif that is also found in other E1 enzymes (Lois and Lima, 2005). It then 
catalyzes the attack of the C-terminal carboxyl group of SUMO itself to ATP to form a 
SUMO-AMP adenylate intermediate that concomitantly releases pyrophosphate. This 
reaction occurs in the so-called adenylation domain, a pocket formed by surfaces of 
both AOS1 and, mostly, UBA2, which strongly resembles the catalytic motif of bacterial 
adenylating enzymes (Lois and Lima, 2005). A conserved zinc-binding motif in UBA2 
has also been proposed to help this protein holding onto SUMO during adenylation and 
preventing the resulting SUMO-AMP intermediate to dissociate from the E1 before the 
formation of the thioester conjugate (Wang and Chen, 2010). Next, the thiol group of 
UBA2’s active site cysteine attacks the SUMO-AMP intermediate, releasing AMP and 
simultaneously forming a high energy thioester linkage between the E1 and SUMO. At 
the same time, the E1 is loaded with a second SUMO molecule, which is adenylated 
while the enzyme still carries the first thioester-bound modifier (Walden et al., 2003). 
The fact that the ATP-binding site and catalytic cysteine of the SUMO E1 are more 
than 3 nm away from each other made it hard to explain how the SUMO adenylate 
could be attacked by the active site thiol group. This mystery has been recently 
cracked by solving the structures of AOS1/UBA2 bound to mimics of the adenylation- 
and thioester-bound forms of SUMO (Olsen et al., 2010). Such structures show that 
when the E1 binds to the SUMO-thioester analogue the α-helix containing the active 
site undergoes a dramatic 130° rotation, which juxtaposes the catalytic cysteine next to 
where the SUMO adenylate would be. Finally, the activated SUMO is transferred to the 
active site cysteine of UBC9, through a ubiquitin-like domain found at the C-terminus of 
UBA2 (Lee and Schindelin, 2008; Lois and Lima, 2005). 
1.2.2 The SUMO E2 (UBC9) 
Unlike the ubiquitylation pathway, which features several conjugating enzymes, only 
one E2, i.e. UBC9, has been identified for SUMO (Desterro et al., 1997). It is a very 
well conserved protein, being 56% identical between yeast and humans, and it is 
essential in all systems tested. UBC9 shares a significant amount of sequence identity 
with ubiquitin E2s, and accordingly it also folds into a structure consisting of four α-
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helices and a four-stranded anti-parallel β sheet that conforms to the typical UBC 
superfold αββββ(βββ)ααα (Giraud et al., 1998).  
UBC9 must contain functionally-important binding surfaces for at least four proteins: 
AOS1/UBA2, SUMO ligases, substrates of sumoylation and SUMO itself.   
UBC9 and AOS1/UBA2 contact with each other through at least two sites. The first one 
involves a surface of the E2 consisting of its α1 helix and the α1β2 loop and the C-
terminal ubiquitin-like domain of UBA2. Although this interaction has not been directly 
proven for the SUMO enzymes, it occurs between the closely related neddylation 
enzymes UBC12 and UBA3 (Huang et al., 2007). Interestingly, in this system the 
thiolation of NEDD8 induces a conformational change within UBA3 that moves the 
UBC12 molecule bound to its C-terminal ubiquitin-like domain to a position where their 
catalytic cysteines face each other (Huang et al., 2007). Additionally, UBC9 also 
interacts with the catalytic pocket of UBA2 through a region surrounding its catalytic 
site (Wang et al., 2007). These observations therefore provide a possible mechanism 
for how the E1-bound SUMO could be directly transferred to the E2 enzyme. 
UBC9 and SUMO ligases may also associate with each other through multiple 
surfaces. The structure of the SUMO-1-UBC9-RANBP2–RANGAP1 complex revealed 
that the four-stranded β-sheet of UBC9 binds to the E3 RANBP2 (Reverter and Lima, 
2005; Tatham et al., 2005). In addition, given that ubiquitin E2s generally associate 
with their cognate E3s through a region formed by their β2β3 and β6α2 loops (Zheng et 
al., 2000), it is possible that an analogous surface could also be involved in the 
interactions between UBC9 and the relevant ligases.  
SUMO often targets lysines that fall within the consensus motif ΨKXD/E (see 1.2.5). 
This phenomenon depends on the ability of a patch surrounding the catalytic cysteine 
of UBC9 (C93), which is located in middle of its 4α2 extended loop, to directly 
recognize such a consensus, which consequently becomes buried in a hydrophobic 
groove of this enzyme (Bernier-Villamor et al., 2002; Tatham et al., 2003b). 
UBC9 interacts with SUMO through both covalent and non-covalent interactions. The 
transfer of the activated SUMO from the E1 enzyme to UBC9 leads to the formation of 
a thioester bond between these proteins. Additionally, UBC9 is also auto-sumoylated 
(Knipscheer et al., 2008). In the mammalian enzyme, this event targets K14 and has 
been shown to be critical for the modification of some sumoylation targets, such as the 
transcription factor SP100, in a manner that depends on its ability to non-covalently 
interact with SUMO. Thus, the auto-sumoylated UBC9 modifies SP100 more efficiently 
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than the unmodified E2 enzyme probably because this transcription factor contains an 
additional binding surface for UBC9 itself, i.e. SUMO (Knipscheer et al., 2008). 
Interestingly, not all of the sumoylation substrates that non-covalently interact with 
SUMO are preferentially modified by the auto-sumoylated UBC9. Thus, it has been 
proposed that in addition to the presence of a SUMO-interacting motif (see 1.3.1) in a 
protein, the particular position of such a domain with respect to the target lysine is also 
important to enable the auto-sumoylated UBC9 to preferentially modify it (Knipscheer 
et al., 2008). SUMO also interacts non-covalently with UBC9, through at least two sites. 
One of these regions (D100 and K101) is located close to the enzyme’s catalytic 
cysteine (Tatham et al., 2003a). Mutating D100 and K101 inhibits the transfer of the 
activated SUMO from the E1 and increases the association rate and decreases the 
dissociation rate of binding of the SUMO-loaded UBC9 to define model substrates 
(Tatham et al., 2003a). Since D100 and K101 are not conserved in other E2s, it is 
possible that these residues could underlie the specificity that UBC9 shows for SUMO, 
in comparison to other UBLs (Tatham et al., 2003a). In addition, SUMO also non-
covalently associates with UBC9 through the β-sheet of this enzyme, distantly from its 
active site, which is important for its chain-building activity (Capili and Lima, 2007; 
Knipscheer et al., 2007).  
1.2.3 The SUMO E3 enzymes 
E3 ligases function by increasing the efficiency and defining the substrate specificity of 
a particular post-translational event. SUMO ligases can be classified into three 
categories, which are described below. 
1.2.3.1 The PIAS/SIZ family of SUMO E3 enzymes 
The largest class of SUMO ligases are the PIAS/SIZ proteins. This family includes: 
PIAS1, PIASx (PIAS2), PIAS3 and PIASy (PIAS4) in mammals, which were initially 
described as protein inhibitors of the activated JAK-STAT signaling pathway, Siz1 and 
Siz2 in budding yeast as well as Pli1 and Nse2 in fission yeast (Watts et al., 2007). 
Interestingly, the modification of many SUMO substrates can be stimulated by more 
than one PIAS or SIZ protein both in vitro and in vivo, thus indicating that there is a 
significant amount of redundancy amongst these enzymes (Martin et al., 2009; Reindle 
et al., 2006). 
PIAS/SIZ proteins share a common modular structure that consists of four domains. An 
N-terminal SAP domain, which mediates interactions with DNA but is not essential for 
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catalytic activity (Okubo et al., 2004; Parker et al., 2008; Suzuki et al., 2009; Takahashi 
and Kikuchi, 2005). A “PINIT” motif, which mediates both the target protein- and target 
site- selectivity of some sumoylation event by directly contacting sumoylation 
substrates (Takahashi and Kikuchi, 2005; Yunus and Lima, 2009b), but it also seems 
to play a role in the localization of PIAS/SIZ ligases (Duval et al., 2003). A Miz-type zinc 
finger fold, also known as SIZ/PIAS RING domain (SP-RING), which is essential for the 
SUMO ligase activity of PIAS/SIZ proteins (Kotaja et al., 2002; Takahashi and Kikuchi, 
2005; Yunus and Lima, 2009b). This domain is related, both in terms of sequence and 
structure, to the classical RING-type zinc fingers found in ubiquitin ligases and thus, 
like such motifs, it probably mediates the E2:E3 contacts necessary to transfer the 
modifier from the E2 to its substrates (Yunus and Lima, 2009b). It therefore seems 
likely that PIAS/SIZ proteins stimulate sumoylation by acting as adaptors between the 
loaded E2 and its targets. The C-terminus of PIAS/SIZ proteins contains a classical 
SUMO-interacting motif (see 1.3.1), which is dispensable for catalytic activity 
(Takahashi and Kikuchi, 2005; Yunus and Lima, 2009b), and an acidic domain, which 
is instead essential for efficient SUMO conjugation, possibly by contacting basic 
residues in the SUMO moiety of the charged UBC9 (Yunus and Lima, 2009b).  
SUMO ligases that contain an SP-RING, but do not belong to the PIAS/SIZ family of 
proteins, also exist and include: MMS21, which is part of a complex that is involved in 
DNA damage sensing and repair as well as telomere homeostasis (Zhao and Blobel, 
2005), and the meiosis-specific yeast enzyme Zip3 (Cheng et al., 2006a). 
1.2.3.2 RANBP2 
RANBP2 defines a second class of SUMO ligases. It is a large vertebrate-specific 
protein that localizes to the cytoplasmic fibrils of the nuclear pore, a big protein 
complex that controls the shuttling of materials across the nuclear envelope, where it 
mainly plays a role in protein import. This role of RANBP2 depends on its ability to 
bind, and thereby recruit to the nuclear pore complex, the RAN GTPase activator 
protein RANGAP1, which only occurs when the latter protein is sumoylated (Mahajan 
et al., 1997; Matunis et al., 1996; Matunis et al., 1998). 
RANBP2 has been shown to enhance the modification of several proteins in vitro, 
including HDAC4, SP100, borealin and PML (Kirsh et al., 2002; Klein et al., 2009; 
Pichler et al., 2002; Tatham et al., 2005). To date, only topoisomerase II has been 
identified as a substrate of RANBP2 in vivo, at least in mouse cells (Dawlaty et al., 
2008). In fact, in Xenopus egg extracts and possibly in some human cell lines 
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topoisomerase II sumoylation seems to depend on PIASy (Azuma et al., 2005; Diaz-
Martinez et al., 2006).  
The E3 ligase activity of RANBP2 is mediated through a 300-amino acid domain, 
which contains two internal repeats (IR1 and IR2) of a 50-amino acid sequence 
separated by a 25-amino acid middle (M) domain that share no similarity with any other 
known protein. A region encompassing the IR1 and the M motifs binds to UBC9 and is 
able to recapitulate the activity of the full-length RANBP2, although the IR1 motif alone 
is also functional (Pichler et al., 2002; Pichler et al., 2004; Saitoh et al., 2002; Tatham 
et al., 2005). The IR1+M region also appears to be mostly unstructured in its free form 
but becomes more compact upon binding to UBC9 (Pichler et al., 2004). Conversely, 
the IR2 and M domains show no activity on their own, but they are somewhat active in 
combination (Pichler et al., 2004; Tatham et al., 2005). Together, the IR2 and M motifs 
can bind SUMO1 but not SUMO2 (Tatham et al., 2005). Yet, RANBP2 enhances the 
modification of model substrates by both SUMO1 and SUMO2, albeit with different 
kinetics, thus indicating that its ligase activity is probably brought about through two 
different mechanisms (Tatham et al., 2005).  
Biochemical and structural data suggest a possible mechanism for how RANBP2 
brings about SUMO ligase activity. Firstly, there is no evidence for this enzyme being 
able to directly contact its substrates (Pichler et al., 2004; Reverter and Lima, 2005). 
Thus, unlike PIAS/SIZ proteins, it probably does not act as a bridging factor between 
the SUMO-charged UBC9 and a substrate. Secondly, the evidence that RANBP2’s 
catalytic core does not require cysteines to enhance sumoylation means that it does 
not function like HECT-type ubiquitin ligases, where the E3 enzyme itself forms a 
thioester bond with ubiquitin before transferring it to a substrate (Pichler et al., 2004). 
Finally, the crystal structure of the sumoylated RANGAP1 in complex with UBC9 and 
RANBP2’s catalytic core shows that RANBP2 contacts both SUMO1 and UBC9 
(Reverter and Lima, 2005). By doing so, RANBP2 has been proposed to position the 
SUMO-UBC9 thioester for optimal attack by a target lysine, which would consequently 
accelerate the rate of SUMO transfer to such residue (Reverter and Lima, 2005).  
1.2.3.3 Other SUMO ligases 
In addition to PIAS/SIZ proteins and RANBP2, two other SUMO ligases have been 
identified, i.e. PC2 and TOPORS, for which, however, the mechanisms of action 
remain unknown.  
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PC2 is a member of the polycomb group family of proteins, which form large nuclear 
complexes that mediate the stable and heritable repression of several genes by 
modifying histones (Kagey et al., 2003). Given its highly confined localization, PC2 is 
likely to have a more limited range of targets compared to other SUMO ligases (Kagey 
et al., 2005). In fact, so far this enzyme has been shown to enhance the sumoylation of 
only four proteins, both in vivo and in vitro, including the transcriptional regulators CtBP 
(Kagey et al., 2003), SIP1 (Long et al., 2005) and HIPK2 (Roscic et al., 2006), which all 
co-localize with PC2 at polycomb complexes. How PC2 exerts its SUMO ligase activity 
remains poorly understood. A mutant of PC2 that binds CtBP and UBC9 and localizes 
to polycomb complexes, but lacks its N-terminal domain, is unable to stimulate CtBP 
modification, thus indicating that these interactions are necessary, but not sufficient, for 
PC2’s SUMO ligase activity (Kagey et al., 2005). The N-terminus of this protein 
stimulates sumoylation in vitro, but not in vivo, where it needs either to be fused to a 
CtBP-binding motif or the concomitant production of PC2’s C-terminal domain (Kagey 
et al., 2005). In addition, the SUMO ligase activity of PC2 has been shown to depend 
on two SUMO-interacting motifs found in this enzyme, one located within its N-terminal 
domain and the other in its C-terminus (Merrill et al., 2010; Yang and Sharrocks, 2010). 
The topoisomerase I-interacting protein TOPORS also has SUMO ligase activity. It 
stimulates the sumoylation of topoisomerase I itself, p53, SIN3A and possibly several 
other proteins, which appear to be mainly involved in chromatin modification and 
transcription regulation (Pungaliya et al., 2007; Weger et al., 2005). Interestingly, 
TOPORS contains a typical RING-type zinc finger domain, which confers to it ubiquitin 
E3 ligase activity (Rajendra et al., 2004). 
1.2.4 SUMO deconjugation 
SUMO proteases are enzymes that catalyze the processing of SUMO to its mature 
form (C-terminal hydrolase activity), its removal from target substrates (isopeptidase 
activity) and the length of polymeric SUMO chains (chain editing activity). These 
proteins belong to the C48 cysteine protease superfamily of proteins and share a 
conserved ~200-amino acid catalytic region, known as ULP domain (Li and 
Hochstrasser, 1999, 2000; Mossessova and Lima, 2000). This domain is generally 
found close to the C-terminus of SUMO proteases, while their N-terminal regions are 
often important for their correct sub-cellular localization. In budding yeast, two such 
proteins exist (Ulp1 and Ulp2), while six have been identified in mammals (SENP1-3, 
SENP5 and SENP6).  
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1.2.4.1 The yeast SUMO proteases 
Budding yeast Ulp1 has C-terminal hydrolase and isopeptidase activities, both of which 
are essential for cell viability (Li and Hochstrasser, 1999). As a SUMO isopeptidase, 
Ulp1 is important for cell cycle progression, in particular at the G2/M transition (Li and 
Hochstrasser, 1999). It is found at nuclear pore complexes in budding yeast (Li and 
Hochstrasser, 1999), but it delocalizes to the nucleoplasm during mitosis in fission 
yeast (Taylor et al., 2002). The targeting of Ulp1 to nuclear pores requires its N-
terminus and is essential for maintaining its functions (Panse et al., 2003). An Ulp1 
mutant that lacks its N-terminal region is found throughout the nucleus and shows 
reduced isopeptidase activity towards its own substrates but an increased one towards 
those proteins normally desumoylated through Ulp2 (Li and Hochstrasser, 2003). 
Consequently, this Ulp1 mutant exhibits several phenotypes including increased DNA-
damage sensitivity (Li and Hochstrasser, 2003; Panse et al., 2003; Zhao et al., 2004a). 
Ulp2 possesses only isopeptidase activity and it localizes throughout the nucleus (Li 
and Hochstrasser, 2000). It is not an essential gene but in its absence cells cannot 
properly segregate chromosomes because of impaired topoisomerase II sumoylation 
(Bachant et al., 2002). Additionally, Ulp2 is also important for resuming cell cycle 
progression following exposure to DNA damaging agents (Schwartz et al., 2007). 
Mutants of ULP2 also accumulate SUMO chains in a way that depends on lysines 
important for the formation of such polymers (see 1.2.6), thus suggesting that Ulp2 may 
have SUMO chain-editing activity (Bylebyl et al., 2003).  
1.2.4.2 The mammalian SUMO proteases 
The mammalian SENPs can be classified into three categories: 1) SENP1 and SENP2, 
which have C-terminal hydrolase activity and act as isopeptidases towards all three 
SUMO paralogues, 2) SENP3 and SENP5, which prefer SUMO2/3 over SUMO1 and 
localize to the nucleolus, and 3) SENP6 and SENP7, which show a preference for 
trimming SUMO2/3 chains and contain a 50-200 amino acid insertion in their ULP 
domains, the functional significance of which remains unclear (Yeh, 2009). From a 
phylogenetic point of view SENP1-3 and SENP5 are more similar to Ulp1, while 
SENP6 and SENP7 are more related to Ulp2. The basic properties of these enzymes 
are summarized in Table 1.1. 
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Table 1.1 - Summary of the properties of mammalian SUMO proteases. The sub-cellular 
localization and enzymatic activities of the six mammalian SUMO proteases are summarized. 1 - 
Gong et al. (2000), 2 - Shen et al. (2006a), 3 - Hang and Dasso (2002), 4 - Itahana et al. (2006), 5 
- Reverter and Lima (2006), 6 - Gong and Yeh (2006), 7 - Cheng et al. (2006b), 8 - Shen et al. 
(2009), 9 - Lima and Reverter (2008), 10 - Mukhopadhyay et al. (2006). 
 
1.2.4.3 The enzymatic activities of SUMO proteases 
The catalytic domains of ULPs and SENPs fold into a similar structure consisting of 
seven α-helices and one two-stranded and one four-stranded -sheets. Residues 
present in α6, β4 and β5 of this structure come together to form the catalytic triad 
cysteine, histidine and asparagine (Lima and Reverter, 2008; Mossessova and Lima, 
2000; Reverter and Lima, 2004; Shen et al., 2006a). The C-terminal hydrolase and 
isopeptidase activities of these enzymes have been analyzed from both biochemical 
and structural perspectives and will be described below. 
1.2.4.3.1 C-terminal hydrolase activity 
C-terminal hydrolase activity involves the cleavage of the peptide bond between the C-
terminal glycine of SUMO and the first amino acid in its C-terminal tail. SENP1 and 
SENP2 are the only mammalian SUMO proteases known to efficiently process SUMO 
precursors, which they do in a paralogue-specific manner (Table 1.1). This specificity 
depends on the length and sequence of the regions C-terminal to the di-glycine motif of 
such modifiers, rather than their affinity for SENPs per se (Mikolajczyk et al., 2007; 
Reverter and Lima, 2004; Shen et al., 2006a). In particular, it is the proline residue 
(P94) found two amino acids after the di-glycine motif of SUMO3 that hinders its ability 
to be processed by SENP1 (Xu and Au, 2005), and probably by SENP2 as well. 
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Similarly, in SUMO1, it is H98 located adjacent to its C-terminal glycine that makes it 
an efficient substrate for maturation by SENP-1 (Xu and Au, 2005). It is now clear that 
these amino acid requirements depends on how SENPs catalyze SUMO maturation. 
When inactive mutants of SENP1’s and SENP2’s catalytic domains bind to the 
immature forms of SUMO, they bring about isomerisation of the modifier’s scissile 
peptide bond to an unstably kinked cis-configuration (Reverter and Lima, 2006; Shen et 
al., 2006a). This conformational change moves the C-terminal tail of SUMO into a 
position such that in SUMO1 its H98 residue is able to form a hydrogen bond with 
SENP1’s G600 (Shen et al., 2006a), thus stabilizing the resulting transition state 
complex. This stabilizing effect cannot occur for SUMO3 because it bears a proline at 
an equivalent position of SUMO1’S H98, which is probably detrimental to isomerisation 
given its rigidity (Shen et al., 2006a). These structural studies also provide a possible 
explanation for why SENP2 is a much more efficient isopeptidase than C-terminal 
hydrolase (Reverter and Lima, 2006). When SUMO2 was crystallized with SENP2, in 
only one of three different configurations was SENP2’s catalytic domain in an 
appropriate position for attacking to SUMO2’s scissile bond (Reverter and Lima, 2006). 
It is therefore possible that the process of SUMO maturation, unlike deconjugation, 
may go through a series of non-productive intermediates. In addition, upon peptide 
bond-isomerization the residues in the C-terminal tail of SUMO adopt a position that 
may hinder interactions with SENP2’s catalytic centre (Reverter and Lima, 2006).  
1.2.4.3.2 Isopeptidase activity 
Isopeptidase activity involves the cleavage of the peptide bond between the C-terminal 
glycine of SUMO and the ε-amino group of a target lysine. The structures of inactive 
mutants of SENP1’s and SENP2’s catalytic domain bound to a sumoylated fragment of 
RANGAP1 show that, like SUMO processing, SUMO deconjugation also proceeds 
through isomerisation of the scissile isopeptide bond, which positions such a linkage in 
a productive arrangement for its cleavage (Reverter and Lima, 2006; Shen et al., 
2006a). Nevertheless, a SUMO-conjugated lysine presents higher flexibility and fewer 
steric impediments in the catalytic pocket of SENPs in comparison to the more rigid 
modifier’s C-terminal tail (see 1.2.4.3.1 and Reverter and Lima, 2006). This observation 
therefore puts forward an additional explanation for why SENP2 works preferentially as 
an isopeptidase.  
The structures presented by Reverter and Lima (2006) and Shen et al. (2006a) also 
provide some insight on how these enzymes specifically desumoylate a certain 
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lysine/protein or SUMO paralogue (Gong and Yeh, 2006). Firstly, these properties are 
unlikely to depend on a direct interaction between the catalytic domain of a SENP and 
a substrate protein itself because SENP1’s and SENP2’s catalytic regions bind the 
sumoylated RanGAP1 mostly through SUMO and make very few contacts with 
RanGAP1 itself (Shen et al., 2006a). Thus, other determinants may be involved in 
enabling SENPs to recognize a specific substrate, such as the regions flanking their 
catalytic domains. Secondly, it has been shown that SENP2 makes greater contact 
with SUMO2 than SUMO1 when they are conjugated to RANGAP1 and that, 
consistently, it desumoylates RANGAP1-SUMO2 more efficiently than RANGAP1-
SUMO1 (Reverter and Lima, 2006). Conversely, although SENP1 binds SUMO1 and 
SUMO2 equally well, it processes RANGAP1-SUMO2 twice as well as RANGAP1-
SUMO1 (Shen et al., 2006a). These observations therefore suggest that the ability of 
SENPs to discriminate amongst SUMO paralogues may not be simply dependent on 
binding affinities.  
1.2.5 The SUMO acceptor sites 
Unlike ubiquitylation, for which no consensus modification sequence has been yet 
identified, SUMO typically targets lysines that fall within the motif ΨKXD/E, where Ψ is 
an aliphatic branched residue and X is any amino acid (Rodriguez et al., 2001), 
although a hydrophobic residues at this position also improves sumoylation efficiency 
(Schwamborn et al., 2008). At least partly, this phenomenon depends on the fact that 
sumoylation is brought about through a single E2, UBC9, which directly recognizes the 
motif ΨKXD/E (Bernier-Villamor et al., 2002; Tatham et al., 2003a), while ubiquitylation 
relies upon many different conjugating enzymes. Several lysines that do not fall within 
this motif can, however, be also sumoylated (Blomster et al., 2009; Blomster et al., 
2010), indicating that other determinants, such as SUMO E3s, may be important for 
targeting SUMO to a particular substrate. For instance, in budding yeast the E3 
enzyme Siz1 mediates the sumoylation of PCNA at the non-consensus lysine K164 
(see 1.3.3). On the other hand, the evidence that not all lysines found within a ΨKXD/E 
sequence are sumoylated may depend on the fact that UBC9 can bind to this motif only 
when it is found in an extended loop or an unstructured region, but not when it is 
located in an α-helix (Bernier-Villamor et al., 2002; Pichler et al., 2005). 
Several extensions of this basic ΨKXD/E sumoylation sequence have been identified. 
The first two types introduce a negative charge near such a consensus motif and 
thereby increase its likelihood/efficiency of being targeted by UBC9. The 
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phophorylation-dependent sumoylation motif (PDSM) was initially identified in the heat 
shock factor HSF1, but since then it has also been found in several other proteins 
(Hietakangas et al., 2003; Hietakangas et al., 2006; Yang and Gregoire, 2006). It 
conforms to the sequence ΨKX(D/E)XX(S/T)P, which can be efficiently sumoylated 
only when its serine/threonine is phosphorylated (Hietakangas et al., 2006; Mohideen 
et al., 2009; Yang and Gregoire, 2006). Thus, the PDSM provides cells with a way to 
control the sumoylation of specific proteins. This phenomenon is directly mediated by 
UBC9 through the presence of a positively-charged patch located close to its active site 
(K65, K74 and K76, Mohideen et al., 2009), which is in an ideal position to 
accommodated the phosphorylated serine/threonine of a PDSM. A second extended 
sumoylation motif consists of the ΨKXD/E sequence followed by negatively charged 
amino acids, called negatively charged residue-dependent sumoylation motif (NDSM), 
and it has been found in several transcription factors (Yang et al., 2006b). These acidic 
amino acids probably perform an analogous function to, and therefore substitute, the 
phosphorylated serine/threonine side chains found in the PDSM. Mutating the basic 
patch of UBC9 formed by K65, K74 and K76 inhibited the modification of a model 
NDSM only slightly (Mohideen et al., 2009). This observation indicates that other 
residues within UBC9 may be important to mediate the enhanced modification of a 
NDSM in comparison to the PDSM, e.g. K59 and R61 (Yang et al., 2006b). The recent 
identification of a large number of endogenous SUMO2-modified peptides in human 
cells by mass spectrometry has also revealed that clusters of basic or hydrophobic 
residues are often found C-terminal to the core sumoylation motif ΨKXD/E and are 
important for its efficient modification (Matic et al., 2010; Schimmel et al., 2010). 
Interestingly, Matic et al. (2010) also found that several human protein are modified at 
sites that conform to an inverted core sumoylation motif, that is, E/DXKΨ. 
1.2.6 Formation and functions of SUMO chains 
The N-terminal tails of the yeast Smt3 protein (10AKPE13, 13VKPE16 and 18VKPE21) and 
the higher eukaryotic SUMO2/3/4 (10VKTE13) contain classic SUMO attachment motifs, 
which can be sumoylated both in vitro and in vivo, leading to the formation of polymeric 
SUMO chains. Although SUMO1 lacks such sequences, it can still polymerize in vitro, 
mainly through K7, K16 and K17 (Pedrioli et al., 2006). In vivo poly-SUMO1 chains 
have not been detected (Matic et al., 2008), however they may exist given that a lysine 
in SUMO1’s N-terminus, which conforms to an inverted sumoylation motif (5EAKP8), 
can be conjugated to SUMO2 in human cells (Matic et al., 2010). SUMO1 has also 
Chapter 1. Introduction 
37 
been found at the end of SUMO2/3 chains, thus suggesting that it may act as a chain-
terminator (Matic et al., 2008; Tatham et al., 2008). Although the SUMO E1 and E2 
enzymes alone are sufficient to generate SUMO chains in vitro, E3s can stimulate this 
process (Johnson and Gupta, 2001; Pichler et al., 2002; Tatham et al., 2001). 
Unlike mono-sumoylation events, for which a downstream function cannot be generally 
predicted (see 1.3), poly-SUMO chains are poly-ubiquitylated, which therefore targets 
them, and the substrates attached to them, for proteasome-mediated degradation. In 
both budding and fission yeasts the key player in this process is a protein called Slx8. It 
contains a RING domain that mediates both ubiquitin ligase activity and binding to Slx5 
in budding yeast, and Rfp1 (or the redundant Rfp2) in fission yeast (Ii et al., 2007a; 
Mullen and Brill, 2008; Prudden et al., 2007; Sun et al., 2007; Uzunova et al., 2007; Xie 
et al., 2007). The presence of multiple SUMO-interacting motifs in Slx5 and Rfp1/2 
enables Slx8 to preferentially bind, and thereby poly-ubiquitylate, poly-SUMO chains 
(Uzunova et al., 2007). In humans, Slx8 and Slx5/Rfp1/Rfp2 have converged into a 
single protein called RNF4, which contains both a RING domain and multiple SUMO-
interaction motifs, and it also mediates the poly-ubiquitylation of poly-sumoylated 
species (Lallemand-Breitenbach et al., 2008; Sun et al., 2007; Tatham et al., 2008). In 
vivo, sumoylated proteins that are simultaneously ubiquitylated have been detected 
(Tatham et al., 2008; Uzunova et al., 2007). The levels of these species increase upon 
loss of the Slx8 complex in yeast or RNF4 in mammalian cells, but also when the 
proteasome is inhibited (Prudden et al., 2007; Sun et al., 2007; Tatham et al., 2008; 
Uzunova et al., 2007). In addition, Slx8/RNF4 proteins can catalyze the formation of 
K11- and K48-linked ubiquitin chains (Mullen and Brill, 2008; Tatham et al., 2008), 
which have degradative functions. Proof that Slx8/RNF4 proteins target poly-
sumoylated species for degradation came from the finding that PML is a target of 
RNF4. Exposure to arsenic trioxide leads to the recruitment of RNF4 and the 
proteasome to PML nuclear bodies and the degradation of PML itself (Lallemand-
Breitenbach et al., 2008; Shao et al., 1998). The latter phenomenon depends on the 
ability PML to be sumoylated, on the presence of RNF4 and an active proteasome 
(Lallemand-Breitenbach et al., 2008; Lallemand-Breitenbach et al., 2001; Tatham et al., 
2008; Weisshaar et al., 2008). In addition, in vitro RNF4 efficiently poly-ubiquitylates 
PML only when it has been previously poly-sumoylated (Tatham et al., 2008; 
Weisshaar et al., 2008).  
The ability of Slx8/RFN4 proteins to target sumoylated species for degradation appears 
to be important for maintaining genome stability. In budding and fission yeasts, SLX8 
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mutants are hypersensitive to the fork-stalling agents hydroxyurea and the DNA 
alkylating agent MMS (Ii et al., 2007b; Kosoy et al., 2007; Mullen and Brill, 2008; 
Mullen et al., 2001; Prudden et al., 2007; Sun et al., 2007; Xie et al., 2007; Zhang et al., 
2006). They also exhibit a high frequency of gross chromosomal rearrangements, gene 
conversion events and small point mutations, which are likely to arise because of 
aberrant repair of double-stranded breaks (DSBs, Burgess et al., 2007; Prudden et al., 
2007; Zhang et al., 2006). In fission yeast a hypomorphic slx8-1 allele is also 
synthetically lethal with deletions of genes involved in homologous recombination 
(Prudden et al., 2007).  
1.2.7 Regulation of SUMO conjugation 
Sumoylation is not a static post-translational protein modification system but it is often 
regulated by specific factors such as environmental/cellular signals or the cell cycle. 
Mechanistically, sumoylation could be controlled by changing the rate of conjugation 
and/or removal of SUMO, globally or more specifically at a certain location in a cell or 
at a particular stage of the cell cycle. All of these scenarios have been reported and will 
be described below.  
Firstly, environmental stimuli affect sumoylation levels. Unlike SUMO1, which is mostly 
found conjugated during unperturbed cell growth, SUMO2/3 mainly exist in their free 
forms under normal conditions but are quickly attached to cellular substrates in 
response to cellular insults such as excessive heat, metabolic stress, osmotic shock, 
hypoxia, etc. (Blomster et al., 2009; Golebiowski et al., 2009; Saitoh and Hinchey, 
2000; van Hagen et al., 2010,Sramko, 2006 #790). How cellular stresses upregulate 
the modification by SUMO2/3 is unknown but, at least in part, it could involve 
controlling the enzyme of the sumoylation pathway. For instance, during keratinocyte 
differentiation, Ca2+ signalling transiently induces transcription of SAE1/SAE2, UBC9, 
SUMO2/3, and PIASx (Deyrieux et al., 2007). In addition, hypoxia stimulates the 
expression of SUMO1 and the sumoylation enhancer RSUME (Carbia-Nagashima et 
al., 2007). RSUME binds UBC9 and increases the non-covalent association between 
this enzyme and SUMO, which enhances UBC9~SUMO thioester formation and 
consequently SUMO conjugation (Carbia-Nagashima et al., 2007). Sumoylation can 
also be regulated by signal-dependent changes in the sub-cellular localization of 
sumoylation pathway enzymes. Pro-inflammatory stimuli lead to the phosphorylation of 
PIAS1, which causes it to re-localize to, and therefore inhibit, PIAS1-responsive 
promoters, probably by promoting the modification of specific proteins at such locations 
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(Liu et al., 2007). Environmental cues do not always stimulate the attachment of SUMO 
but they can also inhibit it. For example, moderate-to-low amounts of oxidative stress 
reduce sumoylation levels (Bossis and Melchior, 2006). This inhibitory effect is caused 
by the formation of a disulphide bond at the catalytic residues of UBA2 and UBC9, 
which effectively inactivates them (Bossis and Melchior, 2006). In vivo, the oxidative 
burst that accompanies the activation of macrophages also results in loss of 
sumoylation, indicating that the oxidation-dependent inhibition of sumoylation is a 
physiologically relevant phenomenon (Bossis and Melchior, 2006).  
Secondly, the cell cycle has also been shown to affect sumoylation. In mammalian 
cells, SUMO1- and SUMO2-modified species are present throughout interphase, 
largely disappear at metaphase but their levels rise again during mitosis (Zhang et al., 
2008). Conversely, in Xenopus egg extracts substrates of SUMO2/3 can be detected in 
mitosis but hardly during interphase (Azuma et al., 2003). The importance of the cell 
cycle in regulating sumoylation has also been demonstrated for specific SUMO 
substrates, such as PCNA (see 1.3.3), topoisomerase II (Agostinho et al., 2008; Azuma 
et al., 2003; Bachant et al., 2002; Dawlaty et al., 2008) and the bud neck-associated 
yeast septins (Johnson and Blobel, 1999). The modification of PCNA is restricted to S 
phase probably because it is efficiently sumoylated only when loaded onto DNA, that 
is, during DNA replication (Parker et al., 2008). Conversely, the sumoylation of septins 
occurs only during mitosis and on the mother-side of the bud neck because their 
modification strictly depends on Siz1, which specifically re-localizes to the mother-cell 
side of a bud neck during mitosis (Johnson and Blobel, 1999; Johnson and Gupta, 
2001). Regulating the sub-cellular localization of SUMO proteases, instead of SUMO 
ligases, during the cell cycle could also help restricting the modification of certain 
proteins at a specific cell cycle stage. This could be the case for the fission yeast Ulp1, 
which is found at the nuclear periphery during interphase but delocalizes throughout 
the nucleus at M phase (Taylor et al., 2002), hence possibly leading to the 
loss/acquisition of defined sumoylation events specifically at mitosis.  
Interestingly, it is becoming increasingly clear that the regulation of several cell cycle- 
or environmentally-controlled sumoylation events could depend on crosstalk between 
sumoylation and other post-translational modification events. For instance, 
phosphorylation can enhance sumoylation of a protein, generally by targeting a PDSM 
(see 1.2.5), but it can also inhibit it, as it seems to be the case for c-JUN, PML, IκBα 
and SREBP-2 (Arito et al., 2008; Desterro et al., 1998; Everett et al., 1999; Muller et 
al., 2000). Sumoylation can also be controlled by other post-translational modifiers that 
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target lysines, e.g. ubiquitylation, acetylation, methylation, etc., potentially as a result of 
competition for the same cojugation site. For example, sumoylation competes with 
TNFα-, IL-1β- or okadaic acid-induced poly-ubiquitylation of IκBα at K21, thereby 
preventing its proteasome-mediated degradation (Desterro et al., 1998). Additionally, 
SUMO also competes with acetylation, as in the case of histones H2A and H2B and 
transcription factors SP3, PGC1α, MEF2 and HIC1 (Gregoire et al., 2006; Muller et al., 
2000; Nathan et al., 2006; Rytinki and Palvimo, 2009; Sapetschnig et al., 2002). For 
the latter two proteins, the acetylation-sumoylation switch is controlled by 
phosphorylation (Shalizi et al., 2006; Stankovic-Valentin et al., 2007). 
1.3 Molecular consequences of sumoylation of DNA-
associated proteins  
Unlike ubiquitylation, which often targets proteins for degradation, the functional 
outcomes of sumoylation are impossible to predict because they can be as varied as 
changing the activity, localization and stability of a specific protein.  
However diverse, the molecular consequences of different sumoylation events have 
been often traced back to a common molecular mechanism, that is, the ability of SUMO 
to alter the interactions of its substrates with other macromolecules. In fact, conjugating 
this modifier to proteins typically either occludes or creates specific binding sites in 
them. In most cases, sumoylation is likely to bring about these changes simply by 
adding an extra surface, i.e. SUMO, at a particular position along a protein, without 
significantly affecting its structure. Yet, in some instances sumoylation has been shown 
to alter the interaction properties of its targets by inducing them to undergo 
conformational changes (Geiss-Friedlander and Melchior, 2007). Although SUMO 
seems to exert its actions mainly by modulating the binding properties of its targets, 
exceptions to this rule have been reported. For instance, sumoylation has been shown 
to obstruct the post-translational modification of certain lysines by other post-
translational modifiers, e.g. IκBα (see 1.2.7).  
Here, I will initially present the general features of how sumoylation can bring about its 
functions. I will then contextualize these properties by describing the way in which 
SUMO affects the functions of two proteins, i.e. the DNA polymerase processivity factor 
PCNA and thymidine DNA glycosylase. I chose these two proteins because the roles of 
their modification are well understood, but also because they exemplify how DNA and 
sumoylation can regulate each other, which has been the main focus of my research.  
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1.3.1 The SUMO-interacting motif (SIM) 
It is becoming increasingly clear that the ability of SUMO to change the binding 
properties of its targets is brought about through a motif that specifically recognizes 
SUMO itself. The best-characterized SUMO-interacting motif (SIM) consists of an 
essential hydrophobic core of four amino acids ([IVL]-X-[IVL]-[IVL] or [IVL]-[IVL]-X-
[IVL]), which is often, but not always, flanked by a cluster of negatively charged amino 
acids or serines/threonines (Hannich et al., 2005; Minty et al., 2000; Song et al., 2004). 
The latter residues have been proposed to allow the controlled introduction of a 
negative charge into a SIM, by being reversibly phosphorylated (Hecker et al., 2006). 
These residues are not essential for the SUMO-SIM interactions, yet, they are 
important in modulating its strength, orientation and, possibly, paralogue specificity 
(see below).  
Structural studies have shown that a SIM adopts an extended β-strand conformation 
and uses its hydrophobic core to bind SUMO within a groove that occurs between the 
α-helix and β2 strand of this modifier. In addition, they have also revealed that SIMs can 
wedge into this site either in a parallel or an anti-parallel orientation with respect to the 
sense of the β2 strand of SUMO (Baba et al., 2005; Reverter and Lima, 2005; Song et 
al., 2005). The specific orientation that a SIM adopts when binding SUMO is influenced 
by at least two factors: 1) the particular amino acid composition of its hydrophobic core, 
and 2) the presence of negatively charged residues around it (Kerscher, 2007). The 
latter of these two factors seems particularly important because the hydrophobic 
groove of SUMO is lined with basic amino acids, such as K39 of SUMO1 (Chupreta et 
al., 2005; Song et al., 2005). This residue occupies a favourable position to interact 
with the acidic residues of a SIM, and there is some evidence suggesting that it may 
actually do so (Hecker et al., 2006). Thus, if such interaction existed, then it would bias 
the biding of a SIM to SUMO towards one orientation rather than the other because 
these motifs can carry negatively charged residues either N- or C-terminal to their 
hydrophobic core. Another residue that may be important to favour the binding of a SIM 
to SUMO is K78 of SUMO1. Unlike K39, which is conserved amongst all SUMO 
paralogues, K78 is unique to SUMO1 and therefore could account for the paralogue 
specificity that some SIMs exhibit (Hecker et al., 2006). This specificity could also 
depend on the somewhat different positions that the hydrophobic grooves adopt with 
respect to the surrounding basic residues in SUMO1 and SUMO2/3 (Kerscher, 2007).  
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Since SIMs and SUMO can bind to each other on their own and with rather low affinity, 
it follows that the high-affinity/high-specificity binding with which SIM-containing factors 
must be targeted to the appropriate sumoylated proteins in vivo probably depends on 
additional elements. These elements could represent extra sites within the sumoylated 
protein that bind to the SIM-containing factor (Geiss-Friedlander and Melchior, 2007). 
Accordingly, although the effector of sumoylated PCNA in budding yeast, i.e. Srs2, can 
bind both SUMO and PCNA on their own, these interactions are significantly weaker 
than the one Srs2 exhibits for the modified PCNA (see 1.3.3 and Papouli et al., 2005).  
In addition to enabling a protein to recognize the modified form of a certain sumoylation 
target SIMs also play other roles. Firstly, many SIM-containing proteins known to date 
have also been found to be sumoylated, in a manner that depends on an intact SIM 
(Lin et al., 2006; Meulmeester et al., 2008; Takahashi et al., 2005). Secondly, SIMs 
have also been identified in, and appear to be important for the activity of, some of the 
enzymes involved in the sumoylation pathway, such as UBA2, RANBP2 and PIAS-
family E3s (Reverter and Lima, 2005; Song et al., 2004).  
To date, at least sixteen different domains have been shown to non-covalently bind 
ubiquitin (Grabbe and Dikic, 2009). It is therefore likely that SIMs other than the one 
described here exist. A variant of such a motif has in fact recently been discovered in 
mammals. It conforms to the consensus sequence [I/V/L]-[D/E]-[I/V/L]-[D/E]-[I/V/L], it is 
flanked to its N-terminus by negatively charged residues and it specifically recognizes 
SUMO-2/3 (Ouyang et al., 2009).  
1.3.2 How do low levels of sumoylation significantly affect the functions 
of a protein? 
RANGAP1 is the only known example of a sumoylation target that is quantitatively 
modified (Mahajan et al., 1997; Matunis et al., 1996). In fact, most other substrates are 
sumoylated at surprisingly low levels (1-2% or even less). Yet, eliminating even such 
small levels of sumoylation from these proteins often has a major effect on their 
properties. How can these apparently contradictory observations be explained? I will 
put forward two non-mutually exclusive models. They are similar to those already 
proposed by Geiss-Friedlander and Melchior (2007) and Johnson (2004), but they have 
been revisited on the basis of more recent findings. The first one of these two models 
speculates that sumoylation may occur, and thereby have an effect, only on a 
functionally active sub-population of a given protein. This scenario could happen if, for 
instance, such a protein sub-population exhibits properties that are different from the 
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general pool, such as sub-cellular localization or structure. Thus, under these 
conditions inhibiting the low sumoylation levels of a protein would be converted into a 
large effect on its functions because it would specifically affect only those molecules 
that are carrying out in a certain function (e.g. PCNA). The second model postulates 
that the entire pool of certain SUMO substrates is being constantly sumoylated. 
However, these proteins normally show low steady-state levels of modification probably 
because they undergo such rapid cycles of sumoylation and desumoylation that their 
modified forms exist only briefly. For some sumoylation events, such a short existence 
may be sufficiently long to exert their functions directly, while for others long-lasting 
effects may be brought about by their persistence even after SUMO has been 
removed. Thus, under these conditions abolishing the sumoylation of a certain protein 
would have a big effect on its properties simply because most of it is sumoylated during 
its normal life (e.g. thymidine DNA glycosylase).  
1.3.3 The sumoylation of PCNA 
PCNA forms a homotrimeric ring that encircles DNA and acts as a processivity factors 
for DNA polymerases during DNA synthesis. In Saccharomyces cerevisiae, PCNA is 
sumoylated mainly at K164 by Siz1, and to a lesser degree at K127 by Siz2 (Hoege et 
al., 2002; Parker et al., 2008; Stelter and Ulrich, 2003). The sumoylation of PCNA 
normally occurs at S phase (Hoege et al., 2002), which is consistent with the fact that 
this protein is efficiently modified only when associated with DNA Parker et al. (2008). 
On the basis of these results and the fact that only a small amount of the total pool of 
PCNA is loaded onto DNA even during replication, (Parker et al., 2008) have proposed 
that a large proportion, if not all, of the DNA-bound trimer could be modified.  
PCNA’s K164 is not only conjugated to SUMO: in response to genotoxic stress it is 
also mono- and poly-ubiquitylated by a group of enzymes known as the RAD6 pathway 
(Hoege et al., 2002). Mono-ubiquitylated PCNA allows stalled replication forks to 
bypass DNA lesions by recruiting damage-tolerant polymerases, while the poly-
ubiquitylated one activates a damage avoidance pathway that relies on homologous 
recombination (Ulrich, 2005). Although SUMO and ubiquitin are attached to the same 
site on PCNA, they do not seem to compete or act antagonistically with each other. 
Instead, PCNA sumoylation has been proposed to divert DNA repair away from 
homologous recombination and into the RAD6 pathway (Papouli et al., 2005). 
The first clue to the roles of PCNA sumoylation came from the observation that the 
helicase Srs2 and PCNA sumoylation belong to the same genetic pathway. An 
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Figure 1.3 - Molecular consequences of sumoylation of DNA-associated proteins. A) At S 
phase PCNA is loaded onto DNA by the Rfc1-5 complex, thereby becoming a suitable substrate 
for sumoylation. The resulting PCNA-SUMO conjugate recruits the Srs2 helicase to replication 
forks, where it prevents the formation of recombinogenic Rad51 filaments.  B) TDG binds and 
cleaves mismatched uracils (U) or thymidines from DNA, producing an abasic site (AP). TDG 
strongly binds to AP sites and to disassociate from them it needs to undergo a sumoylation-
induced conformational change. Once TDG detaches from the DNA, it is probably quickly de-
sumoylated, allowing it to bind damaged DNA again. DNA pol = DNA polymerase, G = guanine, 
APE = AP endonuclease, S = SUMO. 
 
 
unsumoylatable PCNA mutant (pol30K127/164R) or a deletion of SIZ1 or SRS2 all 
suppress equally well the DNA damage sensitivity of rad18∆ cells, where PCNA cannot 
be ubiquitylated. Additionally, deleting SRS2 in rad18∆ siz1∆ or rad18∆ pol30K127/164R 
cells does not suppress their damage sensitivity any further. As expected, given the 
anti-recombinogenic properties of Srs2, such suppressor phenotypes have also been 
shown to depend on the presence of an intact homologous recombination pathway 
(Papouli et al., 2005; Pfander et al., 2005). Homologous recombination involves the 
exchange or replacement of genetic information between two homologous DNA 
regions. This genetic relationship was taken a step forward by demonstrating that Srs2 
preferentially interacts with the sumoylated PCNA both in vivo and in vitro, probably 
because it contains a SIM at its C-terminus (Papouli et al., 2005; Pfander et al., 2005).  
It has therefore been proposed that the sumoylated PCNA recruits Srs2 to replication 
forks, where this enzyme counteracts homologous recombination. Conversely, when 
PCNA cannot be modified, Srs2 is unable to associate with replication forks efficiently, 
A 
B 
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thus explaining the increased rate of homologous recombination that cells demonstrate 
under these conditions (Robert et al., 2006).  
Overall, these observations suggest that sumoylated PCNA, by means of recruiting 
Srs2, prevents stalled replication forks from being repaired by possibly harmful 
homologous recombination, and consequently promotes damage bypass through 
PCNA ubiquitylation (Figure 1.3A, Papouli et al., 2005; Pfander et al., 2005).  
The sumoylation of PCNA is not specific to budding yeast, but it has also been seen in 
Xenopus egg extracts, chicken DT40 cells and human cells (Arakawa et al., 2006; 
Leach and Michael, 2005; Stephen West, personal communication). Its downstream 
functions in these systems remain, however, unclear because although helicases with 
some sequence similarity to Srs2 have been found in higher eukaryotes, none has yet 
been demonstrated to impinge on the RAD6 pathway like Srs2.  
Sumoylation appears to modulate the interactions of PCNA not only with Srs2 but also 
with other proteins. One such factor is Elg1, which plays a role in the maintenance of 
various aspects of genome stability. It binds to Rfc2-5 to form a PCNA-loading complex 
that is functionally distinct from the canonical Rfc1-5 complex. Elg1, through SIMs that 
are located in its N-terminus, preferentially interacts with the sumoylated PCNA 
(Parnas et al., 2010). Although the functional implications of this observation presently 
remain unclear, it has been shown that knocking out ELG1 results in higher levels of 
sumoylated PCNA and Srs2 on chromatin and synthetic sickness in the srs2∆ 
background. In addition, mutating Elg1’s SIMs recapitulates, to a partial degree, the 
genome stability phenotype that is observed in ELG1 knockout cells (Parnas et al., 
2010). On the other hand, sumoylation also seems to interfere with the binding of 
PCNA to at least two of its known interaction partners, i.e. Rfc1 and Eco1. In budding 
yeast, K127 is found within a region of PCNA that acts as its main partner-interaction 
site. The sumoylation of such residue has therefore been proposed to have a general 
effect on the association of PCNA with its partners, essentially acting as an “off-switch” 
to clear the clamp (Moldovan et al., 2006).  
1.3.4 The sumoylation of thymidine DNA glycosylase  
Thymidine DNA glycosylase (TDG) binds and removes thymine or uracil within the GT 
and GU mismatches that are formed from the deamination of 5-methyl-cytosine or 
cytosine, respectively (Barnes and Lindahl, 2004). It is part of a family of enzymes that 
recognize and cleave a narrow spectrum of damaged or modified nitrogenous bases. 
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The abasic sites produced by these enzymes feed into a common pathway that 
involves the initial disassociation of the glycosylase from the DNA and the nicking of its 
damaged strand by the APE1 endonuclease. Subsequently, DNA polymerase β 
removes the baseless sugar backbone and polymerizes across the resulting gap. 
Finally, the XRCC1-ligase III complex seals the patched DNA (Barnes and Lindahl, 
2004). This pathway of DNA repair is known as base excision repair (BER). 
Human TDG is sumoylated at K330 and it contains two SIMs, one N- and one C-
terminal to its central catalytic core (Baba et al., 2005; Hardeland et al., 2002; Mohan et 
al., 2007; Steinacher and Schar, 2005; Takahashi et al., 2005). The crystal structures 
of the central region of TDG conjugated to either SUMO1 or SUMO3 suggest that the 
covalent and non-covalent (through the C-terminal SIM) interactions SUMO makes with 
TDG may extrude a helix from the surface of the glycosylase. When DNA is fitted into 
such a structure, this protruding helix sterically clashes with the duplex, thus indicating 
that a SUMO-induced conformational change may force the enzyme to dissociate from 
DNA (Baba et al., 2005, 2006). In fact, sumoylating TDG strongly reduces its affinity for 
DNA, thereby stimulating its catalytic turnover (Hardeland et al., 2002). The ability of 
SUMO to interact with the N-terminal domain of TDG, which is necessary for tight 
binding to mismatched GT, may also be involved in reducing its affinity for DNA 
because deleting such domain enhances TDG turnover in a way that is “epistatic” with 
SUMO modification. Consistently, the N-terminus of TDG appears to undergo a 
conformational change when the enzyme becomes sumoylated (Steinacher and Schar, 
2005). Altogether, these observations indicate that conjugating SUMO to TDG changes 
the structure of its central catalytic and N-terminal domains, thereby reducing its affinity 
for DNA allowing it to dissociate from the abasic site and promoting catalytic turnover 
(Figure 1.3B, Hardeland et al., 2002; Steinacher and Schar, 2005; Takahashi et al., 
2005). Given that in vivo DNA glycosylases quickly turn over on damaged DNA 
(Barnes and Lindahl, 2004), it follows that TDG probably exists as a SUMO conjugate 
for a very short period of time during its catalytic cycle.  
What happens to the sumoylated TDG after it disassociates from the DNA? It is 
probably quickly desumoylated. This event appears to be an essential pre-requisite to 
allow TDG to translocate to PML bodies. In fact, in exponentially growing cells TDG is 
enriched within PML nuclear bodies (Mohan et al., 2007). Mutating either PML’s 
sumoylation sites or TDG’s SIMs abolishes this co-localization, indicating that it relies 
on the interaction between TDG’s SIMs and sumoylated PML (Mohan et al., 2007; 
Takahashi et al., 2005). Consistently, TDG preferentially binds to sumoylated PML in 
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vitro (Takahashi et al., 2005). The reasons for why TDG would need to localize within 
PML nuclear bodies are unknown but it could involve the acetyl-transferase CBP/p300. 
CBP/p300 localizes to PML bodies and it can acetylate TDG, but only when it is 
unmodified (Tini et al., 2002), thus suggesting that the ability of the glycosylase to 
localize within PML bodies may promote its acetylation (Mohan et al., 2007). 
1.4 Poly(ADP-ribosyl)ation 
In addition to being targeted by SUMO and other common types of protein post-
translational modifiers, proteins can also be covalently conjugate to chains of ADP-
ribose units linked together by glycosidic bonds. Poly(ADP-ribose), or PAR, chains are 
synthesized from NAD+ by members of the poly(ADP-ribose) polymerase (PARP) 
family of enzymes and they are degraded by the combined actions of specific 
glycosylases and lyases. 
1.4.1 The poly(ADP-ribosyl)ation reaction 
The mechanism of PAR formation by PARP-1, the founding member of the PARP 
family of proteins (see 1.5), and probably by the other members of such family, 
involves three enzymatic steps (Figure 1.4B, Alvarez-Gonzalez and Mendoza-Alvarez, 
1995; Alvarez-Gonzalez et al., 1994).  
Initially, PARP-1 hydrolyzes NAD+ (Figure 1.4A) to produce nicotinamide, one proton 
and an ADP-ribose unit, which this enzyme then transfers directly to a substrate. PAR 
can be attached to the side chains of glutamates and, less commonly, aspartates 
through a relatively labile ester linkage as well as that of lysines through a more stable 
peptide bond (Altmeyer et al., 2009; Burzio et al., 1979; Messner et al., 2010; Riquelme 
et al., 1979; Suzuki et al., 1986; Tao et al., 2009).  
In the second reaction, known as elongation step, PARP-1 catalyzes the transfer of 
ADP-ribose moieties onto a mono(ADP-rybosyl)ated protein by linking the 1’-OH group 
of the “nicotinamide” ribose of the second ADP-ribose moiety to the 2’-OH group of the 
“adenine” ribose of the previous ADP-ribose unit via a (1’’-2’) glycosydic bond (Figure 
1.4B). Multiple rounds of this reaction produce chains that can reach up to 200 units in 
length both in vitro and in vivo (Alvarez-Gonzalez and Jacobson, 1987; Alvarez-
Gonzalez et al., 1994; Hayashi et al., 1983). Once a PAR polymer is 20 or more units 
long, PARP-1 can branch it every 20-40 ADP-ribose moieties by catalyzing the 
formation of a (1’’’-2’’) glycosydic bond between the 2’’-OH group of the “nicotinamide”
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Figure 1.4 - The mechanism of reversible parylation. (A) The chemical structure of β-NAD. 
(B) Upon stimulation by a relevant signal, PARPs hydrolyze β-NAD+ to ADP-ribose and 
subsequently attach this molecule to specific lysine (K), glutamate (E) or aspartate (D) residues 
within a target protein. PARPs can further elongate mono(ADP-ribosyl)ated amino acids by 
catalyzing the formation of a 2’-1’’ glycosidic bond between ADP-ribose moieties. Glycosidic 
bonds of the 2’’-1’’’ type can also be generated by PARPs, thus leading to the branching of PAR 
chains. Such polymers are degraded by the combined actions of PARG and ARH. ADP-ribose-
lyase is responsible for cleaving the bond that occurs between the side chain of an amino acid 
and the ADP-ribose moiety attached to it. Ade = adenine, Rib = ribose, Pi = phosphate group. 
Adapted from Schreiber et al. (2006). 
 
 
ribose of a PAR chain and the 1’’’-OH group of the “nicotinamide” ribose of an ADP-
ribose unit (Figure 1.4B, Hayashi et al., 1983; Juarez-Salinas et al., 1982). 
1.4.2  Poly(ADP-ribose) catabolism 
In mammalian cells, the half-life of PAR is very short; it ranges from 30 s to 5 min 
(Alvarez-Gonzalez and Althaus, 1989), which means that it must be quickly degraded. 
PAR degradation depends on at least three different enzymes: poly(ADP-ribose) 
A 
B 
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glycohydrolase (PARG), (ADP-ribosyl)arginine hydrolase-3 (ARH3) and ADP-ribose 
lyase.  
 
1.4.2.1 PARG 
PARG is the best characterized amongst the PAR-degrading enzymes. It hydrolyzes 
the glycosidic linkage between ADP-ribose units both exo- and endo-glycoytically, 
eventually yielding free ADP-ribose (Braun et al., 1994; Brochu et al., 1994; 
Hatakeyama et al., 1986). On the basis of the time-dependent changes that the length 
and abundance of PAR chains undergo in vitro in the presence of PARG, it has been 
proposed that such an enzyme degrades these polymers in a two-step process (Braun 
et al., 1994; Brochu et al., 1994; Davidovic et al., 2001; Hatakeyama et al., 1986). 
Initially, PARG quickly reduces the overall size of the polymers by attacking them using 
both its endo- and exo-glycosidic activities, the latter of which seems to act 
processively (Braun et al., 1994; Hatakeyama et al., 1986). When these oligomers 
reach a critically small size, PARG switches to a slow exo-glycosidic mode of action, 
which appears to proceed distributively (Braun et al., 1994; Hatakeyama et al., 1986). 
These observations are consistent with in vivo data showing that PAR is processed 
through an initial rapid degradation step followed by a slower one (Wielckens et al., 
1983). 
In mammals, several isoforms of PARG have been detected, which appear to be 
generated by alternative splicing and have different properties (Meyer et al., 2007; 
Meyer-Ficca et al., 2004; Niere et al., 2008; Whatcott et al., 2009). One of the two main 
forms is 110 kDa in size and it is exclusively found in the nucleus (Meyer-Ficca et al., 
2004). The other main form of PARG is 65 kDa in size and it localizes to the cytoplasm 
and mitochondria (Mueller-Dieckmann et al., 2006; Whatcott et al., 2009). The size of 
such PARG isoforms can be reduced even further by the use of alternative translation 
start sites to produce a protein of 55 kDa, which localizes only to the mitochondrial 
matrix (Meyer et al., 2007; Niere et al., 2008; Whatcott et al., 2009). These 
mitochondrial species are therefore likely to be responsible for the PAR-degrading 
activity that has been detected in such organelles (Meyer et al., 2007). At present the 
roles of a mitochondrial PAR-degrading activity remain unclear but they could be 
related to the proposed ability of over-activated PARP-1 to trigger the breakdown of the 
mitochondrial membrane potential and the consequent release of apoptosis inducing 
factors (see 1.5.3.2). 
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In mammals, PARG must have essential functions or play essential roles because 
PARG-/- mice die at an early embryonic stage (Koh et al., 2004). Similarly, a loss-of-
function allele of PARG also compromises larval survival in the fruit fly (Hanai et al., 
2004). At least some of PARG’s roles must relate to DNA repair because depleting it 
slows down the repair of single-stranded breaks (SSBs) and DSBs (Ame et al., 2009; 
Fisher et al., 2007). Mice carrying a hypomorphic PARG allele, which eliminates its 110 
kDa form while preserving the 60 kDa one, are also hyper-sensitive to genotoxins 
(Cortes et al., 2004). Consistently, cells derived from these animals show several 
markers of altered DNA repair, such as: the formation of an unusually small number of 
DNA damage-induced XRCC1 foci, delayed γH2AX phosphorylation, decreased DNA 
break intermediates during repair, and increased cell death (Gao et al., 2007). PARG-
depleted cells also demonstrate DNA damage-induced amplification and fragmentation 
of centrosomes, aberrant mitotic cells, aneuploidy, and increased cell death by mitotic 
catastrophe (Ame et al., 2009). The latter observations therefore suggest that PARG 
may impinge on other processes in a cell besides DNA repair, such as transcription 
(Frizzell et al., 2009) and chromatin structure (Tulin et al., 2006).  
1.4.2.2 ARH3 and ADP-ribose lyase 
ARH3 is the second PAR-degrading enzyme that has been identified in mammals 
(Mueller-Dieckmann et al., 2006; Oka et al., 2006). It is located in the mitochondrial 
matrix (Meyer et al., 2007; Niere et al., 2008), and it can also cleave O-acetyl-ADP-
ribose, which is a by-product of the activity of SIR2 family of acetyl-histone 
deacetylases (Ono et al., 2006). 
Although PARG and ARH3 can hydrolyze the glycosidic linkages that hold PAR chains 
together, they are unable to cleave the bond that ties the first ADP-ribose moiety of 
these polymers to an amino acid. This activity is mediated by ADP-ribose lyase (Figure 
1.4B, Oka et al., 1984; Okayama et al., 1978), which remains a poorly characterized 
enzyme. 
1.4.3 The PARP superfamily of proteins  
All seventeen members of the PARP family of proteins share a common β-α-loop-β-α-
loop-β fold known as the “PARP signature” (Ame et al., 2004). This motif is found at the 
C-terminus of all PARPs except for PARP-4, where it is located closer to its N-
terminus. The PARP signature shows a fair amount of variability amongst PARPs in at 
least two respects. Firstly, in terms of the length and sequence of its loops, which have
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Figure 1.5 - The PARP family. The domain architecture of the seventeen members of the 
PARP family from humans is shown. Protein domains are depicted as coloured boxes, as 
indicated in the figure itself.  Within the hypothetical catalytic domains of these proteins (light 
blue boxes), the region similar to the PARP signature (aa 859-908 of PARP-1) and the amino 
acid corresponding to the putative catalytic residue of PARP-1, i.e. E988, are highlighted using 
a darker shade of blue. WGR = tryptophan, glycine and arginine, DBD = DNA-binding domain, 
RRM = RNA-recognition motif; BRCT = BRCA1 C-terminus, WWE = tryptophan, tryptophan, 
glutamate, ANK = ankyrin repeat, SAM = sterile α-motif, UIM = ubiquitin-interacting motif, HPS = 
a domain that contains homopolymeric runs of histidine, vWA = von Willebrand factor type A, 
VIT = vault inter-α-trypsin, MVP-BD = binding site for major vault protein, MLS = mitochondrial 
localization signal, NES = nuclear export signal, NoLS = nucleolar localization signal, NLS = 
nuclear localization signal. Adapted from Schreiber et al. (2006). 
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been proposed to act as protein-protein interaction sites (Ame et al., 2004). Secondly, 
in terms of the presence and/or identity of the catalytic residue carried within such a 
fold. The catalytic glutamate of PARP-1, i.e. E988, is present in PARP-2, PARP-3, 
PARP-4, the tankyrases PARP-5a and 5b, PARP-5c, PARP-11, PARP-12 and PARP-
14 (Ame et al., 2004). They are therefore likely to be active, which has actually been 
shown for some of them (Ame et al., 1999; Smith et al., 1998). On the other hand, 
PARP-1’s E988 appears to be substituted with an aspartate in PARP-15, but is absent 
from PARP-7, PARP-9, PARP-10, PARP-13 and PARP-16, thus raising the question of 
whether these proteins are catalytically active (Ame et al., 2004). Interestingly, while 
PARP-9 seems to be unable to make PAR (Aguiar et al., 2005), some activity has been 
reported for PARP-7 and PARP-10 (Ma et al., 2001; Yu et al., 2005).  
Outside their PARP signature, the members of the PARP family are very 
heterogeneous with respect to the functions of the domains they contain, thus 
suggesting that they probably play roles in a variety of cellular processes. Some of the 
motifs found in these proteins are known to be involved in: nucleic acid binding (zinc 
fingers, SAP and RRM), protein-protein interactions (SAM, ankyrin, BRCT), ubiquitin 
binding (WWE and UIM), ADP-ribose binding (macro domain), and cell signalling 
(hormone binding domains and HPS, Ame et al., 2004). The functional heterogeneity of 
a few of these proteins is increased even further by the controlled exclusion of some of 
their domains through alternative splicing (Schreiber et al., 2006). On the basis of the 
functions of the domains they contain and/or their known roles, the proteins belonging 
to the PARP family have been classified into five categories (Schreiber et al., 2006): 
DNA-activated PARPs (PARP-1 and PARP-2), tankyrases (PARP-5a and PARP-5b), 
CCCH-type PARPs (PARP7, PARP-12 and PARP-13), macroPARPs (PARP-9, PARP-
14 and PARP-15) and other PARPs (PARP-3, PARP-4 and PARP-10). 
1.4.3.1 DNA damage-activated PARPs 
The most salient feature of PARP-1 and PARP-2 is that their catalytic activity is 
strongly induced by DNA strand breaks.  
PARP-1 is a large multi-domain enzyme that plays roles in genome stability, DNA 
repair, cell death and transcription, which I will describe in more detail in 1.5.  
PARP-2 is fairly similar to PARP-1. It was initially discovered because of the presence 
of residual levels of DNA damage-dependent PARP activity in PARP-1-/- mouse 
embryonic fibroblasts (Ame et al., 1999; Shieh et al., 1998). PARP-1 and PARP-2 are 
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likely to be, at least partly, complementary to each other because mice that lack either 
one of these genes are viable while the double knockout is embryonically lethal 
(Menissier de Murcia et al., 2003). In addition, it has been shown that PARP-1 and 
PARP-2 hetero-dimerize and share many partners, including proteins involved in BER 
(e.g. XRCC1, DNA polymerase β and DNA ligase III, Schreiber et al., 2002), hence 
suggesting that PARP-2, like PARP-1, might also be involved in DNA repair. In line with 
this hypothesis it was shown that PARP-2-/- cells repair single-stranded DNA breaks 
more slowly than their wild-type counterparts (Schreiber et al., 2002). Such results 
have however been challenged by a more recent report where PARP-2-deficient cells 
were found to repair their DNA as well as control cells, both in the presence and 
absence of PARP-1 (Fisher et al., 2007). Even though PARP-2 is likely to be partly 
redundant with PARP-1, it probably also has unique features because the phenotypes 
of PARP-2-/- mice are not identical to those observed in PARP-1-/- animals (Menissier 
de Murcia et al., 2003). In fact, while PARP-1 can recognize both DNA nicks and gaps 
and preferentially parylates histone H1 (see 1.5), PARP-2 apparently binds only gaps 
and preferentially parylates histone H2B (Ame et al., 2004).  
1.4.3.2 Tankyrases 
PARP-5a and PARP-5b, also known as tankyrase 1 and tankyrase 2, are paralogous 
proteins with roles in telomere homeostasis, mitotic spindle function and intracellular 
trafficking. 
Both tankyrase 1 and tankyrase 2 include the PARP signature as well as SAM and 
ankyrin domains. Tankyrase 1 also comprises a HPS motif (Ame et al., 2004). The 
SAM motif mediates the homo- and hetero-dimerization of these proteins, while the 
ankyrin domain allows them to interact with other proteins, including TRF1 and NuMA 
(Hsiao and Smith, 2008). Since tankyrase 1 and tankyrase 2 are very similar to each 
other and share most of their protein partners, it is likely that they play overlapping 
and/or redundant functions. It has in fact been recently shown that although individually 
knocking out one or the other tankyrase produces mice that are mostly normal, except 
for a reduced size in the tankyrase 2 mutant (Chiang et al., 2006), the double knockout 
is embryonically lethal (Chiang et al., 2008). 
TRF1 is a negative regulator of telomere length. In vitro, tankyrase 1 parylates TRF1 
and reduces its ability to bind telomeres (Smith et al., 1998). In vivo, over-producing 
tankyrase 1 leads to the loss of TRF1 from telomeres and their consequent elongation 
(Smith and de Lange, 2000). Conversely, tankyrase 1 knock-down leads to telomere 
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shortening (Donigian and de Lange, 2007). The over-production of tankyrase 2 also 
causes telomere lengthening, but the relevance of this observation remains to be 
confirmed because such a protein does not localize to telomeres (Cook et al., 2002).  
Tankyrases also interact with a protein called NuMA, which is essential for the proper 
assembly of mitotic spindles (Chang et al., 2005a; Chang et al., 2005b). This 
interaction is probably physiologically relevant because depleting NuMA leads to the 
loss of tankyrase 1 from the spindle poles, while knocking down tankyrase 1 
compromises the assembly of normal bipolar spindles and triggers to the formation of 
ectopic ones (Chang et al., 2005a; Chang et al., 2005b). Interestingly, NuMA itself 
binds PAR (Chang et al., 2005b).  
1.4.3.3 CCCH-type PARPs 
The CCCH-type PARPs (PARP-7, PARP-12 and PARP-13) contain CX8CX5CX3-like 
zinc fingers, a WWE domain and the PARP fold (Ame et al., 2004). Very little is known 
about the properties of these proteins.  
Transcription of the PARP-7 gene, also known as tiPARP, is induced by the pollutant 
2,3,7,8-tetrachlorodibenzo-p-dioxin and after prolonged long-term potentiation in the 
hippocampus (Ma et al., 2001; Matsuo et al., 2000).  
PARP-13 is produced as two isoforms by alternative splicing (Ame et al., 2004). The 
shorter one lacks the catalytic domain and confers resistance to infection by 
retroviruses by binding to the viral RNA genome through its CCCH motif (Gao et al., 
2002).  
PARP-12 is closely related to PARP-13. 
1.4.3.4 MacroPARPs 
MacroPARPs (PARP-9, PARP-14 and PARP-15) contain the PARP catalytic motif plus 
1-3 macro domains (Ame et al., 2004). These domains are highly conserved in all 
kingdoms of life and directly recognize NAD+ metabolites such ADP-ribose, O-acetyl-
ADP-ribose or PAR (Karras et al., 2005).  
Although the exact functions of the macro domains found in the macroPARPs remain 
unclear, these proteins appear to act as transcription regulators. PARP-9 seems to 
negatively influence transcription and to play a role in lymphocyte migration in vitro 
(Aguiar et al., 2005; Aguiar et al., 2000). Following stimulation by interleukin 4, PARP-
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14 mediates the activation of the STAT6 gene in T cells and protects B cells against 
apoptosis (Cho et al., 2009; Goenka and Boothby, 2006).  
1.4.3.5 Other PARPs 
PARP-3 is a mono-ADP-ribosylase that interacts with PARP-1 and activates it in vitro 
(Loseva et al., 2010). PARP-3 localizes to the daughter centriole within centrosomes 
(Augustin et al., 2003). Although its over-production has no discernable effect on the 
centriole cycle, it interferes with progression into S phase (Augustin et al., 2003). 
PARP-3 also co-localizes with polycomb group bodies and it interacts with several 
proteins involved in genome stability (Rouleau et al., 2007). Yet, knocking down PARP-
3 does not perceivably affect cell survival in response to the genotoxic agent 
camptothecin (Augustin et al., 2003).  
PARP-4, also known as vPARP, is part of barrel-shaped ribonucleoprotein complexes 
called vaults, which play a role in the multi-drug resistance of human tumours 
(Kickhoefer et al., 1999). PARP-4 associates with the vault protein TEP1, which is 
known to interact with telomerase (Liu et al., 2004). PARP-4 knockout mice are viable 
and show no appreciable defect in vault structure or telomere homeostasis, but they 
exhibit an increased incidence of carcinogen-induced colon tumours (Liu et al., 2004; 
Raval-Fernandes et al., 2005). 
PARP-10 is also a mono-ADP-ribosylase (Kleine et al., 2008). It contains an RRM and 
a glycine-rich domain, both of which can mediate interactions with RNA (Ame et al., 
2004). It preferentially localizes to the nucleolus where it is phosphorylated at the G1-S 
and prometaphase-to-cytokinesis transitions (Chou et al., 2006). PARP-10 interacts 
with and strongly inhibits the cell transformation properties of the proto-oncoprotein c-
MYC (Yu et al., 2005).  
So far, nothing is known about the functions of PARP-6, PARP-8 and PARP-11.  
1.5 The poly(ADP-ribose) polymerase 1 (PARP-1) 
The human PARP-1 is a modular protein of 1014 amino acids and 113 kDa. It is 
encoded by the PARP-1 gene which is located at 1q41-42, is 43 kbp long, contains 23 
exons and encodes for an mRNA with an open reading frame of 3042 nt. PARP-1 is 
present in all higher eukaryotes, but not in yeast.  
PARP-1 is a chromatin-associated protein that resides mainly in the nucleus, where it 
is somewhat enriched in the nucleolus (Meder et al., 2005) as well as at the nuclear 
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membrane and nuclear matrix (Fakan et al., 1988; Kaufmann et al., 1991; Mosgoeller 
et al., 1996). Additionally, PARP-1 has also been found in the mitochondria (Fakan et 
al., 1988; Rossi et al., 2009). It is the most abundant member of the PARP family, it 
accounts for 90% of the parylation activity in vivo (Shieh et al., 1998), and it is also the 
main, but not the sole, acceptor of PAR (Satoh and Lindahl, 1992). It has been 
estimated that between 2  105 to 2  106 molecules of the polymerase exist in a cell, 
depending on the type (Ludwig et al., 1988; Yamanaka et al., 1988), which gives about 
one molecule of this protein for every 1,500-15,000 bp of the human genome. PARP-1 
plays a critical role in genome stability, but it also controls gene transcription and 
apoptosis. For some of these functions its catalytic activity is not required. 
1.5.1 The structure of PARP-1 
PARP-1 can be divided into three functionally distinct domains: an N-terminal DNA-
binding domain (DBD), an auto-modification domain (AD) and a C-terminal catalytic 
domain (CAT, Figure 1.6, Kameshita et al., 1984).  
1.5.1.1 The DNA-binding domain 
The DBD comprises the initial 373 aa of PARP-1 and contains three zinc fingers.  
The first two fingers are similar to each other and conform to the consensus sequence 
CX2C-X28/30-WHX2C. This kind of domain is known as PARP-type zinc finger and it has 
been found in other proteins such as DNA ligase III, ZDP, a DNA 3'-phosphoesterase 
from A. thaliana, and many others by bioinformatics means (Petrucco and Percudani, 
2008). It folds into a structure consisting of an N-terminal three-stranded anti-parallel β-
sheet, which contains a long loop joining the first and second β-strands, and a C-
terminal region that includes two α-helices (Nagashima et al., 2005). The extended 
loop and the C-terminal portion of the first α helix show significant variability amongst 
the PARP-type zinc fingers, and could account for their different DNA binding 
properties (Petrucco and Percudani, 2008). In fact, exchanging the first α helix of 
PARP-1’s finger I motif with that of its second zinc finger imparts finger I-like DNA 
binding properties onto the finger II motif (Gradwohl et al., 1990).  
The first and second zinc fingers of PARP-1 are widely believed to recognize both 
altered structures in DNA, and consequently activate the polymerase, and possibly also 
specific DNA sequences (see 1.5.2). They bind DNA breaks independently of the 
remainder of PARP-1 and they may dimerize in the process of doing so (Menissier-de 
Murcia et al., 1989; Pion et al., 2003; Pion et al., 2005). Additionally, the first two
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Figure 1.6 - The domain structure of the human PARP-1 protein. The domain architecture of 
the human PARP-1 protein is shown. Numbers indicate amino acid positions. Red scissors 
show the position of PARP-1’s caspase cleavage site. DBD = DNA-binding domain, AD = auto-
modification domain, WRG/CAT = catalytic domain, FI-III = zinc finger domains I through III, 
NLS = nuclear localization signal, BRCT = BRCA1 C-terminus domain, WRG = tryptophan, 
arginine and glycine domain, core = PARP signature. If available, the tertiary structure of 
individual PARP-1 domains is shown. Secondary structure elements are colour in red, for α-
helices, green, for β-strands, and pink for the Zn2+ ion. The cartoon representations of protein 
structures were created with PyMOL (http://pymol.sourceforge.net/). 
 
 
fingers of PARP-1 also seem to mediate interactions of the polymerase with other 
proteins, such as DNA polymerase α (Dantzer et al., 1998), histones (Griesenbeck et 
al., 1997), the transcription factor TEF1 (Butler and Ordahl, 1999) and the hormone 
receptor RXRα (Miyamoto et al., 1999). It however remains to be undoubtedly 
confirmed that these interactions are direct and not mediated through DNA.  
An intact finger I motif is essential for the activation of the polymerase in response to 
both single- and double-stranded breaks (Altmeyer et al., 2009; Ikejima et al., 1990), 
indicating that it is probably involved in recognizing both types of lesions. Interestingly, 
this domain must be able to act in trans to form a catalytically active complex of PARP-
1 with DNA because incubating a mutant polymerase missing its first zinc finger with 
one lacking its finger III motif or its catalytic residue restores PAR formation in vitro 
(Altmeyer et al., 2009). These in vitro data apparently contradict the finding that in the 
fruit fly a PARP-1 mutant devoid of its finger I domain is activated as well as the wild 
type polymerase in response to ionizing radiation (Kotova et al., 2010). Instead, this 
mutant demonstrates an unusually strong localization within euchromatin and a 
concomitant decrease in that within heterochromatin, thus resulting in an increased 
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mobilization of the transposable elements normally found in these regions (Kotova et 
al., 2010). 
The finger II motif of PARP-1 directly recognizes SSBs and it is essential for the 
activation of the polymerase in their presence, but not in response to DSBs (Gradwohl 
et al., 1990; Ikejima et al., 1990). Binding of PARP-1 to nicked DNA, probably through 
its second zinc finger, protects 7 bp of DNA on both sides of the break (Gradwohl et al., 
1990; Menissier-de Murcia et al., 1989).  
The third zinc finger of PARP-1 is structurally and functionally different from the other 
two. It folds into three anti-parallel β-strands and it conforms to the consensus 
sequence CX2C-X12(loop)-C-X9-C, which resembles a classic zinc ribbon motif 
(Langelier et al., 2008; Tao et al., 2008). It does not appear to bind DNA, at least on its 
own (Tao et al., 2008), and inactivating it in the context of the full-length polymerase 
does not affect its binding to dsDNA oligonucleotides bearing free ends (Langelier et 
al., 2008). Although this motif is not essential for the catalytic activity of PARP-1 per se, 
mutating or deleting it abolishes the ability of the polymerase to become activated in 
response to DNA damage (Altmeyer et al., 2009; Langelier et al., 2008; Tao et al., 
2008). Interestingly, incubating PARP-1 mutants with an inactive or missing zinc finger 
III motif together with a wild type version of this domain alone reconstituted their 
capacity to generate PAR. A similar effect was also observed when these mutants 
were mixed with a catalytically dead version of the polymerase (Altmeyer et al., 2009; 
Langelier et al., 2008; Tao et al., 2008). This apparent ability of PARP-1’s third zinc 
finger to act in trans has been interpreted as to mean that it must aid the DNA-
dependent activation of the polymerase by mediating intra-molecular interactions 
between its DBD bound to damaged DNA and its catalytic domain (Langelier et al., 
2008). Such interactions are likely to be mediated by the extended loop that is part of 
the finger III domain because mutating specific residue within this region also abolishes 
the DNA-dependent activation of PARP-1 (Langelier et al., 2010). These findings 
cannot be easily reconciled with the observation that the finger III motif of the 
polymerase does not appreciably bind any other PARP-1 domain, either in the 
presence or absence of DNA (Langelier et al., 2008). It has however been proposed 
that these interactions may be either too weak to be detected or that they may occur 
only in the context of full-length PARP-1, when DNA and/or NAD+ are also present 
(Langelier et al., 2008). The crystal structure of PARP-1’s third zinc finger has revealed 
that it can form a dimer in the crystal lattice (Langelier et al., 2008). The relevance of 
this finding is unclear because in solution this domain exists as a monomer (Langelier 
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et al., 2010; Tao et al., 2008). Nevertheless, mutating the residues that line this 
hypothetical dimerization surface between finger III motifs in the full-length PARP-1 
reduces the ability of this enzyme to compact chromatin and consequently to inhibit 
transcription in vitro, but not its DNA-dependent activation (Langelier et al., 2010).  
The DBD also includes a bipartite nuclear localization signal of the type KRK-X11-
KKKSKK (aa 207-226) that targets PARP1 to the nucleus (Schreiber et al., 1992). 
1.5.1.2 The auto-modification domain 
The AD is located between amino acids 373 and 525 of the human PARP-1. It acts as 
the main acceptor region for the auto-parylation activity of this enzyme, but only when it 
is physically linked to its catalytic domain (Kameshita et al., 1986). Some auto-
modification also seems to occur within the DBD (Desmarais et al., 1991).  
The AD is positively charged and contains 15 of the 28 glutamates that have been 
hypothesized to be parylated in PARP-1 (Desmarais et al., 1991; Kameshita et al., 
1984; Kawaichi et al., 1981; Mendoza-Alvarez and Alvarez-Gonzalez, 1999). The 
modification of some of these residues (D387, E488, and E491) has been directly 
proven by mass spectrometry (Tao et al., 2009). Mutating them however reduces but 
does not abolish PARP-1 auto-modification, thus suggesting that other sites must also 
be modified (Tao et al., 2009). Altmeyer et al. (2009) also showed that a PARP-1 
mutant lacking its BRCT motif (see below) and all of the remaining glutamates found 
within its AD was auto-parylated as well as the wild-type protein. Instead, they 
demonstrated that mutating K498, K521 and K524 was sufficient to almost completely 
abolish the auto-parylation of the polymerase, thus indicating that lysines, rather than 
glutamates, might be the major sites of PARP-1 auto-parylation, at least in vitro.  
In addition to acting as the main acceptor region of PAR, PARP-1’s AD also functions 
as a binding site for a variety of proteins, such as ribosomal proteins (Koyama et al., 
1999), the transcription factors YY1 (Oei et al., 1997), OCT1 (Nie et al., 1998) and 
E2F1 (Simbulan-Rosenthal et al., 2003), UBC9 (Masson et al., 1997), p21 (Cazzalini et 
al., 2010), the human papillomavirus type 18 E2 protein (Lee et al., 2002), XRCC1 
(Masson et al., 1998), PARG (Keil et al., 2006) and histones (Buki et al., 1995). These 
interactions could be mediated by the BRCT domain present within the AD, which is 
well-known to act as a protein-protein interaction motif in other polypeptides. In fact, 
this appears to be the case for XRCC1 (Masson et al., 1998) and the human 
papillomavirus type 18 E2 protein (Lee et al., 2002). These binding events could 
alternatively be dependent on a leucine zipper that has been hypothesized to exist at 
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the N-terminus of PARP-1’s AD (Uchida et al., 1993), which has also been proposed to 
possibly mediate PARP-1 homo-dimerization and/or hetero-dimerization with PARP-2 
(Schreiber et al., 2002; Uchida et al., 1993).  
1.5.1.3 The catalytic domain 
The CAT domain is located between amino acids 526 and 1014 of the human PARP-1, 
however, the minimal region that is able to support normal PAR activity maps to the C-
terminal most 40 kDa of the enzyme (Simonin et al., 1990). The activity of this domain 
is very limited and is not stimulated by damaged DNA, which means that it corresponds 
to the basal activity of the full-length PARP-1 (Simonin et al., 1990).  
The first 80-90 residues of PARP-1’s CAT region form a WGR domain, which is named 
after its most-conserved residues: tryptophan (W), glycine (G) and arginine (R). It is 
essential for the DNA-dependent enzymatic activity of PARP-1 (Altmeyer et al., 2009), 
and, on the basis of its structure, it has been proposed to bind nucleic acids 
(Nagashima et al., 2005).  
The core of PARP-1’s catalytic domain is a region of approximately 50 residues that 
extends over amino acids 859 and 908 in the human enzyme, which corresponds to 
the PARP signature (Ame et al., 2004). It acts as PARP-1’s NAD+-binding pocket and 
contains the active site (Ruf et al., 1996). Its structure resembles that of the catalytic 
domain of bacterial mono(ADP-ribosyl)ating enzymes but not other common NAD+-
binding motifs, such as the Rossman fold (Ruf et al., 1996). On account of this 
similarity, it has been proposed that E988 of the human PARP-1 could act as the 
catalytic residue (Marsischky et al., 1995). Mutating it almost completely abolishes the 
ability of the polymerase to extent PAR chains but has a comparatively minor effect on 
its mono(ADP-ribosyl)ation activity (Rolli et al., 1997). Thus, these observations 
indicate that E988 is essential for PARP-1 to extend PAR polymers, but other residues 
must mediate the initial mono(ADP-ribosyl)ation step. The presence of two 
dinucleotide-binding motifs in PARP-1’s catalytic core, i.e. 892GKG894 and 952GKT954, the 
first one of which is important for PARP-1 activity (Kim et al., 1997), also provides a 
rationale for how this enzyme can catalyze the formation of a glycosidic bond between 
two ADP-ribose moieties. 
PARP-1’s CAT domain also appears to play functions that are independent of its 
catalytic activity. Firstly, it could be involved in DNA binding because a fragment of the 
polymerase encompassing the C-terminal region of its DBD, AD and CAT domains 
bound to a DNA substrate more strongly that an equivalent construct lacking the 
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catalytic motif (Desmarais et al., 1991). Secondly, the CAT domain may promote the 
dimerization of PARP-1 and thereby regulate this protein because such a motif, on its 
own, can form dimers, regardless of DNA being present or not (Mendoza-Alvarez and 
Alvarez-Gonzalez, 2004). Thirdly, the CAT domain is essential for the ability of PARP-1 
to regulate chromatin structure. In vitro, the full-length polymerase can trigger the 
compaction of a nucleosomal array in a manner that depends on an intact DBD 
(Wacker et al., 2007). Yet, although PARP-1’s DBD is unable to condense chromatin 
on its own, it can do so when it is artificially fused to the CAT domain (Wacker et al., 
2007). 
1.5.2 Binding of PARP-1 to DNA 
The earliest recognized property of PARP-1 was its ability to become activated in 
response to damaged DNA both in vitro and in vivo, where this event leads to a rapid 
drop in the cellular pools of NAD+ (Durkacz et al., 1980; Yoshihara, 1972). Because of 
its ability to directly bind SSBs, PARP-1 has been long viewed by many as a molecular 
DNA nick sensor; yet, it can recognize other kinds of DNA damage and also intact 
DNA, as I will describe in more detail below.  
1.5.2.1 Interactions with damaged DNA 
The interactions between PARP-1 and damaged DNA occur through its DBD and have 
been best characterized for single- and different kinds of double-stranded breaks. 
Measurement of tryptophan fluorescence decay upon binding of PARP-1’s DBD to 
different types of DNA strand interruptions (SSBs, blunt DSBs or DSBs bearing 5’ or 3’ 
overhangs) indicate that it binds to all of them equally well (Lilyestrom et al., 2010; Pion 
et al., 2005). Yet, PARP-1 is activated by 3’ overhangs better than 5’ ones, which in 
turn stimulate the polymerase more efficiently than SSBs (Benjamin and Gill, 1980; 
D'Silva et al., 1999). The effects of blunt DSBs on PARP-1 activation are instead less 
clear: although a plasmid containing this type of interruption activates the polymerase 
more strongly than those bearing 3’ or 5’ ends and both 8 bp- and 201 bp-long dsDNA 
oligonucleotides have also been shown to stimulate it (Benjamin and Gill, 1980; D'Silva 
et al., 1999; Hengartner et al., 1991), Pion et al. (2005) detected no PARP-1 activation 
in the presence of a 66 bp-long dsDNA oligonucleotide. The phosphorylation state of 
DSBs also dictates how well they can activate PARP-1, as those bearing 
dephosphorylated ends stimulate the polymerase better than those with 3’ 
phosphorylated termini and, in turn, 5’ phosphorylated ones (Benjamin and Gill, 1980).  
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Although plenty of evidence shows that the binding of PARP-1 to damaged DNA 
activates this enzyme, only recently the first, low resolution, image of how such a 
phenomenon may occur at the molecular level has been reported. By using small-angle 
X-ray diffraction scattering (SAXS), Lilyestrom et al. (2010) showed that a region of 
PARP-1 encompassing its DBD and BRCT motif (PARP aa 1-486) seems to consist of 
two, or possibly more, folded domains connected by bendy hinges that make it highly 
flexible in its free form. In the presence of SSBs and DSBs, PARP-1(1-486) binds to 
them and becomes more elongated. The extent of this elongation is more pronounced 
for blunt DSBs than those bearing 3’ overhangs or single-stranded breaks, thus 
indicating that PARP-1 binds to different DNA interruptions in different ways (Lilyestrom 
et al., 2010). Upon binding to DNA breaks the two SAXS diffraction peaks shown by 
DNA-free PARP-1(1-486), but not those produced by a domain of the polymerase 
containing only its first and second zinc fingers, coalesce into one. Such observations 
have been interpreted to mean that PARP-1(1-486) probably undergoes a structural 
change in the presence of damaged DNA that involves a region outside its first two 
finger motifs, that is, its third zinc finger and BRCT domains. This hypothesis would be 
consistent with the fact that the third finger motif of PARP-1 seems to mediate inter-
domain contacts that are important for the activation of the polymerase (see 1.5.1.1). 
Lilyestrom et al. (2010) and other groups have also uncovered other aspects of how 
PARP-1 binds to DNA damage. Firstly, they have shown that the DBD of this enzyme 
protects less DNA on oligonucleotides containing blunt DSBs than those bearing SSBs 
or 3’ overhangs (Lilyestrom et al., 2010; Pion et al., 2003; Pion et al., 2005). For the 
latter type of damage, the DBD was found to bind proximally to the single-to-double-
stranded region of the DNA substrate in an asymmetric manner with respect to the 
break itself, i.e. the double-stranded portion of this oligonucleotide was protected more 
than the single-stranded one (Lilyestrom et al., 2010; Pion et al., 2003; Pion et al., 
2005). Secondly, tryptophan fluorescence decay data suggest that PARP-1(1-214) 
dimerizes upon binding to 5’ double-stranded breaks with positive cooperativity. This 
observation is consistent with the evidence that catalytically-active PARP-1 may exist 
as a dimer (Altmeyer et al., 2009; Mendoza-Alvarez and Alvarez-Gonzalez, 1993). 
Having said that, the diffraction and sedimentation equilibrium ultracentrifugation data 
presented by Lilyestrom et al. (2010) indicate that PARP-1(1-486) binds to its DNA 
substrates as a monomer.  
PARP-1 does not only recognize DNA strand interruptions but it also apparently binds, 
and thereby becomes activated by, other kinds of insults, such as the cross-linking type 
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of DNA damage caused by UV light, e.g. pyrimidine dimers (Vodenicharov et al., 2005), 
or platinum, e.g. mostly 1,2-d(GpG) (Zhu et al., 2010). 
1.5.2.2 Interactions with intact DNA 
In addition to its well-characterized ability to recognize DNA strand breaks, PARP-1 
can also interact with intact forms of DNA, including specific sequences, non-B type 
DNA and possibly standard undamaged DNA duplexes. 
PARP-1 can recognize specific DNA sequences. They are often, but not always, found 
in transcription regulatory regions where they probably help the polymerase exert some 
of its gene expression-related roles (see 1.5.3.3.3). These sequences include the IUR 
element (TCGATCTGGAACTCC) in the CXCL1 gene (Nirodi et al., 2001), the MCAT-1 
sequence (CATTCCT) in the cardiac troponin T gene (Butler and Ordahl, 1999), the 
TxRE element (TGACGACA) in the HTLV1 promoter (Zhang et al., 2002), a cis-
element in the REG promoter (TGCCCCTCCCAT, Akiyama et al., 2001), the 37-bp 
MBR region of the BCL2 promoter (Yang et al., 2010), a silencer-binding region 
(GATGGGTTTCACAATTTTTCAAGCA) within the BRCA2 promoter (Wang et al., 
2008a) and an intronic sequence (TTGANNACAA) at the BCL6 locus (Ambrose et al., 
2007). In addition, PARP-1 also binds nuclear matrix attachment DNA sequences and 
certain repetitive elements found within human centromeric sequences, such as 
GTGAAAAAG and ATGTATATATGTGTATATAGACATAAAT (Earle et al., 2000; 
Galande and Kohwi-Shigematsu, 1999). Interestingly, the latter interaction could 
explain why PARP-1 is enriched at active centromeres in human cells, especially 
during mitosis and replication, independently of heterochromatin nucleation (Earle et 
al., 2000).  
By using a variety of biochemical techniques, e.g. plasmon surface resonance, atomic 
force microscopy, foot-printing and electrophoretic mobility shift assays, and in many 
cases circular or end-protected DNA substrates, many groups have shown that PARP-
1 can also bind related non-B DNA structures. These structures include stable or 
transiently-forming simple hairpins or loops, three-way, i.e. replication fork, and four-
way, i.e. Holliday, junctions (Jorgensen et al., 2009; Lonskaya et al., 2005; Pion et al., 
2005; Potaman et al., 2005; Sastry and Kun, 1990; Soldatenkov et al., 2002). What 
feature of such DNA structures PARP-1 recognizes remains unclear. Potaman et al. 
(2005) showed that PARP-1 protects from nuclease cleavage the tip of a stable hairpin 
in an artificial four-way junction but not its cross-over point. Conversely, nuclease 
protection analysis of a cruciform that naturally occurs in plasmid pUC7 revealed that 
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PARP-1 protects one half of the base of this structure, but not its loops (Sastry and 
Kun, 1990). It is therefore possible that although the polymerase binds both loops and 
crossovers, it preferentially recognizes only one of these structures in a particular 
cruciform. Besides binding to hairpins and cruciforms, PARP-1 also seems to 
recognize other non-B DNA structures, such as DNA bends (Sastry et al., 1989), which 
usually occur in AT-rich sequences, and G-quadruplexes (Soldatenkov et al., 2008), 
which are four-stranded secondary structures that are believed to originate in regions 
of high densities of adjacent guanines. With the exception of DNA bends, all of the 
above-described DNA structures can activate PARP-1 in vitro (Jorgensen et al., 2009; 
Lonskaya et al., 2005; Pion et al., 2005; Potaman et al., 2005; Sastry and Kun, 1990; 
Soldatenkov et al., 2002; Soldatenkov et al., 2008). Altogether these observations 
therefore provide a possible explanation for how PARP-1 can parylate several proteins, 
many of which have a role in transcription (see 1.5.3.3), apparently in the absence of 
DNA damage. As a matter of fact, transcriptional regulatory regions are known to 
contain sequences prone to forming unusual non-B type DNA structures (van Holde 
and Zlatanova, 1994). 
To date, whether PARP-1 binds standard B form DNA in a sequence-independent 
manner remains unclear. This hypothesis has in fact never been directly addressed 
and there is evidence both in its favour and against it. On the one hand, Ikejima et al. 
(1990) observed that PARP-1 shows generalized binding to both supercoiled and 
digested plasmids, with only a slight preference for the latter. In the case of the 
digested plasmid, the polymerase also preferentially bound longer DNA fragments, 
which would be consistent with PARP-1 being able to recognize multiple internal sites 
of intact DNA. PARP-1’s DBD was not necessary for these binding events because a 
mutant lacking such a domain could still bind both the supercoiled and digested 
plasmids, only more weakly than the full-length protein. Additionally, Sastry et al. 
(1989) detected binding of PARP-1 to a plasmid that had been cut at a single position 
and then ligated to produce a relaxed circular DNA molecule. PARP-1’s ability to 
interact with a relaxed plasmid is also further supported by the fact that this enzyme 
can introduce negative supercoiling in such a type of DNA (Sastry and Kun, 1988). This 
observation, together with the fact that PARP-1 is able to relax supercoiled plasmids 
(Chasovskikh et al., 2005; Gradwohl et al., 1987; Yung et al., 2004) and to introduce 
significant alternations in the structure of an AT-rich bent DNA substrate (Sastry et al., 
1989), highlight an important property of the enzyme, i.e. its ability to impart structural 
changes onto DNA. On the other hand, Lonskaya et al. (2005) detected no binding of 
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PARP-1 to an end-protected ~300 bp dsDNA oligonucleotide, and Gradwohl et al. 
(1987) showed that the polymerase efficiently binds a plasmid only when it is 
supercoiled. It was hypothesized that the latter phenomenon occurred probably 
because in a supercoiled plasmid the torsional strain to which the DNA is subjected 
may promote the formation of unusual secondary structures, which may be directly 
recognized by PARP-1.  
1.5.3 The functions of PARP-1 
1.5.3.1 Roles of PARP-1 in DNA repair 
Treating cells with genotoxins, such as monovalent alkylating agents (e.g. MMS, 
MNNG, MNU, etc.), H2O2, UV light or double-stranded break-inducing drugs (e.g. γ-
irradiation), leads to the production of PAR during the first few minutes of exposure, in 
a PARP-1-dependent manner (Hagan et al., 2007; Vodenicharov et al., 2005; von 
Kobbe et al., 2003). Parylation is therefore believed to be the first line of response cells 
trigger following DNA damage (Chatterjee and Berger, 1998), which is not surprising 
considering that PARP-1 can directly recognize, and thereby be activated by, broken 
DNA (see 1.5.2.1). The ability of PARP-1 to promptly respond to damaged DNA is 
important to maintain genome stability because PARP-1-/- mice show increased 
sensitivity to a range of genotoxins as well as higher levels of DNA damage-induced 
sister-chromatid exchanges, chromosome breaks and micro-nuclei, in comparison to 
wild type animals (de Murcia et al., 1997; Masutani et al., 1999; Simbulan-Rosenthal et 
al., 1999). Many of these organismal phenotypes have also been observed at the 
cellular level in various types of PARP-1-/- mouse cells or chicken DT40 cells but also in 
human cells depleted of the polymerase (de Murcia et al., 1997; Fisher et al., 2007; 
Trucco et al., 1998). At least in part, the above-described phenotypes are likely to 
depend on the ability of PARP-1 to promote the repair of both SSBs and DSBs.  
1.5.3.1.1 PARP-1 and the repair of single-stranded DNA breaks 
SSBs are the most common type of DNA damage found in a cell. They represent 
breakage of the deoxyribose-phosphate backbone of a DNA duplex, which can occur 
as result of direct attack by chemicals such as H2O2, aborted topoisomerase I activity 
and as normal intermediates of DNA repair processes.  
SSBs activate PARP-1 in vitro and in vivo, where they are mainly repaired by BER  
(see 1.3.4 and Barnes and Lindahl, 2004). Although PARP-1 is not essential for this 
pathway of DNA repair, and BER can in fact be reconstituted in vitro without the 
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polymerase (Kubota et al., 1996), this enzyme seems to enhance it. By employing 
PARP-1-/- mouse embryonic fibroblasts, PARP-1-/- chicken DT40 cells and human cells 
stably depleted of PARP-1, three different groups have demonstrated that in the 
absence of the polymerase, even though the repair of SSBs goes to completion, the 
rate of this process is slowed down in comparison to wild type cells (Dantzer et al., 
2000; Fisher et al., 2007; Trucco et al., 1998; Woodhouse et al., 2008). An earlier 
report by Vodenicharov et al. (2000) challenges this view because the authors did not 
detect any difference in the repair efficiency of DNA breaks between PARP-1-/- and 
PARP-1+/+ cells. The fact that all of the former three studies used a very sensitive 
technique to measure the number of DNA breaks within cells, called the comet assay, 
instead of relying on the incorporation of a labelled nucleotide, as did Vodenicharov et 
al. (2000), may explain such discrepancies. Inhibiting PARP activity also affects how 
efficiently DNA breaks are repaired in vivo, hence suggesting that the catalytic activity 
of PARP-1 may be necessary for its DNA repair-promoting properties (Atorino et al., 
2001; Durkacz et al., 1981; Durkacz et al., 1980; Smith et al., 2005). This phenomenon 
however needs to be considered with care because it is probably the consequence of a 
dominant-negative effect of inactivating PARP-1. In fact, the evidence that auto-
parylated PARP-1 has a lower affinity for DNA than the unmodified enzyme (D'Amours 
et al., 1999; Wacker et al., 2007), probably because of ionic repulsion between the 
negatively charged DNA and PAR polymers bound to it (Ferro and Olivera, 1982), has 
been taken to mean that parylation of PARP-1 is required for its disassociation from a 
DNA break (D'Amours et al., 1999; Satoh and Lindahl, 1992). It follows that a 
catalytically inhibited PARP-1 would tightly bind to DNA breaks without being able let 
go of them, hence preventing other repair proteins from accessing the damaged DNA 
(Fisher et al., 2007; Parsons et al., 2005). Consistent with this hypothesis is the fact 
that PARP-1’s DBD, which should behave similarly to a chemically-inhibited full-length 
enzyme, acts as a trans-dominant mutant of the polymerase when it is over-produced: 
it inhibits DNA damage-induced parylation, it sensitizes cells to DNA-damaging agents 
and it can also induce polyploid nuclei in the absence of genotoxins (Cayuela et al., 
2001; Kupper et al., 1990; Kupper et al., 1995; Molinete et al., 1993; Rudat et al., 
2001).  
1.5.3.1.2 PARP-1 and the repair of double-stranded breaks 
The roles of PARP-1 in the processing of DSBs remain poorly understood and 
controversial. This type of DNA lesion can be repaired by either homologous 
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recombination, which involves the replacement of genetic information between two 
identical or similar DNA sequences, and/or non-homologous end joining, where broken 
DNA ends are directly ligated together without the need for a homologous DNA 
template. In mammalian cells, DSBs are repaired mostly by non-homologous end 
joining (Jackson, 2002).  
The fact that PARP-1 binds to, and is stimulated by, DSBs in vitro (Benjamin and Gill, 
1980) and that DSB-inducing genotoxins activate it in vivo (Dong et al., 2010) would 
suggest that PARP-1 is involved in repairing this type of DNA lesion. Consistently, cells 
devoid of PARP-1 or PARP activity are hypersensitive to genotoxins that cause DSBs, 
show increased levels of DNA re-arrangements, and accumulate unusually high levels 
of sister chromatid exchanges, which are widely believed to result from over-activation 
of homologous recombination (de Murcia et al., 1997; Simbulan-Rosenthal et al., 1999; 
Trucco et al., 1998; Wang et al., 1997). Altered rates of trans-gene integration have 
also been reported following the loss of PARP-1 or PARP activity, a process that 
depends on the processing of DSBs, however, some studies report higher insertion 
rates while others lower ones than wild type cells (Dominguez-Bendala et al., 2006; 
Farzaneh et al., 1988; Waldman and Waldman, 1990). These observations would 
predict that cells devoid of PARP-1 or PARP activity should accumulate DSBs, which 
has in fact been demonstrated (Heacock et al., 2010). The fact that such a 
phenomenon is restricted to cells in S phase of the cell cycle (Heacock et al., 2010), 
however, suggests that it, and by inference also the above-described phenotypes, 
probably arise from DSB that are generated by replicating DNA over unrepaired nicks 
or gaps, rather than because of compromised DSB repair per se (Bryant and Helleday, 
2006; Heacock et al., 2010). This model is supported by many studies showing that 
PARP-1-/- cells have no significant defects in homologous recombination or non-
homologous end joining in comparison to wild type cells (Noel et al., 2003; Schultz et 
al., 2003; Yang et al., 2004). It has however to be mentioned that inhibition of PARP 
activity or loss of PARP-1 has been shown to somewhat sensitize cells to DSB-
inducing genotoxins (Hochegger et al., 2006) and slow down the repair of breaks 
induced by γ-irradiation (Mitchell et al., 2009). 
Although PARP-1 may not be involved in repairing DSBs in normal cells, there is some 
evidence indicating that it becomes important in such a process when the classical 
non-homologous end joining pathway is compromised. In this pathway, DNA ends are 
joined together by the combined actions of the KU70/80/DNA-PKcs complex, which in 
addition to binding and protecting free DNA termini probably also brings them in close 
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proximity, the nuclease Artemis, which seems to polish DNA ends, and the XRCC4-
ligase IV complex, which eventually ligates them together (Jackson, 2002). Firstly, 
PARP-1 parylates KU70 and DNA-PKcs and is phosphorylated by DNA-PKcs (Ariumi 
et al., 1999; Morrison et al., 1997). Secondly, although neither KU80 nor PARP-1 is an 
essential gene in mice, deleting both of them is embryonically lethal (Henrie et al., 
2003). Thirdly, inhibiting PARP activity in cells devoid of the KU complex or where 
DNA-PKcs is also inactivated significantly compromises the repair of DSBs  (Audebert 
et al., 2004; Wang et al., 2006). Inhibition of PARP activity also reduced the efficiency 
of re-ligation of plasmid containing a DSB in KU complex- and ligase IV-deficient cells 
(Wang et al., 2006). 
1.5.3.1.3 How does PARP-1 promote the repair of DNA strand breaks? 
The ways in which PARP-1 cooperates with DNA repair pathways to facilitate the 
mending of damaged DNA have been extensively studied, but they remain poorly 
understood. The most important mechanism is probably dependent on PARP-1’s ability 
to control chromatin structure, yet the polymerase has also been proposed to act as a 
damage sensor/protector and has been shown to have a direct function in BER and 
non-homologous end joining as well as to be able to recruit DNA repair factors at sites 
of DNA damage.  
1.5.3.1.3.1 PARP-1 as a damage sensor/protector 
It has been shown that cell extracts can repair damaged DNA more efficiently in the 
presence of NAD+ than in its absence, in manner that depends on the presence of 
PARP-1. Yet, even in the presence of NAD+, extracts devoid of PARP-1 repair DNA 
breaks as well as, or even better than, PARP-1-proficient ones (Allinson et al., 2003; 
Satoh and Lindahl, 1992; Satoh et al., 1993; Vodenicharov et al., 2000). In addition, 
supplementing extracts made from PARP-1-/- cells with recombinant PARP-1 also 
inhibits their ability to mend DNA damage, both in the presence and absence of NAD+ 
(Vodenicharov et al., 2000). On the basis of these data, it has been proposed that 
PARP-1 could act as a damage sensor/protector (Satoh and Lindahl, 1992). This 
model hypothesizes that PARP-1 is detrimental to DNA repair because it competes 
with DNA repair factors for binding to damaged DNA, thus inhibiting their actions. In the 
presence of NAD+, PARP-1 bound to DNA breaks would become auto-parylated and 
consequently it would disassociate from the DNA, thus allowing DNA repair to take 
place. In support of this model it has been shown that intermediates of SSB repair 
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become particularly sensitive to nuclease cleavage in extracts prepared from PARP-1-/- 
mouse fibroblasts and after depletion of PARP-1 from HeLa cell extracts (Parsons et 
al., 2005).  
1.5.3.1.3.2 Direct functions of PARP-1 in BER 
By analyzing the repair patches generated during the repair of an abasic site, Dantzer 
et al. (2000) found that extracts prepared from PARP-1-/- cells were half as efficient as 
those made from PARP-1+/+ cells at carrying out long-patch BER, but they were only 
slightly affected in short-patch BER. In BER, DNA polymerase β usually removes the 5’ 
deoxyribose-phosphate of an incised abasic site and then fills in the resulting single 
nucleotide gap in a process that is known as short-patch repair. When DNA lesions 
cannot be repaired by this mechanism, an alternative pathway, known as long-patch 
repair is used. It involves the insertion of 2-10 nucleotides across the abasic site by 
displacement DNA synthesis, which results in the formation of a flap, and requires 
PCNA and either DNA polymerase β itself or the replicative DNA polymerases ε and δ 
(Barnes and Lindahl, 2004). These results are consistent with the observation that 
PARP-1 can stimulate displacement DNA synthesis by DNA polymerase β in an in vitro 
reconstituted BER system including only purified components, in a manner that 
depends on PARP-1 catalytic activity and the presence of the flap endonuclease FEN1 
(Prasad et al., 2001). The data reported by Dantzer et al. (2000), however, need to be 
considered with care because the authors did not directly analyze the rate of DNA 
repair, i.e. the resealing of DNA breaks. Instead, they quantified the incorporation of a 
labelled nucleotide at the abasic site and took it as a measure of DNA repair efficiency, 
when, in fact, it may simply represent the length of the repair patch.  
1.5.3.1.3.3 Direct functions of PARP-1 in non-homologous end joining 
In addition to its possible direct roles in BER, PARP-1 also seems to be directly 
involved in joining free DNA ends together. Depleting either the KU70/80/DNA-PKcs or 
XRCC4/ligase IV complexes from HeLa cell extract has barely any effect on their end 
joining activities (Audebert et al., 2004). Instead, cell extracts prepared from either 
PARP-1-/- or XRCC1-/- cells are essentially incapable of performing end joining. Adding 
recombinant PARP-1 to such extracts restores their abilty to join DNA ends. Purified 
PARP-1 also promotes DNA synapsing in vitro between DNA molecules with free ends 
and consequently promotes ligation of these molecules in combination with XRCC1 
and Ligase III (Audebert et al., 2004). For certain kinds of DSBs, i.e. those bearing 
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unphosphorylated 5′-termini, the activity of polynucleotide kinase is required for efficient 
end joining by PARP-1/XRCC1/ligase III (Audebert et al., 2006). The ability of ligase III 
to ligate DSBs is further confirmed by studies showing that this protein accounts for 
most of the DNA end joining activity of HeLa cell extracts and in vivo (Wang et al., 
2005a). Altogether, these observations indicate that PARP-1, XRCC1, and DNA ligase 
III likely define a backup non-homologous end joining pathway that is distinct from the 
classical one, which depends on the KU/DNA-PKcs and XRCC4/ligase IV complexes.  
The roles of PARP-1 in non-homologous end joining are probably not limited to 
providing cells with an alternative mechanism to ligate DSBs. Loss of PARP-1 
sensitizes cells to DSB-inducing drugs and impairs homologous recombination in a 
manner that requires the presence of the KU complex or DNA ligase IV (Hochegger et 
al., 2006).  On the basis of this observation, it has been proposed that PARP-1 could 
help minimizing potential negative effects of non-homologous end joining on 
homologous recombination (Hochegger et al., 2006). Such a model could in turn 
explain why PARP-1-/- cells cannot efficiently restart replication forks (Sugimura et al., 
2008; Yang et al., 2004), given that this process depends on homologous 
recombination.  
1.5.3.1.3.4 Recruitment of DNA repair factors by PARP-1 
PARP-1 and PAR also interact with DNA repair factors and in this way they may 
contribute to the recruitment of such proteins to DNA breaks. Several members of BER 
interact with PARP-1 and some of them, e.g. XRCC1 and DNA ligase III, have been 
shown to directly interact with PAR in vitro (Ahel et al., 2008; Leppard et al., 2003; 
Masson et al., 1998; Pleschke et al., 2000). APLF, a protein that interacts with factors 
involved in BER and non-homologous end joining and is important for the efficient 
repair of DNA strand breaks, has also been shown to bind PAR directly in vitro through 
a motif called PBZ domain (Ahel et al., 2008). In vivo, both XRCC1 and APLF are 
quickly recruited to DNA damage-induced PAR nuclear foci in a manner that depends 
on their ability to recognize PAR (Ahel et al., 2008; El-Khamisy et al., 2003). Both APLF 
and XRCC1 interact preferentially with the auto-parylated PARP-1 and inhibiting PAR 
synthesis in vivo greatly reduces the binding of XRCC1 to PARP-1 (Ahel et al., 2008; 
Masson et al., 1998; Pleschke et al., 2000). In addition, XRCC1 repair foci do not form 
in PARP-1−/− cells treated with genotoxins (El-Khamisy et al., 2003). Interestingly, the 
PBZ domain has been identified by bioinformatics means in many protein with a variety 
of roles in genome stability (Ahel et al., 2008), which suggests that the way in which 
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PARP-1 and PAR impinge on DNA repair is probably more complicated than we 
believe. 
1.5.3.1.3.5 Changes in chromatin structure by PARP-1 
It was recognized very early on that PARP-1 and PAR have a dramatic effect on the 
structure of chromatin (de Murcia et al., 1986; Poirier et al., 1982). Given that the 
compaction state of chromatin affects the efficiency of chromatin-related processes, 
such as DNA repair and transcription (see 1.5.3.3), this function of PARP-1 could 
provide an additional mechanism for how the polymerase controls genome integrity. 
While loosely packed DNA, known as euchromatin, is accessible to proteins and is 
therefore active, heterochromatin is heavily condensed and inert (Grewal and Moazed, 
2003). It appears that PARP-1 and PAR control chromatin structure both directly and 
by regulating its composition and by recruiting chromatin-remodelling factors.  
PARP-1 and PAR directly impinge on chromatin compaction by interacting with 
histones. In the presence of NAD+, PARP-1 relaxes compacted chromatin in a manner 
that depends on its activation (de Murcia et al., 1986; Poirier et al., 1982). Although 
histone H1, which is important to fold chromatin into higher order structures, is 
parylated under these conditions, the above-mentioned phenomenon cannot be 
caused by the loss of parylated H1 from chromatin because it remains associated with 
the DNA (Poirier et al., 1982). At the moment, it cannot be however categorically 
excluded that parylation of H1 may compromise the chromatin-condensing properties 
of this protein without affecting its binding to chromatin. It instead seems that the auto-
modification of PARP-1 itself may cause chromatin relaxation because parylated 
PARP-1 can unfold chromatin on its own (Realini and Althaus, 1992). This property 
probably depends on PARP-1’s ability to release core histone particles from the DNA 
(Panzeter et al., 1993). How auto-parylated PARP-1 achieves this is unclear but it may 
involve a competition between PAR and DNA for binding to histones. PAR in fact non-
covalently interacts with such proteins, but also with histone H1, with an affinity and 
specificity that cannot be explained by simple electrostatic interactions (Panzeter et al., 
1993). Additionally, when histones are mixed with auto-parylated PARP-1 and DNA, 
they bind to DNA only after PAR has been saturated with them (Realini and Althaus, 
1992). It has therefore been proposed that activated PARP-1 may evict histones from 
chromatin, relaxing it, and subsequently act as scaffold for their sequestration (Hassa 
et al., 2006). Adding PARG to PARP-1-relaxed chromatin causes loss of PAR, re-
association of histones with DNA, and chromatin re-compaction (Realini and Althaus, 
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1992), thus indicating that the effects PARP-1 exerts on chromatin structure are 
reversible. The above-described results contrast the more recent observations reported 
by Kim et al. (2004) showing that, in the presence of NAD+, PARP-1 can indeed relax 
chromatin, but without modification or loss of histones from DNA. Thus, the exact 
mechanism by which PARP-1 leads to chromatin de-condensation remains unclear.   
In the absence of NAD+, PARP-1 induces the condensation of relaxed chromatin (Kim 
et al., 2004). The polymerase binds stoichiometrically with nucleosomes at their dyad 
axis, that is, where the DNA that enters a histone core particle meets the one that exits 
it, in a manner that depends on both its DNA binding and catalytic domains (Kim et al., 
2004; Wacker et al., 2007). Adding NAD+ to these reactions leads to PARP-1 activation 
and subsequent chromatin decompaction (Kim et al., 2004). Given that PARP-1 shares 
several properties with histone H1 with respect to how it interacts with nucleosomes 
and induces chromatin condensation (Kim et al., 2004), it is possible that these two 
proteins change chromatin structure through analogous mechanism.  
Given that the way in which PARP-1 affects chromatin structure in vitro depends on its 
activation state, it has been proposed that PARP-1 may regulate chromatin 
accessibility in vivo by being locally inhibited. This phenomenon could occur through 
confined changes in the levels of ATP, which can inhibit PARP-1 (Bauer et al., 2005). 
Thus, in the presence of local high levels of ATP, PARP-1 would bind to chromatin but 
remain enzymatically inactive, thus leading to chromatin compaction. Conversely, the 
local consumption of ATP by chromatin-related processes, such as chromatin 
remodelling and transcription, could lead to an increase in PARP-1 activity and 
consequent chromatin relaxation (Hassa et al., 2006).  
PARP-1 can also control chromatin structure by recruiting specific PAR-recognizing 
chromatin-remodelling factors, i.e. ALC1 and the histone-variant macroH2A1.1, at sites 
of DNA damage. These two proteins have been shown to localize to regions of PARP-1 
activation in a manner that depends on PARP-1, PARP activity and a functional PAR-
interacting macro-domain, which is present in both of these proteins (Ahel et al., 2009; 
Gottschalk et al., 2009; Timinszky et al., 2009). The recruitment of macroH2A1.1 to 
sites of DNA damage causes a transient increase in the DNA density of these areas, 
which probably represents chromatin compaction (Timinszky et al., 2009). ALC1 is also 
likely to mediate chromatin remodelling at sites of PARP-1 activation because PAR 
strongly stimulates the chromatin remodelling activity of this protein in vitro in a manner 
that depends on its macro-domain (Ahel et al., 2009; Gottschalk et al., 2009). 
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Importantly, in vivo ALC1 depletion reduces cell survival against several genotoxins 
and its over-production leads to the accumulation of DNA damage (Ahel et al., 2009).  
1.5.3.2 PARP-1 and cell death 
Cells can die in two different ways: by programmed cell death, also known as 
apoptosis, or by necrosis. Apoptosis is the default pathway of cell death, while necrosis 
happens only after extreme cell-damaging conditions. This probably occurs because, 
unlike necrotic cells, which leak their contents into the surrounding environment leading 
to inflammation, apoptotic ones are cleared by macrophages thereby causing no 
damage to the neighbouring tissues (Fink and Cookson, 2005). A role for PARP-1 in 
cell death has been long known because over-activation of this enzyme, for instance by 
DNA damage, causes dramatic energy depletion possibly leading to cell death by 
“starvation” (Berger, 1985). In addition, it was shown that cells accumulate PAR in the 
early stages of apoptosis (Simbulan-Rosenthal et al., 1998) and that under these 
conditions PARP-1 is cleaved, mainly by caspase 3 and caspase 7 (Kaufmann et al., 
1993; Lazebnik et al., 1994). Caspase-mediated cleavage of PARP-1 is now widely 
used as a marker for cell death. In line with these results it has been shown that the 
loss of PARP-1 impairs hallmarks of apoptosis such as pro-caspase 
cleavage/activation and DNA fragmentation in cycloheximide-treated 3T3-L1 
adipocytes (Smulson et al., 2000), while PARP inhibition leads to increased apoptotic 
body formation in HL-60 cells treated with actinomycin D (Shiokawa et al., 1997). In 
addition, PARP-1-/-, PARP-2-/- mice or wild type mice exposed to PARP inhibitors are 
protected from several pathophysiological conditions, such as post-ischaemic damage, 
which causes cell death in otherwise wild type animals (Jagtap and Szabo, 2005; Shall 
and de Murcia, 2000). Other studies have however shown no significant differences in 
the levels of cell death in a range of PARP-1-/- and PARP-1+/+ cell types and in 
response to a variety of apoptotic signals (Leist et al., 1997). Thus, it is possible that 
the role of the polymerase in apoptosis may dependent on the specific type of cell and 
signals used.  
How PARP-1 controls cell death has been best characterized in the cellular response 
to genotoxins: low-to-moderate amounts of DNA damage lead to apoptosis while more 
extreme levels cause necrosis (Berger, 1985; Berger et al., 1983). PARP-1 regulates 
the balance between these two modes of cell death because inhibiting or depleting it 
shifts the use of necrosis towards apoptosis (Virag et al., 1998a; Virag et al., 1998b). 
This phenomenon has been explained by proposing that in the presence of abnormal 
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amounts of DNA damage PARP-1 over-activation causes NAD+ to be rapidly depleted, 
hence forcing cells to replenish it by consuming two to four molecules of ATP per 
molecule of NAD+, depending on the salvage pathway involved. The consequent loss 
of ATP would lead to cellular dysfunction and eventually necrosis (Berger, 1985; 
Berger et al., 1983). In support of this model, it has been shown that inhibiting PARP 
activity or depleting PARP-1 significantly improves cellular energy levels and viability in 
response to pro-necrotic signals (Jagtap and Szabo, 2005; Shall and de Murcia, 2000). 
Additionally, it has been shown that cells using glycolysis to produce ATP, i.e. 
proliferating cells, are more susceptible to necrosis than non-proliferative ones, which 
instead generate it through oxidative phosphorylation (Zong et al., 2004). This 
phenomenon was observed probably because cells that use the former metabolic 
pathway to make ATP, which takes place in the cytoplasm, would be expected to be 
more vulnerable to drastic changes in the nucleo-cytoplasmic levels of NAD+ than 
those employing the latter one (Zong et al., 2004), which instead occurs in 
mitochondria.   
In addition to mediating cell death through starvation, PARP-1 plays a role in apoptosis 
by controlling the release of the pro-apoptotic factor AIF from mitochondria (Yu et al., 
2002). AIF is found on the inner mitochondrial membrane where it functions as an 
NADH oxidase (Miramar et al., 2001). In response to pro-apoptotic stimuli AIF is 
released from these organelles into the cytoplasm where it associates with cyclophilin 
A to form an active nuclease (Cande et al., 2004). This complex translocates into the 
nucleus, inducing chromatin condensation and DNA fragmentation (Susin et al., 1999). 
Inhibiting PARP activity or loss of PARP-1 prevents the release of AIF from 
mitochondria, reducing susceptibility to apoptosis (Yu et al., 2002). Interestingly, the 
fact that purified PAR alone induces release of AIF from isolated mitochondria, but also 
in cells, where it eventually induces apoptosis (Yu et al., 2006), suggests PAR itself is 
sufficient for AIF-release from mitochondria. At the moment it cannot be however 
excluded that the PARP-1-dependent depletion of NAD+ and ATP in response to DNA 
damage and/or in the presence of reactive oxygen species may also contribute to this 
mode of apoptosis. In fact, injecting NAD+ into cells rescues their ATP levels, blocks 
the translocation of AIF from mitochondria to nuclei and eventually prevents cell death 
(Alano et al., 2004). 
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1.5.3.3 PARP-1 and the regulation of gene transcription 
In addition to being involved in DNA repair and cell death, PARP-1 also plays a critical 
role in the regulation of transcription under basal, signal-activated, and stress-induced 
conditions. PARP-1’s transcription-related functions have been demonstrated on a 
single gene-basis through a large number of reports, some of which will be described 
below. More recently, “genome-wide” expression profiling techniques have also been 
applied to simultaneously compare the expression levels of a huge number of genes 
between various cell lines and tissues proficient in or devoid of PARP-1. Simbulan-
Rosenthal et al. (2000) identified 91 genes amongst the 11,000 ones tested that 
showed at least a 2-fold change in expression between mouse embryonic fibroblasts or 
livers obtained from PARP-1+/+ and PARP-1-/- mice. Interestingly, many of the genes 
down-regulated by the loss of PARP-1 in this study encode for proteins involved in cell 
cycle progression, DNA replication, and chromosome dynamics. In a second report, 
Ogino et al. (2007) compared the expression levels of almost 10,000 genes between 
PARP-/- and PARP-1+/+ embryonic stem cells, embryonic fibroblasts and livers. They 
observed that although ~3.6% of the tested transcripts showed altered expression in all 
of the three systems examined, with ~70% of them being down-regulated by the loss of 
PARP-1, the three pools overlapped very little in terms of their constituents’ identities.  
In the most recent study, Frizzell et al. (2009) compared the expression of over 20,000 
genes between wild type and PARP-1-depleted MCF-7 cells. They found that the 
expression of 8.7% of the studied genes was affected by PARP-1 deficiency. Amongst 
these, 204 genes, mainly involved in metabolism and stress responses, were found to 
be most robustly controlled, with half of them being upregulated upon loss of PARP-1 
(Frizzell et al., 2009).  The importance of PARP-1 in transcription demonstrated by the 
above-described studies is further corroborated by the observation that this enzyme is 
enriched at the promoter of possibly 90% of protein-coding genes in MCF-7 cells, in a 
way that is mutually exclusive with histone H1 (Krishnakumar et al., 2008). Although 
the association of H1 with the promoter of a gene usually inhibits its activation, this 
does not mean that the presence of PARP-1 at such a location would instead stimulate 
it. In fact, depending on which gene is considered, the presence of PARP-1 at its 
promoter can either positively or negatively effect its transcription.  
PARP-1 not only controls basal levels of gene transcription during normal growth but it 
often contributes to the regulation of transcription in response to signals, including 
steroid hormones (Ju et al., 2006), peptide hormones, cytokines, heat shock 
(Ouararhni et al., 2006; Tulin and Spradling, 2003), Ca2+ (Ju et al., 2004) and other 
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extra-cellular signals (Hassa et al., 2005; Kauppinen et al., 2006). Many of these stimuli 
appear to impinge on the transcription-related functions of PARP-1 by inducing its post-
translational modification with PAR (Cohen-Armon et al., 2007), acetyl (Hassa and 
Hottiger, 1999) or phosphate (Kauppinen et al., 2006) groups, which are likely to 
regulate the properties of this enzyme. For instance, activation of macrophages leads 
to PARP-1 acetylation by p300/CBP. This modification event allows PARP-1 to interact 
with, and activate, the transcription factor NFκB leading to the induction of NFκB-
responsive genes (Hassa et al., 2005).  
The roles of PARP-1 in transcription are extremely varied and they have been 
classified into four categories: 1) modulation of chromatin structure, 2) direct binding to 
enhancer sequences, 3) co-regulation functions at specific promoters and 4) insulator 
functions (Kraus, 2008). 
1.5.3.3.1 Regulation of chromatin structure  
In 1.5.3.1.3.5, I described how PARP-1 can control chromatin structure either directly 
or indirectly by modulating its composition and how this property impacts on genome 
stability. Since the transcription of a gene is also heavily controlled by the compaction 
state of the chromatin in which it is found, it is unsurprising that PARP-1 can control 
this process as well. 
Firstly, the ability of PARP-1 to compact chromatin in the absence of NAD+ is inhibitory 
to transcription in vitro, a phenomenon that can be reversed by adding NAD+ to the 
reaction (Kim et al., 2004). Such an in vitro property is likely to be relevant in vivo 
because PARP-1 enzymatic activity has been observed at chromosomal “puffs” within 
Drosophila polytene chromosomes, which are regions of high transcriptional activity 
and chromatin de-condensation (Tulin and Spradling, 2003).  
In addition, PARP-1 may also control chromatin structure and transcription by 
modulating chromatin composition. The recruitment of the chromatin-remodelling 
factors ALC1 and macroH2A1.1 at sites of PARP-1 activation, see 1.5.3.1.3.5, may 
lead to changes in the expression of certain genes, if they fall within transcriptional 
regulatory regions. Consistent with this model it has been shown that macroH2A1.1 
interacts directly with PARP-1, they  are part of the same nucleosome complex and 
they co-localize at the promoter of the HSP70.1 gene (Nusinow et al., 2007; Ouararhni 
et al., 2006). Upon heat shock, both mH2A1.1 and PARP-1 leave the HSP70.1 
promoter, concomitantly several proteins that are associated with it become parylated, 
and gene transcription is activated in a manner that depends on the presence of 
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PARP-1 or mH2A1.1 (Ouararhni et al., 2006). As mentioned earlier, PARP-1 also 
excludes histone H1 from the promoters of several genes, thereby affecting their 
transcription (Krishnakumar et al., 2008). In the case of the oestrogen-responsive pS2 
gene, upon stimulation, the PARP-1-dependent removal of H1 from the promoter of this 
gene is also followed by the recruitment of, amongst other proteins, HMGB1 (Ju et al., 
2006). HMGB1 is an architectural protein with DNA bending properties that is often 
associated with chromatin remodelling and stimulation of transcription (Stros, 2010).  
1.5.3.3.2 Insulator functions  
PARP-1 also seems to control transcription by regulating the activity of insulators. 
Insulators are specific DNA sequences that bind to proteins, e.g. CTCF, and divide the 
genome into distinct regulatory units, hence reducing the effects of enhancers on 
promoters and preventing heterochromatin from spreading into euchromatic regions 
(Wallace and Felsenfeld, 2007). CTCF is parylated and it co-localizes with PARP-1 at 
most CTCF-binding sites. Inhibiting PARP activity or mutating CTFC’s PAR attachment 
sites impairs its insulator functions, thus indicating that parylation plays an important 
role in controlling the properies of this protein (Farrar et al., 2010; Yu et al., 2004). 
Given that PAR can control the global levels of DNA methylation in a cell, probably by 
inhibiting the DNA methyl transferase DNMT1 (de Capoa et al., 1999; Guastafierro et 
al., 2008; Reale et al., 2005), and the activity of genomic insulators generally depends 
on their methylation state (Reale et al., 2005), it is possible that PARP-1 may regulate 
insulator function also by controlling DNA methylation.  
1.5.3.3.3 Direct binding to enhancer sequences 
In a few cases, PARP-1 appears to control transcription by acting as a classical 
enhancer-binding transcription factor, that is, by directly recognizing specific regulatory 
DNA sequences and/or structures within the promoter regions of certain genes. This 
appears to be case for REG (Akiyama et al., 2001), BCL6 (Ambrose et al., 2007), 
CXCL1 (Amiri et al., 2006), BRAC2 (Wang et al., 2008a) and the PARP-1 gene itself 
(Soldatenkov et al., 2002). For instance, in its inactive form, PARP-1 binds to a specific 
DNA sequence within the CXCL1 promoter, thereby hindering its association with the 
transcription factor NF-κB and preventing its expression (Amiri et al., 2006). Activation 
of PARP-1 evicts the polymerase itself from the CXCL1 promoter, therefore allowing it 
to bind NF-κB and be turned on (Amiri et al., 2006). PARP-1 also binds to a specific 
sequence in the first intron of the BCL6 gene and in the BRAC2 promoter (Ambrose et 
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al., 2007; Wang et al., 2008a). Although it is not known whether such binding 
phenomena are directly involved in controlling the expression of these two genes, it 
has been shown that inhibition of PARP activity or depleting PARP-1 can alter their 
transcription (Ambrose et al., 2007; Wang et al., 2008a). Interestingly, PARP-1 also 
recognizes its own promoter, both in vivo and in vitro, and appears to be able to down-
regulate it (Soldatenkov et al., 2002). This binding event has been proposed to stem 
from PARP-1’s ability to recognize certain secondary structures such as hairpins (see 
1.5.2.2), which may be present in its promoter (Soldatenkov et al., 2002). 
1.5.3.3.4 Transcription co-regulator functions 
PARP-1 can also control gene expression by acting as a co-activator or a co-repressor, 
depending on the gene examined. Co-regulators are proteins that generally interact 
with DNA-binding transcription factors and consequently either activate or repress the 
transcription of a gene (Glass and Rosenfeld, 2000). PARP-1 activity is not always 
necessary for its co-regulator functions, e.g. NF-κB, B-MYB, and HTLV TAX1 (Hassa 
and Hottiger, 1999; Kraus and Lis, 2003; Pavri et al., 2005), but when it is, e.g. HES1, 
SP1, NFAT, and ELK1 (Cohen-Armon et al., 2007; Ju et al., 2004; Olabisi et al., 2008; 
Zaniolo et al., 2007), one or more components of the co-regulatory complex with which 
the polymerase is associated are ususally parylated. It is generally believed that, as a 
co-regulator, PARP-1 is recruited to specific promoters by interacting with its partner 
DNA-binding transcription factor (Kraus, 2008). Yet, additional elements must also be 
involved because ChIP-on-Chip analysis shows that the promoter-associated peaks of 
PARP-1 enrichment can be as wide as 3 kbp (Krishnakumar et al., 2008). Although the 
mechanisms by which PARP-1 functions as a co-regulator are poorly understood and 
they are likely to be gene- and/or transcription factor-specific, recent evidence suggests 
that PARP-1 may be involved in exchanging co-regulatory complexes at specific 
promoters. For instance, PARP-1 and PARP activity are necessary to mediate the 
exchange of a repressive complex, consisting of the co-repressor NCoR and the 
histone deacetylase HDAC3, for an activator complex that contains PARP-1, 
topoisomerase IIβ, the co-activator ASC2, and the DNA repair proteins KU70/80 and 
DNA-PK at the promoter of the oestrogen-inducible pS2 gene, upon activation (Ju et 
al., 2006). Interestingly, this PARP-1-dependent coregulator exchange event is 
accompanied by the formation of a topoisomerase IIβ-dependent DSB at the pS2 
promoter and it has been shown to occur at promoters of many other signal-induced 
genes (Ju et al., 2006). Likewise, upon retinoic acid-stimulation PARP-1 is also 
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necessary to convert an inactive CDK8+ Mediator complex to an active CDK8- one and 
thereby to induce transcription from retinoic acid-responsive promoters both in vivo and 
in vitro (Pavri et al., 2005). This phenomenon does not require PARP-1’s catalytic 
domain (Pavri et al., 2005). Conversely, PARP-1 needs to be active to mediate the 
exchange of a PARP-1-containing TLE1 co-repressor complex for a HAT-containing 
co-activator one at the HES1 promoter, upon Ca2+ mobilization in neurons (Ju et al., 
2004).  
1.5.4 PARP-1 and cancer  
1.5.4.1 The involvement of PARP-1 in tumourigenesis 
It is generally believed that tumours and cancers develop during a long period of time 
from a single cell that accumulates several heritable changes, through successive 
rounds of mutation and natural selection, and thereby becomes able to outgrow its 
neighbours. Thus, it seems that a certain amount of genome instability is necessary for 
the development of tumours (Hanahan and Weinberg, 2000). Given the functions that 
PARP-1 plays in maintaining genome integrity, but also in cell death and transcription, 
it would be expected that its partial or complete loss could lead to an increased rate of 
tumour formation in an organism.  
The roles of PARP-1 in tumourigenesis have been investigated in PARP-1-/- mice. 
Three different PARP-1-/- mice have been generated by three different groups, by 
deleting exon 1, 2 or 4 of the PARP-1 gene (de Murcia et al., 1997; Masutani et al., 
1999; Wang et al., 1995). They are all viable and fertile, indicating that PARP-1 is not 
an essential gene for survival under laboratory conditions. Although these mice are 
very susceptible to DNA-damaging agents and show a generalized genome instability 
phenotype (see 1.5.3.1 and Shall and de Murcia, 2000), they are not particularly prone 
to developing cancers spontaneously. One study did however report that PARP-1-/- 
mice naturally develop liver tumours after 12-24 months more frequently than wild type 
animals (Tong et al., 2002). Another study also showed that deleting PARP-1 in the 
severe combined immuno-deficiency (SCID) mouse model also leads to an unusually 
high frequency of spontaneous T cell lymphomas (Morrison et al., 1997). In contrast to 
spontaneous tumour formation, it has been shown that PARP-1-/- mice exposed to 
DNA-damaging drugs, or additionally devoid of other factors involved in maintaining 
genome stability, accumulate unusually high levels of tumours in various organs 
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(Morrison et al., 1997; Nozaki et al., 2003; Tong et al., 2002; Tong et al., 2001; 
Tsutsumi et al., 2001).  
Altogether the observations described above suggest that PARP-1 protects against 
tumourigenesis. This property is evident only when PARP-1-/- mice accumulate 
unusually high levels of DNA damage probably because under these conditions the 
presence of the polymerase becomes essential for efficient DNA repair. Conversely, 
under normal conditions the lesions that spontaneously arise in the genome of the 
PARP-1-/- mice, and would normally be dealt with by PARP-1 itself, may be relatively 
infrequent and therefore could be repaired by some auxiliary mechanism. 
1.5.4.2 PARP as a target for cancer treatment 
Although PARP-1 protects cells from developing malignancies, inhibiting its enzymatic 
activity is one of the most heavily studied and promising strategies for the treatment of 
some types of cancer. At present most of the chemicals used to inhibit PARP-1 are 
also likely to inactivate other PARPs because they act as competitive inhibitors of 
NAD+ (see below), and all PARPs share very similar catalytic cores (see 1.4.3).  
The oldest PARP inhibitor is the nicotinamide analogue 3-aminobezamide (Purnell and 
Whish, 1980). It is not particularly potent or specific for PARP-1 (Rouleau et al., 2010) 
and it also affects the normal functions of the cytoskeleton (Malorni et al., 1995). It is 
therefore not surprising that 3-aminobenzamide can cause serious side effects 
(Horsman et al., 1986). Newer inhibitors, mostly based on the benzamide or purine 
structures, have therefore been engineered are now in their third generation (ABT-888, 
AG014699, AZD2281, BSI-201, CEP-8983 and MK-4827). Although they are more 
potent and specific than 3-aminobenzamide, they still target PARP-1, PARP-2, and 
probably other members of the PARP family (Ferraris, 2010; Rouleau et al., 2010).  
PARP inhibitors are presently used as 1) potentiators of chemo- and radio-therapy 
(Tentori and Graziani, 2005) and 2) cytotoxic agents in their own right for the treatment 
of cancers that bear specific genetic markers, such as mutations in the BRCA-1 or 
BRCA-2 genes (Martin et al., 2008).  
1.5.4.2.1 Potentiation of chemo- and radio-therapy 
The finding that PARP-1 inactivation sensitizes cells to genotoxins (see 1.5.3.1) 
suggested that inhibiting this enzyme could coadjuvate the therapeutic properties of 
common anti-cancer drugs, because they often act by introducing lesions in DNA. 
PARP-1 inhibitors have in fact been shown to potentiate the cytotoxic actions of 
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chemotherapeutics such temozolomide, a DNA alkylating agents, and irinotecan, a 
topoisomerase I poison, as well as radiotherapy, both in cultured cancer cells and in 
tumour xenograft models (Bowman et al., 1998; Miknyoczki et al., 2003).  
PARP inhibition is believed to potentiate the effects of chemotherapeutics by rendering 
cells unable to efficiently repair the lesions inflicted to DNA by these drugs, hence 
causing cell death through the accumulation of unrepairable DNA damage (Martin et 
al., 2008). In line with this model it has been shown that  inhibiting PARP leads to the 
increased accumulation of DNA strand breaks and apoptosis in cells treated with 
temozolomide (Boulton et al., 1995; Tentori et al., 1997). These results have led to the 
approval of the first clinical trial for a PARP inhibitor: the use of AG014699 as a 
potentiator of temozolomide in metastatic myelomas (Plummer et al., 2006). Such a 
study reported promising results in that the combined administration of these two drugs 
suppressed tumour development more strongly than temozolomide alone (Plummer et 
al., 2006).  
PARP inhibitors are presently undergoing analogous clinical trials for the treatment of 
other types of cancers, such as glioblastoma multiforme. 
1.5.4.2.2 PARP inhibitors as cytotoxic agents 
In addition to augmenting the cytotoxicity of cancer therapeutics, PARP inhibitors have 
been shown to be particularly effective in treating cancers that carry mutations in 
specific genes. For example, cells homozygous for mutations in the BRCA1 and 
BRCA2 genes are exquisitely sensitive to inhibition of PARP, unlike the corresponding 
heterozygous mutants or wild type cells (Bryant et al., 2005; Farmer et al., 2005). 
These findings are very important because 80% of the people that carry heterozygous 
BRCA1 or BRCA2 mutations lose the other functional allele of these genes during their 
lives in some of their cells, and thereby develop cancers, mostly of the breast in women 
and of the prostate in men (Venkitaraman, 2002).  
The above-described results suggest that PARP inhibition could be used in BRCA+/- 
patients for “targeted chemotherapy”, that is, to specifically kill the tumour-prone BRCA-
/- cells while leaving all the other heterozygous ones unaffected. Thus, in this particular 
context killing tumour cells should be so specific that the drug’s side effects would be 
expected to be reduced to a minimum. In fact, in a recent clinical trial, the PARP 
inhibitor AZD2281 was demonstrated to stabilize or regress the growth of breast, 
ovarian, and prostate cancers defective in BRCA1 or BRCA2, but not those that carried 
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functional copies of these genes, with fewer side effects for the patients than more 
traditional chemotherapeutic regimes (Fong et al., 2009).   
BRCA1 and BRCA2 are necessary for the orderly progression of homologous 
recombination (Venkitaraman, 2009). This pathway of DNA repair is particularly 
important in mending stalled or collapsed replication forks and therefore plays a critical 
role in cell survival (Helleday, 2010). Inhibiting PARP leads to increased levels of 
homologous recombination in normal cells, probably because under these conditions 
the lesions that would normally be repaired through PARP-1 are instead dealt with by 
homologous recombination (Schultz et al., 2003). It has therefore been proposed that 
the synthetic lethal effect of combining PARP inhibition with mutation in BRCA genes 
occurs because the damaged replication forks that accumulate due to the loss of PARP 
activity cannot be repaired by homologous recombination, hence resulting in their 
irreversible, and lethal, collapse (Bryant et al., 2005; Farmer et al., 2005).  
Importantly, PARP inhibition may not be an effective treatment only for BRCA-defective 
cancers but also for all those sporadic malignancies that exhibit a BRCA-like 
phenotype, either through the epigenetic inactivation of the BRCA genes or the 
disruption of other factors important for homologous recombination (Martin et al., 
2008). In addition, given that a wide range of tumours demonstrate an impaired ability 
to repair DNA (Martin et al., 2008), it is possible that inhibiting PARP may also be 
useful in their treatment.  
1.6 The aims of this thesis 
Sumoylation and DNA heavily interplay with each other: not only can DNA stimulate the 
sumoylation of some proteins, e.g. PCNA (see 1.3.3), and vice versa sumoylation can 
affect the binding of some of its substrates to DNA, e.g. TDG (see 1.3.4), but also, and 
more importantly, the sumoylation pathway itself is crucial to maintain genomic 
information (see 3.1). SUMO plays a role in genome stability probably because it 
controls specific aspects of DNA metabolism. Until not very long ago (Dou et al., 2010; 
Galanty et al., 2009; Morris et al., 2009), how SUMO impinged on DNA metabolism 
was largely unknown as this phenomenon had not yet been correlated to the 
modification of certain proteins by specific ligases. Thus, my research hoped to 
uncover the ways in which SUMO regulated DNA-related processes such as DNA 
replication, recombination and/or repair, and in particular how DNA may be involved. 
To begin accomplishing this objective, I aimed at systematically identifying sumoylated 
proteins from normal and damaged replicating chromatin, because they should be 
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enriched for proteins with a role in DNA metabolism. Subsequently, for a few 
interesting new candidates of sumoylation with a role in DNA metabolism, I aimed at 
characterizing two aspects of their modification. Firstly, I planned to study how it was 
controlled with respect to: 1) the enzymes responsible for it, 2) when and where it took 
place, 3) any susceptibility to cellular and/or environmental signals and 4) whether/how 
DNA impinged on it, because this type of information could provide clues about the 
functional consequences of such sumoylation events.  Secondly, I aimed at 
investigating the roles of the sumoylation of these new sumoylation targets more 
directly by: 1) mapping their SUMO-attachment site and then 2) creating 
unsumoylatable mutants whose properties, in particular the DNA-related ones, could 
be compared against those of the relevant wild type proteins. 
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Chapter 2. Materials and methods 
2.1 Reagents 
2.1.1 Proteins 
Protein Source 
Bovine serum albumin (BSA) Sigma 
GST-Rhinovirus 3C protease Sven Kjaer 
His6-Geminin Vincenzo Costanzo 
His6-Ulp1(aa 403–621) Dale Wigley 
PARP-1(aa 1-214), PARP-1(aa 103-214), PARP-
1R122I( aa 103-214) Sebastian Eustermann 
Phusion DNA polymerase Finnzymes 
Restriction enzymes, T4 DNA ligase, calf intestinal 
phosphatase New England Biolabs 
S. cerevisiae SUMO, SUMO E1 and E2, Siz1(aa 1-
508) and SizG55A, K57A, L60A(aa 1-508) In-house 
Taq DNA polymerase Thermo Scientific 
Topoisomerase I Invitrogen 
Trypsin Promega 
Untagged PARP-1 Enzo Life Sciences 
Untagged SUMO E1, SUMO1 and SUMO2 BostonBiochem 
Zymolyase 20T AMS Biotechnology 
 
Table 2.1 - A list of the proteins used in this study. 
 
2.1.2 Antibodies 
 Specificity Reactivity Source (catalogue #) Dilution 
M
on
oc
lo
na
l 
3-phosphoglycerate 
kinase (PGK) S. cerevisiae Invitrogen (459250)  1:10,000  
c-Myc (clone 9E10) N/A CR-UK 1:5,000 
FLAG (clone M2) N/A SIGMA (F1804) 1:5,000 
Green fluorescent 
protein (GFP) N/A Roche (11814460001) 
WB 1:5,000 
IF 1:1000 
His6 (clone HIS-1)  N/A Sigma (H1029) 1:5,000 
MCM7 Metazoan Abcam (ab2360) 1:200 
ORC1 Xenopus laevis 
CR-UK, Tugal et al. 
(1998) 1:4,000 
Orc1 (clone SB13) S. cerevisiae Santa Cruz (sc-6674) 1:1,000 
Orc2 (clone SB46) S. cerevisiae CR-UK 1:1,000 
Orc6 (clone SB49) S. cerevisiae CR-UK 1:3,000 
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PARP-1 (clone C2-10) Mammalian species 
Enzo Lifesciences (BML-
SA250-0050) 1:5,000 
PARP-1 (clone F1-23) Mammalian species 
Enzo Lifesciences (ALX-
804-211) 1:5,000 
PARP-1 (clone F2) Human Santa Cruz 1:3,000 
PCNA (clone PC-10)  Metazoan CR-UK  1:5,000  
Poly(ADP-ribose) (clone 
10H) N/A 
Trevigen (4335-MC-01K-
AC) 1:1,000 
Tubulin (TAT1) N/A CR-UK 1:100,000 
Ubiquitin (clone P4D1)  Pan Cell Signalling Technology (3936) 1:3,000 
Po
ly
cl
on
al
 
c-Myc (A-14) N/A Santa Cruz (sc-789) 1:3,000 
DNA polymerase α Metazoan species Abcam (ab31777) 1:3,000 
Histone H3, CT Pan Millipore (07-690) 1:3,000 
ORC2 X. laevis Tim Hunt’s laboratory, Tugal et al. (1998) 1:3,000 
PCNA (affinity purified)  S. cerevisiae In-house 1:3,000 
Promyelotic leukaemia 
protein (PML) Human 
Paul Freemont’s 
laboratory  IF 1:200 
RPA70 Metazoan Stephen West’s laboratory 1:3,000 
Smt3 S. cerevisiae In-house 1:5,000 
SUMO1 (affinity purified) Metazoan  In-house 1:200 
SUMO2 (affinity purified) Metazoan In-house 1:200 
 
Table 2.2 - A list of the primary antibodies used in this thesis. Dilutions are for western 
blotting (WB) unless otherwise stated. IF = Immunofluorescence. 
 
 
Antibody Source (catalogue #) Dilution 
HRP-conjugated anti-mouse IgG DakoCytomation (P0447) 1:10,000 
HRP-conjugated anti-rabbit IgG DakoCytomation (P0399) 1:10,000 
HRP-conjugated anti-rabbit IgG 
heavy-chain Sigma (A1949) 1:10,000 
HRP-conjugated anti-mouse IgG 
light-chain 
Jackson ImmunoResearch (115-
035-174) 1:10,000 
HRP-conjugated anti-mouse IgG 
light-chain 
Jackson ImmunoResearch (211-
032-171) 1:10,000 
Alexa Fluor 488 anti-mouse IgG Invitrogen (A-11001) 1:500 
Alexa Fluor 594 anti-rabbit IgG Invitrogen (A-11012) 1:500 
 
Table 2.3 - A list of the secondary antibodies used in this thesis. 
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2.1.3 Chemicals and reagents 
Unless otherwise stated, most chemicals and reagents were obtained from Sigma, 
BDH Chemicals or Fisher Scientific. Those ones purchased from other companies are 
listed below or indicated in the relevant paragraph.  
BD Biosciences: FACSFlow, FACSRinse and FACSClean 
Bio-Rad: ammonium persulfate, bromophenol blue, 30% w/v acrylamide/Bis solution 
(37.5:1 acrylamide:N,N’-methylene-bis-acrylamide electrophoresis purity reagent) 
Duchefa Biochimie: Amino acids for yeast media 
Invitrogen: 0.4% w/v Trypan blue Stain 
London Research Institute’s Peptide Synthesis team: α factor (WHWLQLKPGQPMY) 
Melford: dithiothreitol (DTT) 
National Diagnostics: 20% w/v sodium dodecyl sulfate (SDS) 
New England Biolabs: 10 T4 DNA ligase buffer and 10 buffers for restriction 
enzymes 
2.2 Media and solutions 
2.2.1 Media 
2.2.1.1 Bacterial cells 
Luria Broth (LB) medium and 10 M9 salt solution, LB agar, 4% w/v bacto-agar, 20% 
w/v glucose were prepared by the London Research Institute’s Media Production team.  
Liquid M9 medium without leucine: 1 M9 salt solution, 1 mM MgSO4, 1 µgml-1 
thiamine, 0.5% w/v glucose, and 1 µgml-1 tryptophan and 1 µgml-1 leucine 
M9 agar without leucine: 1.5% w/v bacto-agar, 1 M9 salt solution, 1 mM MgSO4, 1 
µgml-1 thiamine, 0.5% w/v glucose, 1 µgml-1 tryptophan and 1 µgml-1 leucine 
All antibiotics were prepared as 1000 stock solutions, stored at -20C and then added 
to liquid medium or agar plates as desired for the selection of transformed bacterial 
cells.  
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 1000 stock solutions 
(mgmL-1) 
Solvent 
Ampicillin 100 Water, filter sterilized 
Chloramphenical 34 Ethanol 
Kanamycin 50 Water, filter sterilized 
Tetracycline 10 Ethanol 
Gentamycin 7 Water, filter sterilized 
Spectinomycin 100 Water, filter sterilized 
Streptomycin 75 Water, filter sterilized 
 
Table 2.4 - A list of the antibiotic stock solutions used in this thesis. 
 
2.2.1.2 Yeast cells 
Yeast Peptone (YP) medium, Yeast Peptone Glucose (YPD) medium, YPD agar and 
4% w/v bacto-agar were prepared by the London Research Institute’s Media 
Production team. 
Dropout powder: 2 g of p-aminobenzoic acid and 20 g of each of alanine, arginine, 
asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, inositol, 
isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine and 
valine were mixed overnight 
Synthetic Complete (SC) powder: 36.7 g of dropout powder, 4 g of leucine, 2 g of 
histidine, 2 g of tryptophan, 2 g of uracil and 0.5 g of adenine were mixed overnight. 
Specific SC powder stocks were prepared by omitting the desired amino acid   
2.5 SC medium: 5 g of SC powder, 4.25 g of yeast nitrogen base (without amino acids 
and ammonium sulfate, Invitrogen) and 12.5 g of ammonium sulfate were mixed with 1 
L of water, stirred for 30 min and autoclaved 
Liquid SC medium: 200 mL of 2.5 of SC medium, 250 mL of distilled water and 50 mL 
of 20% w/v glucose or galactose 
SC medium agar: 200 mL of 2.5 SC medium, 250 of molten 4% w/v of bacto-agar and 
50 mL of 20% w/v glucose or galactose 
5-FOA SC medium agar: 200 mL of SC complete medium, 250 mL of molten 4% w/v 
bacto-agar, 50 mL of 20% w/v glucose supplemented with 2 mgmL-1 of each of uracil, 
adenine and 5-FOA  
G418 YPD agar: YPD agar supplemented with 200 µgmL-1 G418 
20% w/v galactose: 20 g of galactose was mixed with warm water up to 100 mL and 
autoclaved 
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100 mM CuSO4: 24.97 g of copper sulphate pentahydrate was mixed with water up to 
100 mL and filter-sterilized 
1% w/v KOAc: 9.8 g of potassium acetate was mixed with water up to 100 mL and 
filter-sterilized 
2.2.1.3 Insect cells 
Unless otherwise stated, insect cells were grown in Grace’s medium (without insect 
haemolymph) supplemented with 3.3 g·L-1 lactalbumin hydrolysate and 3.3 g·L-1 
yeastolate (Invitrogen), 10% v/v heat-inactivated (55C for 30 min) foetal bovine serum 
and, when required, antibiotics (50 µgmL-1 gentamycin and 250 ngmL-1 amphotericin 
B). 
2.2.1.4 Mammalian cells 
Unless otherwise stated, all cell lines were maintained in DMEM supplemented with 4.5 
mg·mL-1 glucose, 2 mM glutamine, 15 µg·mL-1 phenol red (11995-040, Invitrogen) as 
well as 10% v/v heat-inactivated (30 min at 55°C) foetal bovine serum, 100 U·mL-1 
penicillin, 100 µg·mL-1 streptomycin and, where appropriate, additional antibiotics (see 
2.5.4). 
2.2.2 Solutions 
2.2.2.1 General 
The London Research Institute’s Media Production team prepared the following 
solutions using standard recipes: 1 and 10 PBS, TE pH 8.0, 0.5 M EDTA pH 8.0, 1 M 
Tris-HCl pH 7.5 and 8.0, 5 M NaCl, 1 M MgCl2 and 1 M MgSO4. 
2.2.2.2 Bacterial cells 
TbfI solution: 30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium 
chloride, 50 mM manganese chloride, 15% (v/v) glycerol, adjusted to pH 5.8 with dilute 
acetic acid; autoclaved 
TbfII solution: 10 mM MOPS, 75 mM calcium chloride, 10 mM rubidium chloride, 15% 
(v/v) glycerol, adjusted to pH 6.5 with dilute NaOH; autoclaved 
2.2.2.3 X. laevis egg extracts 
De-jellying buffer: 20 mM Tris-HCl pH 8.5, 110 mM NaCl 
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5 MMR buffer: 100 mM HEPES-KOH pH 7.5, 2 M NaCl, 10 mM KCl, 5 mM MgSO4, 10 
mM CaCl2, 0.5 mM EDTA 
S buffer: 50 mM HEPES-KOH pH 7.5, 50 mM KCl, 2.5 mM MgCl2, 0.25 M sucrose 
SuNaSp buffer: 0.25 M sucrose, 75 mM NaCl, 0.5 mM spermidine, 0.15 mM spermine 
EB buffer: 50 mM HEPES-KOH pH 7.9, 50 mM KCl, 5 mM MgCl2, 5 mM EGTA, 2 mM 
β-ME 
ELB buffer: 10 mM HEPES-KOH pH 7.7, 50 mM KCl, 2.5 mM MgCl2 
Fixation buffer: 15 mM PIPES-KOH pH 7.2, 80 mM KCl, 15 mM NaCl, 1% v/v formalin, 
2 µgml-1 Hoechst 33258, 50% v/v glycerol 
STOP buffer: 80 mM Tris-HCl pH 8.0, 8 mM EDTA, 0.13% w/v phosphoric acid, 10% 
w/v ficoll, 5% w/v SDS, 0.2% w/v bromophenol blue 
10 TBE: 0.89 M Tris, 0.89 M boric acid, 20 mM EDTA 
2.2.2.4 Yeast cells 
LiT buffer: 10 mM Tris-HCl, pH 7.4, 100 mM lithium acetate; autoclaved 
LiT/PEG solution: 50% w/v PEG 3350 in LiT buffer; autoclaved 
HT DNA solution: herring sperm DNA (type XIV, Sigma) in TE buffer was extensively 
sonicated, subjected to phenol/chloroform extraction followed by ethanol precipitation 
as described by Sambrook and Russell (2001), resuspended in TE buffer at 10 mg·mL-
1 and finally boiled at 95C for 5 min 
Zymolyase solution: 50 µL of a 20 µgµL-1 zymolyase 20T solution and 50 µL of 1 M 
DTT were combined with 900 µL of sterile water just before required 
NaOH/β−ME solution: 925 µL of 2 M NaOH and 75 µL of 100% v/v β-ME were mixed 
just before required 
0.5 M citrate buffer: 0.5 M sodium citrate was mixed with a few mL of 0.5 M citric acid 
until the pH reached a value 7 
Propidium iodide stock solution: 20 µg·mL-1 propidium iodide in 50 mM citrate buffer 
STE buffer: 1.2 M sorbitol, 25 mM Tris-HCl pH 8.0, 25 mM EDTA pH 8.0; filter-sterilized 
STE-Zymolyase solution: 37 µL of STE buffer, 2 µL of 1M DTT and 1 µL of a 20 µgµL-1 
Zymolyase (20T) solution  
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HU buffer: 8 M urea, 5% w/v SDS, 200 mM Tris-HCl pH 6.8, 1 mM EDTA, 0.1% w/v 
bromophenol blue and 50 mM DTT 
2.2.2.5 Mammalian cells 
Trypsin/versene: 0.1% w/v trypsin, 0.7 mM EDTA, 0.2% w/v phenol red in 1 PBS 
(London Research Institute’s Media production team) 
PBS-Tx: 1 PBS + 0.1% v/v Triton X-100 
100 penicillin/streptomycin solution: 10,000 UmL-1 penicillin and 10,000 gmL-1 
streptomycin in 1 PBS (London Research Institute’s Media production team) 
Cell fractionation buffer A: 10 mM HEPES-KOH pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 
0.34 M sucrose and 10% v/v glycerol with freshly supplemented 1 Complete Protease 
Inhibitors (Roche) and 1 mM DTT  
Cell fractionation buffer B: 3 mM EDTA, 0.2 mM EGTA with freshly supplemented 1 
Complete Protease Inhibitors and 1 mM DTT 
2.2.2.6 General manipulation of DNA 
50 TAE: 2 M Tris base, 2 M glacial acetic acid and 50 mM EDTA 
10 TBE: 0.89 M Tris base, 0.89 M boric acid, 20 mM EDTA 
6 DNA Loading buffer: 50% w/v sucrose, 0.1% w/v bromophenol blue and 0.1% w/v 
xylene cyanol FF in TE  
2.2.2.7 General manipulation of proteins 
5 SDS-PAGE running buffer: 125 mM Tris base, 1.25 M glycine and 0.5% w/v SDS 
Coomassie Blue staining solution: 0.25% w/v Brilliant Blue R, 45% v/v methanol and 
10% (v/v) glacial acetic acid; filtered 
De-staining solution: 45% v/v methanol and 10% v/v glacial acetic acid 
Gel Drying solution: 20% v/v methanol and 3% v/v glycerol in water 
SYPRO fixing solution: 50% v/v ethanol and 7% v/v glacial acetic acid 
SYPRO wash solution: 10% v/v ethanol and 7% v/v glacial acetic acid 
Blotting buffer I: 300 mM Tris-HCl pH 10.4 and 15% v/v methanol 
Blotting buffer II: 30 mM Tris-HCl pH 10.4 and 15% v/v methanol 
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Blotting buffer III: 25 mM Tris-HCl pH 9.4, 40 mM 6-aminocaproic acid and 15% v/v 
methanol 
PBS-T: 1 PBS + 0.1% w/v Tween 20 
Blocking solution: 5% w/v non-fat dry milk powder (Sainsbury’s Basic) dissolved in 
PBS-T 
Gentle stripping buffer: 200 mM glycine, 0.1% w/v SDS and 1% v/v Tween 20, adjusted 
to pH 2.2 with HCl just before required 
Harsh stripping buffer: 100 mM Tris-HCl pH 7.5, 10 mM EDTA and 0.5% w/v SDS. 140 
µL of 100% v/v β-ME was added per 20 mL of stripping buffer just before required 
2.2.2.8 Protein purification 
Ni2+-NTA lysis buffer: 50 mM Tris-HCl pH 8, 300 mM, 20 mM imidazole and 2 mM 
freshly added β-ME 
Ni2+-NTA wash buffer: 50 mM Tris-HCl pH 8, 300 mM, 30 mM imidazole and 2 mM 
freshly added β-ME 
Ni2+-NTA elution buffer: 50 mM Tris-HCl pH 8, 300 mM, 250 mM imidazole and 2 mM 
freshly added β-ME 
E1 gel filtration buffer: 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM freshly added DTT  
Protein storage buffer: 20 mM HEPES-KOH pH 7.5, 200 mM KCl, 10% v/v glycerol and 
1 mM freshly added DTT 
E2 lysis buffer: 50 mM phosphate buffer pH 6.5, 50 mM NaCl and 1 mM freshly added 
DTT 
E2 elution buffer: 50 mM phosphate buffer pH 6.5, 300 mM NaCl and 1 mM freshly 
added DTT 
GST wash buffer: 50 mM Tris-HCl pH 8, 300 mM and 1 mM freshly added DTT 
GST elution buffer: 50 mM Tris-HCl pH 8, 300 mM, 15 mM freshly added reduced 
glutathione and 1 mM DTT 
PARP-1 lysis buffer: 50 mM Tris-HCl pH 7.5 and 500 mM NaCl 
2.2.2.9 Generation and affinity purification of polyclonal antibodies 
Antibody elution buffer I: 200 mM Glycine adjusted to pH 2.8 with HCl 
Antibody elution buffer II: 200 mM Glycine adjusted to pH 2.2 with HCl 
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Neutralization buffer: 0.5 M Tris-HCl pH 8 and 1.5 M KCl 
2.2.2.10 Enzymatic reactions 
Sumoylation buffer: 20 mM HEPES-KOH pH 7.5, 110 mM KOAc, 2 mM Mg(OAc)2, 
0.05% Tween 20, 0.2 µg·µL-1 BSA and 1 mM DTT 
Auto-parylation buffer: 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 4 mM MgCl2, 0.1 µg·µl-1 
BSA, 0.4 mM NAD+ and 1 mM DTT 
Extract buffer: 25 mM HEPES-KOH pH 7.9, 70 mM KCl and 1 mM DTT 
3C Cleavage buffer: 50 mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM MgCl2, 20 mM 
imidazole and 1 mM DTT 
Su-DBD wash buffer: 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM MgCl2, 20 mM 
imidazole and 1 mM DTT 
Su-DBD gel filtration buffer: 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM MgCl2 and 1 
mM DTT 
Su-PARP-1 wash buffer: 20 mM HEPES-KOH pH 7.5, 500 mM NaCl, 20 mM imidazole 
and 1 mM DTT 
Su-PARP-1 elution buffer: 20 mM HEPES-KOH pH 7.5, 500 mM NaCl, 400 mM 
imidazole and 1 mM DTT 
2.2.2.11 Analysis of protein-protein interactions 
Hypotonic buffer: 25 mM Tris-HCl pH 7.5, 10 mM KCl, 10 mM EDTA and 0.5% v/v 
Triton X-100 freshly supplemented with 1 Complete Protease Inhibitors 
Co-immunoprecipitation buffer: 25 mM Tris-HCl pH 7.5, 150 mM KCl, 10 mM EDTA 
and 0.1% v/v Triton X-100 
2.2.2.12 Analysis of protein sumoylation 
Ni2+-NTA Buffer A: 6 M guanidine hydrochloride, 100 mM phosphate buffer pH 8, 300 
mM NaCl, and 10 mM Tris-HCl pH 8 and 2 mM β-ME 
Ni2+-NTA Buffer C: 8 M urea, 100 mM sodium phosphate pH 6.3, and 10 mM Tris-HCl, 
pH 6.3. Alternatively, 8 M urea, 100 mM sodium phosphate pH 8.0, 10 mM Tris-HCl 
and 30 mM imidazole 
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RIPA buffer: 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% v/v Triton X-100, 
0.1% v/v sodium deoxycholate, freshly supplemented with 1 Complete Protease 
Inhibitors, 10 µgml-1 of each of leupeptide, pepstatin and chymostatin and 15 mM NEM 
2.2.2.13 Preparation of DNA substrates for in vitro sumoylation 
Topo I buffer: 50 mM Tris-HCl pH 7.5, 50 mM KCl, 10 mM MgCl2, 0.1 mM EDTA, 30 
µg· µL-1 BSA and 0.5 mM DTT 
Annealing buffer: 50 mM Tris-HCl pH 7.5 and 250 mM NaCl 
2.2.2.14 Analysis of protein-DNA interactions 
EMSA binding buffer: 50 mM Tris-HCl pH 7.4, 150 µM ZnSO4, 4 mM DTT, 10% v/v 
glycerol 
2.2.2.15 General methods for NMR spectroscopy 
NMR dialysis buffer: 50 mM Tris-HCl pH 7.0, 200 mM NaCl, 150 µM ZnSO4, 4mM [2H6] 
DTT 
2.3 DNA oligonucleotides 
DNA oligonucleotides were purchased from Sigma-Genosys, except for those that 
were biotinylated, which were instead obtained from Operon.  
# Name Sequence Sense/Use 
453 ScSIZ1 KO down AAGAAGACTCCAACTCAAACAGTTGAGTGTTCCATATACATTCTGTTTCACGTACGCTGCAGGTCGAC 
Sense, amplification of 
knockout cassettes 
454 ScSIZ1 KO up AAATATTTCATGAAAGAGCTGGACGGAACCGTCCAATTTTAGCCTCGTTTATCGATGAATTCGAGCTCG 
Antisense, amplification 
of knockout cassettes 
455 ScSIZ1 KO test CTAGAACTACCATTTTAGAGC Sense, testing of correct knockout  
843 XO GACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCC In vitro DNA substrate 
844 XO-c GGGTGAACCTGCAGGTGGGCAAAGATGTCCTAGCAAGGCACTGGTAGAATTCGGCAGCGTC 
Reverse complement to 
oHU843 
888 
XlSUMO1 PrSc 
down 
CGCGGATCCCTGGAAGTTCTGTTCCAGGGGCCC
ATGTCTGATCAGGAAGCTAAACCATC 
Sense, amplification of 
ORF 
889 XlSUMO1 up GCGCTGCAGTTACCCCCCAGTCTGTTCCTG Antisense, amplification of ORF 
890 XlSUMO2 down GCGCCCGGGCCCATGGCGGACGATAAGCCCAAG Sense, amplification of ORF 
891 XlSUMO2 up GCGCTGCAGTTATCCACCCGTCTGCTGCTG Antisense, amplification of ORF 
896 XlMMS21 down GCGCCCGGGCCCATGTCTGGCCGGTCAGCGCCTGTGG 
Sense, amplification of 
ORF 
897 XlMMS21 up GCGCTGCAGTGTTCAATGACGGCCTTTCTGCTTG Antisense, mutagenesis of ORF 
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972 pQE30 RGS-His6 down GCGCCATGGGAGGATCGCATCACCATCACC 
Sense, amplification of 
vector sequence 
973 pQE 3’UTR up GTCCAAGCTCAGCTAATTAAGCTTGGC Antisense, amplification of vector sequence 
1022 ScSIZ2 KO down CCACAAACGATACACTGATAATCAAGAAACGTATAAGGGAAAAGAGCACGCGTACGCTGCAGGTCGAC 
Sense, amplification of 
knockout cassettes 
1023 ScSIZ2 KO up 
AAATAAAAATAGAATACAATCGGAAAGGAAAGAA
ATCAAAAGACGGTTAAATCGATGAATTCGAGCTC
G 
Antisense, amplification 
of knockout cassettes 
1024 ScSIZ2 KO test GTGTTAATTTATCCATCCATTTTAG Sense, testing of correct knockout 
1048 ScORC1 tag down TAGAAGAAGCCAAAAGAGCCATGAATGAGGATGAGACATTGAGAAATTTACGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassettes 
1049 ScORC1 tag up TAGGTATATGTATGTGTATGCTAGGTCATGAATAATAAAAACCGAATCTAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassettes 
1122 ssDNA-bio 25 ATGCTAGTACACTGCGTTTATGTAT In vitro DNA substrate. 3’ biotinylated  
1123 ssDNA-bio 15 ACTGCGTTTATGTAT In vitro DNA substrate. 3’ biotinylated  
1124 ssDNA-bio 8 TTATGTAT In vitro DNA substrate. 3’ biotinylated  
1125 ssDNA 25 ATACATAAACGCAGTGTACTAGCAT Reverse complement to oHU1122 
1126 ssDNA 15 ATACATAAACGCAGT Reverse complement to oHU1123 
1127 ssDNA 8 ATACATAA Reverse complement to oHU1124 
1132 ScRAD54 tag down CGAGCATCATTACAATGATATCAGTTTTGCATTTCAATATATTTCACATCGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassettes 
1133 ScRAD54 tag up CGAATTCTACTTTTTGTTTTTGTTTTATAAGTACATGTATGTAAGAGATCAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassettes 
1134 ScRAD54 tag test CGTTGAAAGGTTGTTTAGTTC Sense, testing of correct tagging 
1135 ScRFC1 tag down GACTGCCACCAGTAAACCTGGTGGTAGCAAAAAAAGGAAAACGAAAGCACGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassettes 
1136 ScRFC1 tag up CAATGAGAAGAAAAGTGTAATTATAATCTTAGTGTATGAATAAATCAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassettes 
1137 ScRFC1 tag test GTGGATTCACGCGGAAATAC Sense, testing of correct tagging 
1138 ScORC2 tag down CACGTATGCGGAACTTGAAAAACTTCTGAAAACCGTTTTAAATACTCTACGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassettes 
1139 ScORC2 tag up GCTAGCAAGCCTAGTACTATTACAATTGTTCGTGATATGTATACATTTAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassettes 
1140 ScORC2 tag test CCAAGAAGATGTATAAGTTGC Sense, testing of correct tagging 
1150 ScPOL1 tag down GGACGTCGCTACGTTGATATGACTAGCATATTTGATTTCATGCTAAATCGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassettes 
1151 ScPOL1 tag up CTATATAGAATATTCATGAGATCACACAACACATACAAAATACTTACCTAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassettes 
1152 ScPOL1 tag test GACAGCACATGCGGTATAG Sense, testing of correct tagging 
1185 ScORC3 tag down 
AAAGCACCAAGAGTTACGATCTGGTAGAAAAATG
TGTCTGGAGAGGAATTCGTACGCTGCAGGTCGA
C 
Sense, amplification of 
tagging cassettes 
1186 ScORC3 tag up ATATATGTATGGTTATTTATTTACTTATTTATCCGTGCATTCTTTATCTAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassettes 
1187 ScORC3 tag test GAGGCGAATATGACTATCAAC Sense, testing of correct tagging 
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1188 ScORC4 tag down TAAGAAGAATTATCCCCAAATCTAATATGTACTACTCCTGGACACAACTGCGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassette 
1189 ScORC4 tag up TCAGAGTTGCTACCGCCAATAAAATGTCTGTATATTGTTCCCAAGATTCAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassette 
1190 ScORC4 tag test  CGACAATACTATCAAACTATG Sense, testing of correct tagging 
1191 ScORC5 tag down CAGAATCTGTTCATTTCAATATCAGCGATTACTTCAGCGATATTCACGAACGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassette 
1192 ScORC5 tag up 
GTTGTTTCGAACGTATCCTGCCCTCTGGATACCT
TCCAGGGAGATAATCAATCGATGAATTCGAGCTC
G 
Antisense, amplification 
of tagging cassette 
1193 ScORC5 tag test CCCTATTCAAGGTAAGGCGG Sense, testing of correct tagging 
1194 ScORC6 tag down ATATTTGGAAGAAAAGAATTGAAATGGATTTGGCATTAACAGAACCTTTACGTACGCTGCAGGTCGAC 
Sense, amplification of 
tagging cassette 
1195 ScORC6 tag up ATGTCAGGTATTGGTCAAATATATACTTTTAGTTAATACTGGATATGTTAATCGATGAATTCGAGCTCG 
Antisense, amplification 
of tagging cassette 
1196 ScORC6 tag test GATGTGCAGCTTGATGTTGAC Sense, testing of correct tagging 
1199 ScORC1 ORF down GCGCCCGGGAAAAATGGCAAAAACGTTGAAGG Sense, amplification of ORF 
1200 ScORC1 ORF up GCGCACGTGCTCGAGCTATAAATTTCTCAATGTCTCATCC 
Antisense, amplification 
of ORF 
1203 ScORC2 ORF down GCGCCCGGGAAAAATGCTAAATGGGGAAGACTTTG 
Sense, amplification of 
ORF 
1204 ScORC2 ORF up GCCCTGCAGTTATAGAGTATTTAAAACGG Antisense, amplification of ORF 
1286 ARS1 down GAGAGCTTACATTTTATGTTAGCTGG 
Sense, amplification of 
ARS1 from YCp family 
plasmids 
1287 ARS1 up [CACATGTTAAAATAGTGAAGG AGC 
Antisense, amplification 
of ARS1 from YCp 
family plasmids. 5’ 
biotinylated 
1288 ScORC3 ORF down CGCCCGGGAATGAGCGACCTTAACCAATCC Sense, amplification of ORF 
1289 ScORC3 ORF up CGCCTGCAGTCTAAATTCCTCTCCAGACAC Antisense, mutagenesis of ORF 
1291 ScORC4 ORF down CGCCCGGGAATGACTATAAGCGAAGCTCG Sense, amplification of ORF 
1292 ScORC4 ORF up GGGATCCTTCACAGTTGTGTCCAGGAG Antisense, mutagenesis of ORF 
1294 ScORC5 ORF down CGCCCGGGAATGAATGTGACCACTCCGG Sense, amplification of ORF 
1295 ScORC5 ORF up CGGATCCTCATTCGTGAATATCGCTGAAG Antisense, mutagenesis of ORF 
1297 ScORC6 ORF down CGCCCGGGAATGTCCATGCAACAAGTCC Sense, amplification of ORF 
1298 ScORC6 ORF up CGCCTGCAGGTTATAAAGGTTCTGTTAATG Antisense, mutagenesis of ORF 
1299 ScREP1 down GCCAGAGGATGGCGAACC Sense, for testing loss of 2-µ plasmid 
1300 ScREP1 up GCTCGCGTTGCATTTTCG Antisense, for testing loss of 2-µ plasmid 
1339 HsAPLF up TCATTTTCTTTTCATAAACCTTTTTGC Antisense, amplification of ORF 
1340 HsAprataxin down CACCATGAGTAACGTGAATTTGTCCGTC Sense, amplification of ORF 
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1341 HsAprataxin up TTACTCTTGTGATTCTAGGAAGTATTCTG Antisense, amplification of ORF 
1343 HsBLC2 up TTACTTGTGGCCCAGATAGGCACCCAGG Antisense, amplification of ORF 
1346 HsCaspase 3 down CACCATGGAGAACACTGAAAACTCAGTGG Sense, amplification of ORF 
1347 HsCaspase 3 up TCAGTGATAAAAATAGAGTTCTTTTGTGAGC Antisense, amplification of ORF 
1349 HsCaspase 7 up TCATTGACTGAAGTAGAGTTCCTTGGTG Antisense, amplification of ORF 
1351 HsCENP-A up TCAGCCGAGTCCCTCCTCAAGGCCCCG Antisense, amplification of ORF 
1353 HsCENP-B up TCAGCTTTGATGTCCAAGACCTCGAAC Antisense, amplification of ORF 
1355 HsLigase III up TCAGCAGGGAGCTACCAGTCTCCGTTTCC Antisense, amplification of ORF 
1356 Hsp21 down CACCATGTCAGAACCGGCTGGGGATGTCC Sense, amplification of ORF 
1357 Hsp21 up TCAGGGCTTCCTCTTGGAGAAGATCAGC Antisense, amplification of ORF 
1358 Hsp53 down CACCATGGAGGAGCCGCAGTCAGATCC Sense, amplification of ORF 
1359 Hsp53 up TCAGTCTGAGTCAGGCCCTTCTGTCTTG Antisense, amplification of ORF 
1360 HsPARP1 down CACCCATATGGCGGAGTCTTCGGATAAGCTC Sense, amplification of ORF 
1361 HsPARP1 up TTAGGCGCCCCACAGGGAGGTCTTAAAATTG Antisense, amplification of ORF 
1365 HsPARP3 up TCAGAGGTGGACCTCCAGCAGGTAGCG Antisense, amplification of ORF 
1367 HsPCNA up TCAAGATCCTTCTTCATCCTCGATCTTGG Antisense, amplification of ORF 
1373 HsTRF2IP up TCATTTCTTTCGAAATTCAATCCTCCG Antisense, amplification of ORF 
1374 HsWRN down CACCATGAGTGAAAAAAAATTGGAAAC Sense, amplification of ORF 
1375 HsWRN up TCAACTAAAAAGACCTCCCCTTTTCG Antisense, amplification of ORF 
1377 HsXRCC1 up TCAGGCTTGCGGCACCACCCCATAGAGC Antisense, amplification of ORF 
1378 XlSUMO1 down CACCGGCGCCCATATGTCTGATCAGGAAGCTAAACC 
Sense, amplification of 
ORF 
1379 XlSUMO1 up CCTGCATATGGGCGCCAGTCTGTTCCTGATAAACTTC 
Antisense, amplification 
of ORF 
1380 XlSUMO2 down CACCGGCGCCCATATGGCGGACGATAAGCCCAAGG 
Sense, amplification of 
ORF 
1381 XlSUMO2 up CCTGCATATGGGCGCCCGTCTGCTGCTGGAAAACATC 
Antisense, amplification 
of ORF 
1382 PARP1K203R up CTTTCCTTCAGATCTGACTCCTGGGAGCTGC Sense, mutagenesis of ORF 
1383 HsPARP1K203R down GGAGTCAGATCTGAAGGAAAGAGAAAAGGC Antisense, mutagenesis of ORF 
1384 HsPARP1K486R up CTCTGCCCTCACCTCTGCCCCCCAAGGG Sense, mutagenesis of ORF 
1385 HsPARP1K486R down GGCAGAGGTGAGGGCAGAGCCTGTTGAAG Antisense, mutagenesis of ORF 
1411 HsWRN +980 up CTGTTGTACTCCCCCAG Antisense, amplification 
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of partial ORF 
1413 HsWRN +1960 up TTGCTGGAGCAGGCCC Antisense, amplification of partial ORF 
1415 HsWRN +2930 up ATTCCAAATTTTTCGCC Antisense, amplification of partial ORF 
1416 
HsWRN seq7 +3880 
up CAGCTTTCACCGCTTGGG 
Antisense, amplification 
of partial ORF 
1449 
XlSUMO1K27/36/37R 
down 
CAGGAAGCTAGACCATCTAGTGAGGATCTAGGAG
ACAGAAGAGAAGGAGG 
Sense, mutagenesis of 
ORF 
1450 
XlSUMO1K27/36/37R 
up 
CCTCCTTCTCTTCTGTCTCCTAGATCCTCACTAGA
TGGTCTAGCTTCCTG 
Antisense, mutagenesis 
of ORF 
1451 
XlSUMO2K25/27/31R 
down 
GCGGACGATAGGCCCAGGGAAGGAGTTAGGACT
GAGAAC 
Sense, mutagenesis of 
ORF 
1452 
XlSUMO2K25/27/31R 
up 
GTTCTCAGTCCTAACTCCTTCCCTGGGCCTATCG
TCCGC 
Antisense, mutagenesis 
of ORF 
1453 HsAPLF down ATGTCCGGGGGCTTCGAGC Sense, amplification of ORF 
1454 HsCENP-A down ATGGGCCCGCGCCGCCGG Sense, mutagenesis of ORF 
1455 HsLigase III down ATGGCTGAGCAACGGTTCTG Sense, amplification of ORF 
1458 HsPCNA down ATGTTCGAGGCGCGCCTGG Sense, amplification of ORF 
1459 HsPARP-3 down ATGGCTCCAAAGCCGAAGC Sense, amplification of ORF 
1470 BCL-2 down ATGGCGCACGCTGGGAG Sense, amplification of ORF 
1471 HsCaspase 7 down ATGGCAGATGATCAGGGC Sense, amplification of ORF 
1472 HsCENP-B down ATGGGCCCCAAGAGGCGAC Sense, amplification of ORF 
1473 HsPARP-2 down ATGGCGGCGCGGCGGCGACG Sense, amplification of ORF 
1474 HsTRF2IP down ATGGCGGAGGCGATGG Sense, amplification of ORF 
1475 HsXRCC1 down ATGCCGGAGATCCGCCTCC Sense, amplification of ORF 
1566 
HsAPLF up w/o 
STOP TTTTCTTTTCATAAACCTTTTTGC 
Antisense, amplification 
of ORF 
1567 
HsXRCC1 up w/o 
STOP GGCTTGCGGCACCACCCCATAGAGC 
Antisense, amplification 
of ORF 
1593 HsPARP1M890V down CGTGACAGGCTACGTGTTTGGTAAAGGG Sense, mutagenesis of ORF 
1594 HsPARP1M890V up CCCTTTACCAAACACGTAGCCTGTCACG Antisense, mutagenesis of ORF 
1595 HsPARP1D899N down GATCTATTTCGCTAACATGGTCTCCAAG Sense, mutagenesis of ORF 
1596 HsPARP1D899N up CTTGGAGACCATGTTAGCGAAATAGATC Antisense, mutagenesis of ORF 
1605 HsSUMO1T95R down CAGGAACAAAGGGGGGGTCATTC Sense, mutagenesis of ORF 
1606 SUMO1T95R up GAATGACCCCCCCTTTGTTCCTG Antisense, mutagenesis of ORF 
- Dumbbell DNA CGGTCGATCGTAAGATCGACCGGCGCTGGAGGTTCCTCCAGCGC 
In vitro DNA substrate, 
5’ phosphorylated 
- HsPARP-1R138I down GATAGAAAAGGGCCAGGTGATTCTGTCCAAGAAGATGGTGG 
Sense, amplification of 
ORF 
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- HsPARP-1R138I up CCACCATCTTCTTGGACAGAATCACCTGGCCCTTTTCTATC 
Antisense, mutagenesis 
of ORF 
- HsPARP-1R122I down GTATGCCAAGTCCAACATTAGTACGTGCAAGGGGTG 
Sense, amplification of 
ORF 
- HsPARP-1R122I up CACCCCTTGCACGTACTAATGTTGGACTTGGCATAC 
Antisense, mutagenesis 
of ORF 
 
Table 2.5 - A list of the DNA oligonucleotides used in this thesis. Sc = S. cerevisiae, Xl = X. 
laevis, Hs= Homo sapiens. 
 
2.4 Plasmids 
# Plasmid name Description/Origin/References 
82 pGBT9 Yeast two-hybrid vector for production of GAL4 DBD fusion constructs (Clontech) 
145 pGAD424 Yeast two-hybrid vector for production of GAL4 AD fusion constructs (Clontech) 
150 pQE30 Overproduction in Escherichia coli (Qiagen) 
229 pYM6 To create 9myc tagging cassettes carrying the TRP1 marker, Knop et al. (1999) 
233 pFA-HIS3MX6 To create knockout cassettes carrying the HIS3MX6 marker, Wach et al. (1994) 
273 pGAD424-ScUBC9 Yeast two-hybrid assay (In-house)  
452 pFA-KanMX4 To create knockout cassettes carrying the KanMX4 marker, Wach et al. (1994) 
620 pGBT9-ScSMT3 Yeast two-hybrid assay (In-house)  
654 YEp181-ADH/T Constitutive production of a protein in yeast (In-house) 
822 YEp181-CUP1-His6-ScSMT3 Cu
2+-inducible production of His6-Smt3 in yeast (In-house) 
839 pET15b Over-production in BL21(DE3) E. coli (Merck) 
1037 pGAD424-ScSMT3∆GG Yeast two-hybrid assay (In-house)  
1038 pGBT9-ScSMT3∆GG Yeast two-hybrid assay (In-house)  
1237 pET23a-MmUBC9 Over-production of metazoan Ubc9 in E. coli (Frauke Melchior) 
1238 pET11a-HsSUMO1∆C4 
Over-production of mature human SUMO1 in E. coli (Frauke 
Melchior) 
1337 pET21(+) Over-production in BL21(DE3) E. coli (Merck) 
1338 pET-XlPCNA Over-production of His6-PCNA in E. coli, Leach and Michael (2005) 
1551 pET21-XlORC1-His6 Over-production of ORC1-His6 in E. coli, Tugal et al. (1998) 
1558 pDK243 Plasmid stability assay in yeast (1 ARS1, Hogan and Koshland, 1992) 
1559 pDK368-7 Plasmid stability assay in yeast (1 ARS1 + 7 H4 ARS, Hogan and Koshland, 1992) 
1791 pGGWA 
Gateway destination vector for over-production of N-terminally 
GST-tagged and C-terminally His6-tagged proteins in E. coli, 
Busso et al. (2005) 
1795 pDEST22 Gateway destination vector for the generation of GAL4 AD fusions for use in the yeast two hybrid assay (Invitrogen) 
1796 pDEST32 Gateway destination vector for the generation of GAL4 BDB fusions for use in the yeast two hybrid assay (Invitrogen) 
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1797 pGAD424-GW Gateway-compatible pGAD424, Albers et al. (2005) 
1798 pGBT9-GW Gateway-compatible pGBT9, Albers et al. (2005) 
1800 pDEST10 
Gateway destination BAC-to-BAC-compatible vector for the 
production of N-terminally His6-tagged proteins in insect cells 
(Invitrogen) 
1801 pDEST12.2 Gateway destination vector for the constitutive production of non-tagged proteins in mammalian cells (Invitrogen) 
1802 pDEST/TO/FLAG/FRT 
Gateway destination Flp-In-compatible vector for the Tet-inducible 
production of N-terminally FLAG-tagged proteins in mammalian 
cells (Simon Boulton) 
1804 pDEST/N-FLAG3/FRT 
Gateway destination Flp-In-compatible vector for the constitutive 
production of N-terminally FLAG3-tagged proteins in mammalian 
cells (Stephen West) 
1805 pDEST-myc 
Gateway destination vector for the constitutive production of N-
terminally myc-tagged proteins in mammalian cells (Simon 
Boulton) 
1809 pOG44 Constitutive production of 
ScFlp1(F70L) in mammalian cells, 
O'Gorman et al. (1991). For use with Invitrogen’s Flp-In System 
2019 pBIS-GALkFLP(URA3)  Curing yeast of the 2-µm plasmid Tsalik and Gartenberg (1998) 
2021 pET23a-MsUBC9(C93S) 
Over-production of metazoan UBC9(C93S) in E. coli (Frauke 
Melchior) 
2022 pDuet-1-
HsUba2, 
HsAos1 Over-production of human SUMO E1 in E. coli (Christopher Lima) 
- 
pDEST/C-
FLAG3/FRT-PARP-
1 
Constitutive production of the specified C-terminally FLAG3-
tagged PARP-1 construct in mammalian cells (Stephen West) 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K203 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K486R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K233R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K249R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K512R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K203/486R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K233/486R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K249/486R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K486/512R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K305/486R 
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- 
pDEST/C-
FLAG3/FRT-PARP-
1K352/486R 
- 
pDEST/C-
FLAG3/FRT-PARP-
1K442/486R 
- pSG5-His6-HsSUMO1 
Constitutive over-production of mature His6-SUMO1 in 
mammalian cells, Muller et al. (2000) 
 
Table 2.6 - A list of the plasmids used in this thesis that were commercially available or 
were generated by others. Sc = S. cerevisiae, Xl = X. laevis, Hs= H. sapiens. 
 
 
# Name Use/Construction 
1284 pET15b-PrSc-XlSUMO1 
Overproduction of His6-PrSc-SUMO1 in E. coli.  Reverse 
transcription (oHU888/oHU889) from frog egg RNA, cloned 
BamHI/PstI into pHU150. PCR (oHU972/oHU973) from 
this plasmid cloned NcoI/BlpI into pHU839 
1285 pET21-PrSc-XlSUMO2 
Overproduction of His6-PrSc-SUMO2 in E. coli. Reverse 
transcription (oHU890/oHU891) from frog egg RNA, cloned 
BamHI/PstI into pHU150. His6-PrSc-SUMO2 from this 
plasmid was cloned EcoRI/HindIII into pHU1337 
1561 pGAD424-ScORC1 Yeast two-hybrid analysis. PCR from genomic DNA (oHU1199/oHU1200), cloned SmaI/XhoI into pHU145 
1562 pGBT9-ScORC1 Yeast two-hybrid analysis. PCR from genomic DNA (oHU1199/oHU1200), cloned SmaI/XhoI into pHU82 
1563 pGAD424-ScORC2 Yeast two-hybrid analysis. PCR from genomic DNA (oHU1203/oHU1200), cloned SmaI/PstI into pHU145 
1564 pGBT9-ScORC2 Yeast two-hybrid analysis. PCR from genomic DNA (oHU1203/oHU1200), cloned SmaI/PstI into pHU82 
1730 pENTR/D-TOPO-HsPARP-1 
Gateway donor vector. PCR from GeneService IMAGE 
Clone 5193735 (oHU1360/oHU1361) TOPO-cloned into 
pENTR/D-TOPO 
1731 pENTR/D-TOPO-PARP-1(K203R) 
Gateway donor vector. Site-directed mutagenesis of 
pHU1730 (oHU1382/oHU1383) 
1732 pENTR/D-TOPO-PARP-1(K486R) 
Gateway donor vector. Site-directed mutagenesis of 
pHU1730 (oHU1384/oHU1385) 
1733 pENTR/D-TOPO-PARP-1K203/486R 
Gateway donor vector. Site-directed mutagenesis of 
pHU1731 (oHU1384/oHU1385) 
1735 pENTR/D-TOPO-PARP-1M890V, D899N 
Gateway donor vector. Site-directed mutagenesis of 
pHU1730 (oHU1593/1594 and oHU1595/1596) 
1740 pENTR/D-TOPO-SUMO1-PARP-1K203/486R 
Gateway donor vector. PCR from pHU1284 
(oHU1378/oHU1379) cloned with NdeI into pUH1733 
1741 pENTR/D-TOPO-SUMO2-PARP-1K203/486R 
Gateway donor vector. PCR from pHU1285 
(oHU1380/oHU1381) cloned with NdeI into pUH1733 
 
1742 pENTR/D-TOPO-PARP-1K203/486R-SUMO1 
Gateway donor vector. PCR from pHU1284 
(oHU1378/oHU1379) cloned with KasI into pUH1733 
1743 pENTR/D-TOPO-PARP-1K203/486R-SUMO2 
Gateway donor vector. PCR from pHU1285 
(oHU1380/oHU1381) cloned with KasI into pUH1733 
 
1748 pENTR/D-TOPO-PARP-1C21G Gateway donor vector. Fragment from pDONR221-PARP-1C21G (Stephen West) cloned ApaI/BsaBI into pHU1730 
1749 pENTR/D-TOPO-PARP-1R122/138I 
Gateway donor vector. Site-directed mutagenesis of 
pHU1730 (oligonucleotides donated by Sebastian 
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Eustermann) 
1750 pENTR/D-TOPO-PARP-1C298A 
Gateway donor vector. Site-directed mutagenesis of 
pHU1730 (oHU1645/oHU1646) 
1753 pENTR/D-TOPO-PARP-1K203/486R, M890V, D899N 
Gateway donor vector. Fragment from pHU1733 cloned 
NdeI/PstI into pHU1735 
1754 pENTR/D-TOPO-PARP-1K203/486R, M890V, D899N-SUMO1 
Gateway donor vector. PCR from pHU1284 
(oHU1378/oHU1379) cloned with KasI into pUH1735 
1755 pENTR/D-TOPO-PARP-1K203/486R, M890V, D899N-SUMO2 
Gateway donor vector. PCR from pHU1285 
(oHU1380/oHU1381) cloned with KasI into pUH1735 
1756 pCR8⁄GW⁄TOPO-HsAPLF 
Gateway donor vector. PCR from GeneService IMAGE 
clone 6042653 (oHU1453/1339) TOPO-cloned into 
pCR8/GW/TOPO 
1757 pENTR/D-TOPO-HsAprataxin Gateway donor vector. PCR from human cDNA (oHU1340/1341) TOPO-cloned into pENTR/D-TOPO 
1758 pCR8⁄GW⁄TOPO-HsBCL2 
Gateway donor vector. PCR from a plasmid donated by 
Julian Downward (oHU1470/1343) TOPO-cloned into 
pCR8/GW/TOPO 
1760 pENTR/D-TOPO-
HsCaspase 
3 
Gateway donor vector. PCR from human cDNA 
(oHU1346/1347) TOPO-cloned into pENTR/D-TOPO 
1761 pCR8⁄GW⁄TOPO-
HsCaspase 
7 
Gateway donor vector. PCR from human cDNA 
(oHU1471/1349) TOPO-cloned into pCR8/GW/TOPO 
1762 pCR8⁄GW⁄TOPO-HsCENP-A 
Gateway donor vector. PCR from GeneService IMAGE 
clone 3461992 (oHU1454/1351) TOPO-cloned into 
pCR8/GW/TOPO 
1763 pCR8⁄GW⁄TOPO-HsCENP-B 
Gateway donor vector. PCR from GeneService IMAGE 
clone 6470289 (oHU1472/1353) TOPO-cloned into 
pCR8/GW/TOPO 
1764 pCR8⁄GW⁄TOPO-HsLigase III 
Gateway donor vector. PCR from a plasmid donated by 
Tomas Lindhal (oHU1455/1355) TOPO-cloned into 
pCR8/GW/TOPO 
1765 pENTR/D-TOPO-Hsp53 Gateway donor vector. PCR from human cDNA (oHU1358/1359) TOPO-cloned into pENTR/D-TOPO 
1766 pCR8⁄GW⁄TOPO-HsPARP-3 
Gateway donor vector. PCR from GeneService IMAGE 
clone 4763951 (oHU1459/1365) TOPO-cloned into 
pCR8/GW/TOPO 
1767 pCR8⁄GW⁄TOPO-HsPCNA 
Gateway donor vector. PCR from a plasmid donated by 
Svend Petersen-Mahrt (oHU1458/1367) TOPO-cloned into 
pCR8/GW/TOPO 
1768 pENTR/D-TOPO-XlSUMO1 Gateway donor vector. PCR from pHU1284 (oHU1378/oHU1379) TOPO-cloned into pENTR/D-TOPO 
1769 pENTR/D-TOPO-XlSUMO2 Gateway donor vector. PCR from pHU1285 (oHU1380/oHU1381) TOPO-cloned into pENTR/D-TOPO 
1770 pCR8⁄GW⁄TOPO-HsTRF2IP 
Gateway donor vector. PCR from GeneService IMAGE 
clone 5760351 with oHU1474 and 1373 and TOPO-cloned 
into pCR8/GW/TOPO 
1771 pENTR/D-TOPO-HsWRN 
Gateway donor vector. PCR from a plasmid donated by 
Ray Monnat (oHU1374/oHU1375) TOPO-cloned into 
pENTR/D-TOPO 
1772 pCR8⁄GW⁄TOPO-HsXRCC1 
Gateway donor vector. PCR from a plasmid donated by 
Tomas Lindhal (oHU1475/1377) TOPO-cloned into 
pCR8/GW/TOPO 
1774 pCR8 APLF w/o STOP Gateway donor vector. PCR from pHU1756 (oHU1453/oHU1566) TOPO-cloned into pCR8/GW/TOPO 
1775 pCR8 XRCC1 w/o STOP Gatewaty donor vector. PCR from pHU1772 (oHU1475/oHU1567) TOPO-cloned into pCR8/GW/TOPO 
1806 pDEST-eGFP-myc Gateway destination vector for the constitutive production of N-terminally eGFP-myc-tagged proteins in mammalian 
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cells. eGFP from pEGFP-C1 (Clontech) cloned 
NdeI/HindIII into pHU1805 
1810 pDEST12.2-PARP-1 Constitutive over-production in mammalian cells. LR recombination between pHU1730 and pHU1801 
1811 pDEST12.2-PARP-1K203/486R Constitutive over-production in mammalian cells LR recombination between pHU1733 and pHU1801 
1816 pDEST12.2-PARP-1
K203/486R-
SUMO2 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1743 and pHU1801 
1818 pDEST/TO/FLAG/FRT-PARP-1 
Tet-inducible over-production in mammalian cells. LR 
recombination between pHU1730 and pHU1802 
1819 pDEST/TO/FLAG/FRT-PARP-1K203/486R 
Tet-inducible over-production in mammalian cells. LR 
recombination between pHU1733 and pHU1802 
1823 pDEST/TO/FLAG/FRT-PARP-1K203/486R-SUMO2 
Tet-inducible over-production in mammalian cells. LR 
recombination between pHU1743 and pHU1802 
1824 pDEST/N-FLAG3/FRT-PARP1 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1730 and pHU1804 
1825 pDEST/N-FLAG3/FRT-PARP-1K203/486R 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1733 and pHU1804 
1826 pDEST/N-FLAG3/FRT-PARP-1K203/486R-SUMO2 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1743 and pHU1804 
1833 pDEST-eGFP-myc-PARP-1 WT 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1730 and pHU1806 
1834 pDEST-eGFP-myc-PARP-1K203/486R 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1733 and pHU1806 
1836 pDEST-eGFP-myc-PARP-1K203/486R-SUMO2 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1743 and pHU1806 
1841 pDEST10-PARP-1 BAC-to-BAC-based bacmid cloning. LR recombination between pHU1730 and pHU1800 
1842 pDEST10-PARP-1K203R BAC-to-BAC-based bacmid cloning. LR recombination between pHU1731 and pHU1800 
1843 pDEST10-PARP-1K486R BAC-to-BAC-based bacmid cloning. LR recombination between pHU1732 and pHU1800 
1844 pDEST10-PARP-1K203/486R BAC-to-BAC-based bacmid cloning. LR recombination between pHU1733 and pHU1800 
1849 pDEST10-PARP-1
K203/486R-
SUMO2 
BAC-to-BAC-based bacmid cloning. LR recombination 
between pHU1743 and pHU1800 
1850 pDEST10-PARP-1C21G BAC-to-BAC-based bacmid cloning. LR recombination between pHU1748 and pHU1800 
1851 pDEST10-PARP-1R122/138R BAC-to-BAC-based bacmid cloning. LR recombination between pHU1749 and pHU1800 
1852 pDEST10-PARP-1C298A BAC-to-BAC-based bacmid cloning. LR recombination between pHU1750 and pHU1800 
1857 pGGWA-APLF Over-production of GST-APLF-His6 in E. coli. LR recombination between pHU1774 and pHU1791 
1860 pGGWA-XRCC1 Over-production of GST-XRCC1-His6 in E. coli. LR recombination between pHU1775 and pHU1791 
1862 pDEST22-PARP-1 Yeast two-hybrid assay. LR recombination between pHU1730 and pHU1795 
1863 pDEST22-PARP-1K203/486R Yeast two-hybrid assay. LR recombination between pHU1733 and pHU1795 
1868 pDEST22-SUMO1-PARP-1K203/486R 
Yeast two-hybrid assay. LR recombination between 
pHU1740 and pHU1795 
1869 pDEST22-SUMO2-PARP-1K203/486R 
Yeast two-hybrid assay. LR recombination between 
pHU1741 and pHU1795 
1870 pDEST22-PARP-1
K203/486R-
SUMO1 
Yeast two-hybrid assay. LR recombination between 
pHU1742 and pHU1795 
1871 pDEST22-PARP-1K203/486R- Yeast two-hybrid assay. LR recombination between 
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SUMO2 pHU1743 and pHU1795 
1872 pDEST22-APLF Yeast two-hybrid assay. LR recombination between pHU1756 and pHU1795 
1873 pDEST22-Aprataxin Yeast two-hybrid assay. LR recombination between pHU1757 and pHU1795 
1874 pDEST22-BCL2 Yeast two-hybrid assay. LR recombination between pHU1758 and pHU1795 
1876 pDEST22-Caspase 3 Yeast two-hybrid assay. LR recombination between pHU1760 and pHU1795 
1877 pDEST22-Caspase 7 Yeast two-hybrid assay. LR recombination between pHU1761 and pHU1795 
1878 pDEST22-CENP-A Yeast two-hybrid assay. LR recombination between pHU1762 and pHU1795 
1879 pDEST22-CENP-B Yeast two-hybrid assay. LR recombination between pHU1763 and pHU1795 
1880 pDEST22-Ligase III Yeast two-hybrid assay. LR recombination between pHU1764 and pHU1795 
1881 pDEST22-p53 Yeast two-hybrid assay. LR recombination between pHU1765 and pHU1795 
1882 pDEST22-PARP-3 Yeast two-hybrid assay. LR recombination between pHU1766 and pHU1795 
1883 pDEST22-PCNA Yeast two-hybrid assay. LR recombination between pHU1767 and pHU1795 
1884 pDEST22-SUMO1 Yeast two-hybrid assay. LR recombination between pHU1768 and pHU1795 
1885 pDEST22-SUMO2 Yeast two-hybrid assay. LR recombination between pHU1769 and pHU1795 
1886 pDEST22-TRF2IP Yeast two-hybrid assay. LR recombination between pHU1770 and pHU1795 
1887 pDEST22-WRN Yeast two-hybrid assay. LR recombination between pHU1771 and pHU1795 
1888 pDEST22-XRCC1 Yeast two-hybrid assay. LR recombination between pHU1772 and pHU1795 
1900 pDEST32-PARP1 WT Yeast two-hybrid assay. LR recombination between pHU1730 and pHU1796 
1901 pDEST32-PARP1K203/486R Yeast two-hybrid assay. LR recombination between pHU1733 and pHU1796 
1906 pDEST32-SUMO1-PARP-1K203/486R 
Yeast two-hybrid assay. LR recombination between 
pHU1740 and pHU1796 
1907 pDEST32-SUMO2-PARP-1K203/486R 
Yeast two-hybrid assay. LR recombination between 
pHU1741 and pHU1796 
1908 pDEST32-PARP-1
K203/486R-
SUMO1 
Yeast two-hybrid assay. LR recombination between 
pHU1742 and pHU1796 
1909 pDEST32-PARP-1
K203/486R-
SUMO2 
Yeast two-hybrid assay. LR recombination between 
pHU1743 and pHU1796 
1910 pDEST32-APLF Yeast two-hybrid assay. LR recombination between pHU1756 and pHU1796 
1911 pDEST32-Aprataxin Yeast two-hybrid assay. LR recombination between pHU1757 and pHU1796 
1912 pDEST32-BCL2 Yeast two-hybrid assay. LR recombination between pHU1758 and pHU1796 
1914 pDEST32-Caspase 3 Yeast two-hybrid assay. LR recombination between pHU1760 and pHU1796 
1915 pDEST32-Caspase 7 Yeast two-hybrid assay. LR recombination between pHU1761 and pHU1796 
1916 pDEST32-CENP-A Yeast two-hybrid assay. LR recombination between pHU1762 and pHU1796 
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1917 pDEST32-Ligase III Yeast two-hybrid assay. LR recombination between pHU1764 and pHU1796 
1918 pDEST32-p53 Yeast two-hybrid assay. LR recombination between pHU1765 and pHU1796 
1919 pDEST32-PARP-3 Yeast two-hybrid assay. LR recombination between pHU1766 and pHU1796 
1920 pDEST32-PCNA Yeast two-hybrid assay. LR recombination between pHU1767 and pHU1796 
1921 pDEST32-SUMO1 Yeast two-hybrid assay. LR recombination between pHU1768 and pHU1796 
1922 pDEST32-SUMO2 Yeast two-hybrid assay. LR recombination between pHU1769 and pHU1796 
1923 pDEST32-TRF2IP Yeast two-hybrid assay. LR recombination between pHU1770 and pHU1796 
1924 pDEST32-WRN Yeast two-hybrid assay. LR recombination between pHU1771 and pHU1796 
1933 pGAD424-APLF Yeast two-hybrid assay. LR recombination between pHU1756 and pHU1797 
1934 pGAD424-XRCC1 Yeast two-hybrid assay. LR recombination between pHU1772 and pHU1797 
1935 pGBT9-PARP-1 WT Yeast two-hybrid assay. LR recombination between pHU1730 and pHU1798 
1936 pGBT9-PARP-1K203/486R Yeast two-hybrid assay. LR recombination between pHU1733 and pHU1798 
1941 pGBT9-PARP-1
K203/486R-
SUMO1 
Yeast two-hybrid assay. LR recombination between 
pHU1742 and pHU1798 
1942 pGBT9-PARP-1
K203/486R-
SUMO2 
Yeast two-hybrid assay.  LR recombination between 
pHU1743 and pHU1798 
1943 pGBT9-PARP-1M890V, D899N Yeast two-hybrid assay. LR recombination between pHU1735 and pHU1798 
1944 pGBT9-PARP-1
K203/486R, M890V, 
D899N 
Yeast two-hybrid assay. LR recombination between 
pHU1753 and pHU1798 
1945 pGBT9-PARP-1
K203/486R, M890V, 
D899N-SUMO1 
Yeast two-hybrid assay. LR recombination between 
pHU1754 and pHU1798 
1946 pGBT9-PARP-1
K203/486R, M890V, 
D899N-SUMO2 
Yeast two-hybrid assay. LR recombination between 
pHU1755 and pHU1798 
1954 pET11a-SUMO1T95R Over-production of SUMO1(T95R) in E. coli. Site-directed mutagenesis of pHU1238 (oHU1605/oHU1606) 
2020 pCR4Blunt-XlMMS21 Reverse transcription from frog RNA (oHU896/oHU897) TOPO-cloned into pCR4Blunt-TOPO 
2023 pGAD-ScORC3 Yeast two-hybrid assay. PCR from genomic DNA (oHU1288/oHU1289) cloned SmaI/PstI into pHU145 
2024 pGBT9-ScORC3 Yeast two-hybrid assay. PCR from genomic DNA (oHU1288/oHU1289) cloned SmaI/PstI into pH82 
2025 pGAD-ScORC4 Yeast two-hybrid assay. PCR from genomic DNA (oHU1291/oHU1292) cloned SmaI/BamHI into pHU145 
2026 pGBT9-ScORC4 Yeast two-hybrid assay. PCR from genomic DNA (oHU1291/oHU1292) cloned SmaI/BamHI into pH82 
2027 pGAD-ScORC5 Yeast two-hybrid assay. PCR from genomic DNA (oHU1294/oHU1295) cloned SmaI/BamHI into pHU145 
2028 pGBT9-ScORC5 Yeast two-hybrid assay. PCR from genomic DNA (oHU1294 and oHU1295) cloned SmaI/BamHI into pH82 
2029 pGAD-ScORC6 Yeast two-hybrid assay. PCR from genomic DNA (oHU1297/oHU1298) cloned SmaI/PstI into pHU145 
2030 pGBT9-ScORC6 Yeast two-hybrid assay. PCR from genomic DNA (oHU1297/oHU1298) cloned SmaI/PstI into pH82 
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2031 pET15b-XlSUMO1K27/36/37R Over-production in E. coli. Site-directed mutagenesis of pHU1284 (oHU1449/oHU1450) 
2032 pET21-XlSUMO2K25/27/31R Over-production in E. coli. Site-directed mutagenesis of pHU1285 (oHU1451/oHU1452) 
2083 pDEST/N-FLAG3/FRT-APLF Constitutive over-production in mammalian cells. LR recombination between pHU1756 and pHU1804 
2084 pDEST/N-FLAG3/FRT-XRCC1 
Constitutive over-production in mammalian cells. LR 
recombination between pHU1772 and pHU1804 
 
Table 2.7 - A list of the plasmids that were constructed for this thesis. Sc = S. cerevisiae, 
Xl = X. laevis, Hs= H. sapiens. 
 
2.5 Strains and cell lines 
2.5.1 Escherichia coli strains 
Name Use Source Genotype 
Top10  
Propagation of most 
vectors and for DNA 
cloning 
Invitrogen  
F- mcrA ∆(mrr-hsdRMS-mcrBC) 
80lacZ∆M15 ∆lacX74 recA1 
ara∆139 ∆(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG  
DH10Bac  
Production of 
recombinant 
baculovirus DNA 
Invitrogen  
F- mcrA ∆(mrr-hsdRMS-mcrBC) 
80lacZ∆M15 ∆lacX74 recA1 
endA1 araD139 ∆(ara, leu)7697 
galU galK - rpsL 
nupG/pMON14272/pMON7124  
HB101 Propagation of pDK243 and pDK286 
Douglas 
Koshland 
F- hsdS20(rB- mB-) xyl5  λ- recA13 
galK2 ara14 supE44 lacY1 
rpsL20(StrR) leuB6 mtl-1 thi-1 
ccdB 
Survival-
T1R 
Propagation of 
plasmids containing 
the ccdB gene 
Invitrogen 
F- mcrA ∆(mrr-hsdRMS-mcrBC) 
80lacZ∆M15 ∆lacX74 recA1 
ara∆139 ∆(ara-leu)7697 galU galK 
rpsL (StrR ) endA1 nupG tonA::Ptrc-
ccdA 
GM2163 
Generation of 
plasmids devoid of 
methylation 
New England 
Biolabs 
dam-13::Tn 9 dcm-6 hsdR2 leuB6 
his-4 thi-1 ara-14 lacY1 galK2 
galT22 xyl-5 mtl-1 rpsL136 tonA31 
tsx-78 supE44 McrA- McrB- 
BL21-
CodonPlus 
(DE3)-RIL  
Protein production Stratagene  
F- ompT hsdS(rB- mB-) dcm+ TetR 
gal (DE3) endA Hte [argU ileY 
leuW CamR]  
 
Table 2.8 - A list of the E. coli strains used in this thesis. 
 
2.5.2 Yeast strains 
All of the yeast (S. cerevisiae) strains used in this work were congenic with the haploid 
form of the wild type DF5 strain (Finley et al., 1987), except for those employed for 
yeast two-hybrid analysis, which were derivatives of the strain PJ69-4 (James et al., 
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1996). The introduction of an episomal plasmid in any such strains is indicated in the 
relevant figure legend. 
# Name Genotype 
3 DF5a MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52
195 PJ69-4A MATa, trp1-901, leu2-3,112, ura3-52, his3-200, gal4∆, gal80∆, LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ 
196 PJ69-4α MATα, trp1-901, leu2-3,112, ura3-52, his3-200, gal4∆, gal80∆, LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ 
1630 rad53 sml1∆ bar1∆  from Adelina Davies 
MATα, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, 
sml1::hisG-URA3-hisG, bar1::HISMX6, rad53::KanMX 
2198 Orc1-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc1-9myc::klTRP1 
2199 Orc2-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc2-9myc::klTRP1 
2200 Orc3-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc3-9myc::klTRP1 
2201 Orc4-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc4-9myc::klTRP1 
2202 Orc5-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc5-9myc::klTRP1 
2203 Orc6-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc6-9myc::klTRP1 
2204 Rfc1-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, rfc1-9myc::klTRP1 
2205 Rad54-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, rad54-9myc::klTRP1 
2206 Pol1-9myc MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, pol1-9myc::klTRP1 
2210 siz1∆ siz2∆  from Andrea Bucceri 
MATα, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, 
siz1::KanMX6, siz2::HIS3 MX6 
2219 DF5a cir0 MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, cir0 
2220 siz1∆ siz2∆ cir0 MATα, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, siz1::KanMX6, siz2::HIS3 MX6, cir0 
2564 Orc5-9myc siz1∆ MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc5-9myc::klTRP1, siz1::KanMX 
2565 Orc5-9myc siz2∆ MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc5-9myc::klTRP1, siz2::HIS3 
2566 Orc5-9myc siz1∆ siz2∆ 
MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, 
orc5-9myc::klTRP1, siz1::KanMX, siz2::HIS3 
2567 Orc6-9myc siz1∆ MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc6-9myc::klTRP1, siz1::KanMX 
2568 Orc6-9myc siz2∆ MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, orc6-9myc::klTRP1, siz2::HIS3 
2569 Orc6-9myc siz1∆ siz2∆ 
MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, 
orc6-9myc::klTRP1, siz1::KanMX, siz2::HIS3 
2570 Orc5-9myc rad53∆ sml1∆ 
MATa, his3-∆200, leu2-3,2-112, lys2-801, trp1-1(am), ura3-52, 
orc5-9myc::klTRP1, sml1::hisG-URA3-hisG, rad53::KanMX 
 
 
Table 2.9 - A list of the yeast strains used in this thesis.  
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2.5.3 Insect cell lines 
Spodoptera frugiperda (Sf9) and Trichoplusia ni (Hi5) cells were maintained and 
propagated by the London Research Institute’s Cell Production Services by standard 
culturing practices, as described by Richardson (1995). 
2.5.4 Human cell lines 
All cell lines were obtained from the London Research Institute’s Cell Production 
Services who stored, propagated and regularly tested them for mycoplasma infection. 
All cells were maintained as monolayers and grown in a humidified incubator at 37°C 
and 5% v/v CO2. 
Cell line Source Antibiotics 
Flp-In HEK293 Invitrogen 100 µgmL-1 zeocin 
HEK293 ATCC  
HeLa ATCC  
Flp-In T-Rex HEK293 Invitrogen 100 µgmL
-1 zeocin 
15 µgmL-1 blasticidin 
T-Rex HeLa + pcDNA4/TO/N-MRGS 
His6-PrSUMO1 Gerrit Praefcke, 
Weisshaar et al. 
(2008) 
 
150 µgmL-1 zeocin 
5 µgmL-1 blasticidin 
 
T-Rex HeLa + pcDNA4/TO/N-MRGS 
His6-PrSUMO2 
T-Rex HeLa + pcDNA4/TO/N-MRGS 
His6-PrSUMO3 
Flp-In T-Rex HEK293 + 
pDEST/TO/FLAG/FRT Simon Boulton 
150 µgmL-1 
hygromycin B 
15 µgmL-1 blasticidin 
Flp-In T-Rex HEK293 + 
pDEST/TO/FLAG/FRT-PARP-1  
This thesis 
150 µgmL-1 
hygromycin B 
15 µgmL-1 blasticidin 
 
Flp-In T-Rex HEK293 + 
pDEST/TO/FLAG/FRT-PARP-1K203/486R 
Flp-In T-Rex HEK293 + 
pDEST/TO/FLAG/FRT-PARP-1K203/486R-
SUMO2 
Flp-In HEK293 + pDEST/N-FLAG3/FRT-
APLF 
This thesis 150 µgmL-1 hygromycin B Flp-In HEK293 + pDEST/N-FLAG3/FRT-
XRCC1 
Flp-In HEK293 + pDEST/N-FLAG3/FRT Stephen West 
150 µgmL-1 
hygromycin B 
Chapter 2. Materials and methods 
 108
PARP-1-/- mouse embryonic fibroblast 
clone A11 
Zhao-Qi Wang, 
Wang et al. (1997)  
 
Table 2.10 - A list of the mammalian cell lines used in this thesis. 
 
2.6 Molecular biology methods for E. coli 
2.6.1 Preparation of chemically-competent cells 
A fresh overnight culture of E. coli was diluted 100-fold in LB medium, grown at 37°C to 
an OD600 of 0.5 to 0.8, chilled on ice for 15 min and then harvested at 4°C by 
centrifugation at 4,000 g for 15 min. The pellets were washed once in TfbI solution 
(0.4 of the original culture volume) and once in TfbII solution (0.04 of original 
volume) for 15 min each time. The cell suspension was distributed into 100 µL aliquots, 
flash-frozen and stored at -80°C. 
2.6.2 Transformation of chemically-competent cells 
Aliquots of chemically-competent cells were thawed on ice, mixed with DNA and 
incubated on ice for 10 min. Next, the cells were heat-shocked at 42°C for 1 min, put 
back on ice and resuspended with 1 mL of LB medium. When ampicillin was used as 
the selective antibiotic, the cells were immediately harvested by centrifugation at 3,000 
g, resuspended in 100 µL of LB medium and then plated on LB agar plates 
supplemented with ampicillin. Otherwise, they were incubated at 37°C for 1 h before 
being plated as described above.  
If HB101 cells were transformed with pDK243 or pDK368-7, they were incubated for 3 
h at 37C before being plated on M9 medium lacking leucine.  
2.6.3 Isolation of plasmid DNA 
Isolated clones of E. coli were inoculated in LB medium containing the relevant 
antibiotic. The cultures were grown overnight at 37°C with shaking and then used for 
plasmid isolation using Qiagen’s plasmid purification kits according to the 
manufacturer’s instructions. 
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2.7 Molecular biology methods for X. laevis egg extracts 
2.7.1 Preparation of interphase egg extracts 
X. laevis mature females were housed at 18°C in dechlorinated tap water at a density 
of one frog per litre. One week and eighteen hours prior to egg collection the frogs 
were primed with 50 units of pregnant mare serum gonadotrophin and 500 units of 
human chorionic gonadotrophin, respectively. Eggs were collected overnight in laying 
tanks containing 0.25 MMR buffer and subsequently transferred to a beaker. Hiro 
Mahbubani carried out these initial steps. “Bad” eggs (i.e. grey, white, spotted, 
unusually large, etc.) were removed with a large-tip pastette. The remaining eggs were 
de-jellied at room temperature for 5 min in De-jellying buffer supplemented with 5 mM 
DTT, washed 3 times in 0.25 MMR buffer, activated with 2 µL of 10 mg·mL-1 A23187 
(Merck) for 5 min at room temperature, washed again 3 times in 0.25 MMR buffer and 
then 3 times with ice-cold S buffer supplemented with 2 mM β-ME and 10 µg·mL-1 of 
each of leupeptin, pepstatin and chymostatin. The eggs were packed by briefly 
centrifuging them up to 4,000 g in chilled 1.5 mL tubes and then removing the excess 
of liquid with a fine-tip pastette. Spinning the eggs at 16,000 g for 15 min at 4C yielded 
a crude cytoplasmic extract, which was supplemented with 40 µg·mL-1 cytochalasin B 
(Merck), transferred to 1.5 mL polyallomer tubes (Beckman) and then centrifuged again 
at 250,000 g for 15 min at 4°C in a TLA100.3 rotor fitted to a table-top TL-100 TLX 
ultracentrifuge (Beckman). The cleared cytoplasmic and membrane phases were 
collected by pipetting with a severed 200 µL tip, leaving behind all the lipid and 
mitochondrial layers. The resulting extract was supplemented with 30 mM creatine 
phosphate (Merck), 150 µg·mL-1 phospho-creatine kinase (Roche) and 10 µg·mL-1 
cycloheximide, and either used fresh or supplemented with glycerol to a final 
concentration of 3% v/v before being flash-frozen in liquid nitrogen in the form of 22 µL 
beads. These extracts were stored in liquid nitrogen. 
2.7.2 Preparation of demembranated X. laevis sperm nuclei 
X. laevis mature males were housed at 18°C in dechlorinated tap water at a density of 
one frog per litre. One week before the testes had to be removed the frogs were primed 
with 50 units of pregnant mare serum gonadotrophin. On the day of testes removal, the 
animals were anesthetized in 0.1% v/v tricaine and sacrificed by cervical dislocation. 
The testes were dissected out of the frog and cleaned of excess blood and fat with 
dissection forceps. Hiro Mahbubani carried out these initial steps. The clean testes 
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were transferred to a Petri dish containing 20 mL of ice-cold EB buffer, finely chopped 
and homogenized with a dounce homogenizer. The homogenate was filtered through a 
25-µm mesh nylon membrane (Nitex) and then spun at 2,000 g in a swing out rotor for 
5 min at 4°C. The pellet was resuspended in 2 mL of SuNaSp buffer kept at room 
temperature. Nuclei were incubated with lysolecithin to a final concentration of 100 
µg·mL-1 until when more than 95% of nuclei had been demembranated, as judged by 
Hoechst 33258 staining. Quenching of lysolecithin was accomplished by the addition of 
2 mL of ice-cold SuNaSp buffer containing 3% w/v BSA. The sperm nuclei were 
washed twice by sequential centrifugation (2,000 g for 5 min in a swing out rotor) and 
resuspension in ice-cold SuNaSp buffer supplemented with 3% w/v BSA, resuspended 
in 400-500 µl of EB buffer supplemented with glycerol to a final concentration of 30% 
v/v, flash-frozen and stored at -80C. The sperm count of these preparations was 
determined by means of a haemocytometer. 
2.7.3 Handling of interphase egg extracts 
Unless otherwise stated in the relevant figure legend, interphase extracts were always 
supplemented with 2,000-3,000 sperm nuclei·µL-1 of extract and incubated at 23°C with 
gentle mixing by pipetting every 10-15 min to avoid clumping of the DNA.  
2.7.4 Testing the replication competence of interphase frog egg extracts 
The ability of interphase egg extracts to replicate was assessed by supplementing 
them (20 µL) with 2,500 sperm nuclei·µL-1 of extract and 20 pmol of Cy3-dCTP 
(Invitrogen). Following incubation at 23C for 30 min, 1 µl of extract was mixed with 1 
µL of Fixation buffer and analyzed by fluorescence microscopy. Only extracts that 
showed properly condensed nuclei and a strong nuclear Cy3 signal were used for 
downstream applications. 
2.7.5 DNA replication assay 
The extent of DNA replication was determined by measuring the incorporation of [α-
32P]dCMP (GE Healthcare) into sperm DNA as described by Dasso and Newport 
(1990). 20 µl of extract was supplemented with 2,500 sperm nuclei·µL-1 of extract and ~ 
1 µCi of [α-32P]dCTP, and incubated at 23C. After the desired amount of time, 5 µL of 
extract was mixed with 5 µL of STOP buffer, supplemented with proteinase K to a final 
concentration of 2 µg·µL-1, incubated at 37°C for 2 h, and then loaded on a 1% w/v 
agarose gel made in 1 TBE buffer (see 2.11.2). This gel was run at 100 V until when 
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the dye front had migrated approximately 2/3 of its total length. Next it was fixed in 30% 
w/v TCA for 30 min, dried in a gel dryer (Bio-Rad) and exposed to a storage phosphor 
screen (GE Healthcare). The screen was imaged on a Typhoon 9400 scanner using 
the ImageQuant TL software (GE healthcare). 
2.7.6 Chromatin binding assay 
Extracts (50 µL) were mixed with 250 µL ice-cold ELB buffer supplemented with 0.25 M 
sucrose and 1 mM DTT, layered on top of a 1 ml sucrose cushion (0.9 M sucrose in 
ELB buffer) and centrifuged at 10,000 g for 2 min at 4°C in a swing out rotor. After 
aspirating all but 50-100 µL of the supernatant the “pellet” was mixed with 200 µL of 
ELB buffer supplemented with 0.25 M sucrose, 0.6% v/v Triton X-100 and 1 mM DTT. 
This sample was layered on top of a second 1 mL sucrose cushion and treated as 
described above. All but 10 µL of the supernatant was removed by aspiration and it 
was used either as native chromatin or mixed with 40 µL of 1.5 NuPAGE LDS Sample 
Buffer (Invitrogen). Smaller or larger chromatin preparations were carried out by scaling 
up or down this basic procedure. 
2.8 Molecular biology and genetic methods for yeast  
2.8.1 Chemical transformation of yeast cells 
For a single transformation, 3 OD600 equivalents of exponentially growing yeast cells 
were harvested by centrifugation at 800 g for 3 min, resuspended in 100 µL of LiT 
buffer, transferred to a 1.5 mL tube, supplemented with 10 µL of HT DNA solution and 
the relevant transforming DNA (100-400 ng of plasmid or 5-10 µg of an integrative 
cassette), and mixed. Following the addition of 500 µL LiT/PEG solution, the cells were 
vortexed and incubated at room temperature for 20 min with rotation. Next, they were 
supplemented with 50 µL of DMSO, mixed and heat-shocked at 42C for 15 min. The 
cells were eventually collected by centrifugation at 800 g for 30 s, resuspended in 100 
µL of water and plated on the relevant selective medium.  
2.8.2 Induction of His6-SUMO production 
Transformants (a pool of three isolated colonies) obtained by chemical transformation 
of pHU822 into the relevant strains were grown to saturation in medium lacking leucine 
and then switched to an equivalent broth containing 100 µM CuSO4 as well, to induce 
production of His6-SUMO from the CUP1 copper inducible promoter. After an overnight 
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incubation, the cells were diluted to an OD600 of 0.2-0.3 in selective medium 
supplemented with 100 µM CuSO4 and subsequently grown to exponential phase. 
2.8.3 Colony PCR 
A minute amount of cells was collected from isolated colonies by means of a 10 µL tip, 
transferred to PCR tubes that contained 50 µL of freshly prepared Zymolyase solution, 
and then incubated for 15 min at room temperature. The resulting spheroblasts were 
collected by centrifugation in a Rotilabo microcentrifuge fitted with a butterfly-rotor 
(Roth) for 5 min. After the supernatant had been removed, the pellets were boiled at 
95C for 5 min, resuspended in a PCR reaction mix and subjected to PCR amplification 
(see 2.12.1). 
2.8.4 Preparation of total yeast cell extracts 
2.8.4.1 Alkaline lysis method 
Exponentially growing yeast cells (1 OD600 equivalent) were washed once in water and 
then resuspended in 500 µL of ice-cold water supplemented with 75 µL NaOH/β−ME 
solution. After 15 min on ice, the lysate was mixed with 75 µL of 55% w/v TCA and 
incubated for an additional 10 min. The precipitates were collected by centrifugation at 
16,000 g for 10 min at 4C. After removing most of the supernatant by aspiration, the 
pellets were centrifuged again for 30 s to get rid of any remaining traces of it, 
resuspended in 50 µL of HU buffer and incubated at 65C for 15 min. 
2.8.4.2 Mechanical lysis method 
Exponentially growing yeast cells (40-50 OD600 equivalents) were washed once in 
water, resuspended in 500-600 µL of the appropriate lysis buffer and then mixed with 
500-600 µL of zirconia/silica beads (Thistle Scientific) in a 1.5 mL screw-cap tube. 
Lysis was brought about by ultra-vortexing in a FastPrep-24 instrument (MP 
Biomedicals) with eight 30 s pulses at 5.5 ms-1, and 1 min rest time on ice. This crude 
lysate was cleared of beads by puncturing the bottom of the tube containing it with a 
white-hot needle and then spinning it up to 1,500 g into a 2 mL collection tube. Next, it 
was sonicated in a Branson Sonifier with five 10 s pulses at 20% power and 1 min rest 
time on ice and then cleared by centrifugation at 100,000 g and 4C for 15 min in a 
table-top TL-100 TLX ultracentrifuge fitted with a TLA100.3 rotor (Beckman). The 
resulting extract was used for the desired downstream applications. 
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2.8.5 Cell synchronization and cell cycle analysis 
Exponentially growing MATa cells (OD600 ~ 0.7) were arrested at the G1 phase by 
incubating them for 1.5 h at 30C with 10 µgmL-1 of α factor, and then one more hour 
with an additional 5 µgmL-1. To release the cells from this G1-phase block, they were 
washed twice in a solution of 1M sorbitol and 25 mM EDTA, before being resuspended 
in the appropriate growth medium, which was supplemented with either 200 mM HU or 
15 µgmL-1 nocodazole to stop the cells in either S or G2 phase, respectively. Cells 
were collected at the time indicated in the relevant figure legend, immediately killed by 
the addition of 1 mgmL-1 sodium azide to the medium and then harvested by 
centrifugation. 
2.8.6 Flow cytometry 
Approximately 1 OD600 equivalent of cells was washed once in ice-cold water and fixed 
in 70% v/v ethanol for 1 h at 4C. The pellets were washed twice in 50 mM Citrate 
buffer pH 7.0, resuspended in 1 mL of the same solution containing 250 µg of RNase A 
and incubated for 1 h at 50C. Next, they were supplemented with proteinase K (3,000 
U), incubated for an additional 1 h at 50C and then sonicated on a Branson sonifier for 
1-2 s at 10% power. Finally, the cell suspensions (250 µL) were mixed with 1 mL of 
Propidium Iodide Stock solution and analyzed on a FACSCalibur flow cytometer using 
the FACStation software (BD Biosciences, FSC-H threshold = 10, P1 (FSC) = E01, P2 
(SSC) = default, P4 = 830). 
2.8.7 Elimination of the 2-µm plasmid 
Cells were cured of the 2-µm plasmid as described by Tsalik and Gartenberg (1998). In 
summary, the relevant wild type or mutant cells were chemically transformed with 
pBIS-GALkFLP(URA3). Transformants were selected by growth on plates lacking uracil 
and then re-streaked on galactose-containing medium to induce the production of 
Flp1H305L from pBIS-GALkFLP(URA3). This mutant Flp1 protein forms stable covalent 
complexes with the 2-µm circle, thus causing it to be lost from cells at very high 
frequencies. Single colonies from these plates were streaked on 5-FOA medium to 
obtain clones that had been cured of pBIS-GALkFLP(URA3) as well the 2-µm plasmid, 
which was confirmed by colony PCR (see 2.8.3) using oligonucleotides oHU1299 and 
oHU1300. 
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2.8.8 Plasmid stability assay 
The mitotic loss rate of pDK243 and pDK368-7 was measured as previously described 
by Marahrens and Stillman (1992). The plasmids were transformed into the desired 
strains by chemical transformation (see 2.8.1). Transformants were selected on 
medium lacking leucine and individually inoculated in ~ 3 mL of selective broth. After 
30 h at 30C, the cultures were diluted to an OD600 of 0.0003 in liquid YPD medium and 
grown for an additional 30 h at 30C. The resulting cultures were plated in triplicate on 
both YPD agar and selective medium lacking leucine at a dilution that produced 200-
300 colonies on the YPD plates. 
2.8.9 Yeast two-hybrid analysis 
Yeast plasmids carrying the GAL4 activation (AD) or DNA-binding (BD) domain fused 
to relevant genes were chemically transformed into the reporter strains PJ69-4A 
(MATa) and PJ69-4α (MATα), respectively. Since the strains carrying the GAL4 AD 
and BD domain-fusion proteins were of different mating types, mixing them together 
yielded diploid cells carrying both plasmids. A loopful of transformants (10-20 medium-
sized colonies) was resuspended in 100 µL of liquid YPD medium, mixed together in 
the relevant combinations and then spotted (3.5 µL) on solid YPD medium. Following 
an overnight incubation at 30C, the cells were replicated onto medium lacking 
tryptophan and leucine, and grown for an additional 24 h at 30C. Approximately 1-2 
mm3 of the cells that grew on such selective plates were inoculated in 100 µL of water 
and then plated (3.5 µL) on medium lacking different amino acids. The presence of 
both the GAL4 AD and BD plasmids was confirmed by growth on plates lacking leucine 
and tryptophan. Positive interactions were determined by growth on plates lacking 
leucine, tryptophan and histidine, whereas stronger interactions were detected on 
plates lacking adenine as well.  
2.8.10 Construction of mutants by mating and tetrad dissection 
Fresh colonies or liquid cultures of the relevant haploid mutant strains of opposite 
mating types were mixed, spotted on YPD agar and incubated for 3-5 h at 30 C. Next, 
zygotes were picked using a MSM micromanipulator (Singer), allowed to grow for 2 
days at 30C, resuspended in 1 mL of 1% w/v KOAc and then incubated for an 
additional 2-3 days at 30C with shaking. The cell suspension (10 µL) was combined 
with 10 µL of STE-Zymolyase solution, incubated at room temperature for 15 min and 
then streaked on YPD agar. Tetrads were dissected using a MSM micromanipulator. 
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By testing the ability of the germinated spores to grow on certain selective media, those 
carrying the desired set of markers/mutations were identified.  
2.9 Molecular biology methods for insect cells and 
baculoviruses 
2.9.1 Generation of recombinant bacmids 
Invitrogen’s BAC-to-BAC system was used to generate recombinant bacmids as 
described by the manufacturer. In summary, chemically-competent DH10Bac E. coli 
cells (Invitrogen) were transformed with 100-400 ng of pDEST10 vector carrying the 
relevant PARP-1 construct and then plated on LB agar supplemented with 50 µg·mL-1 
kanamycin, 7 µg·mL-1 gentamycin, 10 µg·mL-1 tetracycline, 100 µg·mL-1 BluO-gal 
(Invitrogen) and 40 µg·mL-1 IPTG. After incubating the plates for 2 days at 37°C, 
successful transposition of the pDEST10 vectors into the bacmid DNA carried by the 
DH10Bac strain resulted in white, rather than blue, colonies due to disruption of the 
lacZ gene present in such a DNA. These colonies were re-streaked on fresh LB agar 
plates containing the same supplements as those described above to obtain isolated 
clones, which were then inoculated in 200 mL of liquid LB medium supplemented with 
50 µg·mL-1 kanamycin, 7 µg·mL-1 gentamycin and 10 µg·mL-1 tetracycline, and grown 
overnight at 37°C. The recombinant baculovirus DNA was isolated using Qiagen’s 
Plasmid MIDI Kit following the manufacturer’s instructions. To confirm integration of the 
PARP-1 gene into the recombinant bacmid, PCR amplification (see 2.12.1) was 
employed using a primer annealing to the bacmid itself (M13 forward -20, Invitrogen) 
and one to the 5’ end of the PARP-1 gene (oHU1482). Positive clones generated a 
product of ~2.5 kbp. 
2.9.2 Generation of the P0 baculovirus stocks 
Approximately 6·106 exponentially growing Sf9 cells were seeded into a 100 mm  
dish and allowed to adhere for 1 h. For each transfection, 45 µL of Cellfectin II 
(Invitrogen) and 6 µg of DNA were diluted in 0.5 mL of plain Grace’s medium. The 
diluted DNA and Cellfectin II were combined, mixed gently, and incubated for 20 min at 
room temperature. In the meanwhile, the cells were washed once with plain Grace’s 
medium and supplemented with 5 mL of the same medium. DNA-lipid complexes were 
added to the plates drop-wise and allowed to be taken up by the cells for 5 h before 
replacing the transfection mixture with 10 mL of Grace’s medium supplemented with 
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10% v/v heat-inactivated foetal bovine serum, 50 µg·mL-1 gentamycin and 250 ng·mL-1 
amphotericin B. After incubating the cells for 4 days at 27°C to allow accumulation of 
the virus in the culture medium, the cells’ supernatant was collected, centrifuged at 
2,000 g for 5 min, filtered through a low-protein binding 0.22-µm PES filter (Millipore), 
and stored away from light at 4°C in a plastic container. The titre of this P0 virus stock 
was assumed to be 1·106 pfu·mL-1. 
2.9.3 Amplification of the P0 virus stocks 
About 1.5 ml of a P0 virus stock was added to 1.8·107 exponentially growing Sf9 cells 
seeded in 150 mm  plates in a total volume of 30 mL of complete Grace’s medium. 
After 3 days at 27°C, the budded viruses were collected as described in 2.9.1 and used 
for either further virus amplification or for protein production. The titre of this P1 stock 
was estimated by the end-point dilution assay. Briefly, 1·106 exponentially growing Hi5 
cells were seeded in each well of a 6-well plate in 2 mL of complete Grace’s medium. 
100, 10, 1 or 0 µL of the virus stock was added to each well, in duplicate. Often, 10 µL 
of virus supernatant was sufficient to produce a synchronous infection (i.e. uniformly 
large cells), after a 2-day incubation at 27°C. The titre of this P1 stock was therefore 
estimated to be approximately 1-5·108 pfu·mL-1. 
2.10 Molecular biology methods for human cells 
2.10.1 Passaging and harvesting cells 
Cells were passaged when sub-confluent, or every 3-4 days, by incubating them with 
0.2 mL per 10 cm2 of Trypsin/Versene solution for 2-3 min. Upon cell detachment, 
trypsin was neutralized by adding a two-fold volume excess of complete DMEM. The 
resulting cell suspension was inoculated into a new flask at a dilution ratio of between 
1:8 and 1:15 or subjected to centrifugation at 200 g for 5 min to harvest the cells. 
Alternatively, harvesting was achieved by gently scraping a cell monolayer that had 
been rinsed in ice-cold PBS with a rubber policeman.  
2.10.2 Cell counting 
The cell count of cell suspensions prepared by trypsinization as described in 2.10.1 
was determined with a Countess Automated Cell Counter (Invitrogen), using default 
parameters and following the manufacturer’s instructions.  
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2.10.3 Total cell extracts for western blotting analysis 
Usually, 5-10 µL of cells was resuspended in 50-150 µL of a solution of 8 M urea and 
100 mM Tris-HCl pH 6.8. The lysate was sonicated for 2-3 s on a Branson sonifier at 
10% power, analyzed by the Bradford assay (2.13.4.3) and adjusted to 1.5 µg of 
protein per µL of extract. Next, the extracts were mixed at a 3:1 ratio with 3 NuPAGE 
LDS Sample Buffer supplemented with a reducing agent and incubated at 65°C for 15 
min. Generally, 5-15 µL were loaded onto a gel for western blotting analysis.  
2.10.4 Transient transfection 
Cells were transfected with either Lipofectamine 2000 (Invitrogen) or Fugene HD 
(Roche) according the manufacturer’s instructions, using OptiMEM I reduced-serum 
medium (Invitrogen) as a dilution agent. The exact cell confluency, amounts of DNA 
and transfection reagent and post-transfection harvesting time used for each 
transfection are indicated in the relevant figure legend. 
2.10.5 Stable transfection 
Invitrogen’s Flp-In system was used to generate clones of the Flp-In 293 and Flp-In T-
Rex 293 cells lines that were stably integrated with the relevant expression plasmid, 
according to the manufacturer’s manual. The cells were grown in 60 mm  dishes to 
90% confluence and co-transfected with pHU1809 (0.5 µg, Invitrogen) and the relevant 
Flp-In-compatible expression plasmid (3.5 µg) using Fugene HD (16 µL), as described 
in 2.10.4. After 24 h, the cells were transferred to a 150 mm  plate containing 
complete DMEM supplemented with 200 µg·mL-1 hygromycin B and, when appropriate, 
15 µg·mL-1 blasticidin. After a week, isolated colonies were handpicked, individually 
grown in 6-well plates and then tested for transgene expression by western blotting 
(see 2.13.5). Three clones that produced similar levels of the relevant recombinant 
protein were pooled together and submitted to the London Research Institute’s Cell 
Production Services for maintenance, mycoplasma testing and storage. 
2.10.6 Indirect immunofluorescence 
For localization studies, cells were handled in 8-well CultureSlides (BD Biosciences). 
The cells were fixed in 4% v/v paraformaldehyde in PBS for 10 min, washed in PBS-Tx 
for 2 min, permeabilized in PBS supplemented with 0.5 % Triton X-100 for 3 min, and 
then washed twice more in PBS-Tx for 5 min. The slides were blocked for 1 h at room 
temperature in 3% w/v BSA in PBS and then washed once in PBS-Tx for 5 min. Next, 
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100 µL of PBS-Tx supplemented with 0.3% w/v BSA and the relevant primary 
antibodies (Table 2.2) was added to each well of the slide. Following an overnight 
incubation at 4°C in a humid chamber, the slides were washed three times for 5 min in 
PBS-Tx before being incubated with the appropriate secondary antibodies (Table 2.3) 
in 100 µL of PBS-Tx supplemented with 0.3% w/v BSA and 0.1 µg·mL-1 DAPI. At last, 
the cells were washed in PBS-Tx four more times for 5 min and then mounted with 10 
µL of ProLong Gold Antifade Reagent (Invitrogen). Images were captured at multiple Z-
sections using the Volocity 4.3.2 software (Improvision) on a Zeiss Axio Imager M1 
microscope fitted with a Plan APOCHROMAT 100/1.4 oil objective (Zeiss) and 
attached to an ORCA-ER camera (Hamamatsu). 
2.10.7 Cellular fractionation  
Cellular fractionation analysis was carried out by Rajvee Shah. Cells harvested from a 
confluent 35 mm  dish were washed once in PBS and then resuspend in 1 mL of ice-
cold PBS. The resulting cell suspension (100 µL) was mixed with 100 µL of 2 
NuPAGE LDS Sample Buffer supplemented with a reducing agent and immediately 
boiled at 95°C for 5 min (“Input” sample). The cells present in the remaining 900 µL of 
the suspension were collected by centrifugations (200 g for 5 min), resuspended in 180 
µL of Cell fractionation buffer A, supplemented with Triton X-100 to a final 
concentration of 0.1% v/v, mixed by inversion and incubated on ice for 5 min in order to 
dissolve the plasma membrane. The nuclei were precipitated by centrifugation at 1,300 
g for 5 min at 4°C. The resulting supernatant was clarified at 16,000 g for 15 min at 
4°C, 100 µL of it was mixed with 100 µL of 2 NuPAGE LDS Sample Buffer 
supplemented with a reducing agent before being boiled at 95°C for 5 min (“Cytoplasm” 
sample). The pellet was washed once in 200 µL of Cell fractionation buffer A, gently 
resuspended in 180 µL of Cell fractionation buffer B, incubated on ice for 30 min to lyse 
the nuclei and then centrifuged at 1,700 g for 5 min at 4°C to precipitate the chromatin. 
The resulting supernatant (100 µL) was mixed with 100 µL of 2 NuPAGE LDS Sample 
Buffer supplemented with a reducing agent and immediately boiled at 95°C for 5 min 
(“Nucleoplasm” sample). The pellet was instead washed once with 200 µL of Cell 
fractionation buffer B, resuspended in 200 µL of 2 NuPAGE LDS Sample Buffer 
supplemented with a reducing agent and immediately boiled at 95°C for 5 min 
(“Chromatin” sample). All samples (15 µL) were subjected to western blotting analysis 
as described in 2.13.5. 
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2.10.8 Preparation of extracts from PARP-1-/- mouse embryonic fibroblasts 
Cell extracts from PARP-1-/- mouse embryonic fibroblasts were prepared exactly as 
described by Vodenicharov et al. (2000). 
2.10.9 Cycloheximide chase experiment 
The relevant stably-transfected clones of FLP-In T-Rex 293 cells (~5·105 cells) were 
seeded in 60 mm  plates. After 24 h, the medium was supplemented with 1 µg·mL-1 
doxycycline and incubated for an additional 24 h. Next, the cells were washed in PBS 
and supplemented with complete DMEM containing 50 µg·mL-1 cycloheximide with or 
without 30 µM MG132. Cells were harvested at the relevant times by scraping, and 
processed for western blotting analysis (see 2.13.5).  
2.11 General methods for DNA manipulation  
2.11.1 Determination of DNA concentration  
The concentration of ssDNA or dsDNA in solution was determined by measuring the 
OD260 on a Nanodrop ND-1000 spectrophotometer (Thermo Scientific) and making the 
assumption that a solution of 33  µg·mL-1 ssDNA or 50  µg·mL-1 dsDNA would yield an 
absorbance of 1 at 260 nm. 
2.11.2 Native agarose gel electrophoresis  
Agarose gels contained 0.5-2% w/v UltraPure agarose (Invitrogen) in 1 TAE or 1 
TBE buffers. DNA samples were mixed at 5:1 ratio with 6 DNA Loading buffer and run 
at 80 V (~ 5 V·cm-1) in a Jencons Scientific horizontal gel electrophoresis apparatus. 
New England Biolabs’ 100 bp and 1 kbp DNA ladders were used as size standards.  
2.11.3 Native and denaturing PAGE  
Native (1 TBE) or denaturing (8 M urea in 1 TBE) polyacrylamide gels were prepared 
using Invitrogen’s X-Cell SureLock Mini-Cells as described by Sambrook and Russell 
(2001). DNA samples were mixed at a 5:1 ratio either with 6 DNA Loading buffer, for 
native PAGE, or 100% v/v formamide and incubated at 65°C for 10 min, for denaturing 
PAGE, and then run in 1 TBE buffer at 80 V for 2.5 h. 
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2.12 General methods for molecular cloning  
2.12.1 Polymerase chain reaction (PCR)  
DNA products were generated with Phusion DNA polymerase (Finnzymes), according 
to the manufacturer’s manual, typically using 1 pmol of template and the following 
thermal cycling protocol: an initial denaturing step at 98C for 1 min and then 30 cycles 
of 98C for 20 s, 50-65C (depending on the melting temperature of the 
oligonucleotides employed) for 20 s and 72C for 20 s·kbp-1. A final 5 min incubation at 
72C was included in order to polish the ends of the resulting PCR products. All PCR 
reactions were performed in a DYAD Thermal Cycler (MJ Research). 
2.12.2 Site-directed mutagenesis  
Site-directed mutagenesis was carried out using the same procedure as that described 
in Stratagene’s QuikChange II Site-Directed Mutagenesis Kit with the only difference 
that Phusion DNA polymerase (Finnzymes) was used instead of Pfu DNA polymerase. 
2.12.3 Cut-and-paste cloning  
For a typical cut-and-paste cloning procedure 1-2 µg of plasmid or PCR product was 
digested for 3 h in a 50 µL reaction supplemented with 20-30 U of the relevant 
restriction endonuclease and the corresponding reaction buffer. Whenever needed, 1 
µL of calf intestinal phosphatase was added to the reaction during the last hour of 
incubation. The products were resolved by agarose gel electrophoresis (see 2.11.2) 
and extracted using the JETSORB Gel Extraction kit (Genomed) according to the 
manufacturer’s instructions. Ligation reactions were performed using 25 ng of vector 
DNA and a 3-fold molar excess of insert in total volume of 10 µL supplemented with 0.5 
µL of QuickStick ligase and 2.5 µL of 4 QuickStick buffer (Bioline) for 15 min at 25C. 
2.12.4 TOPO cloning 
Blunt PCR products were cloned into pCR-Blunt II-TOPO or pENTR/D-TOPO 
(Invitrogen) following the manufacturer’s instructions. For cloning into the TA-based 
cloning vector pCR8/GW/TOPO (Invitrogen), 3' “A overhangs” had to be added to the 
PCR products generated by Phusion DNA polymerase. In order to do so, these DNA 
fragments were resolved by agarose gel electrophoresis (see 2.11.2), purified from the 
gel using JETSORB Gel Extraction kit and then incubated (1 pmol) at 72C for 30 with 
0.2 mM dATP, 1 Taq polymerase buffer (Thermo Scientific), 2 U of Taq DNA 
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polymerase (Thermo Scientific) in a total volume of 50 µL. The resulting products were 
used in a standard TOPO cloning reaction as described by the manufacturer.  
2.12.5 Gateway cloning 
Site-directed recombination between a Gateway Donor vector (attP1/2) and a Gateway 
Destination vector (attR1/2) was achieved by combining 70 ng of each plasmid and 0.5 
µL of the Gateway LR Clonase II enzyme mix (Invitrogen) in a total volume of 4 µL and 
incubating it for 1 h at 25C.  Next, the reaction was supplemented with 0.5 µL of the 
Proteinase K solution provided with the LR Gateway LR Clonase II kit (Invitrogen) and 
incubated for 15 min at 37C.  
2.12.6 DNA sequencing   
Sequencing reactions consisted of 3-4 fmol of template, 3.2 pmol of oligonucleotide, 
3.5 µL of 5 BigDye Sequencing buffer (Applied Biosystems) and 0.5 µL of BigDye 
Terminator Ready v3.1 Reaction mix (Applied Biosystems). They were carried out in a 
DYAD Thermal Cycler using the thermal cycling protocol recommended by Applied 
Biosystems. The resulting products were purified using DyeEx 2.0 columns (Qiagen), 
dried in an Eppendorf’s Vacufuge and finally run on an ABI3730 DNA Analyzer 
(Applied Biosystems) by the London Research Institute’s Equipment Park team. 
2.12.7 Visualization of DNA by ethidium bromide, SYBR green and SYBR 
Safe staining 
For agarose gels, ethidium bromide (0.5 µg·mL-1, Seven Biotech), SYBR Green I (1, 
Invitrogen) or SYBR Safe (1, Invitrogen) was added to the gel before it solidified. 
Electrophoresed polyacrylamide gels were instead soaked for 30 min in 1 TBE buffer 
supplemented with the same concentrations of the above-mentioned stains. DNA was 
visualized by exposing the gel to UV light at 254 nm in a BioDoc_it UV transilluminator 
(UVP) for ethidium bromide, or visible light at 460nm in a LAS-3000 scanner (Fujifilm) 
using the AIDA software (Raytest), for SYBR Green and SYBR Safe. 
2.13 General methods of protein manipulation  
2.13.1 SDS-PAGE 
SDS-PAGE was carried out using either 4-12% NuPAGE Novex gels in 1 MOPS 
running buffer (Invitrogen), according to the manufacturer’s instructions, or Tris-Glycine 
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polyacrylamide gels prepared as described by Sambrook and Russell (2001) in Bio-
Rad’s Mini-PROTEAN system or Invitrogen’s X-Cell SureLock Mini-Cells. For both 
systems the protein samples were mixed either with NuPAGE LDS Sample Buffer 
containing a reducing agent (Invitrogen), and boiled at 95°C for 5 min, or with HU 
buffer, and incubated at 65°C for 15 min. Pre-stained peqGOLD Protein-Markers IV 
(PeqLab) were used as molecular weight standards.  
2.13.2 Coomassie blue staining  
Electrophoresed gels were incubated on an orbital shaker for 15 min with 5-10 mL of 
the Coomassie Blue-based stain InstantBlue (Novexin). Alternatively, they were soaked 
for either 2-3 h or overnight in Coomassie Blue Staining solution and then de-stained 
through several washes in Coomassie Blue De-staining solution. In both cases, the 
gels were immersed in a Gel Drying solution for 1 h before being imaged on a LAS-
3000 scanner.  
2.13.3 SYPRO Ruby staining  
Electrophoresed gels were washed twice for 30 min in SYPRO Fixing solution, to fix 
them, and then incubated overnight on an orbital shaker with 10-20 mL of SYPRO 
Ruby Protein Gel Stain (Invitrogen) at room temperature. Next, the gels were washed 
once in SYPRO Wash solution and once in water before being imaged on Typhoon 
9400 scanner using the ImageQuant TL software. 
2.13.4 Determination of protein concentration  
2.13.4.1 Absorbance at 280 nm (OD280) 
The extinction coefficient (ε) of a protein was calculated using the following formula:  
ε = 5690  (# of Try) + 1280  (# Tyr) + 120  (# of Cys) M-1·cm-1 
The OD280 of a protein sample was measured on a Nanodrop ND-1000 
spectrophotometer (Labtech International) and then used to calculate its protein 
concentration by means of Beer’s law:  
Concentration = OD280/(Path length·ε) 
2.13.4.2 Comparison by Coomassie staining  
Different volumes of a relevant protein sample and known amounts of BSA were 
resolved by SDS-PAGE (see 2.13.1) on the same gel and subsequently subjected to 
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Coomassie staining (see 2.13.2). An image of this gel was acquired on a LAS-3000 
scanner and then used to quantify the intensity of the stained bands by means of the 
AIDA software. The amount of protein of interest loaded onto the gel was determined 
by comparing the intensity of its corresponding bands to those of known amounts of 
BSA. 
2.13.4.3 Bradford’s method  
Bio-Rad’s Protein Assay was used to determine protein amounts by the Bradford’s 
method (Bradford, 1976), according to the manufacturer’s instructions.  The OD595 was 
measured in Eppendorf’s Biophotometer. The amount of protein present in a certain 
solution was determined by comparing its OD595 to that of known amounts of BSA.  
2.13.5 Western blotting by the semi-dry transfer method 
Electrophoresed gels were blotted onto a 45 µm Immobilon-P PVDF membrane 
(Millipore) by the semi-dry transfer method as follows. The filter was activated in 
methanol for 30 s and then equilibrated in Blotting buffer II for 5-10 min. In the 
meanwhile, two pieces of gel blotting paper (GB003, Whatman) pre-wetted in Blotting 
buffer I were set onto the anode plate of a semi-dry transfer cassette (Roth) and 
overlaid with another piece, which had been immersed in Blotting buffer II. The PVDF 
membrane was placed on top of these three layers, followed by the gel and three 
additional pieces of blotting paper soaked in Blotting buffer III. The resulting transfer 
stack was covered with the cathode plate of the transfer cassette. Proteins were 
electro-blotted onto the membrane at a maximum voltage of 25 V and at a constant 
current of either 40 mA for 1 h, for Bio-Rad’s Mini-PROTEAN gels, or 50 mA for 1.5 h, 
for Invitrogen’s NuPAGE Novex gels. Next, the membrane was rinsed in PBS, blocked 
for 1 h at room temperature in Blocking solution and incubated with a primary antibody 
(Table 2.2) either overnight at 4°C or for 2 h at room temperature. After four 5-10 min 
washes in PBS-T, the membrane was incubated in Blocking solution containing the 
relevant secondary antibody (Table 2.3) for 1 h at room temperature, and then washed 
again in PBS-T for three additional times. Finally, the membrane was developed using 
PerkinElmer’s ECL Western Lightning Plus kit, according to the manufacturer’s 
instructions, and imaged either on a LAS-3000 scanner (Fujifilm) or by exposure to 
Hyperfilm ECL (GE Healthcare) followed by chemical development in an X-Ray film 
processor (JP-33, Jungwon Precision Industry). When needed, the membrane was 
stripped of bound antibodies by washing it three times, for 10 min each, with Gentle 
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Stripping solution at room temperature or once with Harsh Stripping solution at 50°C for 
30 min. In both cases, the membrane was rinsed extensively with PBS before being 
blocked and probed again as described above.  
2.14 Protein purification 
2.14.1 Protein production and purification in E. coli 
2.14.1.1 Induction of gene expression and lysate preparation  
Chemically-competent BL21-CodonPlus (DE3)-RIL E. coli cells (Stratagene) were 
transformed with the desired expression plasmid (Table 2.6 and Table 2.7). Single 
clones were inoculated in liquid LB medium supplemented with the relevant antibiotic 
and propagated overnight at 37°C with shaking. The resulting saturated culture was 
diluted 100-fold typically in 2 L of liquid LB medium supplemented with the relevant 
antibiotic and grown at 37°C to an OD600 of 0.5-0.8. Transgene expression was induced 
by adding 1 mM IPTG (MP Biomedicals) to the culture and subsequently incubating it 
for 3 h at 37°C, in the case of SUMO, UBC9 or ORC1 over-production, or for 5 h at 
25°C to produce the SUMO E1, APLF and XRCC1. Cells were harvested by 
centrifugation at 3,000 g for 10 min at 4°C, resuspended in 50 mL of the appropriate 
lysis buffer devoid of any reducing agent or protease inhibitors and flash-frozen in liquid 
nitrogen. On the day of purification, the cells were quickly thawed at 37°C, 
supplemented with 1 mM DTT (or 2 mM β-ME) and 1 Complete Protease Inhibitors, 
lysed by five 30 s pulses of sonication on a Branson sonifier at 50% output, with 2 min 
rest on ice, and finally centrifuged at 100,000 g for 1 h at 4°C to yield a cleared lysate. 
2.14.1.2 Purification of AOS1/UBA2 (SUMO E1)  
The SUMO E1 was purified essentially as described by Yunus and Lima (2009a). The 
cleared lysate was incubated with 4 mL of pre-equilibrated Ni2+-NTA (Qiagen) for 2 h at 
4°C with rotation. The bound proteins were washed with 60 mL of Ni2+-NTA Wash 
buffer and eluted with 20 mL of Ni2+-NTA elution buffer. The fractions containing the E1 
enzyme were pooled, concentrated to 2 mL in a centrifugal concentrator (30,000 
MWCO, Vivaspin) and applied to a HiLoad 16/60 Superdex 200 gel filtration column 
(GE Healthcare) equilibrated in E1 Gel Filtration buffer. The fractions that included the 
E1 enzyme were combined, diluted with an equal volume of E1 Gel Filtration buffer 
devoid of any salt and applied to an anion exchange column (Mono Q HR 5/5, 1 mL, 
GE Healthcare). The protein was eluted on a 50-500 mM NaCl gradient over 20 column 
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volumes. E1 enzyme-containing fractions were pooled, dialyzed overnight at 4°C 
against Protein Storage solution, concentrated to 1-2 µg·µL-1 and flash-frozen in liquid 
nitrogen. 
2.14.1.3 Purification of UBC9 (SUMO E2) 
UBC9 was purified essentially as described by Werner et al. (2009). The cleared lysate 
was applied to 10 mL of pre-equlibrated HiTrap SP HP resin (GE Healthcare). The 
bound proteins were washed with 100-120 mL of E2 Lysis buffer and eluted with 30 mL 
of E2 elution buffer. The fractions containing UBC9 were combined, concentrated to 2 
mL in a centrifugal concentrator (3,000 MWCO, Vivaspin) and applied to a HiLoad 
16/60 Superdex 200 gel filtration column equilibrated in Protein Storage buffer. UBC9-
containing fractions were pooled, concentrated to 2-5 µg·µL-1 and flash-frozen in liquid 
nitrogen. 
2.14.1.4 Purification of His6-SUMO and Orc1-His6 
His6-tagged SUMO1, SUMO2 and Orc1 were purified using fundamentally the same 
protocol as that employed to isolate the SUMO E1 enzyme (see 2.14.1.2), with the 
exception that the anion exchange step was omitted and the protein was concentrated 
to 1-2 µg·µL-1, in the case of Orc1, or 5-10 µg·µL-1, for SUMO, before being stored. 
2.14.1.5 Purification of non-tagged SUMO 
The cleared lysates prepared in Ni2+-NTA Lysis buffer devoid of imidazole were 
ultrafiltered twice through a centrifugal concentrator (30,000 MWCO, Vivaspin). The 
resulting flow-through was concentrated to 1 mL in a centrifugal concentrator (3,000 
MWCO, Vivaspin) and then applied to a Superdex 75 HR 10/30 gel filtration column 
(GE Healthcare) equilibrated in Protein Storage buffer. The fractions containing SUMO 
were combined, concentrated to 5-10 µg·µL-1 and finally flash-frozen in liquid nitrogen.  
2.14.1.6 Purification of APLF and XRCC1 
The lysate of cells producing N-terminally GST-tagged and C-terminally His6-tagged 
APLF and XRCC1 were incubated with 3 mL of pre-equilibrated Ni2+-NTA resin and 
handled thereafter essentially as described in 2.14.1.2. Imidazole was removed from 
the eluate by repetitively concentrating it in a centrifugal concentrator (10,000 MWCO, 
Vivaspin) and diluting it with a solution devoid of any imidazole. The resulting 
preparation was incubated with 3 mL of glutathione sepharose 4B (GE Healthcare) for 
1 h at 4°C. Bound proteins were washed with 40 mL of GST Wash buffer and eluted 
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with 15 mL of GST Elution buffer. The fractions containing the relevant protein were 
combined, dialyzed against PBS supplemented with 1 mM DTT and 10% v/v glycerol, 
concentrated to 1-2 µg·µL-1 and flash-frozen in liquid nitrogen. 
2.14.2 Protein production and purification in insect cells 
2.14.2.1 Over-production of PARP-1 
Exponentially growing Sf9 or Hi5 cells (1·109) were harvested by centrifugation at 200 
g for 5 min and typically mixed with 25-50 mL, or a volume large enough to give a MOI 
of 3, of the relevant virus stock and plain Grace’s medium to a final volume of 100 mL, 
and then incubated for 1h to allow the virus to bind to the cells. Next, the suspension 
was diluted with 900 mL of Grace’s medium supplemented with 10% v/v heat-
inactivated foetal bovine serum and grown in suspension for 48-72 h at 27°C. Finally 
the cells were harvested by centrifugation at 1,000 g for 10 min, washed in ice-cold 
PBS, resuspended in 20 mL of PARP-1 Lysis buffer, flash-frozen in liquid nitrogen and 
stored at -80°C.  
2.14.2.2 Preparation of 3-AB resin 
The competitive PARP-1 inhibitor 3-aminobenzamide (3-AB) was covalently coupled to 
ECH Sepharose 4B (GE Healthcare) exactly as described by Dantzer et al. (2006). 
2.14.2.3 Purification of PARP-1 
PARP-1 was purified using a modified version of the original purification strategy 
described by Dantzer et al. (2006). Cleared lysates were prepared from frozen cell 
suspensions freshly supplemented with 1 Complete Protease Inhibitors and 5 mM -
ME essentially as described in 2.14.1.2. Next, they were supplemented with 1 µgµL-1 
protamine sulfate, centrifuged at 50,000 g for 15 min, slowly diluted with an equal 
volume of PARP-1 Lysis buffer devoid of salt and then incubated with 4 mL of pre-
equilibrated 3-AB resin for 2 h at 4°C with rotation. The bound proteins were washed 
sequentially with 40 mL of each of PARP-1 Lysis buffer and equivalent solutions 
containing 500 or 800 mM NaCl. PARP-1 was eluted with 25 mL of PARP-1 Lysis 
buffer freshly supplemented with 1 mM 3-methoxybenzamide, mixed with an equal 
volume of PARP-1 Lysis buffer devoid of salt and applied to a HiTrap Heparin HP 
column (1 mL, GE Healthcare) pre-equilibrated in PARP-1 Heparin buffer. Proteins 
were eluted on a 100-1000 mM NaCl gradient over 20 column volumes. PARP-1-
containing fractions were pooled, concentrated to 2 mL in a centrifugal concentrator 
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(30,000 MWCO, Vivaspin), applied to a HiLoad 16/60 Superdex 200 gel filtration 
column pre-equilibrated in Protein Storage buffer. The fractions that included PARP-1 
were combined, concentrated to 1-2 µg·µL-1 and flash-frozen in liquid nitrogen. 
2.15 Generation and affinity purification of polyclonal 
antibodies 
2.15.1 Anti-SUMO rabbit polyclonal serum  
Recombinant His6-SUMO was used to immunize four rabbits by Harlan Sera-Lab UK, 
using 200 µg of protein for the initial immunization and 100 µg for the subsequent five 
boosts for each animal. The terminal bleed sera of rabbits ADA-11 (His6-SUMO1) and 
HU-4 (His6-SUMO2) were used for all downstream applications because they showed 
the highest affinity and specificity for the epitope against which they had been raised, 
as determined by western blotting analysis. 
2.15.2 Preparation of SUMO1 and SUMO2 affinity resins 
His6-SUMO was covalently coupled overnight at 4°C to CNBr-activated Sepharose 4B 
(GE Healthcare) at a ratio of 2 mg of protein per mL of pre-swollen resin according the 
manufacturer’s instructions with the only exception that after inactivation of the reactive 
groups the beads were also washed with 200 mM glycine pH 2.5.  The conjugated 
resin was stored in PBS supplemented with 0.02% w/v sodium azide.  
2.15.3 Affinity purification of antibodies 
The SUMO-sepharose resin (1 mL) was initially washed three times in PBS and then 
incubated overnight with 10 mL of the appropriate serum at 4°C with rotation. Next, the 
beads were washed with 20 mL of PBS and then eluted with 10 mL of Antibody Elution 
buffer I and 10 mL of Antibody Elution buffer II as 1 mL aliquots in tubes containing 200 
µL of Neutralization buffer. These fractions were pooled, dialyzed overnight at 4°C 
against PBS plus 1 mM DTT and concentrated in a centrifugal concentrator (3,000 
MWCO, Vivaspin). The resulting preparations were supplemented with 50% v/v 
glycerol, flash frozen in liquid nitrogen and stored at -80°C (long-term) or -20°C (short-
term). 
Chapter 2. Materials and methods 
 128
2.16 Analysis of protein sumoylation 
2.16.1 Denaturing Ni2+-NTA pull down method 
His6-SUMO-modified species were isolated from frog sperm chromatin (2.7.6, ~ 1.5106 
nuclei), total yeast cell extracts prepared by the alkaline lysis method (2.8.4.1, 50-100 
OD600 equivalents of cell) or mammalian cell pellets (1.0-1.5107 cells) by essentially 
the same procedure. They were resuspended in 1 mL of Ni2+-NTA buffer A 
supplemented with 15 mM imidazole and 0.15 mM Tween 20 and incubated at room 
temperature for 1 h with rotation. The resulting preparations were sonicated for 20 s on 
a Branson Sonifier at 20% power to reduce the viscosity of the resulting lysate, in the 
case of frog sperm chromatin and mammalian cells, or centrifuged at 16,000 g for 10 
min to clear it of large particulates, in the case of the yeast cell pellets. Next, 20 µL of 
Ni2+-NTA resin pre-equilibrated in Ni2+-NTA buffer A was added to the lysates and 
incubated overnight at room temperature with rotation. The resin was washed, by 
rounds of centrifugation (800 g for 15 s) and resuspension, in Ni2+-NTA buffer A 
supplemented with 20 mM imidazole for three times, and twice more in Ni2+-NTA buffer 
C, adjusted to either pH 6.3 or pH 8.0 and also supplemented with 35 mM imidazole. 
Excess of buffer was removed from the resin, which was finally resuspended in 35 µL 
of 1.5 NuPAGE LDS Sample Buffer supplemented with a reducing agent. 
2.16.2 Immunoprecipitation method 
Total cell extracts from either yeast (2.8.4.2, ~ 50 OD600 equivalents) or mammalian 
cells (2.18.1, ~ 5106 cells) were prepared in RIPA buffer and then subjected to a 
common immunoprecipitation protocol. The exact amounts of cell extract and antibody 
used for a specific experiment are reported in the relevant figure legend. Generally, 
total cell extracts (2-4 mg of protein in 1-2 ml of RIPA buffer) were initially pre-cleared 
by incubating them with ~ 500 µL of plain Sepharose 4B resin (GE Healthcare) for 30 
min at 4C with rotation. Next, the extracts were separated from the resin by 
centrifugation at 3,000 g for 30 s, subjected to the Bradford’s assay (see 2.13.4.3) and 
adjusted to the desired volume and protein concentration. The extracts were then 
transferred to silicon-coated 1.5 mL tubes, supplemented with the relevant antibody 
(usually 5-10 µg) and incubated with rotation at 4°C. After 2 h, the lysate-antibody 
mixture was spun at 16,000 g for 15 min, to remove any particulate that might have 
formed, and then transferred into new silicon-coated 1.5 mL tubes containing 15 µL of 
pre-equilibrated protein A/G resin (protein A for rabbit polyclonal antibodies, and 
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protein G for mouse monoclonal ones), which had been previously blocked with 10 
mgmL-1 BSA in PBS. Following an additional 1 h at 4C with rotation, the resin was 
washed through subsequent rounds of centrifugation (800 g for 15 s) and resuspension 
in the following solutions: 1) RIPA buffer, 2) the same as RIPA buffer but containing 
500 mM NaCl, 3) the same as RIPA buffer but containing 0.1% w/v SDS instead of 
0.1% w/v sodium deoxycholate, 4) the same as RIPA buffer but containing 125 mM 
NaCl and no detergents. Finally, the beads were resuspended in 30 µL of 1.5 
NuPAGE LDS Sample Buffer supplemented with a reducing agent.  
2.17 Enzymatic reactions 
2.17.1 Sumoylation reactions 
Sumoylation reactions were typically carried out in 20 µL of Sumoylation buffer 
containing: 25 nM SUMO E1 (either His6-tagged or untagged), 150 nM SUMO E2, 300 
nM SUMO1 or SUMO2 (either His6-tagged or untagged), 150 nM of the relevant SUMO 
substrate and 2 mM ATP. These reactions were allowed to proceed for 2 h at 30°C 
before being used to either purify a sumoylated substrate under native conditions 
(2.17.1.1 and 2.17.1.2) or to determine the extent of its modification by western blotting 
analysis (3-4 µL of the reaction). Any departures from this basic protocol are indicated 
in the relevant figure legend.  
2.17.1.1 Purification of sumoylated PARP-1’s DBD 
PARP-1’s DBD was sumoylated in a large-scale reaction using a buffer devoid of any 
BSA or Tween 20 and in the presence of His6-SUMO containing a rhinovirus 3C 
protease cleavage site between the tag and the modifier, and a supercoiled plasmid 
(250 ng per 20 µl of reaction). The final volume of the reaction is reported in the 
relevant figure legend. Once the reaction was complete, it was slowly supplemented 
with NaCl and imidazole to a final concentration of 500 mM and 20 mM, respectively, 
and then applied to a 1 mL HisTrap HP column (GE Healthcare). The bound proteins 
were washed with 20 mL of Su-DBD Wash buffer, which was subsequently exchanged 
for 3C Cleavage buffer over five column volumes. A GST-tagged version of the 
rhinovirus 3C protease was added to 1.1 mL of such a solution at a protease:SUMO 
molar ratio of 1:40, injected into the column and then incubated overnight at 4C. Next, 
the HisTrap HP column was connected in series to a 1 mL GSTrap HP one (GE 
Healthcare) and then slowly washed with 15 mL of 3C Cleavage buffer to “elute” the 
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sumoylated proteins and simultaneously remove the protease. The eluate was 
concentrated to 0.5 mL in a centrifugal concentrator (3,000 MWCO, Vivaspin) and 
applied to a Superdex 75 HR 10/30 gel filtration column pre-equilibrated in Su-DBD gel 
filtration buffer. The fractions containing the sumoylated PARP-1’s DBD were pooled, 
concentrated to 1-2 µg·µL-1 and stored at 4C. 
2.17.1.2 Purification of sumoylated full-length PARP-1  
His6-PARP-1 was sumoylated in a large-scale reaction using a buffer devoid of any 
BSA or Tween 20 and in the presence of untagged SUMO E1, untagged SUMO1 and a 
supercoiled plasmid (250 ng per 20 µl of reaction). The final volume of the reaction is 
reported in the relevant figure legend. Once the reaction was complete, it was slowly 
supplemented with NaCl and imidazole to a final concentration of 500 mM and 20 mM, 
respectively. The sumoylated His6-PARP-1 was captured onto 50 µL of Ni2+-NTA resin, 
washed four times with 1 mL of Su-PARP-1 Wash buffer and eluted four times with 200 
µL of Su-PARP-1 elution buffer. The eluate was dialyzed against either 100 mM 
ammonium acetate, before being concentrated to 50 µL for mass spectrometry analysis 
(see 2.21), or Protein Storage buffer, before being concentrated to 50 µL and flash-
frozen in liquid nitrogen. 
2.17.2 Parylation reactions 
A complete parylation reaction contained 17.5 nM PARP-1 and 40 ng of DNase I-
activated calf thymus DNA in a 20 µL total volume of either Auto-parylation buffer, if the 
polymerase was the only protein present in the reaction, or in Extract buffer if a cell 
extract (25 µg) was also included. The reactions were incubated at 25°C for the 
required lengths of time, stopped by the addition of 10 µL of 3 NuPAGE LDS Sample 
Buffer supplemented with a reducing agent, boiled for 5 min at 95°C and subjected to 
western blotting (10 µL, see 2.13.5). 
2.18 Analysis of protein-protein interactions  
2.18.1 Anti-FLAG co-immunoprecipitation  
Frozen pellets of cells (100 µL) that had been transfected as indicate in the relevant 
figure legend were resuspended in 500 µL of Hypotonic buffer and incubated for 10 min 
on ice. The resulting lysates were supplemented with KCl to a final concentration of 
150 mM, set on ice for an additional 5 minutes, subjected to two 5 s sonication pulses 
on a Branson sonifier at 10% power and then cleared by centrifugation at 16,000 g for 
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10 min at 4C. Next, the extracts were subjected to the Bradford assay (see 2.13.4.3) 
and then adjusted to 1.5 µg·µL-1 of total protein. FLAG M2 agarose (30 µL, SIGMA) 
was added to 1 mL of this lysate and incubated overnight at 4C with rotation. Finally, 
the resin was washed four times with Co-immunoprecipitation Wash buffer before 
being resuspended in 35 µL of 1.2 NuPAGE LDS Sample Buffer supplemented with a 
reducing agent. 
2.18.2 Glutathione pull-down assays 
Typically, defined amounts of a GST-tagged polypeptide (the bait) and a second 
protein (the prey), as indicated in the relevant figure legends, were combined in 100 µL 
final volume of PBS-Tx supplemented with 1 mM DTT. The reactions were mixed and 
incubated at 4C for 2 h. Next, 10 µL of glutathione resin (GE Healthcare) was added 
to the tubes and incubated for an additional 1 h at 4C with rotation. The beads were 
washed four times with PBS-Tx plus 1 mM DTT before being resuspended in 30 µL of 
1.2 NuPAGE LDS Sample Buffer and a reducing agent. 
2.19 Preparation of DNA substrates for sumoylation reactions 
2.19.1 Preparation of digested, nicked and relaxed pHU2020 
Double- or single-stranded breaks were inflicted on pHU2020 (11 µg) by incubating it in 
a total volume of 120 µL with 110 U of PstI, EcoRV or EcoRI for 3 h at 37C, or 
Nb.BsrDI (New England Biolabs) for 3 h at 65C. Supercoiling was released from 
pHU2020 (5 µg) in the presence of 5 U of topoisomerase I (Invitrogen) for 3h at 37C in 
500 µL of Topo I buffer. The resulting DNA was purified using Qiagen’s QIAquick Spin 
columns according to the manufacturer’s instructions. Successful digestion was 
confirmed by agarose gel electrophoresis (see 2.11.2).  
2.19.2 Annealing of oligonucleotides 
Double-stranded DNA oligonucleotides were generated by combining the appropriate 
pair of ssDNA oligonucleotides in Annealing buffer to a final concentration of 50 µM, 
boiling the resulting mixture at 98C for 3 min and then allowing it to cool to room 
temperature in 2C steps every 2 min, with a 2 min rest time, at a rate of 0.1Cs-1 in a 
DYAD Thermal Cycler. Sebastian Eustermann created the nicked dumbbell substrate 
by diluting the corresponding ssDNA oligonucleotide to a concentration of 50 µM in 
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Annealing buffer, incubating it on boiling water for 3 min and then allowing it to slowly 
cool down to room temperature.   
2.19.3 Ligation of nicked dumbbell  
The nicked dumbbell (20 µM) was ligated in a total volume of 40 µL containing 2,000 U 
of T4 DNA ligase for 16 h at 25C. The reaction was terminated by incubating it at 65C 
for 5 min. Successful ligation of the nicked dumbbell was assessed by comparing its 
migrating patterns to that of a mock-ligated substrate by denaturing PAGE (see 2.11.3).  
2.20 Analysis of protein-DNA interactions 
Analysis of protein-DNA interactions was carried out by Sebastian Eustermann.  
2.20.1 Electrophoretic mobility shift assay 
DNA ligand (400nM) was mixed with PARP-1’s DBD (200 nM, 400, nM, 800 nM, 1600 
nM) in EMSA binding buffer in a total volume of 10 µL and incubated for 30 min at room 
temperature. The samples were resolved by native PAGE as described in 2.11.3. 
2.21 General methods of mass spectrometry 
Mass spectrometry analysis was carried out by the Protein Analysis and Proteomics 
team of the London Research Institute. 
2.21.1 Sample preparation 
Poly-acrylamide gel slices or proteins in solution (resuspended in 4 M urea and 50 mM 
ammonium bicarbonate) were prepared for mass spectrometry analysis using the 
Janus Liquid Handling System (PerkinElmer). The samples were placed in a 96-well 
microtitre plate and destained with 50% v/v acetonitrile and 50 mM ammonium 
bicarbonate, reduced with 10 mM DTT and then alkylated with 55 mM iodoacetamide. 
An additional 2 µl of 10 mM DTT was added to the samples to neutralize excess 
iodoacetamide and subsequently incubated overnight at 37C with 6 ngµL-1 of trypsin. 
In the case of gel slices, the peptides were extracted in a solution of 2% v/v formic acid 
and 2% v/v acetonitrile.   
2.21.2 Peptide analysis by LC-MS/MS 
The peptides were separated at a flow of 300 nLmin-1 with a gradient of acetonitrile on 
a nanoACQUITY UPLC system (Waters) attached to a C18 Symmetry µ-Precolumn (5 
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µm, 180 µm  20 mm, Waters) in series with a C18 BEH130 analytical UPLC column 
(1.7 µm, 75 µm  100 mm, Waters). The column outlet was directly interfaced with an 
LTQ Orbitrap XL/ETD instrument (Thermo Scientific) via a modified nano-flow 
electrospray ionisation source. Data-dependent analysis was performed using a 
resolution of 30,000 for the full MS spectrum, followed by eight MS/MS spectra in the 
linear ion trap.  MS spectra were acquired with an automatic target gain control of 5105 
and a maximum injection fill-time of 100 ms over an m/z range of 300-2,000.  MS/MS 
scans were collected using an automatic gain control value of 4104 and a threshold 
energy of 35 for collision-induced dissociation.  The data were analyzed against the 
UniProt database by means of the MASCOT algorithm (Matrix Science) using the 
following parameters: a precursor tolerance of 5 ppm, a fragment ion mass tolerance of 
0.8 Da, one missed trypsin cleavage site and variable modifications for oxidized 
methionine, carbamidomethyl cysteine, pyroglutamic acid, phosphorylated serine, 
threonine and tyrosine.  MS/MS data were manually curated and validated using the 
Scaffold programme (Proteome Software). 
2.22 General methods of NMR spectroscopy 
NRM spectroscopy was carried out by Sebastian Eustermann. 15N- and 13C-labelled 
SUMO-PARP-1’s DBD (see 2.17.1.1) was dialyzed against NMR dialysis buffer and 5% 
v/v D2O.  NMR data were acquired on a DMX600 spectrometer (Bruker) fitted with a 
triple resonance (1H/15N/13C) cryoprobe. Experiments were performed at 300K and 1H, 
15N and 13C chemical shifts (δ) were calibrated using sodium 3,3,3-
trimethylsilylpropionate as an external 1H reference.  Spectra were processed using 
either the program TOPSPIN (Bruker) or SPARKY (Goddard T.D. and Kneller D.G., 
University of California, San Francisco).  Resonance assignments of PARP-1 residues 
were made using a standard suite of triple resonance NMR experiments.  15N,1H 
resonances of protein backbone amide groups of PARP-1’s DBD in the context of the 
sumoylated domain were assigned by comparing its (15N,1H) heteronuclear single 
quantum coherence spectrum to that of the unmodified PARP-1’s DBD.  A large 
majority of resonances were found at closely corresponding peak positions so that 
perturbed signals could be unambiguously identified and assigned.  Amide group 
chemical shift perturbation between PARP-1’s DBD and SUMO-PARP-1’s DBD was 
calculated as follows, ∆δ = √((δ1H)2 + (δ15N/5)2). 
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Chapter 3. Results I: Isolation and identification of 
sumoylated proteins from normal and challenged 
replicating chromatin 
3.1 Introduction 
Sumoylation plays an important role in the maintenance of genome stability. In both 
budding and fission yeasts, mutations within the members of the sumoylation pathway 
lead to hypersensitivity to different genotoxins (Andrews et al., 2005; Ho and Watts, 
2003; Maeda et al., 2004; Zhao and Blobel, 2005), accumulation of chromosomal 
rearragements (Motegi et al., 2006), defective chromatid segregation (Tanaka et al., 
1999), failure to properly retain mini-chromosomes (Takahashi et al., 2006) and 
telomeric defects (Rog et al., 2009; Tanaka et al., 1999; Xhemalce et al., 2004; Zhao 
and Blobel, 2005). In human cells, disrupting the normal regulation of sumoylation also 
leads to the accumulation of damaged DNA and impairs its repair (Galanty et al., 2009; 
Li et al., 2000; Morris et al., 2009; Potts and Yu, 2005). In addition, proteins involved in 
controlling DNA metabolism, and therefore also genome integrity, have been found to 
be sumoylated, including members of nucleotide excision repair (e.g. XPC and XRCC4, 
Wang et al., 2005b; Yurchenko et al., 2006), BER (e.g. thymine DNA glycosylase, see 
1.3.4), homologous recombination (e.g. Rad52, PCNA, BRCA1 and the RECQ family of 
DNA helicases, Eladad et al., 2005; Galanty et al., 2009; Hoege et al., 2002; Kawabe 
et al., 2000; Morris et al., 2009; Sacher et al., 2006), non-homologous end joining (e.g. 
Ku70, Zhao and Blobel, 2005), topoisomerase I (Horie et al., 2002; Mao et al., 2000b), 
topoisomerase II (Azuma et al., 2003; Bachant et al., 2002; Mao et al., 2000a) and 
proteins involved in telomere protection (Potts and Yu, 2005). 
Although our understanding of how sumoylation impinges on biological processes has 
improved considerably, the exact mechanisms by which SUMO protects cells against 
DNA damage remain largely unknown because it has often not been possible to 
correlate a specific phenotype to the modification of a certain protein by specific E3 
ligases. When I started my research work several proteomic studies had been carried 
out in both yeast and vertebrates with the aim of identifying possible targets of 
sumoylation (Denison et al., 2005; Hannich et al., 2005; Rosas-Acosta et al., 2005; 
Vertegaal et al., 2006; Vertegaal et al., 2004; Wohlschlegel et al., 2004; Zhao et al., 
2004b; Zhou et al., 2004). Amongst the candidates that were found, proteins involved 
in DNA replication and repair appeared to be somewhat under-represented in 
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comparison to, for example, transcription factors, probably because their sumoylation 
levels were too small in comparison to the entire “sumoylome” of a cell to be efficiently 
detected by mass spectrometry. I reasoned that if I could identify proteins that were 
sumoylated during S phase and/or after challenge with genotoxic stress then I could 
gain more insight on how sumoylation controls genome stability. Towards this goal, I 
decided to identify SUMO conjugates during unchallenged replication or in the 
presence of genotoxins from chromatin, because it should be enriched for proteins with 
established roles in DNA metabolism.  
As a source of chromatin for these experiments I decided to use sperm DNA incubated 
in X. laevis egg interphase extracts for several reasons. Firstly, several published 
studies had already shown that frog egg extracts could be successfully used to identify 
sumoylated species from mitotic chromosomes as well as to study diverse aspects of 
sumoylation, often in a target-specific manner (Azuma et al., 2003; Leach and Michael, 
2005; Lee et al., 1998; Saitoh et al., 1998). Secondly, in frog egg extracts 
chromosomes are rapidly, synchronously and efficiently replicated under the same 
controls that exist in vivo: only once per cell cycle by semi-conservative DNA synthesis. 
Since such extracts can be extensively manipulated in a biochemically-tractable 
manner, they have been instrumental to exploring the mechanics of DNA replication 
under normal conditions and in the presence of DNA damage (Blow and Laskey, 1986; 
Coleman et al., 1996; Costanzo et al., 2001; Costanzo et al., 2004).  
For all the studies presented in this chapter I used interphase extracts supplemented 
with cycloheximide. These extracts consist of essentially pure egg cytoplasm and 
membranes that are obtained by centrifuging mature frog eggs, which are naturally 
arrested at metaphase of the second meiotic division (Walter and Newport, 1999). The 
addition of calcium to the eggs activates them, that is, it leads to degradation of mitotic 
cyclins, the subsequent exit from metaphase and entry into interphase. When hyper-
condensed sperm chromatin is added to the extracts it undergoes a series of 
remodelling events that include decondensation, exchange of sperm protamines for 
egg histones and packaging into structures that resemble interphase nuclei before 
being replicated (Blow, 1996). The addition of cycloheximide to the extracts inhibits the 
de novo synthesis of proteins such as mitotic cyclins, which are required for mitotic 
entry, thus ensuring that they do not progress past the end of DNA replication 
(Solomon et al., 1990).  
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The aim of this part of my study was: 1) to show that chromatin isolated from frog egg 
extract associates with sumoylated proteins during DNA replication and in response to 
genotoxic stress, 2) to isolate and identify such SUMO conjugates and 3) to confirm the 
sumoylation of such proteins. 
3.2 Results 
3.2.1 Generation of anti-SUMO1- and anti-SUMO2-specific antibodies  
Towards the end of identifying sumoylated species from DNA that is being replicated, I 
initially wanted to confirm that sumoylated species do indeed associate with replicating 
chromatin. For this purpose, and because I discovered that the specificity of 
commercially-available antibodies against SUMO1 or SUMO2 leaves a lot to be 
desired, I set out to generate antibodies that specifically recognized either one SUMO 
paralogue. Since the primary sequence of the mature forms of SUMO2 and SUMO3 
differ only by three amino acids, I assumed that a polyclonal antibody raised against 
SUMO2 would recognize SUMO3 as well. The antibodies against SUMO1 or SUMO2 
were generated in rabbits by five subsequent injections of either His6-SUMO1 or His6-
SUMO2. The SUMO-specific antibodies were captured from terminal-bleed sera on a 
resin produced by cross-linking either His6-SUMO1 or His6-SUMO2 to activated 
 
Figure 3.1 - Characterization of anti-SUMO1 and anti-SUMO2 antibodies. A) Increasing 
amounts of His6-SUMO1 or His6-SUMO2 were spotted onto a nitrocellulose membrane and 
probed overnight at 4C with 1 µg of anti-SUMO1 and anti-SUMO2 antibodies per mL of 5% w/v 
milk in PBS + 0.1% v/v Tween 20. Detection was carried out by chemiluminescence. B) 
Interphase extracts (10 µL) were supplemented with His6-SUMO1 or His6-SUMO2 to a final 
concentration of 0, 2, 5, 10, 20 or 40 µM and incubated for 1 h at 23C. For western blotting, 1 
µL of extract was analyzed against SUMO1 or SUMO2.  
B 
A 
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sepharose, and isolated by acid elution. To estimate the affinity and test the specificity 
of these antibodies, I analyzed them by western blotting on a filter spotted with 
increasing amounts of purified His6-SUMO1 or His6-SUMO2. Figure 3.1A shows both 
the anti-SUMO1 and anti-SUMO2 antibodies specifically recognized the relevant 
SUMO paralogue against which they were raised and purified. The data also indicate 
that the antibodies must have minimal cross-reactivity towards the His6 tag because 
both recombinant SUMOs spotted on the membrane carried it. Although other types of 
cross-reactivity in total cell extracts cannot be excluded, these results suggest that they 
are not likely. Western blotting analysis of egg extracts supplemented with increasing 
amounts of His6-SUMO1 or His6-SUMO2 also showed a dose-dependent rise in the 
levels of several species spanning a range of molecular weights, which in all likelihood 
represent SUMO conjugates (Figure 3.1B).  
Altogether, these data indicate that I generated specific antibodies against SUMO1 and 
SUMO2. Importantly, they also demonstrate that the His6-tagged SUMO1 and SUMO2 
I added to the extracts were functional, that is, they could be actively conjugated to 
proteins.  
3.2.2 SUMO conjugates associate with chromatin during interphase 
Having generated antibodies that recognize SUMO1 and SUMO2, I used them to verify 
that SUMO conjugates associate with DNA during interphase. I isolated chromatin at 
mid-S phase from extracts that were supplemented with sperm nuclei alongside a 
control buffered solution, SUMO1, SUMO2 or their respective His6-tagged versions 
before being allowed to replicate, and analyzed them by western blotting. I added 
recombinant SUMO to the extracts because I wanted to inspect the behaviour of 
sumoylated species under the same conditions that I would be using in subsequent 
experiments to generate SUMO conjugates that bear a His6 tag and can therefore be 
captured under denaturing conditions. Figure 3.2 shows that replicating chromatin 
associated with both SUMO1 and SUMO2 conjugates. Expectedly, supplementing the 
extracts with recombinant untagged SUMO enhanced the levels of such species. The 
addition of His6-SUMO afforded a similar increase and resulted in the incorporation of 
the tagged protein into high-molecular weight species, which must have been 
generated by de novo sumoylation. These observations also suggest that the His6 tag 
does not significantly impair the conjugation of SUMO to its targets. The SUMO 
adducts shown in Figure 3.2 were bona fide DNA-binding proteins because they were 
not detected in a mock isolation carried out on extracts devoid of chromatin.  
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Figure 3.2 - SUMO1- and SUMO2-modified species associate with chromatin during 
interphase. Interphase extracts (25 µL) were supplemented with either a control buffer, 
untagged SUMO1/2 or His6-SUMO1/2 to a final concentration of 20 µM. Where indicated, sperm 
nuclei (2,500 nucleiµL-1 of extract) were added. Chromatin was isolated from the extracts after 
an incubation of 1 h at 23C and analyzed by western blotting against SUMO1, SUMO2, His6 
and PCNA (loading control). 
 
3.2.3 The levels of chromatin-associated SUMO1 conjugates change 
during and depend on entry into S phase 
Having found SUMO1- and SUMO2-conjugated species on replicating chromatin, I was 
interested in determining whether their levels changed during the course of DNA 
replication. Interphase extracts were supplemented with sperm nuclei and either His6-
SUMO1 or His6-SUMO2 prior to replication. Chromatin was isolated from these extracts 
at three time-points: soon after addition of nuclei (0 h), during DNA replication (1 h) or 
after replication was completed (2 h) and analyzed by western blotting against the His6 
tag. The amount of PCNA loaded on the chromatin was used as a rough estimate to 
monitor progression through S phase. Figure 3.3A shows that the levels of both 
SUMO1 and SUMO2 species on DNA peaked during S phase and disappeared 
thereafter. 
To confirm that such a trend depended on DNA replication and it was not simply a 
time-dependent effect of the incorporation of the His6-SUMO into conjugates, I 
repeated the above-described experiment in the absence or presence of recombinant 
geminin (a gift from Vincenzo Costanzo). Geminin is normally absent at the G1 phase 
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Figure 3.3 - The levels of chromatin-associated SUMO1- and SUMO2-modified species 
change during interphase. Interphase extracts (25 µL) were supplemented with 2,500 
nucleiµL-1 of extract and either His6-SUMO1 or His6-SUMO2 to a final concentration of 20 µM. 
Chromatin was isolated from the extracts at the indicated times and analyzed by western 
blotting against His6, PCNA and ORC1 (loading control). 
 
 
and it accumulates during S and G2 phases, when it blocks the loading of the MCM2-7 
helicase on replication origins by binding to and inhibiting the essential replication 
factor CDT1, thus preventing re-replication of DNA (McGarry and Kirschner, 1998; 
Tada et al., 2001; Wohlschlegel et al., 2000). If exogenous geminin is added to egg 
extracts before replication origins fire, it inhibits DNA replication. For this experiment, I 
isolated DNA at increasing time points from interphase extracts supplied with His6-
SUMO1 and analyzed it by western blotting against the His6 tag. The kinetics of 
replication was followed by quantifying the incorporation of [α-32P]dCMP into genomic 
DNA (Figure 3.4C). In the absence of geminin, the levels or extent of modification of 
sumoylated proteins on DNA appeared to follow, although with a delay, the course of S 
phase (Figure 3.4A, left panel). In the absence of chromosomal replication, that is, in 
the presence of geminin, very little on-chromatin sumoylation was observed (Figure 
3.4A, middle panel). To exclude an inhibitory effect of geminin itself on sumoylation, I 
examined the dynamics of modification in the soluble fraction of the extracts. Although 
geminin did slightly inhibit sumoylation in this fraction (Figure 3.4B), the effect was 
almost an order of magnitude smaller than what I observed for DNA-associated 
proteins.  
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Altogether these results indicate that progression through S phase is critical for the 
presence of sumoylated species on the chromatin and suggest that sumoylation may 
play an important role during DNA replication. 
3.2.4 Genotoxic stress does not visibly alter the modification of 
chromatin-associated proteins by SUMO1 
I was interested in determining whether the pattern of sumoylation of chromatin-
associated proteins changed in response to genotoxic stress. In that case, the 
modification of certain proteins might be important in maintaining genome stability. As a 
source of genotoxic stress I used aphidicolin, which inhibits replicative DNA 
polymerases, leading to the accumulation of ssDNA and activation of several pathways 
of DNA damage detection and repair such as the DNA damage checkpoint (Lupardus 
et al., 2002), homologous recombination (Saintigny et al., 2001) and post-replication 
repair (Chang et al., 2006).  
I isolated DNA at increasing time-points from interphase extracts supplemented with 
His6-SUMO1 in the absence or presence of aphidicolin and examined it for sumoylation 
by western blotting. Figure 3.4A, right panel, shows that analogously to the addition of 
geminin, although to a lesser extent, the presence of aphidicolin reduced the level of 
sumoylated species on the chromatin. The conjugates that however did appear 
accumulated with similar kinetics to those observed for the untreated sample (Figure 
3.4A, left panel), but did not disappear at the later time-point. Taking into account that 
progression through S phase seems to be required for the presence of sumoylated 
species on DNA (Figure 3.4A, left and middle panel) and that aphidicolin arrests DNA 
replication at an early stage, this observation is likely to reflect the inability of the 
extract to complete S phase. The slightly higher levels of sumoylated species observed 
on the DNA of the aphidicolin-treated extract compared to the geminin-treated one, 
where progression through S phase is prevented by inhibiting origin licensing and not 
DNA replication, suggests that between these two events some proteins may become 
sumoylated. Unfortunately, I also observed that the distribution and the relative 
intensities of the SUMO1 conjugates from the extracts treated with aphidicolin 
appeared very similar to those observed in the non-damaged extracts, thus indicating 
that replicative stress does not noticeably alter the sumoylation of the bulk of 
chromatin-associated proteins. I, however, reasoned that given the relatively low 
abundance of individual sumoylated species, small changes in their modification could 
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Figure 3.4 - Progression through S phase, but not genotoxic stress, affects the 
sumoylation of chromatin-associated proteins in interphase extracts. A) Interphase 
extracts (25 µL) were supplemented with 2,500 nucleiµL-1 of extract and His6-SUMO1 to a final 
concentration of 20 µM. Where indicated a control buffer, geminin (8 nM) or aphidicolin (40 µM) 
were also added. Chromatin was isolated from the extracts at the indicated times and analyzed 
by western blotting against His6, PCNA and histone H3 (loading control). B) The soluble 
fractions of the extracts prepared as described in A) were analyzed by western blotting against 
His6, PCNA and H3 (loading control). C) DNA replication was analyzed as described in 2.7.5. U 
= % of [α-32P]dCMP incorporation. 100% was defined as the amount of [α-32P]dCMP 
incorporated in the genomic DNA of the control sample at 150 min. 
 
 
not be excluded because they may be hard to discern in blots like those shown in 
Figure 3.4, where discrete bands are not obvious.  
3.2.5 Identification of SUMO conjugates from replicating chromatin by 
mass spectrometry and western blotting 
To identify the SUMO conjugates that I observed in Figure 3.4, I devised the following 
strategy. Chromatin was isolated during S phase from a large preparation of 
undamaged or aphidicolin-treated interphase extracts that were supplemented with 
His6-SUMO1 or His6-SUMO2. The covalent nature of the bond between SUMO and its 
targets and the ability of the His6 tag to bind to a Ni2+NTA matrix even in the presence 
of 6 M guanidine HCl allowed me to capture sumoylated species by denaturing affinity 
chromatography (Figure 3.5A). By using this tactic, I expected to inactivate SUMO 
A 
B 
C 
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Figure 3.5 - Isolation of sumoylated species from replicating chromatin under normal 
conditions and in the presence of genotoxic stress. A) Experimental strategy used to isolate 
and identify chromatin-associated substrates of sumoylation. B) Interphase extracts (1 mL) were 
supplemented with 2,500 nucleiµL-1 of extract and His6-SUMO1 or His6-SUMO2 to a final 
concentration of 20 µM. Where indicated aphidicolin (Aph, 40 µM) or just DMSO was also 
added. Chromatin was isolated from the extracts after 1 h and resuspended in 1 mL of a 
buffered solution containing 6 M guanidine HCl. His6-SUMO1/2-modified species were captured 
as described in 2.16.1 at room temperature with 50 µL of Ni2+-NTA resin. Affinity purified 
proteins were subjected to SDS-PAGE followed by SYPRO Ruby staining or western blotting 
against SUMO1/2. PD = Ni2+-NTA pull-down. 
 
 
isopeptidases and therefore minimize the loss of sumoylated species that may 
otherwise occur during the enrichment procedure (Vertegaal et al., 2006; Vertegaal et 
al., 2004). I also expected to disrupt most non-covalent interactions, thus ensuring that 
only proteins covalently linked to SUMO would be isolated. To account for the 
recognized non-specific affinity of the Ni2+NTA resin towards the many histidine-rich 
proteins present in eukaryotes, a control mock purification was also performed using 
chromatin isolated from extracts supplied only with a buffered solution.  
The proteins extracted by the above-described procedure were resolved by SDS-
PAGE and visualized by SYPRO Ruby staining. Figure 3.5B shows that, with the 
exception of some discrete bands and a stronger “general” staining observed 
specifically in the experimental samples, the protein patterns of the mock and 
experimental purifications were similar. However, when such samples were analyzed 
by western blotting against SUMO1 and SUMO2, I observed a significant enrichment of 
A B 
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Table 3.1 - Identification of sumoylated species from replicating chromatin under normal 
conditions and in the presence of genotoxic stress by mass spectrometry. Sumoylated 
proteins isolated as described in Figure 3.5B were analyzed by LC-MS/MS. * Maximum number 
of peptides detected within one band for proteins identified in two or more bands. 
 
    peptides   
 Identified  Protein 
Uniprot 
Accession SUMO1
SUMO1 
+ Aph SUMO2
SUMO2+ 
Aph 
Modification 
by SUMO1/2 
Aphidicolin 
dependence?
D
N
A
 re
pl
ic
at
io
n 
an
d 
re
pa
ir 
Aprataxin Q7T287 - - 5 3 SUMO2 No 
ATR Q9DE14 - 9 - 5 Both Yes 
DNA pol α  
(catalytic subunit) Q9DE46 - 8* - 19* Both Yes 
PARP-1 P31669 - - 14 - SUMO2 Yes 
PCNA P18248 - - - 2 SUMO2 Yes 
PLK1 P34331 - - - 2 SUMO2 Yes 
RAD50 Q92878 2 2 - - SUMO1 No 
RAD52 P39022 - - - 2 SUMO2 Yes 
RAD54B Q9DG67 6* - 2* - Both No 
RFC1 P35251 - 2 - 3 Both Yes 
RTEL1 Q9NZ71 - - - 4 SUMO2 Yes 
TOP2A O42130 5 - 28* 17* Both No 
TOP2B O42131 - 4 9* 9* Both No 
WDHD1 O13046 - - - 4* SUMO2 Yes 
C
hr
om
at
in
 re
m
od
el
in
g 
CHD1 O14646 9 8* 9* 4* Both No 
CHD3 Q12873 - 7 12* 4* Both No 
CHD4 Q14839 - - 21 11 SUMO2 No 
CHD6 Q8TD26 4 9* 5* 9* Both No 
CHD7 Q9P2D1 7* 26* 28* 25* Both No 
HDAC1 Q91695 - - 9 4 SUMO2 No 
ISW1 Q24368 - - 5* - SUMO2 Yes 
ISW2 Q8RWY3 - 2 5* 4* Both No 
JHD2C Q15652 2 5 5* 6* Both No 
N-COR1 O75376 - - 2 - SUMO2 Yes 
N-COR2 Q9Y618 - 5 6 5 Both No 
RBBP4 Q3MHL3 - - 2* 8* SUMO2 No 
RBBP7 Q9I8G9 4 - 2* 2* Both No 
SNF2 O60264 - - 6* 4 SUMO2 No 
TRRAP Q9Y4A5 3 4 8 - Both No 
Tr
an
sc
rip
tio
n 
ARID5B Q14865 - 2 - - SUMO1 Yes 
CTBP1 Q13363 2 3 9* 12* Both No 
HIC 2 Q15652 - - 2 2 SUMO2 No 
RBM39 Q14498 - 2 - - SUMO1 Yes 
SAL-like protein 1 Q9NSC2 - 3 8* 12 Both No 
SAL-like protein 4 Q9UJQ4 - - 4 - SUMO2 Yes 
SIN3A Q96ST3 - 9 9* 7 Both No 
Transcription 
repressor p66 Q86YP4 5* 2 5* 3* Both No 
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Zn finger  
protein 143 P52747 - - 11* 4 SUMO2 No 
Zn finger  
protein 462 Q96JM2 - 5 7* - Both No  
Zn finger  
protein 687 Q8N1G0 - - 3* - SUMO2 Yes 
O
th
er
/C
yt
op
la
sm
ic
 
CDK11 Q9BWU1 - - - 3* SUMO2 Yes 
Afadin P55196 - - - 3 SUMO2 Yes 
BAT2 P48634 - 4 2 4 Both No 
BRE1 Q60YN5 2 - - - SUMO1 Yes 
CAM kinase II γ 
chain Q13555 - - 4* 5* SUMO2 No 
Cyclin T1 Q6T8E9 - - 3 - SUMO2 Yes 
GPR27 Q9NS67 2 - - - SUMO1 Yes 
LIS1 P43033 - - - 7* SUMO2 Yes 
NOL3 O60936 - - - 3* SUMO2 Yes 
Phenylalanyl-
tRNA synthetase 
β chain 
Q1971 6 - - - SUMO1 No 
PP1 subunit 10 Q6GLQ4 2 - 4 5 Both  
 
sumoylated species from 40 kDa to over 190 kDa in size specifically in the 
experimental samples (Figure 3.5B). No free SUMO1 or SUMO2 were found bound to 
the chromatin, indicating that these proteins do not bind on their own to DNA (data not 
shown). Because I could not discern discrete band in the western blotting shown in 
Figure 3.5B, but also to ensure that only targets of sumoylation were identified and all 
the possible contaminants were excluded, the experimental and control lanes of the gel 
were divided into 40 bands, each of which was subjected to in-gel trypsin digestion. 
The resulting peptides were extracted and analyzed by the Protein Analysis and 
Proteomics team of the London Research Institute on a ThermoScientific LTQ Orbitrap 
XL/ETD mass spectrometer coupled to a Waters NanoACQUITY UPLC system (LC 
MS/MS), both in terms of their mass (MS) and their sequence (MS/MS). This 
information was used by the Mascot algorithm to identify the proteins which the 
peptides came from by searching the Swiss-Prot database. Only metazoan proteins 
were included in such searches. For the experimental samples a hit was defined as a 
protein identified by two tryptic peptides with an Xcorr value greater than 10.0. I used 
looser screening criteria to establish hits within the control sample, a single tryptic 
peptide with an Xcorr value of 5.0, to guarantee that all the possible contaminants were 
included in the analysis. Upon comparison of the control and experimental samples, I 
found several proteins to be unique to the His6-SUMO purifications; a list of such 
proteins is included in Table 3.1 and its features are discussed in detail below. 
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Protein identified Uniprot accession 
Cortactin Q01406 
Actin Multiple 
Amplaxin Q14247 
Bromodomain-containing protein 3 Q15059 
EF2 P29691 
Gephyrin Q9NQX3 
IL8  P08317 
Lamin A  P11048 
Lamin A/C Q3ZD69 
LIMA1 Q9UHB6 
MCM2 P49736 
MCM3 P49739 
Myosin 11 P10587 
ORC4 O93479 
PINK1 Q9BXM7 
Protein polybromo 1 Q86U86 
Supervillin O95425 
Triadin Q13061 
Ubiquitin protein ligase E3B Q7Z3V4 
 
Table 3.2 - Proteins identified in the Ni2+-NTA pull-down that was carried out on 
chromatin isolated from extracts devoid of His6-SUMO.  
 
 
Comparing the datasets described in other sumoylation-centred proteomic studies with 
each other reveals that relatively limited overlap exists amongst the SUMO targets 
identified. This means that such studies did not find all of the SUMO substrates in a 
cell, but in fact only a few. To examine whether the proteomic approach I carried out 
also missed some sumoylation targets, I analyzed the His6-SUMO1 and control 
purifications by western blotting with antibodies available at the Clare Hall Laboratories 
that could recognize the Xenopus orthologues of proteins involved in DNA metabolism, 
such as ORC1, MCM7 and RPA70. PCNA was used as a positive control because it 
had been previously reported to be sumoylated on chromatin during S phase in frog 
egg extracts (Leach and Michael, 2005). Figure 3.6 confirms that PCNA was 
sumoylated in this system. In addition, it shows that ORC1, and possibly RPA70, were 
also modified since a slow-migrating form of the proteins was observed solely in the 
His6-SUMO1 affinity purifications. No modification of MCM7 was detected. These 
results indicate that the proteomic approach described here did not identify the 
complete cohort of chromatin-associated targets of SUMO in frog egg extracts. 
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Figure 3.6 - Identification of sumoylated species from replicating chromatin under normal 
conditions and in the presence of genotoxic stress by western blotting. Sumoylated 
Xenopus proteins isolated as described in Figure 3.5B were analyzed by western blotting with 
antibodies against ORC1, PCNA, MCM7 and RPA70. I = Input chromatin, PD = Ni2+-NTA pull-
down. 
 
3.2.6 Validation of sumoylation substrates in frog egg extracts and 
budding yeast 
To validate the proteomic approach described in the previous paragraph, I needed to 
confirm by western blotting the modification of some of the novel sumoylation targets 
that were identified. The catalytic subunit of DNA polymerase α (Pol α) was an 
interesting candidate because it was detected only in the presence of aphidicolin and I 
found a commercially available antibody that could recognize the Xenopus orthologue 
of this protein. When chromatin-associated His6-SUMO1 conjugates were analyzed by 
western blotting to visualize Pol α, a distinct slow-migrating form of the protein was 
detected only in the presence of genotoxic stress (Figure 3.7A). However, the 
observation that under such conditions the quantity of Pol α bound to the DNA was 
greatly increased in comparison to the untreated extract raised the possibility that this 
result originated from a difference in the amounts of the polymerase present in the 
input material. To address this issue, I analyzed the amount of sumoylated polymerase 
present in His6-SUMO1 conjugates isolated from a quantity of untreated and 
aphidicolin-treated chromatin that contained equivalent levels of Pol α. I observed that, 
even under these experimental conditions, in the presence of genotoxic stress the 
levels of the sumoylated Pol α were increased (Figure 3.7B). However, I also noticed 
that when the extracts were treated with aphidicolin the non-specific binding to the Ni2+ 
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Figure 3.7 - The catalytic subunit of DNA polymerase α bound to interphase chromatin is 
sumoylated. A) Sumoylated Xenopus proteins isolated as described in Figure 3.5B were 
analyzed by western blotting with antibodies against the catalytic subunit of Pol α. I = Input 
chromatin, PD = Ni2+-NTA pull-down. B) The experiment described in A) was repeated using 
amounts of chromatin that contained equivalent levels of Pol α. Aph = aphidicolin. 
 
 
resin of the unmodified Pol α itself was enhanced (Figure 3.7B). These data indicate 
that although Pol α is likely to be sumoylated in frog egg extracts, this modification 
appears to be largely independent on genotoxic stress. 
To further substantiate the validity of the proteomic approach I employed, I needed to 
confirm that those sumoylated proteins identified by means of adding exogenous 
SUMO to the extracts were also modified in the presence of endogenous levels of the 
modifier. Towards this end, I attempted to immunoprecipitate Pol α from untreated and 
aphidicolin-treated chromatin that had been solubilized by sonication. Unfortunately, 
the antibody was unable to efficiently isolate enough protein to analyze the 
immunoprecipitate by western blotting against SUMO1 and/or SUMO2 (data not 
shown).  
To circumvent these limitations and provide stronger evidence of the validity of the 
above-described screen, I decided to explore the possibility that particularly interesting 
hits amongst the proteins reported in Table 3.1 may be sumoylated beyond X. laevis. 
As a matter of fact, many of them are well-conserved throughout evolution and show 
orthologues in lower organisms such as S. cerevisiae. If the sumoylation of these 
 
A 
B 
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Figure 3.8 - Orc1, Rfc1 and Rad54 are sumoylated in S. cerevisiae. A) and C) Exponentially 
growing cells (75 OD600) transformed with a control or a His6-SUMO expression plasmid were 
lysed under alkaline conditions (2.8.4.1). His6-SUMO-modified species were captured as 
described in 2.16.1 and subjected to western blotting against the 9myc tag. I = input, HU = 
hydroxyurea, 200 mM for 1.5 h. B) and D) Extracts (2 mg of total protein in 1 ml of RIPA buffer) 
of exponentially growing cells (75 OD600) were obtained by mechanical lysis in RIPA buffer 
followed by centrifugation (2.8.4.2). An anti-Myc antibody (8 µg) was incubated with the extracts 
for 3 h at 4C and then captured as described in 2.16.2. Immunoprecipitated proteins were 
analyzed by western blotting against the 9myc tag and SUMO. IP = immunoprecipitation. 
 
 
proteins were conserved among different species, I could take advantage of the 
strengths of each system to investigate the modification’s functions. Consequently, I 
created yeast strains in which the orthologues of Xenopus ORC1, RAD54B, RFC1 and 
Pol α (POL1) were C-terminally fused to the 9myc tag at their endogenous locus. 
MEC1, the yeast orthologue of ATR, was not included in this analysis because all my 
attempts to append a tag to it were unsuccessful. These strains were transformed with 
either a control or a His6-SUMO expression plasmid, which allowed me to isolate their 
SUMO conjugates by denaturing Ni2+-NTA affinity chromatography. Since RFC1 and 
the catalytic subunit of Pol α were identified only from the chromatin of aphidicolin-
treated frog egg extracts, the strains carrying Rfc1-9myc and Pol1-9myc were also 
treated with hydroxyurea, which causes problems similar to those of aphidicolin in 
yeast cells and it is able to cross their cell wall. Western blotting of such purifications 
showed the presence of slow-migrating forms of Orc1-9myc, Rad54-9myc and Rfc1-
A 
C D 
B 
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9myc, but not Pol1-9myc (Figure 3.8A and C) only in those strains expressing His6-
SUMO, thus showing that they are sumoylated. In addition, the presence of 
hydroxyurea did not significantly alter the extent of Rfc1p-9myc sumoylation. To 
confirm that the 9myc-fusions of Orc1, Rad54 and Rfc1 were modified even in the 
absence of His6-SUMO, I isolated them from native lysates prepared from strains 
expressing normal SUMO levels, by means of an anti-Myc antibody, and analyzed 
them by western blotting against SUMO itself. Figure 3.8B and D show that even after 
stringent washing of the immunoprecipitates Orc1-9myc and Rfc1-9myc co-purified 
with sumoylated species of the expected size for a covalent SUMO conjugate of such 
proteins, thus demonstrating that they are bona fide sumoylation targets in yeast. 
Unfortunately, the endogenous levels of Rad54-9myc were too low to isolate enough 
protein for detection of sumoylation products, thus it remains to be determined whether 
Rad54p is a genuine SUMO target in budding yeast. 
3.3 Discussion 
Although sumoylation clearly plays an important role in controlling DNA metabolism 
and therefore in maintaining genome stability, to date the modification of only a handful 
of proteins has been shown to be stimulated by genotoxic stress and/or linked to this 
biological process. To overcome such shortcomings, I decided to identify and compare 
the population of sumoylated species that bind to chromatin during unperturbed and 
challenged replication. Using frog egg interphase extracts as a model system, I initially 
confirmed the presence of sumoylated proteins on replicating DNA and then studied 
their abundance throughout S phase. Having observed a population of SUMO 
conjugates on the chromatin whose abundance largely depended on entry in S phase 
but was not visibly affected by genotoxic stress, I isolated such species and identified 
them by both mass spectrometry and western blotting. Interestingly, a few novel 
sumoylation targets were identified exclusively in the presence of genotoxic stress. 
3.3.1 Is the proteomic dataset valid? 
Given the initial aims of this part of my research (see 3.1), I evaluated the validity of the 
proteomic dataset presented here against three criteria: 1) the complexity of the 
dataset, that is, the enrichment of proteins that associate with DNA versus those that 
do not, 2) the likelihood of the identified proteins to be true SUMO substrates, and 3) 
the probability of those hits detected only in the presence of genotoxic stress to be 
bona fide DNA damage-induced SUMO.  
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3.3.1.1 Dataset complexity 
The overall complexity of the dataset seems to be satisfactory. Most of the identified 
candidates fall within one of three functional categories, which mainly encompass 
proteins important for DNA metabolism, such as: DNA replication and repair, chromatin 
remodelling and transcription. A few proteins (11 out of 51) that are known not to 
associate with DNA were detected in the experimental samples (Table 3.1). The most 
obvious example of these is RANGAP1, which is one of the most abundant SUMO1 
substrate in higher eukaryotes and therefore it may not be an unexpected contaminant 
(Mahajan et al., 1997; Saitoh et al., 1997). Comparing the functional distribution of the 
sumoylation targets that were detected in the present analysis with those from previous 
proteomic studies also indicates that I enriched for chromatin-associated proteins. In 
such studies, 40-50% of the hypothetical SUMO substrates identified fall within one of 
the three above-mentioned categories (Denison et al., 2005; Rosas-Acosta et al., 
2005), this percentage rises to 80% in the current dataset. Additionally, several 
proteins involved in processes other than DNA metabolism were identified in those 
studies, such as cell metabolism, cell cycle, apoptosis, signalling, translation, mRNA 
processing and nucleocytoplasmic transport (Golebiowski et al., 2009; Rosas-Acosta et 
al., 2005; Vertegaal et al., 2006; Zhao et al., 2004b), which were instead barely 
detected in the present analysis. It must be mentioned that a few proteins involved in 
cell metabolism and cell cycle were identified only in the experimental samples but 
these were not included in Table 3.1 because they were detected by a single low-
confidence peptide. Interestingly, in contrast to previous proteomic studies where 
transcription factors often represented a significant proportion of the identified SUMO 
substrates (Golebiowski et al., 2009; Rosas-Acosta et al., 2005; Vertegaal et al., 2006), 
the present analysis discovered relatively few of them. It is possible that the 
sumoylated forms of some of these factors may not be associated with the chromatin, 
de facto excluding them from the current analysis. Alternatively, transcription factors 
themselves may not be an abundant population of proteins that associates with 
chromatin in frog egg extracts, where in fact very little transcription occurs (Masui and 
Wang, 1998). 
3.3.1.2 Are the identified hits true SUMO targets? 
The likelihood of the identified hits being true SUMO substrates is also good. Many of 
them have meanwhile been reported to be sumoylated in other proteomic studies or 
more directly by pull-down experiments and western blotting, from budding yeast to 
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human cells. With respect to proteins involved in DNA metabolism, this includes PCNA 
(Arakawa et al., 2006; Hoege et al., 2002; Leach and Michael, 2005), RAD52 (Sacher 
et al., 2006), PARP1 (Blomster et al., 2009; Golebiowski et al., 2009; Martin et al., 
2009; Messner et al., 2009; Rosas-Acosta et al., 2005) and topoisomerase II (Azuma et 
al., 2003; Bachant et al., 2002; Mao et al., 2000a). Recently a thorough quantitative 
proteomic approach also showed that the sumoylation of the catalytic subunit of Pol α, 
RFC1 and RAD54B is increased after heat shock in human cells (Golebiowski et al., 
2009). Several factors involved in chromatin remodelling and transcription have also 
been shown elsewhere to be modified by SUMO, such as HDAC1 (David et al., 2002), 
NCOR1/2 (Tiefenbach et al., 2006), SALL1 (Netzer et al., 2002), SALL4 (Golebiowski 
et al., 2009), SIN3A (Pungaliya et al., 2007), TRRAP (Golebiowski et al., 2009), RBBP7 
(Golebiowski et al., 2009) and p66 (Gong et al., 2006). It is conceivable that some of 
the remaining hits may represent false positives, that is, proteins that are not truly 
sumoylated, which could arise when a protein that spuriously binds to the Ni2+-NTA 
resin is not detected in the control purification. To minimize the occurrence of false 
positive, I analyzed the raw data against stringent filtering criteria, as described earlier, 
and lowered the threshold for identifications from two peptides for the SUMO 
purification to one peptide for the control purification. 
3.3.1.3 SUMO substrates from intact and aphidicolin-treated 
chromatin  
Amongst the proteins with a role in genome stability that were identified in the present 
proteomic analysis, some were exclusively detected within the samples of intact 
(RAD54B and PARP1) or aphidicolin-treated chromatin (the catalytic subunit of Pol α, 
RFC1, ATR, RTEL1, WDHD1, PLK1 and PCNA), while others in both of them 
(aprataxin, RAD50 and topoisomerase IIα/β). I was particularly interested in verifying 
that the hits present in the second category were true DNA-damage-induced SUMO 
substrates. As a prototypical example I studied the sumoylation of the catalytic subunit 
of Pol α. Figure 3.7 strongly suggests that the sumoylated form of this protein was 
detected exclusively from aphidicolin-treated chromatin because Pol α itself is heavily 
enriched on DNA under such conditions. These observations illustrate an important 
limitation of the strategy used in the current proteomic study. The big changes in 
protein composition that chromatin undergoes throughout replication and upon certain 
stimuli (Khoudoli et al., 2008) makes it hard to distinguish between a factor that is 
specifically sumoylated during replication or after DNA damage from one, for instance, 
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that is either constitutively modified but associates with DNA only in the presence of 
genotoxins or one that is not normally sumoylated but becomes conjugated to SUMO 
when it binds to DNA, irrespectively of whether it is damaged or not. The second one of 
these three scenarios is likely to be true for Pol α and possibly ATR, which has been 
previously shown to preferentially interact with damaged DNA (Costanzo et al., 2003). 
Given the limited quantitative nature of the proteomic approach I employed, a firm 
conclusion about the DNA-damage dependency of those SUMO substrates detected in 
the aphidicolin-treated chromatin only by two peptides, such as PCNA and PLK1, is 
also hard to draw. In fact, the sumoylation of PCNA was not enhanced by aphidicolin 
when this was analyzed by western blotting (Figure 3.6). On the other hand, RAD54 
and PARP1 were identified only during unperturbed replication (Table 3.1). Although it 
is possible that aphidicolin may inhibit the sumoylation of these proteins, it is also not 
improbable that it could lead to a transient loss of RAD54B and PARP1 from the 
chromatin. In conclusion, the chromatin-associated SUMO substrates that were 
identified only in response to genotoxic stress represent an interesting group of 
proteins whose modification could be linked to damaged DNA. In the future, it will be 
useful to prove that these findings are true on an individual basis.  
Although only a few proteins with a role in genome stability were identified in both 
normal and aphidicolin-treated DNA (see above), most chromatin remodeling and 
transcription factors fell in this category, thus suggesting that their sumoylation may be 
related to a process that is unaffected by genotoxic stress.  
3.3.2 Is the proteomic dataset complete? 
The proteomic dataset described in this chapter is unlikely to represent the complete 
cohort of SUMO substrates that bind to the chromatin during normal and disrupted 
replication for at least two reasons. Firstly, using western blotting I could identify 
sumoylated proteins on the chromatin that were not detected by mass spectrometry, 
such as ORC1 (Figure 3.6). These proteins may have been missed because they do 
not bind well to the affinity resin or because they are modified at such low levels that 
they cannot be detected by mass spectrometry. As a matter of fact, the sensitive 
proteomic approach used by Golebiowski et al. (2009) allowed them to identify several 
proteins with a role in genome stability that were not detected in the current study. 
Although I cannot exclude that such proteins may be sumoylated away from DNA, at 
least some of them are likely to be modified on chromatin. The presence of false 
positives, that is, those proteins that are truly sumoylated but were not included in 
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Table 3.1 because they were identified in both the control and SUMO purifications, 
also contributes to limiting the completeness of the dataset presented. This may have 
been, for instance, the case of MCM2 and MCM3, which were identified in both the 
control and His6-SUMO2 purifications, but they are in fact likely to be true SUMO2 
substrates because they have been detected in another proteomic study (Golebiowski 
et al., 2009). Although the modification of MCM2 and MCM3 were not directly 
confirmed in such report, the highly stringent tandem affinity purification they used to 
isolate sumoylated proteins argues in favour of such hits being true SUMO targets 
rather than common contaminants of Ni2+-NTA-based SUMO-enriching protocols.  
3.3.3 Modification by SUMO1 vs. SUMO2 
Although the proteomic strategy described here is mostly qualitative, it allowed me to 
notice some differences with respect to the levels and distribution of SUMO1- and 
SUMO2-modified proteins. Overall, more peptides and proteins were identified from the 
SUMO2 purifications compared to those of SUMO1 (Table 3.1). Only six proteins were 
identified exclusively as a SUMO1 substrate, while 23 hits were detected only from the 
SUMO2 purifications. The 22 remaining SUMO1 substrates were also modified by 
SUMO2. Interestingly, when equivalent amounts of His6-SUMO1 and His6-SUMO2 
were added to interphase extracts, His6-SUMO2 species appeared to be more 
abundant than those conjugated to His6-SUMO1 on the chromatin (Figure 3.2). 
The exclusive, or near exclusive, identification of many chromatin-associated proteins 
only in the His6-SUMO2 purifications suggests that even when SUMO1 is added in 
excess to the extract a certain degree of paralogue-specific modification may be 
maintained. For example, topoisomerase II, which is a prototypical chromatin-
associated substrate of SUMO2 (Azuma et al., 2005; Azuma et al., 2003), was mostly 
modified by SUMO2 (Table 3.1). Given that topoisomerase II was originally identified 
as a SUMO1 substrate in frog egg extracts, it was not unexpected to detect some 
modification of this protein also by SUMO1 (Azuma et al., 2003). On the other hand, 
the identification of topoisomerase II itself as a SUMO substrate on replicating 
chromatin was surprising because this modification event normally occurs in mitosis 
(Azuma et al., 2005; Azuma et al., 2003). Although it cannot be excluded that even if 
cycloheximide-treated interphase extracts were used some nuclei may have “leaked” 
into mitosis, thus providing the ideal conditions for topoisomerase II sumoylation, it is 
possible that the addition of exogenous SUMO to the extract may have loosened the 
cell cycle-dependence or paralogue-specificity of this modification event. 
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Interestingly, SUMO2 was detected in the His6-SUMO1 purifications, thus suggesting 
that some of the identified proteins may be either simultaneously sumoylated by 
SUMO1 and SUMO2 at different sites, such that when His6-SUMO1 is immobilized 
SUMO2 is carried over, or conjugated to a mixed SUMO2/1 chain where the SUMO1 
moiety may act as a termination signal (Golebiowski et al., 2009; Matic et al., 2008). 
The latter possibility in turn suggests that those proteins identified in both the SUMO1 
and SUMO2 purifications may not be species that are directly conjugated to SUMO1. 
Conversely, why SUMO1 was not detected in the His6-SUMO2 purifications is harder to 
explain, but it may be because of the small amounts of this modifier in such samples. 
The good size-resolution of the dataset presented here, achieved by slicing the control 
and experimental lanes in many bands, revealed that several of those proteins 
identified in the His6-SUMO2 purifications, and only a few in the His6-SUMO1 samples, 
were detected in two or more bands (Table 3.1). For instance, topoisomerase II, CHD1 
and CHD7 were detected in up to seven or eight bands (data not shown). The good 
correlation between the size of the identified hits and their positions on the gel (data not 
shown) argues in favour of them being modified by either single SUMO2 moieties at 
multiple sites, or more likely, by a SUMO2 chain, rather than representing partial 
degradation of sumoylated proteins. 
3.3.4 Advantages and limitations of the proteomic approach employed 
I identified advantages and disadvantages for three key aspects of the proteomic 
approach described in this chapter: the model system and the tag that I used to purify 
sumoylated species and the mass spectrometry technique employed to identify them. 
The innate ability of DNA added to frog egg extracts to replicate synchronously means 
that in this system replicating chromatin can be caught more easily than in mammalian 
or yeast cells where time-consuming synchronization techniques are otherwise 
needed. Chromatin can be isolated in just a few minutes from egg extracts, with very 
little contamination from cyto- and nucleoplasmic proteins.  Much lengthier and difficult 
protocols have to be used to isolate chromatin from yeast or mammalian cells, thus 
increasing the chance of SUMO isopeptidases acting on their substrates. As I 
discussed earlier, identifying sumoylated species from replicating DNA also helped to 
enrich for those proteins whose modification could be important in DNA metabolism. 
On the other hand, using frog egg extracts and chromatin as a model system was 
disadvantageous for two reasons. Firstly, the significant changes in protein composition 
that chromatin experiences throughout S phase and in response to certain stimuli 
Chapter 3. Results I 
 155
(Khoudoli et al., 2008) makes it a rather heterogeneous input material to work with. The 
recent development of a strategy to isolate significant amounts of highly purified 
sumoylated species from total cell extracts (Golebiowski et al.) could be a solution to 
this problem because the total levels of a certain protein is unlikely to change in 
response to DNA damage in total cell extracts as much as it would do in the chromatin 
fraction. Secondly, only a relatively small amount of chromatin can be isolated from 
interphase extracts, even when large preparations are used, in comparison to what 
could be obtained from large volumes of yeast or mammalian cell cultures. For 
example, Golebiowski et al. (2009) used fifty dishes ( = 150 mm) of HeLa cells per 
condition they tested in their recent proteomic survey. If the cells were collected when 
they were 80-90% confluent (~2·107 cells per dish), it follows that they must have used 
~ 1·109 cells per condition. In frog egg extracts, sperm nuclei are typically used at a 
concentration of 2,000-3,000 units per µL of extract to ensure that DNA replication 
proceeds at a “normal” rate and is properly controlled. Thus, to isolate ~ 1·109 
replicating frog nuclei one would need to use between 300 mL and 500 mL of Xenopus 
egg extracts. This is likely to be a conservative estimate because it does not take into 
account the difference in size between a diploid human genome ( 6 pg) and that of a 
haploid frog nucleus ( 3 pg). A good batch of eggs normally yields 2-3 mL of extract.  
By using His6-tagged SUMO, I was able to isolate sumoylated species by metal affinity 
chromatography under stringent denaturing conditions, thus minimizing the activity of 
SUMO isopeptidases and the chance of co-purifiying proteins that non-covalently 
interact either with SUMO itself or with a sumoylated protein because, for example, 
they are part of the same complex. The small size of the His6 tag fused to SUMO also 
reduced the chance of compromising the sumoylation of certain substrates, which has 
been reported when bigger tags are used (Wohlschlegel et al., 2004). On the other 
hand, as it has been described in previous proteomic studies (Vertegaal et al., 2004; 
Wohlschlegel et al., 2004), the non-specific affinity of the Ni2+ resin for highly abundant 
and/or histidine-rich proteins combined with the low abundance of sumoylated species 
means that although His6-SUMO purifications are enriched for SUMO conjugates, they 
unavoidably contain contaminants. I have taken several steps towards eliminating such 
proteins, as described in 3.2.5. In other proteomic studies, these limitations have been 
partly circumvented by using different types of tandem-affinity purification tags 
(Denison et al., 2005; Golebiowski et al., 2009; Hannich et al., 2005; Zhou et al., 2004), 
which do yield much cleaner preparations of SUMO conjugates but they have to be 
used under native conditions. An interesting alternative to both denaturing and native 
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approaches could be the use of a biotinylated form of SUMO, which can be captured 
on a streptavidin support under partially denaturing conditions (Li et al., 2004b). 
The employment of LC MS/MS and Orbitrap technologies was another important 
advantage of the proteomic study presented here. Its high sensitivity, accuracy and 
specificity compared to other spectrometric techniques was instrumental in identifying 
and sequencing complex mixtures of low-abundance peptides such as those obtained 
from a pool of sumoylated protein. Additionally, the very good mass accuracy of the 
instrument employed (<2 ppm) gave us confidence in the relevance of even those 
proteins detected by only one or two peptides. The low abundance of chromatin-
associated species that are sumoylated, and consequently of the peptides derived from 
them, made it difficult to quantify differences between the different populations of 
modified proteins, even if using semi-quantitative approaches such as comparing the 
signal intensity or the number of fragment spectra of peptides belonging to a certain 
protein. The employment of more quantitative spectrometric techniques, rather than 
simply scoring for the presence or absence of a protein in a sample, could have yielded 
more information, especially with respect to those species for which genotoxic stress 
upregulated, rather than absolutely induced, their sumoylation. The development of 
highly comparative and quantitative spectrometric techniques such as stable isotope 
labelling with amino acids in cell culture (SILAC), which has been successfully used to 
identify heat shock-induced targets of sumoylation (Blomster et al., 2009; Golebiowski 
et al., 2009), may be a solution to this problem. 
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Chapter 4. Results II: Sumoylation of ORC in frog 
egg extracts and S. cerevisiae 
4.1 Introduction 
Amongst the targets of sumoylation that were identified in the screen I described in the 
previous chapter, I analyzed further the modification of ORC1 for several reasons. 
ORC1, as part of the origin recognition complex (ORC), plays a central role in the 
initiation of DNA replication (see below). Although it has been shown that sumoylation 
can protect replication forks during S phase in the presence of DNA damage (Branzei 
et al., 2006) and that SUMO chain formation is important for the response to DNA 
replication arrest (Skilton et al., 2009), little is known about whether SUMO normally 
impinges on DNA replication. Additionally, the finding that ORC1 is sumoylated in both 
yeast and frog egg extracts raised the possibility that this modification might play an 
important role throughout evolution. 
ORC was originally identified in budding yeast as a six-subunit complex (Orc1-6) that 
specifically bound to an origin of DNA replication (Bell and Stillman, 1992). Since then, 
evolutionarily related six-membered complexes have been identified in and/or purified 
from various organisms, including the fruit fly (Gossen et al., 1995), frog egg extracts 
(Tugal et al., 1998) and humans (Dhar and Dutta, 2000). With the exception of ORC6, 
which is poorly conserved throughout evolution, orthologues of the yeast Orc1-5 have 
been found in all eukaryotes. These proteins share a conserved AAA+ ATPase fold 
that contains Walker A and Walker B motifs, which are absent from ORC6. ORC1-5 are 
therefore thought to have a common evolutionary origin (Duncker et al., 2009). 
In all the organisms analyzed to date, ORC is essential for the initiation of DNA 
replication. Its principal function is to bind origins of replication and act as a landing pad 
for the ordered recruitment of several factors collectively known as the pre-replication 
complex (pre-RC), reviewed by Takeda and Dutta (2005). During late mitosis and early 
G1 phase, the ORC bound to replication origins becomes competent to recruit CDC6 to 
the DNA, thus allowing CDT1 to load the replicative helicase MCM2-7 at such locations 
and producing a pre-RC. As cells progress into S phase, pre-RCs are converted into 
replication forks through a series of steps. CDC6 and CDT1 leave the pre-RC, MCM10 
binds to it and the activities of DBF4-dependent (DDK) and cyclin-dependent kinases 
(CDK) increase, which lead to the recruitment of CDC45, Dbp11 (TOPBP1 in higher 
eukaryotes), SLD2/3 and GINS. These events allow unwinding of the DNA around the 
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origin of replication and the subsequent loading of the ssDNA-binding protein RPA and 
DNA polymerase α, which initiates DNA synthesis (Mimura et al., 2000). Once origins 
of replications have fired, they are prevented from doing so again until the next cell 
cycle through various mechanisms. These safeguards ensure that genomic DNA is not 
re-replicated, which could otherwise lead to genome instability, reviewed by Blow and 
Dutta (2005). The increase in CDK activity that occurs from the beginning of S phase 
until the end of mitosis leads to inactivation of the pre-RC through the phosphorylation 
of CDC6 and CDT1, which are consequently exported from the nucleus or degraded 
depending on the organism examined. MCM2-7 and ORC are also phosphorylated by 
CDKs and thereby inactivated. The drop in CDK activity that occurs at the end of 
mitosis allows the assembly of new pre-RCs. In higher eukaryotes, an additional 
mechanism has evolved to prevent DNA re-replication, which depends on the protein 
geminin. Geminin, which is absent in the G1 phase but accumulates throughout the cell 
cycle, binds to CDT1 and prevents it from interacting with MCM2-7.  
Although the essential functions of ORC appear to be conserved throughout evolution, 
the way in which the complex recognizes origins of replication and is regulated during 
the cell cycle can vary between organisms. In budding yeast, all origins of replication 
contain an 11 bp consensus sequence, which is essential for ORC binding, plus 
additional elements that also contribute to this event (Bell and Stillman, 1992; Rao and 
Stillman, 1995; Rowley et al., 1995). In fission yeast, origins do not share any 
consensus but they often contain two or more asymmetric AT-rich sequences (Okuno 
et al., 1999; Segurado et al., 2003), which are recognized by AT-hook motifs found 
within the Orc4 subunit (Chuang and Kelly, 1999). In human cells, origins can localize 
to defined genomic loci (Giacca et al., 1994; Heintz and Hamlin, 1982), yet any 
sequence can act as one, provided it is long enough (Heinzel et al., 1991). Factors 
other than sequence therefore appear to define the location of our origins, such as 
transcriptional activity (Lin et al., 2005), epigenetic mechanisms (DNA methylation, 
histone acetylation and chromatin compaction, Goren et al., 2008; Mechali, 2001; Rein 
et al., 1999), the presence of specific DNA binding elements (Danis et al., 2004) and 
nuclear organization (Li et al., 2001). Transcription may also be responsible for those 
changes in origin specification that are observed in early embryonic systems such as 
frog and fly embryos. During the first few cleavages after fertilization, origins occur 
apparently randomly along the DNA but are nevertheless evenly spaced; when zygotic 
transcription starts at the mid-blastula transition the locations of origins become more 
specific (Hyrien et al., 1995).  
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In addition to having different modes of defining replication origins, the ORCs from 
yeast, frog egg extracts and mammalian cells are regulated in somewhat different ways 
with respect to their post-translational modifications and binding to chromatin during the 
cell cycle. In budding yeast, ORC remains bound to origins throughout the cell cycle 
(Liang and Stillman, 1997). Orc2 and Orc6 are phosphorylated by CDKs from S phase 
until mitosis, which helps to prevent the re-assembly of pre-RCs until the next G1 phase 
(Nguyen et al., 2001). In interphase frog egg extracts, ORC quickly binds to sperm 
chromatin during interphase and it is released from it only at mitosis, probably due to its 
CDK-dependent phosphorylation. The recruitment of MCM2-7 to pre-RCs also leads to 
a weakening of the binding of ORC to chromatin, which is detected as a change in its 
patterns of salt extraction from the DNA (Rowles et al., 1999). In mammalian cells, a 
core ORC2-5 complex remains bound to chromatin throughout the cell cycle (Ohta et 
al., 2003). ORC1 also stably associates with DNA during the G1 phase, but as cells 
progress through to S phase this binding weakens, which causes ORC1 to be 
selectively released from the chromatin and subsequently ubiquitylated (Li and 
DePamphilis, 2002). Depending on the cell line tested the ubiquitylated ORC1 may or 
may not be degraded by the proteasome (Li and DePamphilis, 2002; Mendez et al., 
2002). In those cells where ORC1 persists throughout the cell cycle, it becomes 
phosphorylated during mitosis, which may prevent its re-association with ORC2-5 (Li et 
al., 2004a). Once this phase is completed ORC1 is re-synthesized and/or becomes 
competent to bind chromatin again (Mendez et al., 2002). 
Even though the main function of ORC is in DNA replication, this complex, or parts of it, 
have been shown to play roles in other processes as well. Some of these alternative 
functions, such as the regulation of the S phase checkpoint and the attachment of 
properly condensed chromosome to the mitotic spindle (Gibson et al., 2006), are likely 
to be secondary effects of disturbing ORC’s role in replication and therefore will not be 
described here (Sasaki and Gilbert, 2007). ORC plays a conserved role in establishing 
transcriptionally inert chromatin. In budding yeast, Orc1 interacts with Sir1, which 
mediates the formation of silent chromatin at the mating type loci HMR and HML (Bell 
et al., 1993; Triolo and Sternglanz, 1996). In both the fruit fly and human cells, ORC 
interacts with and is important for the correct localization of HP1 (Lidonnici et al., 2004; 
Pak et al., 1997), which represents the fundamental unit of heterochromatin packaging 
in higher eukaryotes. Additionally, ORC also appears to play a role in establishing 
sister chromatid cohesion in budding yeast (Shimada and Gasser, 2007). Depleting 
Orc2 after the firing of replication origins causes signs of precocious separation of 
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sister chromatids, the activation of the spindle assembly checkpoint and mitotic arrest 
with normal levels of chromatid-loaded cohesin. Re-expressing ORC2 at the G2/M 
transition rescues this phenotype, thus indicating that ORC mediates cohesion 
independently of cohesin or replication. Finally, an intriguing function of ORC6 has 
been uncovered in fly and mammalian cells, where the protein localizes to the cleavage 
furrow during cytokinesis (Chesnokov et al., 2003; Prasanth et al., 2002). Knocking 
down ORC6 in such systems leads to the accumulation of multi-nucleated cells, which 
probably originate from cells that completed mitosis but not cytokinesis.  
The aim of this part of my thesis was: 1) to confirm that ORC1 is a true target of 
sumoylation in frog egg extracts and yeast, 2) to explore whether this modification 
event is controlled at the spatial and/or temporal levels, as this information could 
provide clues about the roles it may have, and finally 3) to investigate its possible 
functions.  
4.2 Results 
4.2.1 ORC1 is a bona fide sumoylation target in frog egg extracts 
The results presented in Figure 3.6 indicated that in frog egg extracts ORC1 might be 
a target of sumoylation, possibly on the chromatin only. To further confirm this finding, I 
studied the sumoylation of this protein in more detail by multiple approaches. 
Firstly, I asked whether ORC1 could be sumoylated in an in vitro sumoylation reaction. 
Recombinant His6-ORC1 or a more native source of the protein, i.e. chromatin isolated 
from interphase extracts, was mixed with SUMO1, SUMO conjugating enzymes and 
ATP, incubated, and then analyzed by western blotting against ORC1. Figure 4.1A 
shows that only when all the required reagents were present both the recombinant and 
chromatin-associated ORC1 proteins were sumoylated. I also noticed that the SUMO-
modified ORC1 produced in the complete reaction supplemented with chromatin ran at 
the same size as a slow-migrating, and very weak, form of ORC1 that was present in 
the control reactions. 
This result prompted me to explore the possibility that such slow-migrating form of 
ORC1 may represent sumoylation on the chromatin. I separated chromatin-associated 
proteins from the soluble fraction of the extracts at mid S phase and then analyzed 
them by western blotting against ORC1. Figure 4.1B shows that in addition to a major 
~130 kDa species, the soluble ORC1 displayed two slow-migrating forms. These bands 
may be ubiquitylated forms of such protein, which have been previously detected in the 
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Figure 4.1 - ORC1 is a true substrate of sumoylation in frog egg extracts. A) Recombinant 
ORC1-His6 (3 pmol) and interphase chromatin (30,000 nuclei) were sumoylated in vitro in 
standard reactions (see 2.17.1) containing all the required components or lacking individual 
ones and then analyzed by western blotting against ORC1. B) Interphase extracts were 
supplemented with 2,500 nucleiµL-1 and incubated for 20 min at 23C before being separated 
into soluble and chromatin fractions. For western blotting analysis, I loaded 20,000 nuclei of 
the chromatin fraction and 0.4 µL of the total and soluble ones (15 µg). C) Soluble (15 µg) 
and chromatin fractions (20,000 nuclei) prepared as described in B) were incubated in the 
presence or absence of 50 nM of the catalytic domain of Ulp1 in a total volume of 20 µL for 1 h 
at 30C. The products of the reactions were resolved on both 4-12% and 6% gels and then 
analyzed by western blotting against ORC1 and PCNA (loading control). D) Sumoylated 
proteins isolated as described in Figure 3.5B were analyzed by western blotting against ORC1.  
 
 
non-chromatin-associated fraction of extracts prepared from mammalian cells (Li and 
DePamphilis, 2002). Conversely, the chromatin-associated ORC1 was resolved as one 
major and one retarded band only, the latter running at a smaller size than those 
observed in the soluble fraction. To determine whether any of these putative modified 
forms of ORC1 was a SUMO conjugate, I immunoprecipitated chromatin-associated 
and soluble ORC1 from plain interphase extracts and analyze them by western blotting 
against SUMO. I did not detect any sumoylated species in the anti-ORC1 
A 
B 
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immunoprecipitate prepared from the soluble fraction of the extracts (data not shown). 
Unfortunately the anti-ORC1 antibody failed to precipitate an amount of chromatin-
associated ORC1 that would be sufficient to detect sumoylated species. To circumvent 
this problem I incubated the soluble and chromatin-associated fractions obtained from 
plain extracts with the catalytic domain of the desumoylating enzyme Ulp1 (a gift from 
Dale Wigley) and then analyzed them by western blotting against ORC1. Figure 4.1C 
shows that Ulp1 converted all of the modified ORC1 in the chromatin fraction directly 
into the ~110 kDa form. Conversely, treatment with Ulp1 did not alter the abundance of 
any of the modified ORC1 species observed in the soluble fraction.  
Finally, I examined whether ORC1 is modified by SUMO1 only, or whether it can also 
be conjugated to SUMO2. Chromatin-bound sumoylated species were isolated by Ni2+-
NTA affinity chromatography from interphase extracts supplied with His6-SUMO1, His6-
SUMO2 or just a buffer solution as a control, and analyzed by western blotting against 
ORC1. Figure 4.1D shows that ORC1 was modified both by both SUMO1 and 
SUMO2. 
Altogether these data show that ORC1 is a bona fide sumoylation target in Xenopus 
egg extracts and suggest that this modification may occur specifically on the chromatin.  
4.2.2 ORC is sumoylated in budding yeast  
In addition to having shown that ORC1 is sumoylated in frog egg extracts, I observed 
that an Orc1-9myc fusion was also modified in budding yeast (Figure 3.8A). Figure 
3.8B also revealed that Orc1-9myc co-precipitated with sumoylated species other than 
itself even after stringent washing of the immunoprecipitate with a buffered solution 
containing 500 mM NaCl and 0.1% v/v SDS. Since Orc1 is part of ORC, which is a 
complex that is stable over a range of salt concentrations, I investigated whether such 
species could represent sumoylated Orc2-6. Towards this end, the yeast ORC2-ORC6 
genes were tagged with the 9myc epitope at their C terminus and tested for 
sumoylation by denaturing Ni2+-NTA chromatography and immunoprecipitation as 
described in 3.2.6. Figure 4.2A and Figure 4.2B show that 9myc-tagged Orc2-Orc6 
were also sumoylated. In addition, they show that multiple sumoylated species were 
detected for Orc2, Orc4, Orc5 and Orc6, thus indicating that these proteins could be 
either modified at multiple sites or by a short SUMO chain. The absence of detectable 
amounts of sumoylated species in the immunoprecipitate of Orc1-9myc and Orc3-9myc 
reported in Figure 4.2B can be possibly explained by the minute modification 
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Figure 4.2 - Orc1-6 are sumoylated in S. cerevisiae. A) Sumoylated proteins isolated from 
strains carrying 9myc-tagged ORC subunits were analyzed by western blotting against the His6 
and 9myc tags, as described in Figure 3.8A. I = input. B) Orc1-6 tagged with the 9myc-epitope 
were immunoprecipitated and analyzed by western blotting against the 9myc-tag and SUMO, as 
described in Figure 3.8B. C) ORC1-6 and an unconjugatable smt3 mutant (SUMO∆GG) were 
expressed as fusions of Gal4 DNA-binding (BD) or activation (AD) domain in the yeast two-
hybrid reporter strain PJ69-4A as described in 2.8.9. -LW = medium lacking leucine and 
tryptophan, -HLW medium lacking leucine, tryptophan and histidine, -HLWA = medium lacking 
leucine, tryptophan, histidine and adenine. Since Ubc9 and SUMO as well as Orc4 and Orc5 
have been previously shown to interact with each other in the yeast two-hybrid assay (Matsuda 
et al., 2007; Uetz et al., 2000), I used them as positive controls. They are shown separately from 
the other interactions for presentation purposes only, in fact they were grown on the same 
plates. 
A 
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levels of these ORC subunits in comparison to the others, as shown in Figure 4.2A. 
Although the immunoprecipitates obtained from this experiment were washed very 
stringently, it was possible that some of the sumoylated species observed in Figure 
4.2B could have been isolated with the epitope-tagged ORC subunits as a result of 
their ability to non-covalently interact with SUMO. To address this issue, I examined 
whether any of the six ORC subunits could bind to an unconjugatable form of SUMO 
using the yeast two-hybrid system. Figure 4.2C shows that Orc1-6 did not appear to 
interact with SUMO non-covalently. Overall, these data show that in budding yeast the 
whole of ORC is sumoylated.  
The results presented in Figure 4.2 led me to hypothesize that besides ORC1 other 
ORC subunits may be sumoylated in frog egg extracts as well. Having found an 
antibody against the frog ORC2, I explored the possibility that this protein may also be 
modified by SUMO. In preliminary experiments analogous to those described in 4.2.1, I 
did not detect any slow-migrating forms of ORC2 (data not shown). Since the 
modification of ORC1 was hardly detectable when I analyzed the chromatin isolated 
from frog egg extracts (Figure 4.1C), to exclude the possibility that the extent of ORC2 
sumoylation may be even lower, I isolated sumoylated species by denaturing pull-down 
from extracts supplemented with His6-SUMO1 or His6-SUMO2 and analyzed them by 
western blotting against ORC2. Unfortunately, this experiment was inconclusive 
because the anti-ORC2 antibody I used heavily cross-reacted with the His6 tag. 
4.2.3 The budding yeast ORC is sumoylated through Siz1 and Siz2 
Since the addition of SUMO to a substrate in vivo often depends on a SUMO ligase 
and the bulk of sumoylation in budding yeast relies upon the E3 enzymes Siz1 and 
Siz2 (Johnson and Gupta, 2001), I investigated which one of them aids ORC 
sumoylation. I tested the extent of modification of Orc5-9myc and Orc6-9myc, the two 
subunits of ORC that showed the strongest sumoylation (Figure 4.2A), by denaturing 
Ni2+-NTA chromatography in wild type cells and in the single and double siz1∆ siz2∆ 
mutants expressing His6-SUMO. Consistent with the evidence that both Siz1 and Siz2 
often contribute to the modification of the same SUMO target in budding yeast (Reindle 
et al., 2006), I found that the modification of Orc5-9myc and Orc6-9myc was reduced in 
both the siz1∆ and siz2∆ single mutants and it was completely abolished in the double 
siz1∆ siz2∆ mutant (Figure 4.3A). 
 
Chapter 4. Results II 
165 
Figure 4.3 - ORC is sumoylated through Siz1 and Siz2 in budding yeast. A) Sumoylated 
proteins isolated from strains carrying Orc5-9myc or Orc6-9myc, His6-tagged Smt3 and a 
deletion of SIZ1, SIZ2 or both were analyzed by western blotting against the His6 and 9myc 
tags, as described in Figure 3.8A. B) Recombinant yeast ORC (0.5 pmol) was sumoylated in 
vitro in standard reactions (see 2.17.1) containing all the required components or lacking 
individual ones, both in the presence or absence of Siz1 (aa 1-508), and then analyzed by 
western blotting against Orc1, Orc2 and Orc6. When Siz1 was included a reaction only 25 nM of 
Ubc9 was used instead of 150 nM, which was normally employed for mixtures devoid of an E3. 
 
 
To further substantiate these results I asked whether the budding yeast ORC could be 
sumoylated in a Siz1-dependent manner in vitro. The recombinant ORC (a gift from 
John Diffley) was incubated with all the essential sumoylation reagents and in the 
presence or absence of Siz1 (aa 1-508). Western blotting analysis of these reactions 
(Figure 4.3B) with antibodies against Orc1, Orc2 and Orc6 showed that these subunits 
were sumoylated only in the presence of Siz1. I did not analyze whether Orc3, Orc4 
and Orc5 were also modified due to the lack of antibodies against these proteins. 
Altogether these results strongly suggest that the yeast ORC is a Siz1- and Siz2-
dependent sumoylation target. 
A 
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4.2.4 Sumoylation of the budding yeast ORC is not significantly 
enhanced in the presence of origin DNA 
The evidence presented here that ORC could be a substrate of SUMO in both budding 
yeast and frog egg extracts put forward the possibility that this modification event may 
be controlled by a common mechanism in both systems. Although the way in which 
ORC recognizes origins in different species varies, binding to DNA is a critical property 
of the complex in all the organisms analyzed to date. Since the frog ORC1 appeared to 
be sumoylated in its chromatin-associated state (Figure 4.1) and the modification of 
other DNA-associated proteins has been shown to depend on DNA binding (Parker et 
al., 2008), I asked whether the sumoylation of ORC may be modulated by the presence 
of DNA. Being able to sumoylate the yeast ORC in vitro (Figure 4.3) allowed me to 
address this question directly. The recombinant complex was incubated with a 841 bp 
DNA fragment containing the prototypical ORC binding sequence, ARS1, and ATP, 
which is necessary for binding of ORC to DNA (Speck et al., 2005), before proceeding 
to the addition of the relevant sumoylation reaction mix. Figure 4.4 shows that in the 
 
Figure 4.4 - In vitro sumoylation of the budding yeast ORC is not significantly enhanced 
in the presence of a replication origin. Recombinant yeast ORC (0.5 pmol) was incubated at 
25C for 20 min with ATP (1 mM) in the presence or absence an 841 bp PCR product (0.5 
pmol) containing the ARS1 sequence. These samples were sumoylated in vitro in standard 
reactions (see 2.17.1) supplemented with wild type Siz1 (aa 1-508) or one mutated within its 
SAP domain (G55A/K57A/L60A, SAP*) and then analyzed by western blotting against Orc1, 
Orc2 and Orc6. When Siz1 was included in a reaction only 25 nM of Ubc9 was used instead of 
150 nM, which was normally employed for mixtures devoid of an E3. 
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presence of ARS1-containing DNA, the ORC complex was sumoylated slightly more 
efficiently than its absence. This effect was not dependent on the ability of Siz1 (aa 1-
508) to bind to DNA through its SAP domain because although mutating it did cause 
some loss of ORC sumoylation, this effect probably originated from the lower activity of 
the mutant Siz1 (aa 1-508) compared to the wild type protein (Parker et al., 2008). 
4.2.5 Sumoylation of the frog ORC1 and yeast Orc5-9myc appear to be 
cell cycle-regulated but the latter does not depend on origin firing 
In addition to DNA binding, another important and conserved property of ORC is that its 
activity is tightly linked to DNA replication and the cell cycle. Thus I explored whether 
the extent of ORC sumoylation may change during DNA replication in both frog egg 
extracts and budding yeast. 
In Xenopus, I isolated chromatin at increasing time points from interphase extracts 
supplemented with a control solution or His6-SUMO1, to enhance the low levels of 
ORC1 modification, and analyzed it by western blotting against ORC1 and PCNA. 
Although the overall modification levels were low, I noticed that sumoylated ORC1 
accumulated just prior to or at the beginning of S phase, it then disappeared as the 
extracts progressed through full-blown replication and it eventually re-appeared as S 
phase was completed (Figure 4.5A). 
To determine whether this phenomenon may be conserved in budding yeast, I 
examined the levels of Orc5-9myc sumoylation in synchronized cells as they 
progressed through DNA replication from an α factor-induced G1-arrest. These cells 
were released into medium containing the microtubule-destabilizing drug nocodazole to 
stop them at the G2-M phase. At each time point, cells were analyzed by flow 
cytometry, to confirm they progressed through the cell cycle, and processed to isolate 
sumoylated species by denaturing Ni2+-NTA chromatography. Western blotting analysis 
of such samples showed that, similarly to what I observed for the sumoylation of the 
frog ORC1, the amount of sumoylated Orc5-9myc dipped as the cells progressed into 
S phase but it rose again as they accumulated at the G2-M boundary (Figure 4.5B). 
Conversely, the levels of sumoylated PCNA, a prototypical S phase-specific SUMO 
substrate (Hoege et al., 2002), peaked as cells replicated their DNA. 
Having observed that the sumoylation of both ORC1 in frog egg extracts and Orc5-
9myc in budding yeast disappeared or decreased as the genome started being 
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Figure 4.5 - Sumoylation of the frog ORC1 and yeast Orc5-9myc during DNA replication 
and origin firing. A) Interphase extracts (25 µL) were supplemented with 2,500 nucleiµL-1 of 
extract and either a control solution or His6-SUMO1 to a final concentration of 20 µM. Chromatin 
was isolated from the extracts at the indicated times and analyzed by western blotting against 
ORC1 and PCNA. B) and C) Wild type and rad53∆ sml1∆ strains carrying the 9myc-tagged 
ORC5 were synchronized in G1 phase with an α factor peptide (10 µgmL-1 for 2.5 h) and then 
released into fresh medium containing nocodazole (15 µgmL-1). Cells were collected at the 
indicated time points and analyzed by flow cytometry (see 2.8.6). Sumoylated species were 
isolated as described in Figure 3.8A and analyzed by western blotting against the His6 and 
9myc tags and PCNA (loading control). A = asynchronous, α = α factor-arrested D) Wild type 
and rad53∆ sml1∆ strains carrying the 9myc-tagged ORC5 were synchronized in G1 phase with 
an α factor peptide (10 µgmL-1 for 2.5 h) and then released into fresh medium containing HU 
(200 mM for 1.5 h). Cells were processed as described in B). 
 
A 
B 
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replicated, I asked whether this phenomenon may depend on the firing of replication 
origins. To address this question, I examined the levels of Orc5-9myc sumoylation in 
wild type and rad53∆ sml1∆ cells released from a G1-arrest into medium containing 
hydroxyurea (HU). During an unperturbed S phase, DNA is duplicated from many 
replication origins, some of which are activated at the onset of S phase (early-firing 
origin) and others later on (late-firing origin). In wild type yeast, the checkpoint kinase 
Rad53 ensures that the firing of late replication origins is inhibited in the presence of 
genotoxins such as hydroxyurea. Deleting RAD53 relieves this inhibition, thus allowing 
late replication origins to fire early (Santocanale and Diffley, 1998). It follows that if the 
firing of replication origins were responsible for reducing the levels of ORC 
sumoylation, then releasing G1-arrested cells into a medium containing hydroxyurea 
should afford a larger decrease in ORC sumoylation in the rad53∆ sml1∆ mutant than 
in the wild type, because more origins fire in the former case. First of all, since RAD53 
plays a role in the initiation of DNA replication that is independent of its checkpoint 
functions (Dohrmann and Sclafani, 2006), I examined whether knocking it out by itself 
affected the cell cycle-related changes in Orc5-9myc sumoylation I described earlier. 
Figure 4.5B shows that, like in the wild type, the sumoylated Orc5-9myc disappeared 
during S phase in the rad53∆ sml1∆ mutant. I also observed that there was no 
significant difference in the levels of Orc5-9myc sumoylation between wild type and 
rad53∆ sml1∆ cells upon their release into HU-containing medium from a G1-arrest, 
which could not be explained by the smaller amount of His6-SUMO pulled down from 
the mutant (Figure 4.5D). Additionally, in both the wild type and the rad53∆ sml1∆ 
mutant there was no difference in the amount of sumoylated Orc5-9myc between the 
G1-arrested cells and those that had fired replication origins (HU).  
Altogether these data suggest that ORC sumoylation could be cell cycle-regulated in 
both frog egg extracts and budding yeast, but this phenomenon is unlikely to depend 
on the firing of replication origins, at least in the latter system. 
4.2.6 Sumoylation does not noticeably alter the association with 
chromatin of the frog ORC1  
Sumoylation has been shown to modulate the association with chromatin of proteins 
such as topoisomerase II (Azuma et al., 2003), TDG (Hardeland et al., 2002) and some 
transcription factors (Goodson et al., 2001; Tsuruzoe et al., 2006). In the case of 
topoisomerase II, abolishing its modification by adding a dominant negative mutant of 
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Figure 4.6 - Changing the normal levels of sumoylation in egg extracts does not alter the 
association of ORC1 with chromatin. Interphase extracts (25 µL) were supplemented with 
2,500 nucleiµL-1 of extract and the following proteins: 20 µM UBC9 (C93S) and 2 µM Ulp1 
(catalytic domain) to reduce sumoylation, a buffered solution to preserve normal sumoylation 
levels in the extract or 20 µM wild type UBC9 and 20 µM His6-SUMO1 to enhance normal 
sumoylation levels. The extracts were incubated for 20 min at 23C. Chromatin was isolated 
through sucrose cushions containing 50, 100 and 150 mM KCl and analyzed by western blotting 
against ORC1, ORC2, PCNA and histone H3 (loading control). DN = dominant negative. 
 
 
UBC9 to egg extracts led to an increase in the amount of enzyme that remained tightly 
bound to chromosomes (Azuma et al., 2003). Thus, I asked whether this may also be 
the case for the frog ORC1.  
To address this question, I isolated chromatin through sucrose cushions containing 
increasing concentrations of KCl from three kinds of interphase extracts: one 
supplemented with a dominant negative mutant of UBC9 and the catalytic domain of 
Ulp1 to reduce sumoylation, one supplemented with wild type UBC9 and His6-SUMO1 
to induce hyper-sumoylation and one supplemented with a buffered solution, where 
normal levels of sumoylation should be maintained. Figure 4.6 shows that at the lowest 
salt concentration a slow-migrating form of ORC1 was detected in the control sample. 
This band increased in intensity after the addition of the wild type UBC9 and His6-
SUMO1 to the extract and it disappeared when the dominant negative UBC9 and Ulp1 
were used, indicating that it represents sumoylated ORC1. I also observed that the 
salt-extraction patterns of the unmodified ORC1, and another ORC subunit, ORC2, did 
not differ in the three kinds of extracts described above. Additionally in both the control 
extracts and those supplemented with the wild type UBC9 and His6-SUMO1, the 
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sumoylated and the unmodified ORC1 were released from the chromatin by similar salt 
concentrations.  
Overall, these results suggest that sumoylation does not noticeably alter the 
association of ORC1 with chromatin in frog egg extracts. 
4.2.7 Influencing the normal levels of sumoylation in frog egg extracts 
and budding yeast has no major effect on the efficiency of DNA 
replication 
ORC is essential for DNA replication from yeast to humans. Thus, if sumoylation 
impinged on the structure or function of this complex, then abolishing or enhancing it 
should have an impact on DNA replication. Since changing the modification of ORC 
exclusively was not a trivial task, I explored whether altering the levels of the bulk of 
sumoylation may regulate DNA replication. 
To address this question in Xenopus, I measured the kinetics of DNA replication in 
extracts prepared as described in 4.2.6. These extracts were supplemented with [α32-
P]dCTP and the extent of replication was determined by measuring the incorporation of 
the labelled nucleotide into the genomic DNA isolated at multiple time-points. Figure 
4.7A and Figure 4.7B show that the control extracts behaved similarly to the hypo- and 
hyper-sumoylated extracts with respect to the length of the initial lag phase, when the 
sperm chromatin is remodelled, ORC binds to DNA and forms pre-RCs, the rate of 
DNA replication and the amplitude of the final plateau phase, which represents the total 
amount of replicated DNA. Similarly, Simona Fiorani and Vincenzo Costanzo (Clare 
Hall Laboratories) did not detect any reproducible difference in the replication kinetics 
of somatic nuclei, as well as sperm chromatin, incubated in the three kinds of 
interphase extracts describe earlier (personal communication).  
To determine whether a different situation may apply to budding yeast, I measured the 
transmission fidelity of mini-chromosomes containing different numbers of replication 
origins in wild type and a siz1∆ siz2∆ cells. I reasoned that if Siz1- and Siz2-dependent 
sumoylation played a role in DNA replication through the modification of either ORC 
(Figure 4.3) or possibly other proteins, then deleting such SUMO ligases should affect 
the efficiency of the initiation of DNA replication and consequently the rate of mini-
chromosome loss. Adding extra replication origins to a mini-chromosome increases its 
chance of being replicated and transmitted to daughter cells and therefore it can be 
used to distinguish a phenotype that is caused by a problem with chromosome 
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Figure 4.7 - Normal levels of sumoylation are not critical for efficient replication in 
budding yeast and frog egg extracts. A) DNA replication was analyzed as described in 2.7.5. 
U = % of  [α-32P]dCMP incorporation. 100% was defined as the amount of [α-32P]dCMP 
incorporated in the genomic DNA of the control sample at 90 min. C) Wild type cir0 and siz1∆ 
siz2∆ cir0 cells were transformed with either pDK243 (1 ARS1) or pDK368-7 (1 ARS1 + 7 H4 
ARS). Three colonies per condition were cultured as described in 2.8.8. Eighteen plates (9 YPD 
and 9 devoid of leucine) containing between 100 and 300 colonies were counted per condition. 
The graph shown is a representative example of multiple experiments that yielded similar 
results. Error bars represent the standard deviations calculated from nine plates in one 
experimental replicate. DN = dominant negative. 
 
 
segregation rather from one that instead involves replication (Hogan and Koshland, 
1992). For the experiments described below, I used strains that were cured of the 
naturally occurring 2-µm plasmid (cir0) because it accumulates at such massive levels 
in the siz1∆ siz2∆ mutant that it causes cells to grow slowly and form “nibbled” colonies 
on solid medium (Chen et al., 2005), which I found difficult to reliably count. Thus, wild 
type cir0 and siz1∆ siz2∆ cir0 cells transformed with mini-chromosomes containing 
either one or eight replication origins were propagated in selective medium to maintain 
B 
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the plasmids, diluted and grown for 30 h in non-selective medium, to allow loss of the 
plasmids, and then spread on plates of either selective or non-selective media, to 
determine the percentage of cells that lost the plasmids. Figure 4.7C shows that mini-
chromosome stability was slightly enhanced in the siz1∆ siz2∆ mutant compared to the 
wild type, however this difference is not statistically significant. As expected, the 
plasmid containing eight origins of replication was maintained more efficiently than that 
harbouring one only, however this effect was very similar between the wild type and 
siz1∆ siz2∆ mutant. 
Altogether these data show that altering the normal homeostasis of sumoylation in frog 
egg extracts or budding yeast has no considerable effect on the efficiency of DNA 
replication, thus indicating that ORC sumoylation is unlikely to control this process. 
4.3 Discussion 
4.3.1 ORC as a conserved target of sumoylation 
Figure 4.1 and Figure 4.2 show that ORC1 in frog egg extracts and each one of the 
six subunits of the budding yeast complex are bona fide targets of SUMO. Interestingly, 
ORC1, ORC2, ORC3, ORC5 and ORC6 have also been identified as SUMO2 targets 
in a recent proteomic analysis of sumoylation substrates from human cells 
(Golebiowski et al., 2009). Although formal proof will be required, these observations 
suggest that ORC, as a whole, is likely to be a target of sumoylation from yeast, 
through frogs, to humans. This is not a completely unexpected finding since other 
proteins for which orthologues exist in lower and higher eukaryotes have been 
identified as conserved SUMO substrates. For one these proteins, topoisomerase II, a 
large number of studies have confirmed that its sumoylation plays analogous functions 
and is similarly regulated at the temporal and spatial level in both lower and higher 
eukaryotes (Lee and Bachant, 2009). Thus it is possible that the sumoylation of ORC 
may also have an evolutionarily conserved role.  
4.3.2 Spatio-temporal regulation of ORC sumoylation 
The data presented in Figure 4.1 and Figure 4.5 provide some evidence in favour of 
the possibility that the sumoylation of ORC may be regulated both at the spatial and 
temporal level. 
By separating chromatin-bound proteins from soluble ones in frog egg extracts, I 
noticed that only the ORC1 associated to chromatin was sumoylated. However, since 
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both the recombinant and the chromatin-associated ORC1 were modified to a similar 
extent in vitro and the sumoylation of the yeast ORC was not significantly enhanced by 
the presence of origin DNA in vitro, it is likely that factors other than the physical 
binding of the complex to the DNA may promote its sumoylation. These factors may 
include a DNA-associated E3 or another post-translational modification of ORC, such 
as phosphorylation, which can stimulate the sumoylation of certain proteins (see 1.2.5). 
However, given that the way ORC recognizes DNA varies in different organisms, I 
cannot categorically exclude that DNA may not affect the modification of the complex in 
other systems.  
The sumoylation of ORC1 in frog egg extracts and that of Orc5-9myc in yeast also 
seemed to disappear as DNA was being replicated (Figure 4.5). In yeast, this 
phenomenon was not dependent on the firing of replication origins, thus indicating that 
other processes could be involved. Sumoylation of ORC could therefore be regulated 
at level of the cell cycle stage. This possibility could be tested in budding yeast by 
mutating the protein kinase Cdc7. Under the appropriate conditions, a cdc7 mutant 
progresses from a G1-arrest through the cell cycle with normal changes in CDK levels 
but fails to initiate DNA replication (Hartwell, 1973). Since the addition of geminin has a 
similar effect on DNA replication and cell cycle progression in frog egg extracts, it could 
be used to explore whether or not the cell cycle controls ORC1 sumoylation in this 
system. It has to be mentioned that although the loss of Orc5-9myc sumoylation during 
DNA replication was reproducible, the quantity of unmodified Orc5-9myc that non-
specifically bound to the affinity resin followed a similar pattern, indicating that Orc5-
9myc itself may undergo small changes in amount throughout replication. Analogously, 
although I did observe a similar loss of sumoylated ORC1 during replication in various 
experiments, I cannot rule out that a small decrease in the amount of protein recovered 
with chromatin during replication may be disproportionately enhanced with respect to 
the modified ORC1, given its paucity. If the loss of sumoylated ORC1 from replicating 
DNA were a real effect then it would be unlikely to be linked to the weakening of 
binding that ORC experiences upon pre-RC firing, because this phenomenon has been 
shown to persist until mitosis, when the complex leaves the chromatin (Rowles et al., 
1999), while sumoylated ORC1 re-appeared at the end of DNA replication (Figure 4.5).  
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4.3.3 What are the possible functions of ORC sumoylation? 
The observations that I described in this chapter do not allow me to conclude what the 
function of ORC sumoylation is, however they do help ruling out what this modification 
may not be doing.  
The data collected from many proteomic studies aimed at identifying large numbers of 
SUMO targets have revealed that these proteins very often cluster within well-defined 
multi-subunit complexes (Denison et al., 2005; Golebiowski et al., 2009; Wohlschlegel 
et al., 2004). ORC appears to abide to such pattern. Although the mechanisms 
underlying this phenomenon are unknown, it has been proposed that multiple 
sumoylation events within the same protein complex may act as a “molecular glue” to 
facilitate their assembly and/or to maintain their structures (Matunis et al., 2006). This 
hypothesis comes from the observation that the assembly of PML nuclear bodies 
requires the sumoylation of PML itself but also its ability to interact non-covalently with 
SUMO through a SIM (Shen et al., 2006b). Thus, PML bodies may be held together by 
a network of interactions between the SUMO moiety conjugated to a sumoylated PML 
and a SIM on another. The presence of SIMs in other proteins, such as the 
transcriptional repressor DAXX, can also mediate their recruitment in or out of PML 
nuclear bodies (Lin et al., 2006). Whether or not SUMO may also be important for 
keeping ORC together is an interesting possibility, but perhaps an unlikely one for 
several reasons. Firstly, an unconjugatable mutant of SUMO did not bind to any of the 
yeast ORC subunits in the yeast two-hybrid system, which means that these protein 
are unlikely to interact with each other, at least strongly. Very weak interactions 
between SUMO and ORC that fall below the detection threshold of the yeast two-hybrid 
assay cannot be however excluded. Secondly, I did not detect any sumoylated species 
in the preparation of recombinant ORC purified from yeast cells (data not shown). This 
loss of ORC modification can be probably explained by the isopeptidase-mediated 
removal of SUMO during the purification procedure, which in turn suggests that 
sumoylation is not necessary to maintain the structure of the complex. It remains to be 
determined whether the in vivo assembly, rather than the maintenance, of ORC and/or 
its interactions with other proteins may be controlled by SUMO.  
Another intriguing consideration from the observations presented here is that although 
the Orc6 protein from budding yeast and fission yeast/metazoans bear so little 
sequence similarity that they may in fact have different evolutionary origins (Duncker et 
al., 2009), they are both targets of SUMO. In humans, ORC6 is somewhat of a puzzle 
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because even though its depletion causes defects in DNA replication (Prasanth et al., 
2002) and it is part of ORC in vivo (Siddiqui and Stillman, 2007), it binds weakly to the 
rest of the complex. A similar behaviour applies to the human ORC1, which associates 
with the rest of ORC non-stoichiometrically (Vashee et al., 2001) and it is able to 
independently dissociate from chromatin upon entry into S phase (Li and DePamphilis, 
2002). It is therefore possible that the subunit composition of the human ORC, and 
potentially that of complexes from other organisms, may change during the cell cycle to 
define unique ensembles with different functions. Since SUMO is conjugated to all of 
the six subunits of ORC in both budding yeast and probably in humans, I hypothesize 
that this modification event may be important in a conserved role of ORC that requires 
the complex to exist as a six-subunit entity. It follows that sumoylation is unlikely to play 
a role in those functions of ORC that depend on either a single subunit within the intact 
complex, such as the establishment of transcriptionally silent chromatin, which is 
mediated through ORC1 in both budding yeast and Drosophila (Pak et al., 1997; Triolo 
and Sternglanz, 1996), or an ORC subunit on its own, such as the regulation of 
cytokinesis by ORC6 (Chesnokov et al., 2003; Prasanth et al., 2002). 
If SUMO impinged on the initiation of DNA replication by modifying ORC, or possibly 
other proteins, then altering the normal levels of sumoylation in a cell should have an 
impact on such a process. Surprisingly, I found that abolishing the sumoylation of ORC 
in yeast by deleting SIZ1 and SIZ2 did not significantly alter the transmission efficiency 
of mini-chromosomes with different numbers of replication origins in comparison to the 
wild type (Figure 4.7). This result was somewhat unexpected because the siz1∆ siz2∆ 
mutant had been previously reported to lose mini-chromosomes more easily than the 
wild type, in a manner that depended on topoisomerase II sumoylation (Takahashi et 
al., 2006). The use of different yeast backgrounds, strains that lack or harbour the 2-µm 
circle and different ways of scoring for those cells that lost the plasmid could have 
accounted for such discrepancy. In fact, altering the normal levels of sumoylation had 
no significant impact on the kinetics of DNA replication in frog egg extracts either. 
Additionally, a similar phenotype was observed for a temperature sensitive mutant of 
UBC9 (ubc9-1) in budding yeast: ubc9-1 cells grown at a semi-permissive temperature 
progressed through S phase from a G2-M arrest and a brief incubation in HU as well as 
the wild type, but they accumulated at the G2 phase after a few duplications (Branzei et 
al., 2006). The ubc9-1 mutation leads to an almost complete loss of the protein at the 
restrictive temperature, but only a small decrease at the semi-permissive temperature 
(Betting and Seufert, 1996). It is therefore possible that in the ubc9-1 mutant some 
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proteins may remain sufficiently sumoylated at the semi-permissive temperature to 
carry out their normal functions.  
The presence of residual amounts of protein sumoylation has also been used to 
explain why the almost complete loss of SUMO conjugation in the siz1 siz2∆ mutant 
causes only a mild phenotype, after removal of the 2-µm plasmid (Chen et al., 2005; 
Johnson and Gupta, 2001), while UBC9 and SMT3 are essential genes in budding 
yeast. It has been proposed that even in the absence of SIZ1 and SIZ2 indispensable 
sumoylation events must still occur, which could be mediated either by Ubc9 directly or 
possibly by another E3 ligase (Johnson and Gupta, 2001), such as Mms21. Although I 
cannot categorically exclude that residual amounts of ORC sumoylation in the siz1∆ 
siz2∆ mutant may have allowed the complex to show a wild type-like behaviour with 
respect to the rate of mini-chromosome loss, I deem it an unlikely possibility because 
deleting these E3 ligases reduced the modification of at least two ORC subunits to 
undetectable levels, even after a prolonged exposure of the western blot membrane 
(Figure 4.3 and data not shown). Similarly, if the sumoylation of ORC1 modulated DNA 
replication in frog egg extracts, even at severely reduced levels, then I cannot exclude 
that the comparable replication kinetics observed for the hypo-sumoylated extracts 
(Figure 4.7) may have arisen because of the incomplete removal of SUMO from 
ORC1, which was hard to assess given the minute extent of this modification event. 
Even by taking these problems into account, the observations that I have discussed in 
this paragraph still indicate that under conditions whereby the sumoylation of ORC is 
reduced to undetectable levels in two different experimental systems, DNA replication 
is not significantly affected. By inference, this suggests that the sumoylation of ORC 
may not play an essential or general role in the establishment of pre-RCs. 
At the moment, what the sumoylation of ORC does remains an open question. Since 
this modification event is very likely to be conserved and therefore to have an important 
function, I believe that it is a very interesting, but certainly not an easy, problem to 
explore for several reasons. Firstly, deleting E3 ligases or over-producing SUMO 
proteases to abolish the sumoylation of ORC and then to study the consequences on 
processes that the complex is involved in is a good way to quickly screen for a positive 
phenotype. However, when one such phenotype is found, confirming that it specifically 
depends on the sumoylation of ORC would involve showing that a sumoylation-
deficient mutant of the complex exhibits similar problems. In the case of ORC, this is an 
enormous undertaking because each subunit of the complex is sumoylated, probably at 
multiple locations (Figure 4.2), which means that 8-10 sites would need to be identified 
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in a ~400 kDa complex. To complicate this problem further, some ORC subunits do not 
even have any obvious sumoylation consensus motifs, and mutating lysines targeted 
by SUMO can activate cryptic sumoylation sites (Jacobs et al., 2007; Onishi et al., 
2009). Secondly, even if all the possible sumoylation sites within ORC are identified 
and mutated, thereafter resulting in a phenotype, the question remains of whether 
introducing so many mutations by itself may “damage” the complex, independently of 
sumoylation. Thirdly, studying the functions of ORC sumoylation in frog egg extracts is 
a major technical challenge because of the need to deplete ORC from the extract and 
then reconstitute it with either a wild type or a sumoylation-deficient complex produced 
from a recombinant source. By taking into account these problems and the fact that the 
modification of ORC is barely detectable in vivo, I decided to shift the focus of my 
attention to studying the modification of another SUMO target I identified earlier, that is, 
PARP-1. The choice fell on this protein because preliminary experiments revealed that 
its ability to bind DNA might be important for its modification. From this starting point, I 
studied the role of DNA in PARP-1 sumoylation further and I also investigated what the 
functions of this modification may be. 
As I discussed above, studying the roles of ORC sumoylation is a tough problem to 
address experimentally. Being able to easily introduce mutations in one or multiple 
genes in budding yeast makes it an ideal system to explore this question in vivo. 
Additionally, the availability of conditional ORC mutants in S. cerevisiae, such as orc2-1 
(Foss et al., 1993), would allow studying how sumoylation impinges on the functions of 
the complex when its integrity is compromised. In fact, this stratagem may be 
neccesary to see any effect given that the roles of the sumoylation of other proteins, 
such as PCNA and Rad52 (Papouli et al., 2005; Pfander et al., 2005; Torres-Rosell et 
al., 2007), became apparent only in certain mutant backgrounds. The very recent 
reconstitution of a pre-RC that can load Mcm2-7 onto DNA using only purified proteins 
(Remus et al., 2009), together with the fact that ORC can be sumoylated in vitro 
(Figure 4.3), open the possibility to study whether sumoylation directly affects any step 
in the assembly of pre-RCs. 
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Chapter 5. Results III: The sumoylation of PARP-1 in 
vivo 
5.1 Introduction 
PARP-1 is another one of the potential targets of sumoylation I identified from 
replicating chromatin incubated in frog egg extracts (Table 3.1). It is a very abundant 
chromatin-bound protein that is the founding member of a large superfamily of 
enzymes that catalyze the transfer of ADP-ribose moieties from NAD+ onto certain 
target proteins to form long poly(ADP-ribose) chains (see 1.4). PARP-1 is best known 
for its ability to recognize DNA breaks, which strongly activate it, and for playing roles 
in genome stability, apoptosis and transcription (see 1.5). As I will describe in more 
detail in Chapter 6, in vitro PARP-1 sumoylation is strongly stimulated by DNA. This 
finding prompted me to characterize such a modification event in vivo as well. I decided 
to address this problem using mammalian cells as a model system for three reasons. 
Firstly, this choice meant that I could take advantage of an established range of tools 
and assays that had been designed to study the properties of PARP-1 in such an 
experimental system. Secondly, almost all of what is known about PARP-1 has been 
gathered from mammalian cells. Lastly, others had also identified PARP-1 as a 
possible target of SUMO in human cells (Gocke et al., 2005; Rosas-Acosta et al., 2005; 
Stephen West, personal communication). 
The aim of this part of my thesis was: 1) to confirm that PARP-1 is a true sumoylation 
target in vivo, 2) to map its sumoylation sites, 3) to study the possible roles of this 
modification event by taking into account the known functions of SUMO and PARP-1, 
and 4) to verify in vivo the in vitro data described in Chapter 6 about the interplay 
between PARP-1 sumoylation and DNA.  
5.2 Results  
5.2.1 PARP-1 is a bona fide sumoylation target in human cells that is 
preferentially modified by SUMO3 
Although in frog egg extracts PARP-1 was identified only within a pool of chromatin-
associated proteins modified by SUMO2, but not SUMO1 (Table 3.1), in human cells it 
had been reported in proteomic studies as a possible target of SUMO1 (Gocke et al., 
2005; and Stephen West, personal communication), SUMO2 (Blomster et al., 2009; 
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Golebiowski et al., 2009), and SUMO3 (Rosas-Acosta et al., 2005). It was therefore 
important to confirm that PARP-1 was sumoylated in vivo, and by which paralogue of 
SUMO, by alternative means than mass spectrometry. Thus I isolated sumoylated 
species from HeLa cells that conditionally produced His6-tagged SUMO1, SUMO2 or 
SUMO3 (a gift from Gerrit Praefcke) by denaturing Ni2+-NTA chromatography. Western 
blotting analysis of these purifications (Figure 5.1A) showed the presence of at least 
two slow-migrating forms of PARP-1, one significantly more abundant than the other, 
only in the cells that produced His6-tagged SUMO (+ DOX). This figure also revealed 
that the SUMO3-modified PARP-1 was more abundant than the corresponding SUMO1 
or SUMO2 conjugates. 
 
Figure 5.1 - PARP-1 is sumoylated in human cells, preferentially by SUMO3. A) HeLa cells 
producing His6-SUMO1/2/3 under the control of a doxycycline-inducible promoter were 
incubated in the presence or absence of doxycycline for 24 h. The cells (~107) were subjected 
to denaturing Ni2+-NTA pull-down experiments, as described in 2.16.1, and analyzed by western 
blotting against PARP-1 and the His6 tag. DOX = doxycycline. B) Total extracts (1.5 mg of total 
protein in 1 ml of RIPA buffer) of untreated or H2O2-challenged (10 mM for 5 min) HEK293 cells 
were incubated with 2-3 µg of each of three anti-PARP-1 antibodies (F2, F1-23 and C2-10) or 8-
9 µg of anti-FLAG antibody for 3 h at 4C and then processed as described in section 2.16.2. 
The immunocaptured proteins were eluted and subjected to western blotting analysis against 
PARP-1 (7.5% of the eluate) and SUMO2/3 (75% of the eluate). IP = immunoprecipitation. 
 
A 
B 
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To confirm that PARP-1 was also sumoylated in cells expressing normal levels of 
SUMO, I subjected total cell extracts from HEK293 cells to immunoprecipitation using 
an anti-FLAG antibody, as a control, or an anti-PARP-1 antibody. These 
immunoprecipitates were analyzed by western blotting against SUMO2/3 and PARP-1. 
Figure 5.1B shows that, under these conditions, I could not detect any SUMO2/3-
modified forms of PARP-1. This result was not completely unexpected, given that I 
estimated the sumoylated PARP-1 to represent considerably less than 1% of the total 
amount of this enzyme. To overcome these limitations, I repeated the above-described 
experiment, but this time I immunoprecipitated PARP-1 from extracts of cells that had 
also been exposed to H2O2 for a short period of time. This treatment stimulates the 
general modification of proteins by SUMO2/3, without the need to artificially 
overproduce any protein (Saitoh and Hinchey, 2000). Indeed, Figure 5.1B shows that 
in the presence of H2O2 PARP-1 co-immunoprecipitated with several sumoylated 
species, which were of the appropriate sizes for a multiply sumoylated PARP-1. 
In conclusion, these results show that PARP-1 is a bona fide target of sumoylation in 
human cells and they also indicate that, at least in our system, the polymerase is 
preferentially modified by SUMO3. 
5.2.2 PARP-1 sumoylation is enhanced by oxidative stress, and possibly 
other environmental stimuli, but not DNA damage 
Having observed that PARP-1 was preferentially modified by SUMO3 prompted me to 
investigate whether the extent of this modification event may be affected by certain 
environmental cues because the conjugation of SUMO2/3 to proteins has been shown 
to increase in response to various stimuli (Saitoh and Hinchey, 2000). To answer this 
question, I isolated sumoylated species by denaturing Ni2+-NTA chromatography from 
His6-SUMO3-producing HeLa cells that were subjected to heat (42C), osmotic (0.7 M 
NaCl), metabolic (7% EtOH) or oxidative (10 mM H2O2) shock, and then analyzed them 
by western blotting against PARP-1, SUMO2/3 and the His6-tag. Figure 5.2A shows 
that the levels of sumoylated PARP-1 were enhanced in response to oxidative stress 
and, to a lesser degree, to osmotic shock as well. The extent of this upregulation 
correlated well with the increase in the total levels of SUMO2/3-modified species seen 
under the same conditions. Consistently, I also observed that heat or metabolic shocks 
did not appreciably alter the sumoylation of PARP-1, nor did they visibly enhance the 
overall levels of SUMO2/3 conjugates. 
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Figure 5.2 - PARP-1 sumoylation is enhanced by environmental stimuli but not DNA 
damage. HeLa cells producing His6-SUMO3 (Figure 5.1A) were subjected to various 
environmental shocks A) or DNA-damaging agents B), as specified in the figure itself. His6-
SUMO-modified species were captured and analyzed as described in Figure 5.1A. Cpt = 
Camptothecin. 
 
 
These data strongly suggested that the H2O2-dependent increase in PARP-1 
sumoylation arose simply because of the general stimulatory effect that such a 
treatment has on SUMO2/3 conjugation, rather than being exclusive for PARP-1. 
Nonetheless, a specific role for H2O2 in triggering the modification of the polymerase 
could have been possible because this chemical introduces single-stranded breaks in 
the DNA, which strongly activate PARP-1 (Dantzer et al., 2006). Thus, to explore 
whether this possibility was true or whether DNA damage might in fact have an 
inhibitory effect on the modification of PARP-1, I analyzed the extent of PARP-1 
sumoylation in cells that were mock-treated or exposed to various DNA damaging 
agent (γ-irradiation, MMS, H2O2 and camptothecin), which are known to activate 
PARP-1 (see 1.5.2). Figure 5.2B shows that the levels of sumoylated PARP-1 isolated 
from the mock-treated cells and those incubated in the presence of genotoxins were 
comparable.  
Altogether, these data indicate that damaging DNA does not directly affect PARP-1 
sumoylation, which instead seems to be stimulated by the same environmental stimuli 
that enhance the general levels of SUMO2/3 conjugates in a cell. 
5.2.3 PARP-1 is mainly sumoylated at K203 and K486 
Having demonstrated that PARP-1 was a new target of sumoylation, I was interested in 
exploring the possible functions of this modification event. This question is best
A B
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Figure 5.3 - PARP-1 is mainly sumoylated at K203 and K486. A) By using the SUMOsp 2.0 
algorithm (http://sumosp.biocuckoo.org/), I identified several potential sumoylation sites in 
PARP-1. The table contains a selection of such lysines including their neighbouring sequence, a 
score representing their likelihood of being true sumoylation sites and whether or not they 
conform to the classical ΨKXD/E sumoylation consensus site. Shading = confirmed sumoylation 
sites. B) The positions of the hypothetical sumoylation sites identified in A) were mapped onto a 
graphical representation of PARP-1’s domain structure. ZF = zinc finger, NLS = nuclear 
localization signal, bold font = confirmed sumoylation sites. C) HEK293 cells (35 mm  dish, 
60% confluent) were co-transfected by lipofection (6 µL of Fugene HD) with a plasmid encoding 
His6-SUMO1 and another encoding C-terminally FLAG3-tagged PARP-1 WT or the indicated 
mutants (1 µg of each). After 48 h, His6-SUMO-modified species were captured and analyzed 
by western blotting against the FLAG tag, as described in Figure 5.1A. 
 
 
addressed by comparing the properties of a wild type protein to those of a mutant in 
which the SUMO attachment sites have been mutated to prevent their modification.  
Sumoylation often, but not always, targets lysines that are found within the consensus 
sequence ΨKXD/E (see 1.2.5). A bioinformatics analysis of PARP-1’s primary 
sequence using the SUMOsp 2.0 algorithm (Ren et al., 2009) identified several 
residues as potential sumoylation sites. From this pool of lysines, the five highest-
scoring ones (K486, K233, K203, K512, K249), that is, those that were most likely to be 
true sumoylation sites, were tested for whether they could be sumoylated in vivo. 
A 
B 
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Rajvee Shah transfected HEK293 cells transiently producing His6-SUMO1 with 
plasmids encoding C-terminally FLAG3-tagged constructs of the wild type PARP-1 or 
mutants in which an hypothetical SUMO acceptor lysine was mutated to arginine. 
Sumoylated species were enriched for by denaturing Ni2+-NTA chromatography and 
then analyzed by western blotting against the FLAG-tag. Figure 5.3B shows that 
mutating K203 resulted in the loss of one of the two main sumoylated forms of PARP-1, 
while changing K486 to arginine significantly reduced the levels of the other one. 
Individually mutating K233, K249 or K512 did not appreciably alter the sumoylation of 
PARP-1 in comparison to the wild type protein. Interestingly, I also noticed that 
abolishing the conjugation of SUMO to K203 enhanced the levels of sumoylation of 
K486, and/or possibly that of another site, and vice versa. These observations 
suggested that there must be a third minor sumoylation site in PARP-1 whose 
modification could become obvious/relevant only when K486 is mutated. Consistently, 
although the K203/486R mutant of PARP-1 was almost completely devoid of 
sumoylation, some residual modification could still be detected (Figure 5.3C). Next, the 
possibility that K233, K249 or K512 may actually represent the third sumoylation site of 
PARP-1, but this event may become experimentally detectable only when K486 is 
mutated was explored. Rajvee Shah analyzed the modification patterns of PARP-1 
K486R mutants that also carried a second mutation at one of the above-mentioned 
lysines. Figure 5.3C shows that all of the tested double mutants exhibited a pattern of 
sumoylation essentially identical to that of PARP-1 K486R, thus indicating that none of 
them was likely to be the exclusive third sumoylation site. This of course does not 
exclude a redundancy between individual sites. 
Altogether these data show that PARP-1 is mainly sumoylated at K203 and K486, but 
they also suggest that at least one more minor and/or cryptic modification site may 
exist as well. These in vivo results were also confirmed in vitro (see 6.2.6 and Figure 
6.7).  
5.2.4 APLF and XRCC1 preferentially interact with PARP-1-SUMO in the 
yeast two-hybrid system 
Although sumoylation can affect the properties of proteins as diverse as activity, 
localization or stability, it is becoming increasingly clear that these functional 
consequences are often brought about by factors that specifically recognize the 
sumoylated forms of such proteins (see 1.3). Conversely, in a few cases sumoylation 
has been shown or proposed to disrupt the interactions between partner proteins
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Figure 5.4 - Schematic representation of the linear SUMO-PARP-1 fusion constructs used 
in this chapter. 
 
 
(Mohan et al., 2007; Moldovan et al., 2006). Thus, if I identified receptors specific for 
the sumoylated PARP-1 then I could use this information to narrow down the range of 
roles that this modification event might play. To tackle this question, I initially covalently 
fused SUMO to either the N- or C-terminus of PARP-1 to create fusion constructs that 
may behave as mimics of the truly sumoylated PARP-1 (Figure 5.4). Then, I analyzed 
how well these constructs interacted with known partners of the polymerase in 
comparison to the wild type PARP-1, the K203/486R mutant, SUMO1 and SUMO2 
alone, using the yeast two-hybrid assay. The complete list of known PARP-1-
interacting proteins, and the relevant references, can be accessed using GeneID 142 
at the National Center for Biotechnology Information’s Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene). Given the important role of PARP-
1 in genome stability, I included several partners of the polymerase that had 
established functions in such a biological process – DNA repair (PARP-3, XRCC1, 
Ligase III, Aprataxin, APLF, TERF2IP) and replication (PCNA, p21, Werner’s helicase). 
Since PARP-1 has an important function in apoptosis as well, I also included proteins 
with a role in this process that had been reported to interact with the polymerase (p53, 
Caspase 3, Caspase 7 and BCL2). In addition, the centromere factors CENP-A and 
CENP-B were also added to this analysis because they had been shown to interact 
with PARP-1 and to be parylated in response to DNA damage (Saxena et al., 2002). 
 
Figure 5.5 - APLF and PARP-1 preferentially interact with PARP-1-SUMO in the yeast two-
hybrid assay. A), B and D) Yeast two-hybrid analysis was carried out as described in 2.8.9. BD 
= Gal4 DNA-binding domain, AD = Gal4 activation domain. - LW = lacking leucine and 
tryptophan, - LWH = lacking leucine, tryptophan and histidine, - LWHA = lacking leucine, 
tryptophan and adenine, WRN = Werner’s helicase, PARP-1* = PARP-1 M890V/D899N. C) and 
E) Total extracts were prepared as described in 2.8.4.1 from cells carrying yeast two-hybrid 
plasmids that encoded for the BD fusions of the indicated PARP-1 constructs and analyzed by 
western blotting against PARP-1, PAR and PGK (loading control). 
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On the other hand, even though PARP-1 plays a role in transcription and it had been 
shown to interact with transcription factors (Kraus, 2008), with the exception of p53 I 
did not include such proteins in this analysis because how, or more importantly if, 
PARP-1 directly binds to them and affects their functions is not clear in most cases. 
Figure 5.5A and Figure 5.5B show the results of this large interaction analysis. The 
most striking observation from these data was that, in this type of yeast two-hybrid 
assay, neither the wild type PARP-1 nor the K203/486R mutant was able to interact 
with any of the tested baits, except for XRCC1. Even in this instance, XRCC1 
interacted with PARP-1 in one direction of the yeast two-hybrid system only (BD-
PARP-1  AD-XRCC1). The examined baits did not interact with SUMO1 or SUMO2 
alone either, except for Caspase 7 (AD-SUMO2  BD-Caspase 7). Interestingly, I also 
observed that APLF and XRCC1 interacted with the PARP-1-SUMO1/2 fusions, but not 
the SUMO1/2-PARP-1 constructs, better than they did with either PARP-1 or SUMO1/2 
alone. p53 exclusively interacted with the PARP-1-SUMO2 construct in the orientation 
C D 
E 
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opposite to the APLF and XRCC1 interactions (AD-PARP-1-SUMO2  BD-p53). The 
signals obtained with the GAL4 AD fusions of p21, Werner’s helicase and Caspase 7, 
were certainly false-positives caused by the auto-activation of the relevant reporter 
genes by these constructs, as they were also detected in the presence of the empty 
GAL4 BD vector. 
When PARP-1 is ectopically produced in budding yeast, it constitutively parylates itself 
even in the absence of DNA damage (Kaiser et al., 1992). APLF and XRCC1 interact 
with PAR (Ahel et al., 2008; Pleschke et al., 2000). It was therefore possible that their 
preferential binding to PARP-1-SUMO1/2 could have been the result of an increased 
auto-parylation activity of the fusion constructs in comparison to the unmodified PARP-
1. To investigate this possibility, I transformed yeast cells with an empty two-hybrid 
vector or the equivalent plasmids encoding wild type PARP-1, the K203/486R mutant 
or the PARP-1-SUMO fusions. I prepared total extracts from such cells and then 
analyzed them by western blotting against PARP-1, PAR and PGK (loading control). 
Figure 5.5C shows that all of the examined PARP-1 constructs were produced at 
similar levels and generated comparable amounts of PAR.  
To corroborate these results I also examined the interaction of APLF and XRCC1 with 
catalytically deficient PARP-1 mutants. Two point mutations (M890V and D899N) were 
introduced into PARP-1, which have been shown to individually reduce catalytic activity 
to less than 1% of that of the wild type protein (Rolli et al., 1997). Figure 5.5D shows 
that although abrogating the enzymatic activity of PARP-1 weakened the binding of 
APLF and XRCC1 to the PARP-1-SUMO1/2 fusions, the interactions were still stronger 
than those detected in the presence of the “non-sumoylated” PARP-1 M890V/D899N 
mutants. A possible explanation for these results was that, in addition to inactivating 
PARP-1, mutating M890 and D899 could also destabilize the protein, hence reducing 
its steady-state levels in comparison to the wild type polymerase. Indeed, when total 
extracts from yeast cells producing the PARP-1 M890V/D899N constructs or the 
corresponding wild type counterparts were analyzed by western blotting the levels of 
the former were significantly lower than those of the latter (Figure 5.5E). 
Altogether these results show that, by yeast two-hybrid analysis, APLF and XRCC1 
interacted better with PARP-1-SUMO than they did with PARP-1, independently of the 
enzyme’s catalytic activity.  
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5.2.5 Interactions of APLF and XRCC1 with sumoylated PARP-1 in vitro 
Since I observed that appending SUMO to PARP-1 affected its interactions with APLF 
and XRCC1 in the yeast two-hybrid system, it was important to confirm this finding by a 
more biochemically tractable method. I therefore carried out in vitro binding assay 
using recombinant proteins. GST alone, N-terminally GST-tagged APLF or XRCC1 
were mixed with equal amounts of His6-PARP-1 K203/486R and His6-PARP-1-SUMO2, 
incubated, captured on glutathione resin and then analyzed by western blotting against 
PARP-1. After this analysis the membrane was stained with Coomassie to confirm the 
even loading of the GST-tagged proteins in the pull-down samples and the comparable 
amounts of PARP-1 and the PARP-SUMO2 fusion in the input material (Figure 5.6A). 
This experiment revealed that both APLF and XRCC1 interacted with PARP-1-SUMO2 
almost as well as they did with PARP-1 alone.  
Although the PARP-1-SUMO2 construct used in this experiment was a useful and 
easy-to-handle tool, it nevertheless remained an artificial mimic of PARP-1 modified at 
K203 and K486. It was therefore important to demonstrate that a “truly” sumoylated 
PARP-1 could behave similarly to the fusion construct with respect to the way it 
interacted with APLF and XRCC1. To address this question, I subjected PARP-1 to two 
kinds of in vitro sumoylation reactions. Both of them contained His6-PARP-1 and 
AOS1/His6-UBA2, SUMO2 K25/27/31R, which was used to reduce chain formation, 
and plasmid DNA, which was added to enhance the otherwise low levels of the 
modification (see 6.2). One reaction was supplemented with the wild type UBC9 while 
the control one with the catalytically inactive UBC9 C93S mutant. Following incubation 
at 30°C for 2 h, the polymerase was purified by metal affinity chromatography under 
 
Figure 5.6 - Interactions of APLF and XRCC1 with sumoylated PARP-1 in vitro. A) GST, 
GST-APLF and GST-XRCC1 (20 pmol) were mixed with His6-PARP1 (30 pmol) and His6-
PARP1-SUMO2 (30 pmol) in a final volume of 100 µL PBS + 0.1% Triton X-100 and subjected 
to pull-down analysis as described in 2.18.2. The western blotting membrane was also stained 
with Coomassie. B) His6-PARP-1 (450 pmol) was subjected to a 3 mL sumoylation reaction 
supplemented with SUMO2 K25/27/31R, a supercoiled plasmid (18 µg) and either UBC9 WT or 
UBC9 C93S. All subsequent stages were performed as described in 2.17.1.2. C) GST, GST-
APLF and GST-XRCC1 (20 pmol) were combined with a mix of the mock modified and 
sumoylated PARP-1 proteins (60 pmol of PARP-1 in total) and then analyzed by pull-down 
analysis as described in A). D) GST, GST-APLF and GST-XRCC1 (30 pmol) were mixed with 
His6-tagged PARP-1 (90 pmol), His6-SUMO1 or His6-SUMO2 (1 nmol) and then subjected to 
pull-down analysis as described in A). E) HEK293 cells stably producing FLAG3-APLF or 
FLAG3-XRCC1 (90% confluent, 60 mm  dish) were transfected with a plasmid (8 µg) encoding 
for PARP-1-SUMO2 by lipofection (20 µL of lipofectamine 2000). After 24 h, total extracts (1.75 
mg in 1 mL of RIPA buffer) were prepared and subjected to anti-FLAG immunoprecipitation as 
described in 2.16.2. Immunoprecipitated proteins were eluted and then analyzed by western 
blotting against PARP-1 (75% of the eluate) and the FLAG3 tag (7.5% of the eluate).  
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stringent ionic conditions to remove the DNA and the other proteins present in the 
reaction, except for negligible amounts of the SUMO activating enzyme, which was 
also His6-tagged. The purified proteins were resolved by SDS-PAGE and visualized by 
SYPRO Ruby staining (Figure 5.6B). As expected, the His6-PARP-1 isolated from the 
reaction containing UBC9 C93S appeared as a tight single band that ran at the right 
size for an unmodified polymerase (120 kDa). Conversely, when the wild type UBC9 
was used in the reaction, the purified His6-PARP-1 was converted into multiple slow-
migrating bands, which mainly correspond to sumoylation of K203 and K486 (Figure 
6.7B). With these protein preparations in hand, I repeated the above-described pull-
down experiment, but this time the GST-tagged APLF and XRCC1 were incubated with 
a mix of the mock-modified and sumoylated PARP-1. Figure 5.6C shows that APLF 
and XRCC1 interacted with the modified forms of PARP-1 essentially as well as they 
did with the mock-sumoylated polymerase.  
A noteworthy observation transpiring from these results was that the preferential 
binding of APLF and XRRC1 to the sumoylated PARP-1 in vitro was minimal in 
comparison to that observed in the yeast two-hybrid system (Figure 5.5B). I therefore 
wondered whether APLF and XRCC1 bound PARP-1 somewhat better when it was 
sumoylated simply because this conjugation event led to the addition of their individual 
affinities for PARP-1 and SUMO, instead of a “synergistic” effect, which would have 
been instead expected for a true receptor of sumoylated PARP-1. To partly address 
this question I looked at how well APLF and XRCC1 interacted with SUMO1 and 
SUMO2 in comparison to PARP-1 by in vitro pull-down analysis. GST alone, GST-
tagged APLF or XRCC1 were mixed with His6-tagged SUMO1, SUMO2 or PARP-1, 
incubated, captured on glutathione resin and then analyzed by western blotting against 
SUMO1, SUMO2 and PARP-1. Figure 5.6D shows that, as expected, both APLF and 
XRCC1 interacted with PARP-1 and that they were able to bind SUMO1 and, 
somewhat preferentially, SUMO2. In addition, it was evident that APLF and XRCC1 
bound comparable amounts of SUMO and PARP-1. Since I used ten times more 
SUMO than PARP-1 in such binding assays, these results suggested that APLF and 
XRCC1 probably interact more weakly with SUMO than they do with PARP-1. By a 
very rough estimate, the strength of interaction between APLF/XRCC1 and SUMO was 
in the same order of magnitude as the minimal increase in binding affinity that such two 
proteins exhibited towards the sumoylated PARP-1 in comparison to the unmodified 
protein (Figure 5.6A and Figure 5.6C). In addition, I also observed that APLF and 
XRCC1 interacted with PARP-1-SUMO2 essentially as well as they did with PARP-1 
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alone when they were immunoprecipitated from extracts of HEK293 cells that produced 
PARP-1-SUMO2 at endogenous PARP-1 levels (Figure 5.6E). 
Altogether these data indicate that in vitro APLF and XRCC1 do not probably have any 
significant preference for the sumoylated PARP-1 vs. the unmodified polymerase that 
cannot be traced back to the simple addition of two protein-protein interaction events 
(APLF/XRCC1  SUMO and APLF/XRCC1  PARP-1), which probably occured 
when SUMO was conjugated to PARP-1. 
5.2.6 Sumoylation of PARP-1 does not significantly alter its enzymatic 
activity 
Sumoylation has been shown to affect the enzymatic activity of certain proteins 
(Hardeland et al., 2002; Morris et al., 2009; Vethantham et al., 2008). Having isolated a 
recombinant form of PARP-1 that had been sumoylated at K203 and K486 enabled me 
to determine whether SUMO may impinge on PARP-1’s catalytic activity. To answer 
this question, I initially examined the auto-parylation of PARP-1 by mixing the mock-
modified and sumoylated forms of this protein with DNase I-activated calf thymus DNA, 
to stimulate their catalytic activity, and NAD+, which is used by the enzyme as a source 
of ADP-ribose. Samples of these reactions were collected at increasing time points and 
analyzed by western blotting against PAR. Figure 5.7A shows that the unmodified 
PARP-1 and its sumoylated counterpart were auto-parylated with similar kinetics and to 
similar extents.  
The above-described data showed that sumoylation did not directly affect the auto-
parylation activity of PARP-1, at least when it was analyzed in a minimalistic in vitro 
assay. However, they did not exclude the possibility that under more “physiological” 
conditions a difference may have become more apparent. This situation could have 
occurred by means of, for instance, regulatory proteins that specifically recognize the 
sumoylated polymerase. Factors that influence the activity of PARP-1, such as ERK2 
and histones, have been identified (Cohen-Armon et al., 2007; Kun et al., 2004). 
Therefore, it would have been ideal to analyze the enzymatic activity of the unmodified 
and physiologically sumoylated PARP-1 in vivo. Given the extremely low levels of the 
latter, this type of experiment proved technically unfeasible. As an alternative, I 
measured the levels of PAR in cells depleted of the endogenous PARP-1 by RNA 
interference and reconstituted with recombinant PARP-1 or the PARP-1-SUMO 
constructs. Unfortunately, I was never able to reliably detect a reproducible PAR signal 
in these experiments. I therefore opted for a “hybrid” in vitro/in vivo approach whereby I 
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Figure 5.7 - Sumoylation does not affect the parylation activity of PARP-1. A) Parylation 
reactions in the presence of mock-modified or sumoylated His6-PARP-1 (40 ng) were carried 
out under standard conditions as described in 2.17.2. B) As in A) but in the presence of nuclear 
extracts prepared from PARP-1-/- mouse embryonic fibroblasts (25 µg) as described in 2.10.8. 
 
 
assayed the activity of the unmodified and sumoylated His6-PARP-1 in nuclear extracts 
prepared from PARP-1-/- mouse embryonic fibroblasts (a gift from Zhao-Qi Wang). 
These extracts were used under reaction conditions that had been previously shown to 
support DNA repair (Vodenicharov et al., 2000). They were supplemented with either ~ 
0.45 pmol of modified or unmodified PARP-1 per 30 µg of extract, which is equivalent 
to the quantity of the polymerase present in the same amount of PARP-1+/+ nuclear 
extracts (Vodenicharov et al., 2000), or with a buffered solution to account for 
background PAR activity from PARP-2 (Schreiber et al., 2002). In these reactions 
PARP-1 activity was analyzed in the presence of DNase I-activated calf thymus DNA 
and NAD+. Samples were collected at increasing time points and analyzed by western 
blotting against PARP-1 and PAR. Figure 5.7B shows that even under these 
A 
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conditions the unmodified and sumoylated His6-PARP-1 catalyzed similar levels of PAR 
with similar kinetics. This polymer was specifically produced by the recombinant His6-
PARP-1 because almost no PAR was detected in the reactions supplemented with a 
buffered solution only.  
Overall these data show that SUMO does not significantly alter the enzymatic activity of 
PARP-1. 
5.2.7 Sumoylation of PARP-1 does not alter its subcellular localization 
SUMO controls the subcellular localization of certain proteins in both lower and higher 
eukaryotes (Dawlaty et al., 2008; Liu and Gerace, 2009; Mahajan et al., 1997; Matunis 
et al., 1998; Takahashi and Strunnikov, 2008; Yurchenko et al., 2006; Zhu et al., 2009). 
For some of these factors, artificially fusing them to SUMO has been shown to mimic 
their physiological modification. For example, fusing SUMO to XRCC4 rescues the 
localization phenotype of the corresponding unsumoylatable mutant (Yurchenko et al., 
2006), and a SUMO-topoisomerase II fusion is correctly targeted to its biologically 
relevant subcellular address (Dawlaty et al., 2008). PARP-1 is mainly a chromatin-
associated nuclear protein, although it has been recently detected in mitochondria as 
well (Rossi et al., 2009).  Within the nucleus, PARP-1 is somewhat enriched in 
transcriptionally active nucleoli (Meder et al., 2005), at least at specific stages of the 
cell cycle (Sugimura et al., 2008). To examine whether sumoylation may affect the 
subcellular localization of PARP-1, I transfected HeLa cells with plasmids encoding 
eGFP alone, as a control, or N-terminally eGFP-tagged wild type PARP-1, the 
K203/486R mutant, or the C-terminal SUMO fusions. The cells were fixed and the 
localization of the eGFP-tagged proteins was determined by fluorescence microscopy. 
Figure 5.8A shows that fusing the wild type PARP-1 to eGFP restricted to the nucleus 
the pan-cellular signal observed in the cells producing this tag alone, which indicated 
that eGFP-tagging of PARP-1 did not disrupt its proper subcellular localization. 
Additionally, it showed that the PARP-1 K203/486R mutant and the PARP-1-SUMO 
constructs also localized exclusively to the nucleus, with distribution patterns 
comparable to those seen for the wild type protein. 
In order to corroborate these results, and also to explore whether sumoylation may 
control the association of PARP-1 to chromatin without affecting its nuclear retention, 
the subcellular distribution of the wild type PARP-1 was compared to that of the 
K203/486R mutant and the PARP-1-SUMO2 fusion by cellular fractionation. I 
transfected HEK293 cells with plasmids encoding an N-terminally FLAG3-tagged
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Figure 5.8 - Sumoylation does not affect the subcellular localization of PARP-1. HeLa cells 
(60% confluent, 8-well Cultureslide) were transfected with plasmids (250 ng) encoding for eGFP 
alone or the indicated N-terminally eGFP-tagged PARP-1 constructs by lipofection (1 µL of 
Fugene HD). After 24 h, the cells were fixed and subjected to immunofluorescence as described 
in 2.10.6. B) HEK293 cells (90% confluent, 100 mm  dish) were transfected with plasmids (10 
µg) encoding the specified N-terminally FLAG3-tagged constructs of PARP-1 by lipofection (40 
µL of Fugene HD). After 24 h, total extracts prepared from these cells were fractionated into 
cytoplasmic, nucleoplasmic and chromatin phases, as described in 2.10.7, and analyzed by 
western blotting against the FLAG tag. 
 
  
version of the above-mentioned constructs. Rajvee Shah prepared total extracts from 
these cells, fractionated them into cytoplasmic, nucleoplasmic and chromatin phases 
and then analyzed them by western blotting against the FLAG3 tag. Figure 5.8B shows 
that the distribution patterns of the FLAG3-PARP-1 K203/486R mutant and the FLAG3-
PARP-1-SUMO2 fusion were very similar to that of the wild type protein, in fact, all of 
them were almost completely associated with the chromatin. 
Altogether these results indicate that, at least under unchallenged growth, SUMO does 
not appreciably affect the subcellular localization of PARP-1.  
5.2.8 The PARP-1-SUMO fusion proteins are poly-sumoylated in vivo 
Interestingly, the cell fractionation experiments shown in Figure 5.8B revealed that 
FLAG3-PARP-1-SUMO2 was resolved as one main band, which expectedly ran 
somewhat more slowly than the wild type polymerase, and several slower-migrating 
A 
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forms. This finding was exciting because it suggested that appending SUMO2 to 
PARP-1 led to the further post-translational modification of this protein. By inference, it 
was possible that sumoylating PARP-1 at K203 and K486 could also trigger a similar 
effect. Crosstalk between sumoylation and other types of post-translational modifiers 
has been reported before (Desterro et al., 1998; Mohan et al., 2007; Prudden et al., 
2007; Sun et al., 2007; Wu and Chiang, 2009). In addition PARP-1 can be conjugated 
to SUMO, PAR, ubiquitin (Wang et al., 2008b) and acetyl groups (Hassa et al., 2005) in 
vivo. It was interesting to determine whether any of these modifiers was specifically 
conjugated to PARP-1-SUMO2. Towards this end, Rajvee Shah transfected HEK293 
cells with plasmids carrying the eGFP-PARP-1 constructs described in 5.2.7 or the 
empty eGFP vector as a control. She prepared total extracts from these cells and then 
captured the eGFP-tagged proteins with an anti-GFP antibody under conditions of high 
ionic strength. These immunoprecipitates were analyzed by western blotting against 
GFP, ubiquitin and PAR. In addition, they were probed for SUMO1 to determine 
whether fusing SUMO2 to PARP-1 stimulated the attachment of polymeric SUMO 
chains to this construct. Although only SUMO2/3 appear to be able to make chains in 
vivo (Matic et al., 2008; Tatham et al., 2008), I used an anti-SUMO1 antibody to 
explore this issue for two reasons. Firstly, if I employed an anti-SUMO2/3 antibody then 
I would have not been able to distinguish between the western blotting signal from the 
SUMO2 moiety artificially fused to PARP-1, in the PARP-1-SUMO2, construct and that 
from true polymeric SUMO chains that may be conjugated to it. Secondly, although 
SUMO1 does not seem to form chains in vivo, it can be part of the naturally occurring 
SUMO2/3 polymers as a termination signal (Matic et al., 2008; Tatham et al., 2008). 
Figure 5.9A showed that, in comparison to the wild type protein, appending SUMO2 to 
PARP-1 did not significantly alter its low background levels of auto-parylation in the 
absence of DNA damage or the extent to which it was ubiquitylated. Nevertheless, the 
average size of the ubiquitylated PARP-1-SUMO2 was larger than that of the 
ubiquitylated wild type enzyme. Conversely, the PARP-1-SUMO2 fusion was heavily 
conjugated to SUMO1. Such a modification event did not depend on which tag was 
appended to the fusion construct because it was detected for both the eGFP- (Figure 
5.9A) and FLAG3-tagged (Figure 5.8B) versions. In addition, I also observed this 
phenomenon when untagged PARP-1-SUMO2 was ectopically produced in PARP-1-/- 
mouse embryonic fibroblasts (data not shown). Last but not least, the identity of the 
SUMO paralogue fused to PARP-1 did not significantly affect the ability of the resulting 
construct to be further modified (Figure 5.9B). 
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Figure 5.9 - The PARP-1-SUMO constructs are poly-sumoylated in vivo. A) HEK293 cells 
(60% confluent, 100 mm  dish) were transfected with plasmids (10 µg) encoding for eGFP 
alone or the indicated N-terminally eGFP-tagged PARP-1 constructs by lipofection (40 µL of 
Fugene HD). After 48 h, total extracts (1 mg in 1 mL of RIPA buffer) from these cells were 
subjected to overnight immunoprecipitation as described in section 2.16.2 in the presence of 
anti-GFP resin (10 µL). The immunocaptured proteins were analyzed by western blotting 
against GFP, PAR, ubiquitin and SUMO1 (10% of eluate). B) Total extracts from HEK293 cells 
transfected as described in A) were subjected to western blotting analysis against GFP. 
 
 
In conclusion, these data show that appending SUMO to PARP-1 stimulates its poly-
sumoylation, most likely through SUMO2/3 chains bearing a SUMO1 moiety at their 
very ends. 
5.2.9 Proteasomal inhibition leads to further post-translational 
modification of the sumoylated PARP-1 
Through the action of specific SUMO-targeted ubiquitin ligases, polymeric SUMO 
chains have been shown to tag proteins for poly-ubiquitylation and subsequent 
proteasome-mediated degradation (see 1.2.6). Having found that the PARP-1-SUMO 
fusions were heavily polysumoylated in vivo, I was curious to explore whether this 
phenomenon might lead to their poly-ubiquitylation and destruction. Thus, I incubated 
HEK293 cells producing N-terminally FLAG-tagged wild type PARP-1, the K203/486R 
A 
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Figure 5.10 - PARP-1-SUMO2 becomes further modified following proteasomal inhibition. 
A) HEK293 producing FLAG-tagged constructs of PARP-1 WT, the K203/486R mutant or the 
PARP-1-SUMO2 fusion were incubated with MG132 (30 µM), or an equivalent volume of 
DMSO. After 5 h, total extracts made from these cells were analyzed by western blotting against 
the FLAG tag and tubulin (loading control). B) Total extracts (750 µg in 0.75 mL of RIPA buffer) 
prepared from cells treated as described in A) were subjected to an overnight 
immunoprecipitation with an anti-FLAG resin (30 µL) as described in 2.16.2. The 
immunoprecipitated proteins were analyzed by western blotting against the FLAG tag (7.5% of 
the eluate), ubiquitin (30% of the eluate) and SUMO2/3 (30% of the eluate). C) HeLa cells 
producing His6-SUMO3 (Figure 5.1A) were incubated for 5 h in the presence of MG132 (30 µM) 
or an equivalent volume of DMSO before proceeding to the isolation of sumoylated species as 
described in Figure 5.1A. 
 
 
mutant or the PARP-1-SUMO2 fusion in the presence of the proteasome inhibitor 
MG132 or DMSO. I prepared total extracts from these cells and analyzed them by 
western blotting against the FLAG tag or tubulin. Figure 5.10A shows that the steady-
state levels of the wild type PARP-1 and the K203/486R mutant were largely 
A C 
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unaffected by treatment with MG132. On the other hand, proteasomal inhibition led to 
an almost complete loss of the signal for PARP1-SUMO2.  
This last observation was rather counter-intuitive unless I assumed that inhibiting the 
proteasome might have led to the accumulation of long ubiquitin chains on a protein, 
i.e. PARP1-SUMO2, that was already being heavily poly-sumoylated. Such a 
substantial amount of modification could have potentially converted the PARP-1-
SUMO2 fusion into a range of high-molecular weight conjugates so wide that their 
signal seemingly disappeared due to a “dilution effect”, or their sheer size. To 
substantiate this hypothesis, I repeated the above-described experiment, but this time I 
immunoprecipitated the recombinant PARP-1 constructs by means of an anti-FLAG 
antibody. Western blotting analysis of these preparations showed that inhibiting the 
proteasome apparently reduced the amount of immunoprecipitated PARP-1-SUMO2 
but it also led to the accumulation of several slow-migrating forms of this protein (Fig. 
Figure 5.10B). Analysis of these immunoprecipitates with an anti-SUMO2/3 antibody 
also revealed that proteasomal inhibition converted the unmodified PARP-1-SUMO2 
construct into a smear of greater signal intensity, which migrated all the way up to the 
well of the gel. Given these results, I was not surprised to observe that in the presence 
of MG132 PARP-1-SUMO2 also co-isolated with ubiquitylated species. 
The above-presented data showed that inhibiting the proteasome boosted the poly-
sumoylation of PARP-1-SUMO2 and its association with poly-ubiquitylated species, 
probably through covalent interactions. I was therefore interested in establishing 
whether the sumoylation of PARP-1 at K203 and K486 was also susceptible to 
proteasomal inhibition. To address this problem, I isolated sumoylated species by 
denaturing Ni2+-NTA chromatography from His6-SUMO3-expressing HeLa cells that 
were incubated in the presence of MG132 or DMSO. Western blotting analysis of these 
purifications, Figure 5.10C, showed that proteasomal inhibition led to the apparent loss 
of the main sumoylated forms of PARP-1. From a longer exposure of this same 
western blotting membrane I noticed that the MG132-depedent loss of the (mono)-
sumoylated PARP-1 was accompanied by the appearance of a faint but noticeable 
high-molecular weight smear. This observation strongly suggested that inhibiting the 
proteasome led to further modification of the sumoylated PARP-1.  
Altogether these data indicate that upon proteasomal inhibition both the PARP-1-
SUMO2 fusion construct and the physiologically sumoylated PARP-1 were further 
conjugated to SUMO and/or ubiquitin.  
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5.2.10 Proteasomal inhibition leads to the accrual of PARP1-SUMO2 into 
nuclear foci that do not co-localize with PML nuclear bodies 
The unexpected finding that PARP-1-SUMO2 specifically associated with ubiquitylated 
species of lower molecular weight than PARP-1 itself (Figure 5.10B) put forward the 
possibilities that some of them might have been generated by partial proteolysis of the 
ubiquitylated fusion protein. Alternatively, they could have been ubiquitylated proteins 
isolated through non-covalent interactions with PARP-1-SUMO2. Such a phenomenon 
could have occurred if, for instance, the fusion construct relocalized to, and thereby 
became entrapped in, PML nuclear bodies. These nuclear structures are heavily 
enriched in species conjugated to SUMO and/or ubiquitin and they have been 
proposed to act as degradation factories (Bailey and O'Hare, 2005). To explore this 
possibility, I transfected HeLa cells with the eGFP constructs described in 5.2.7 and 
then treated them with MG132 or DMSO only. The cells were fixed, subjected to 
indirect immunofluorescence against PML and finally analyzed by fluorescence 
microscopy. Figure 5.11 shows that upon proteasomal inhibition eGFP-PARP-1-
SUMO2 accrued into well-defined nuclear foci in more than 30% of the transfected 
cells. These foci did not co-localize with PML nuclear bodies and were not detected for
 
Figure 5.11 - PARP-1-SUMO2 accrues into nuclear foci that do not co-localize with PML 
nuclear bodies, upon inhibition of the proteasome. A) HeLa cells were transfected and 
processed for immunofluorescence as described in Figure 5.8A, but before being fixed they 
were incubated in the presence of MG132 (30 µM) or an equivalent volume of DMSO for 5 h. B) 
Quantification of the percentage of the GFP-positive HeLa cells that displayed 5 or more nuclear 
PARP-1 foci. 
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the eGFP-tagged wild type PARP-1 or the K203/486R mutant. 
These data, together with those presented in the previous paragraph, show that when 
PARP-1-SUMO2 becomes further modified by SUMO and possibly ubiquitin, it 
relocalizes to nuclear structures that do not correspond to PML nuclear bodies. 
5.2.11 Sumoylation of PARP-1 is a signal for proteasome-mediated 
degradation 
The data presented above suggested that both the physiologically sumoylated PARP-1 
and the PARP-1-SUMO2 fusion could be ubiquitylated. Consequently, it was possible 
that they might be degraded by the proteasome. To address this question, I compared 
the stability of the wild type PARP-1, the K203/486R mutant and the PARP-1-SUMO2 
fusion in a cycloheximide chase experiment. HEK293 cells producing N-terminally 
FLAG-tagged versions of such constructs (Figure 5.10) were incubated in the 
presence of cycloheximide alone or cycloheximide and MG132. I harvested these cells 
at increasing time points, prepared total extracts and then analyzed them by western 
blotting against the FLAG tag and tubulin. Figure 5.12 shows that inhibiting the 
proteasome drastically reduced the moderately fast degradation rate of the wild type 
PARP-1. Mutating the two main sumoylation sites of the polymerase afforded a similar 
stabilization effect, thus indicating that sumoylation of PARP-1 controls its stability. 
Since appending SUMO2 to PARP-1 enabled the polymerase to become further 
modified by SUMO and ubiquitin (Figure 5.9 and Figure 5.10), I expected that the 
PARP-1-SUMO2 fusion would behave similarly to the wild type protein, with respect to 
its stability. Instead, I found that it was as stable as the K203/486R mutant in the 
presence of cycloheximide only. When MG132 was also present in the medium, such a 
 
Figure 5.12 - Sumoylation targets PARP-1 for proteasomal degradation. HEK293 cells 
producing PARP-1 WT, the K203/486R mutant or the PARP-1-SUMO2 construct (Figure 5.10A) 
were subjected to cycloheximide-chase analysis as described in 2.10.9. Total extracts were 
prepared from them and analyzed by western blotting against the FLAG tag and tubulin (loading 
control). CHX = cycloheximide. 
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construct disappeared at a rate similar to that at which the wild type PARP-1 was 
degraded, probably because such fusion was heavily modified under these conditions 
(Figure 5.10). 
On one hand, these data indicate that PARP-1 must be sumoylated at K203 and K486 
in untreated cells and that this event leads to its degradation by the proteasome. On 
the other hand, they also reveal that the PARP-1-SUMO2 construct is probably not 
targeted for proteasome-mediated degradation, or at least not as fast as the wild type 
protein. 
5.3 Discussion 
While I was completing the experiments presented in this part of my thesis, four other 
groups reported PARP-1 as a target of sumoylation (Blomster et al., 2009; Martin et al., 
2009; Messner et al., 2009; Ryu et al., 2010). Like I did, they uncovered many of the 
properties of this modification event, including the identity of the modification sites, the 
signals that trigger it and its possible functions. I will therefore discuss several of my 
results in light of such studies.  
5.3.1 PARP-1 as a target of sumoylation 
Here, I demonstrated that PARP-1 is a true sumoylation substrate in human cells by 1) 
isolating sumoylated species under denaturing conditions from cells producing His6-
SUMO and 2) immunoprecipitating PARP-1 from cells expressing endogenous levels of 
the modifier (Figure 5.1). I also showed that the polymerase was preferentially 
conjugated to SUMO3, in comparison to SUMO1 or SUMO2 (Figure 5.1A). The latter 
observation was unexpected because it is widely believed that the mature forms of 
SUMO2 and SUMO3, being essentially identical, cannot be distinguished even in vivo 
(Wang and Dasso, 2009). Yet, it is possible that SUMO2 and SUMO3 could target 
different subsets of proteins because this hypothesis has never been examined and at 
least one other protein besides PARP-1, i.e. the transcriptional repressor p66, has also 
reported to be preferentially modified by SUMO3 over SUMO2 (Liu and Warbrick, 
2006).  
This phenomenon could have potentially arisen by controlling the sumoylation of 
PARP-1 in at least four different ways. Firstly, it is possible that it may have been 
simply caused by higher overall levels of SUMO3 in the cells compared to those of the 
other modifiers. Alternatively, it could have stemmed from the presence of a SUMO3-
specific SIM in the target of sumoylation. In fact, not only can SIMs aid the modification 
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of the proteins that carry them (Knipscheer et al., 2008; Zhu et al., 2008), but, being 
able to discriminate between SUMO1 and SUMO2/3, they can also specify which 
SUMO paralogue will be attached to a polypeptide (Hecker et al., 2006; Meulmeester 
et al., 2008; Ouyang et al., 2009; Zhu et al., 2008). This scenario, however, appears 
unlikely since Messner et al. (2009) did not detect any non-covalent interaction 
between PARP-1 and any of the SUMO paralogues. In addition, a SIM that can 
dinstinguish between SUMO2 and SUMO3 probably does not exist because these two 
SUMO paralogues interact with known SIMs through a region that is identical between 
them. Thirdly, the preferential conjugation of SUMO3 to PARP-1 could depend on a 
SUMO ligase that has a preference for SUMO3. PIASy seems to be the relevant E3 
enzyme for PARP-1 sumoylation because depleting it abolishes this modification event 
in vivo and it can also stimulate the modification of the polymerase in vitro by SUMO1 
or SUMO2 (Martin et al., 2009). PIASy has been shown to mediate the modification of 
several other proteins by either SUMO1 or SUMO2 (Azuma et al., 2005; Dahle et al., 
2003; Subramanian et al., 2003). It therefore seems unlikely that this SUMO ligase may 
able to distinguish amongst SUMO paralogues and consequently promote the 
sumoylation of PARP-1 specifically by SUMO3. In the future it will be however 
important to directly prove this issue in the context of PARP-1. Lastly, the preferential 
modification of PARP-1 by SUMO3 could depend on the action of a SENP that is able 
to remove SUMO1 and SUMO2 from PARP-1 more efficiently than SUMO3. Although 
no such protein has been reported, it might nevertheless exist. Some SENPs can 
actually deconjugate SUMO1 and SUMO2/3 with different efficiencies (Table 1.1). They 
can also process the immature forms of SUMO1 and SUMO2 better than that of 
SUMO3, because of the different extensions that they bear after their di-glycine motifs 
(Bailey and O'Hare, 2004; Gong et al., 2000; Gong and Yeh, 2006; Kolli et al., 2010; 
Mikolajczyk et al., 2007; Shen et al., 2009).  
It is also possible that PARP-1 is preferentially modified by SUMO3 because this 
particular form of the protein is functionally distinct from those conjugated to SUMO1 or 
SUMO2. There is in fact some evidence suggesting that SUMO3 may control 
processes that are distinct, at least partly, from those mediated by SUMO1 and/or 
SUMO2: depleting SUMO3 from cells impairs the formation of PML nuclear bodies, 
which can only be rescued by ectopically over-producing SUMO3 but not SUMO1 or 
SUMO2 (Fu et al., 2005). This scenario, however, seems unlikely because SUMO1/2/3 
are attached to the same lysine residues within PARP-1 (Figure 5.3, Martin et al., 
2009; Messner et al., 2009).  
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Martin et al. (2009), Messner et al. (2009) and I have identified K486 and K203 as the 
main sumoylation sites of PARP-1, with a third one also likely to exist (Figure 5.3). The 
observation that individually mutating PARP-1’s K203 or K486 (or K482 in X. laevis) 
enhances the sumoylation of other residues in human cells (Figure 5.3), in vitro 
(Figure 6.7) and also in frog egg extracts (Ryu et al., 2010) raises the possibility that 
the third sumoylation site of PARP-1 may be very minor or cryptic. It therefore could 
become relevant only when the main sumoylated lysines are not accessible, which is a 
phenomenon that has been shown for other sumoylation substrates (Jacobs et al., 
2007; Onishi et al., 2009). 
5.3.2 Regulation of PARP-1 sumoylation 
The observations presented in this thesis, together with those reported in other studies 
(Martin et al., 2009; Messner et al., 2009; Ryu et al., 2010), demonstrate that in vivo 
the sumoylation of PARP-1 is not a static event but it changes under different 
conditions.  
5.3.2.1 Regulation of PARP-1 sumoylation by environmental stimuli 
In human cells, PARP-1 appears to be only mono-sumoylated at low levels during 
normal growth (Figure 5.1, Blomster et al., 2009; Martin et al., 2009; Messner et al., 
2009), but it becomes more heavily mono-sumoylated and also poly-sumoylated in 
response to acute heat (Blomster et al., 2009; Martin et al., 2009). This phenomenon 
would be consistent with the evidence that upon heat shock PARP-1 K203/486R does 
not activate HSP70.1 transcription as well as the wild type protein (Martin et al., 2009). 
Nevertheless, I found that PARP-1 sumoylation was also upregulated in response to 
osmotic and metabolic stresses (Figure 5.2), which, like excessive heat, are known to 
boost the overall levels of SUMO2/3-modified species in a cell (Saitoh and Hinchey, 
2000). The extent of such increase correlated well with the degree to which PARP-1 
sumoylation was enhanced under the same conditions (Figure 5.2). These results 
therefore suggest that the increase in sumoylation that PARP-1 experiences in 
response to a variety of environmental stimuli is not a specific event, instead it is 
probably the consequence of their ability to boost the general levels of SUMO2/3 
conjugates. In support of this view, PARP-1 sumoylation has been shown to impinge 
on the roles of the polymerase in transcription not only following heat shock, but also 
after hypoxia (Messner et al., 2009), which can also stimulate the overall levels of 
SUMO2/3 conjugates in vivo (van Hagen et al., 2010).  
Chapter 5. Results III 
206 
5.3.2.2 Regulation of PARP-1 sumoylation by the cell cycle 
PARP-1 sumoylation also seems to be controlled at the level of the cell cycle, at least 
in frog egg extracts, where it occurs specifically at mitosis (Ryu et al., 2010). Since in 
Xenopus egg extracts, SUMO2/3 conjugates accumulate on the chromatin during 
mitosis (Azuma et al., 2003), it is possible that this phenomenon may not be specific for 
PARP-1 either. In order to corroborate the importance of this result, it will therefore be 
useful to examine the cell cycle patterns of PARP-1 sumoylation in human cells 
because, unlike frog egg extracts, here the levels of SUMO2/3 conjugates drop at 
beginning of metaphase but then progressively grow throughout mitosis (Zhang et al., 
2008).  
Although the increase in sumoylation that PARP-1 experiences in response to 
environmental cues and at specific cell cycle stages may not be PARP-1-specific, this 
does not mean that they are functionally relevant. They could in fact elicit a 
downstream process that is important to deal with all of these situations, such as 
controlling gene transcription/expression, in which PARP-1 sumoylation actually seems 
to play a role (Martin et al., 2009; Messner et al., 2009). These speculations raise the 
possibility that the poly-sumoylated PARP-1 is observed only under stressful conditions 
(Figure 5.2, Blomster et al., 2009; Martin et al., 2009) because it has different 
functions, e.g. promote degradation, compared to the mono-sumoylated polymerase. 
Although this scenario may not seem very likely, it has been demonstrated for other 
modification events, such as the mono- and poly-ubiquitylation of PCNA (see 1.3.3). 
Whether this situation also applies to PARP-1 should be investigated further, as could 
be the way in which the balance between the mono and poly-sumoylated forms of 
PARP-1 is controlled. In order to do so, it will be useful to study PARP-1 sumoylation in 
cells that produce SUMO2/3 mutants that are unable to form chains.  
5.3.3 Are the PARP-1-SUMO fusion constructs functionally relevant 
mimics of the sumoylated PARP-1? 
5.3.3.1 A rationale for using SUMO-PARP-1 fusions as mimics of the 
physiologically sumoylated PARP-1 
Recognizing the biological consequences of a sumoylation event is difficult because 
they cannot be generally predicted and only a tiny amount of a protein is usually 
modified at any time. It therefore follows that being able to quantitatively sumoylate a 
protein could facilitate this endeavour. Although achieving this goal in vivo is technically 
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impossible at present, it has been shown that artificially fusing SUMO to an 
unsumoylatable version of certain proteins can restore their wild type-like behaviour, 
and in some cases drive it even further (Carter and Vousden, 2008; Dawlaty et al., 
2008; Hishida et al., 2006; Ross et al., 2002; Sugimura et al., 2008; Takahashi and 
Strunnikov, 2008; Takahashi et al., 2006; Yurchenko et al., 2006). This phenomenon 
seems to occur because the exact residues to which a modifier is attached within a 
protein may not matter at all to trigger a physiologically relevant event (Ross et al., 
2002; Sacher et al., 2006). For these reasons I decided to investigate the function of 
PARP-1 sumoylation by using, in addition to the K203/486R mutant, SUMO-PARP-1 
fusion constructs whenever I could not use a PARP-1 protein that had been 
sumoylated at K203 and K486.  
To create these SUMO-PARP-1 constructs I recombinantly fused SUMO to either the 
N- or C-terminus of the PARP-1 K203/486R mutant. Importantly, the C-terminal di-
glycine motif of these SUMO appendages, which would normally be required for their 
conjugation and deconjugation to/from proteins, was mutated to GA for two reasons. 
Firstly, to prevent the SUMO protease-mediated desumoylation of the N-terminal 
SUMO fusion constructs. Secondly, to avoid the enzymatic attachment of the SUMO 
moiety appended at the C-terminus of PARP-1 to other polypeptides, which has been 
reported for other SUMO-fused proteins (Carter and Vousden, 2008). Instead of fusing 
SUMO3 to PARP-1, which would have been the ideal choice (Figure 5.1A), I used 
either SUMO1 or SUMO2 because when I created and analyzed the fusion constructs I 
only knew that 1) PARP-1 was likely to be modified by SUMO1, SUMO2 and SUMO3 
and 2) a significant difference in the extent to which PARP-1 was modified by SUMO2 
vs. SUMO3 seemed improbable, given that they had been deemed indistinguishable in 
most situations (Wang and Dasso, 2009). The properties of PARP-1 fused to SUMO1 
or SUMO2, which are only 45% identical, are nevertheless noteworthy because 
whenever one of them displayed a specific property the other behaved exactly the 
same way. These results therefore indicate that such effects must have arisen by 
appending a SUMO moiety to PARP-1, regardless of its exact identity. 
The results presented in this part of my thesis showed that fusing SUMO to PARP-1 
changed the properties of the polymerase in at least two different ways: 1) how it 
interacted with some of its partners, and 2) how it was post-translationally modified. 
The features and biological relevance of these two phenomena will be discussed 
below.  
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5.3.3.2 Fusing SUMO to PARP-1 affects its interactions with APLF 
and XRCC1  
The main question that arises from the data indicating that APLF and XRCC1 
preferentially interact with the sumoylation mimics of PARP-1 is whether APLF and 
XRCC1 are actually genuine “downstream effectors” of the physiologically sumoylated 
polymerase.  
5.3.3.2.1 Yeast two-hybrid system 
By means of the yeast two-hybrid system, I found that two known partners of PARP-1, 
that is, the DNA break repair factors APFL and XRCC1 (Brem and Hall, 2005; Iles et 
al., 2007), interacted with the PARP-1-SUMO constructs drastically better than they did 
with either SUMO or PARP-1 on their own (Figure 5.5). The fact that this phenomenon 
occurred only when SUMO was fused to the C-terminus of PARP-1, but not its N-
terminus, was slightly surprising because the two known sumoylation sites of PARP-1 
are located within the first half of the protein (Figure 5.3). One possible explanation for 
such an occurrence is that the SUMO moiety attached to the C-terminus of PARP-1 
adopted at a more physiological position than that fused to the N-terminal, probably 
thanks to PARP-1’s large size and modular structure. An alternative scenario is that the 
PARP-1-SUMO constructs may be able to accommodate a greater variety of 
conformations than the SUMO-PARP-1 fusions. This situation is possible because in 
the PARP-1-SUMO constructs the polymerase and SUMO’s core domain are 
separated by a linker, i.e. the N-terminal tail of the modifier, which is long and highly 
flexible (Melchior, 2000). Instead, in the N-terminal fusions SUMO is attached to PARP-
1 through its shorter C-terminal conjugation tail. To study the latter one of these two 
possibilities one could examine the affinities of APLF and XRCC1 for the SUMO-
PARP-1 constructs where the modifier flexible N-terminal tail is removed from the C-
terminal fusions and/or a long flexible linker is added to the N-terminal constructs.  
Given that PARP-1 is constitutively active when ectopically produced in budding yeast 
(Figure 5.5, Kaiser et al., 1992) and that APLF and XRCC1 bind PAR (Ahel et al., 
2008; Pleschke et al., 2000), it follows that their ability to preferentially recognize the 
PARP-SUMO constructs could have arisen from a SUMO-dependent increase in the 
autoparylation activity of such constructs. I excluded this possibility by showing that 
APLF and XRCC1 preferentially interacted with the PARP-SUMO fusions even when 
their PARP-1 moieties were catalytically inactive (Figure 5.5D). In addition, I 
demonstrated  that the wild type PARP-1 and the SUMO fusion constructs produced 
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similar levels of PAR (Figure 5.5C) and that ligase III, which is also a PAR-binding 
protein (Ahel et al., 2008; Pleschke et al., 2000), did not show the same preference for 
PARP-1-SUMO as APLF and XRCC1 did (Figure 5.5B).  
5.3.3.2.2 In vitro and in vivo 
Surprisingly, the significantly higher affinity that APLF and XRCC1 displayed towards 
the PARP-1-SUMO constructs in the yeast two-hybrid system could not be 
recapitulated in vitro, using purified proteins, or in vivo (Figure 5.6). 
The reasons for why APLF and XRCC1 did not interact with the PARP-1-SUMO 
constructs with the same degree of preference in all the three employed experimental 
systems are unclear. Many of the biological properties of PARP-1, possibly including 
the way in which it interacts with its partners, are heavily influenced by DNA 
(Soldatenkov and Potaman, 2004). I can therefore speculate that the above-described 
discrepancies may have originated from the different forms in which DNA was present 
in the different experiments: chromatin-packaged intact DNA in the yeast two-hybrid 
system, no DNA in the in vitro pull-down assays and solubilized chromatin in the 
mammalian cell extracts. A possible way to address this issue would be to assess how 
inactivating PARP-1’s DNA binding activity in the yeast two-hybrid system or including 
different kinds of DNA molecules in the in vitro binding assays affects the interactions 
between PARP-1-SUMO and APLF/XRCC1.  
In vitro APLF and XRCC1 were able to weakly interact with SUMO alone (Figure 
5.6D). By a very rough estimate, the strength of this interaction seems to be in the 
same order of magnitude as the very minimal increase in affinity that these proteins 
demonstrate for the sumoylated PARP-1 (Figure 5.6A). Thus, such phenomenon may 
have simply been the result of the mathematical addition of the individual affinities of 
APLF and XRCC1 themselves for SUMO and PARP-1 independently, which may have 
occurred as a result fusing/conjugating them together. It therefore follows that APLF 
and XRCC1 are unlikely to be true receptors/effectors of the sumoylated PARP-1 
because such a protein should recognize a PARP-1-SUMO conjugate with an affinity 
that is higher than the sum of its individual affinities for PARP-1 and SUMO alone. As a 
matter of fact, a function for APLF or XRCC1, which play a role in the repair of SSBs 
(Brem and Hall, 2005; Iles et al., 2007), downstream of sumoylated PARP-1 would be 
inconsistent with the findings that 1) SSBs inhibit PARP-1 sumoylation in vitro (see 
6.2), and 2) the sumoylation of PARP-1 appears to have a role in controlling 
transcription rather than DNA repair (Martin et al., 2009; Messner et al., 2009).  
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Even though the results discussed above may not reflect physiologically relevant 
interactions, they nevertheless uncovered the previously unknown finding that APLF 
and XRCC1 can non-covalently interact with SUMO, albeit weakly. The amino acids 
responsible for these interactions should be located within the first BRCT motif of 
XRCC1 (aa 170-428) and the C-terminal domain of APLF (aa 360-511) because such 
regions also preferentially recognize the PARP-1-SUMO constructs in the yeast two-
hybrid system (data not shown). Both of these protein fragments contain a hypothetical 
SIM that conforms to classic consensus sequences (see 1.3.1). Mutating such motifs 
did not however affect the binding between APLF/XRCC1 and PARP-1-SUMO (data 
not shown), thus suggesting that other types of SUMO-interacting sequence must be 
involved in these interaction events.  
5.3.3.3 Fusing SUMO to PARP-1 affects its post-translational 
modification 
Another intriguing property of the PARP-1-SUMO constructs was that they became 
heavily conjugated to SUMO when ectopically produced in mouse or human cells 
(Figure 5.9 and data not shown). Such conjugates almost certainly represent SUMO 
chains because their number was simply too big to have been produced by multiple 
mono-sumoylation events (Figure 5.9). Having said that, I cannot categorically exclude 
that they may have originated from a mixture of mono- and poly-sumoylation events. 
Showing that the number and/or abundance of these sumoylated species are reduced 
by over-producing SUMO1 or SUMO2/3 mutants that are unable to form chains could 
help to confirm these deductions.  
5.3.3.3.1 On the specificity of PARP-SUMO sumoylation  
The ability of the PARP-1-SUMO fusion constructs to become poly-sumoylated 
appears to be a specific event in at least three respects.  
Firstly, with regard to which organisms it happened in. In fact, I detected it only in 
mammalian cells but not in budding yeast (Figure 5.5C), where no orthologues of 
PARP-1 exist, or in insect cells (data not shown), where only one PARP protein is 
present (Uchida et al., 1993).  
The second level of specificity relates to PARP-1 itself. Poly-sumoylation has not been 
reported for several other proteins over-produced as SUMO fusions in mammalian 
cells, whether or not they are known SUMO substrates (Babic et al., 2006; Liu et al., 
2008; Muromoto et al., 2006; Peroutka et al., 2008; Tan et al., 2008).  
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Thirdly, with respect to the part of the PARP-1-SUMO construct that was poly-
sumoylated. SUMO appears to be a better candidate than PARP-1 because while the 
polymerase employed to generate the fusion constructs had its sumoylation sites 
mutated, their SUMO moieties contained residues that could be used to form SUMO 
chains. That said, this assumption is inconsistent with the fact that both the SUMO1 
and the SUMO2 fusions of PARP-1 were poly-sumoylated equally well (Figure 5.9), 
even though only SUMO2/3 is capable of forming chains efficiently in vivo (Tatham et 
al., 2001).  
On the basis of these speculations two scenarios are conceivable to explain how the 
PARP-1-SUMO constructs may have been poly-sumoylated. On the one hand, it is 
possible that fusing SUMO to PARP-1 facilitated the recruitment of the sumoylation 
machinery to the polymerase, thus boosting the modification of its third sumoylation 
site. On the other hand, given that SUMO1 can potentially form chains (Pichler et al., 
2002; Yang et al., 2006a), it is imaginable that appending it to PARP-1 could have 
placed the modifier at an ideal position, e.g. next to a chromatin-bound SUMO ligase, 
to be further modified. A possible way to distinguish between these two possibilities 
could be to examine the consequences of depleting PIASy and/or mutating all of the 
lysines within the SUMO moiety of the PARP-SUMO fusions on the poly-sumoylation of 
these constructs. Interestingly, there is some evidence in support of the latter scenario: 
after heat shock, UBC9, PIASy and PARP-1 become heavily enriched at the same 
chromatin region, i.e. at the promoter of the HSP70.1 gene (Martin et al., 2009). 
Although at present there is no data on whether this recruitment phenomenon also 
occurs during normal cell growth, this possibility seems likely because: 1) PARP-1 and 
PARP-1-SUMO are modified during normal growth conditions (Figure 5.1, Martin et al., 
2009; Messner et al., 2009) and 2) inhibiting the sumoylation of the polymerase affects 
HSP70.1 transcription even in non-stressed cells (Martin et al., 2009). In the future, it 
will be therefore interesting to corroborate these observations by chromatin 
immunoprecipitation (ChIP) analysis of PARP-1, PIASy and UBC9, against either 
known PARP-1-bound and -free regions or, preferably, the entire genome.  
5.3.3.3.2 On the physiological relevance PARP-1-SUMO sumoylation 
In addition to being specific, the conjugation of SUMO2/3 chains to PARP-1-SUMO 
appears to be physiologically relevant because the wild type polymerase has also been 
observed to be poly-sumoylated in vivo (Figure 5.2, Blomster et al., 2009; Martin et al., 
2009). That said, while poly-sumoylated PARP-1 was exclusively detected under  
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conditions of cellular stress, poly-sumoylated PARP-1-SUMO was also visible during 
normal growth (Figure 5.9). This difference probably arose because appending SUMO 
to PARP-1 increased the “sumoylation potential” of the resulting fusion enough to allow 
it to become poly-sumoylated even in non-stressed cells. It therefore follows that some 
poly-sumoylated PARP-1 may also exist in untreated cells but we may not be able to 
detect it because it is not very abundant. This hypothesis is realistic as poly-SUMO 
chains can lead to the poly-ubiquitylation of their targets and their subsequent 
proteasome-mediated degradation (Lallemand-Breitenbach et al., 2008; Tatham et al., 
2008; Uzunova et al., 2007). Consistently with this scenario I found that under normal 
growth conditions mutating the sumoylation sites of PARP-1 prevented its proteasome-
mediated degradation (Figure 5.12). In the presence of MG132, sumoylated and 
ubiquitylated species also accumulated so heavily on both the physiologically 
sumoylated PARP-1 and the PARP-1-SUMO2 constructs that they were apparently 
depleted (Figure 5.10). On the one hand, these observations indicate that sumoylation 
is indeed likely to target PARP-1 for ubiquitylation and subsequent proteasome-
mediated degradation. On the other hand, they further corroborate the physiological 
relevance of the polymeric SUMO chains that form on the PARP-1-SUMO constructs.  
If these SUMO chains truly mimicked the degradative functions of those polymerized 
on the wild type PARP-1, then the PARP-1-SUMO constructs should have been turned 
over as well as the wild type protein, if not better. Instead, I found that PARP-1-
SUMO2, which carries the K203/486R mutations, was as stable as the unmodified 
PARP-1 K203/486R mutant and consequently more so than the wild type protein 
(Figure 5.12). How can these apparently contradictory findings be reconciled? It is 
possible that PARP-1-SUMO2 could actually be degraded better than the K203/486R 
mutant, but maybe not quickly and/or efficiently enough to be detected during the 
relatively short cycloheximide-chase assay I performed. In this respect, it is worthwhile 
to mention that when the C- and N-terminal SUMO fusion constructs of PARP1 were 
transiently produced in mammalian cells, the former was always produced at higher 
levels than the latter (data not shown). In the future, it will be interesting to examine 
whether this phenomenon occurred simply because appending SUMO to the N-
terminus of PARP-1 had an intrinsic destabilizing effect on the polymerase or because 
such a construct was in fact a better mimic of the sumoylated PARP-1 than PARP-1-
SUMO2, and it was therefore degraded more quickly.  
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5.3.3.3.3 Do the SUMO chains conjugated to PARP-SUMO have different 
functions than those polymerized on the wild type polymerase? 
The above-discussed considerations suggest that the SUMO chains attached to the 
wild type PARP-1 may not carry out the same function as those conjugated to the 
PARP-1-SUMO constructs. Such a possibility is based on the conclusion that poly-
sumoylation targets PARP-1 for proteasome-mediated degradation, which could have 
actually been incorrectly drawn from the presented data. The increase in PARP-1’s 
half-life caused by mutating K203 and K486 (Figure 5.12) may have not been the 
result of abolishing its SUMO-dependent poly-ubiquitylation, but rather its direct poly-
ubiquitylation. PARP-1 is in fact poly-ubiquitylated at a site within its DBD (Wang et al., 
2008b), which includes K203, hence suggesting that the polymerase could be 
sumoylated and ubiquitylated at the same lysine. Thus, in order to convincingly 
demonstrate that SUMO affects the stability of PARP-1, it will be necessary to show 
that abolishing its sumoylation by mutating other residues than the lysine within the 
ΨKXE motifs in which K203 and K486 are found also stabilizes the polymerase. That 
said, there is evidence supporting the possibility that sumoylated PARP-1 is actually a 
target of ubiquitylation and degradation because it appears to be a substrate of the 
SUMO-targeted ubiquitin ligase RNF4 (Martin et al., 2009). Although interesting, this 
conclusion needs to be taken with caution because, except for a minor increase in the 
levels of sumoylated PARP-1 upon RNF4 depletion, it is backed up only by 
experiments that involved over-producing RNF4 in cells where PARP-1 was also 
hyper-sumoylated. Under such artificial conditions these two proteins may have been 
forced to interact, even though they would not normally do so, simply because RNF4 
can bind and ubiquitylate any poly-sumoylated protein (Tatham et al., 2008). Thus, in 
order to confirm that PARP-1 is indeed a target of RNF4, it will be important to 
demonstrate that the half-life of PARP-1 also increases in the absence of RNF4 and 
that this effect is epistatic with that caused by abolishing PARP-1 sumoylation.  
5.3.4 Cross-talk between PARP-1 sumoylation and other post-
translational modification events 
PARP-1 is not only sumoylated and ubiquitylated (Wang et al., 2008b), but it is also 
parylated, acetylated (Hassa et al., 2005) and phosphorylated (Kauppinen et al., 2006). 
It is therefore possible that the ability of the sumoylated PARP-1 to cross-talk with other 
modification events may not be limited to ubiquitin. As a matter of fact, Messner et al. 
(2009) have shown that sumoylating PARP-1 at K486 impairs its binding to the acetyl-
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transferase CBP/p300, thereby reducing its acetylation. Given that such a SUMO-
dependent inhibition of acetylation seems to be common amongst proteins that are 
targeted by both post-translational modifiers (Gregoire and Yang, 2005; Mohan et al., 
2007; Shalizi et al., 2006; Zhang et al., 2008), it is possible that sumoylation may act as 
a general inhibitor of acetylation. Conversely, as it has meanwhile been shown by 
others (Messner et al., 2009; Ryu et al., 2010), I found that sumoylation does not 
significantly alter the catalytic activity of PARP-1 (Figure 5.7). 
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Chapter 6. Results IV: DNA controls the sumoylation 
of PARP-1 in vitro 
6.1 Introduction 
The possibility that PARP-1 could be a target of sumoylation encouraged Sebastian 
Eustermann (MRC-LMB, Cambridge), who works on PARP-1’s DBD, and I to examine 
the relevance of a hypothetical sumoylation consensus motif found within such a 
domain, that is, 202VKSE205. We reasoned that if K203 were truly sumoylated in vivo, a 
hypothesis that has now been proven (Figure 5.3 and Martin et al., 2009), then its 
proximity to a domain critical for DNA binding resembled what had already been 
described for another target of SUMO, i.e. TDG (see 1.3.4). This enzyme is sumoylated 
near its DNA-binding/catalytic domain and, as a result, it undergoes a conformational 
change that reduces its affinity for, and hence allows it to disassociate from, the DNA. 
We were therefore curious to explore whether sumoylation may also impinge on the 
DNA-binding properties of PARP-1, especially in the context of its DBD. Since 
Sebastian Eustermann, and several other scientists, have developed many tools and 
assays to analyze this aspect of PARP-1’s biology in vitro, we decided to address the 
above-described question in a test-tube. Using this type of experimental approach 
meant that I had to be able to generate a fair amount of sumoylated protein to use in 
downstream functional assays. In order to efficiently modify a protein in vitro almost 
always requires the presence of the relevant E3 enzyme in the reaction. At the start of 
this project, very little was known about PARP-1 sumoylation, let alone which SUMO 
ligase specifically enhanced it. I therefore tried to modify PARP-1’s DBD (aa 1-214, 
Figure 1.6) in vitro in the presence AOS1/UBA2 and UBC9 only, but, as expected, this 
reaction proved to be very inefficient (Figure 6.1A). While testing several conditions in 
the hope to improve the modification of PARP-1’s DBD, I observed that mixing a 
heavily digested plasmid with this domain enhanced its sumoylation (Figure 6.1A). 
This preliminary result was very interesting because it put forward the possibility that 
DNA may play a role in the modification of PARP-1.  
Following up on these observations, the aim of this part of my thesis was: 1) to 
characterize the roles of DNA in the sumoylation of PARP-1 with respect to which 
features of the DNA and PARP-1 itself underlain it, and 2) to explore whether the 
conjugation of SUMO to PARP-1’s DBD may bring about structural changes that could 
alter its ability to bind DNA. 
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6.2 Results 
6.2.1 Sumoylation of PARP-1’s DBD is enhanced in the presence of a 
plasmid, but not when it contains single-stranded breaks 
Having observed that in the presence of a digested plasmid the sumoylation of PARP-
1’s DBD was strongly enhanced (Figure 6.1A), I wanted to ensure that this 
phenomenon was specific for such a domain and it was not caused simply by a 
plasmid-induced increase in the overall rate of sumoylation. In the reactions presented 
here, the rate of sumoylation must depend on AOS1/UBA2 and UBC9, which also 
mediate the formation of SUMO1 polymers in vitro (Pichler et al., 2002; Tatham et al., 
2001; Yang et al., 2006a). It therefore follows that if a plasmid non-specifically boosted 
the rate of sumoylation then I should be able to detect it as an increase in the amount 
of SUMO1 chains, in addition to that of the sumoylated DBD in the reactions shown in 
Figure 6.1A. When these samples were analyzed by western blotting against SUMO1 
(Figure 6.1A, right panel), I found that in the presence of a plasmid the formation of 
SUMO1 chains was certainly not enhanced, instead it was somewhat reduced, 
probably because of the increased attachment of the modifier to PARP-1’s DBD. 
Similarly, in reactions that contained only AOS1/UBA2, UBC9 and SUMO1, but no 
PARP-1’s DBD, a plasmid did not stimulate the formation of SUMO1 chains (Figure 
6.1B).  
An intact supercoiled plasmid does not activate PARP-1’s catalytic activity in vitro; 
conversely, those that contain either blunt breaks or free DNA ends bearing 3’ or 5’ 
single-stranded overhangs can do so, yet with different efficiencies (Benjamin and Gill, 
1980). Since the plasmid I used to stimulate the sumoylation of PARP-1’s DBD in 
Figure 6.1A harboured a heterogeneous mixture of DSBs, I was curious to explore 
whether this phenomenon may have been triggered by DNA interruptions and, if so, by 
what kind. To address this question, I digested a supercoiled plasmid with restriction 
endonucleases that produced the three types of DSBs described above. Each enzyme 
cut the plasmid twice, hence generating four free ends per plasmid molecule (Figure 
6.1C). Since PARP-1 also binds to nicks or gaps in a DNA duplex, I treated the plasmid 
with a nicking endonuclease that was expected to inflict five SSBs per molecule 
(Figure 6.1C). Subsequently, I assessed how well these preparations of damaged 
DNAs, alongside that of the intact supercoiled plasmid as a control, stimulated the 
sumoylation of PARP-1’s DBD. Figure 6.1D shows that the plasmids bearing DSBs 
enhanced the sumoylation of PARP-1’s DBD as well as the intact template. 
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Figure 6.1 - PARP-1’s DBD is strongly sumoylated in the presence of a plasmid, but not 
when it carries nicks. A), E) and F) PARP-1’s DBD (3 pmol) was subjected to in vitro 
sumoylation reactions under standard conditions (see 2.17.1) in the absence or presence of the 
relevant plasmid (240 ng), and then analyzed by western blotting against PARP-1 or SUMO1. 
B) Sumoylation reactions containing SUMO E1/E2, His6-SUMO1 and ATP were carried under 
standard conditions in the presence or absence of intact plasmid (240 ng), and then analyzed 
by western blotting against SUMO1. C) The plasmids used in D) and E) were enzymatically 
treated as described in 2.19.1, resolved by agarose gel electrophoresis (2.11.2) and then 
stained with SYBR Safe (2.12.7). Unless otherwise stated, the same plasmid backbone was 
used for all the relevant reactions shown in this chapter, pHU2020 (Table 2.7). Digested plasmid 
= various restriction endonucleases, Nicked = Nb.BsrDI, 5’ digested = PstI, Blunt digested = 
EcoRV, 3’ digested = EcoRI, Relaxed = topoisomerase I. 
 
 
On the other hand, I observed that the nicked plasmid stimulated the modification of 
PARP-1’s DBD less than the intact supercoiled template. 
Nicking a supercoiled plasmid introduces breaks in its backbone but it also relieves the 
torsional strain that it is under. The binding of PARP-1 to a plasmid is affected by its 
superhelical state: the enzyme interacts with a supercoiled template better than a 
relaxed one, probably because it recognizes some secondary DNA structures, such as 
loops and cruciforms, which can be extruded from DNA molecules as a consequence 
of supercoiling (Gradwohl et al., 1987). Thus, the nicked plasmid might have been 
unable to enhance the sumoylation of PARP-1’s DBD as well as the supercoiled 
template either because it contained nicks or because it was relaxed. To distinguish 
between these two possibilities, I studied how well a plasmid that had been almost 
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completely relaxed with topoisomerase I (Figure 6.1C), and therefore should contain 
no SSBs, stimulated the modification of PARP-1’s DBD in comparison to the nicked 
and intact templates. Figure 6.1E shows that the supercoiled and relaxed plasmids 
enhanced the modification of PARP-1’s DBD equally well and considerably more than 
the nicked template. 
Altogether the results presented in this paragraph demonstrate that the sumoylation of 
PARP-1’s DBD is specifically stimulated by DNA in the form of an intact or digested 
plasmid, but not when it carries SSBs. 
6.2.2 The length of a plasmid, rather than its sequence or methylation 
state, may play a role in the sumoylation of PARP-1’s DBD at K203 
Having observed that DNA stimulated the modification of PARP-1’s DBD, it was 
important to study this phenomenon further with respect to where the sumoylation 
occurred within the domain and what properties of the plasmid triggered it.  
The data presented elsewhere in this thesis (Figure 5.3) and those reported by Martin 
et al. (2009) show that PARP-1 is sumoylated at K203 and K486 in vivo. Since K203 
falls within the DBD of PARP-1 and it is also part of a sumoylation consensus motif, it 
was the most likely site of modification in the reactions described above. In order to 
corroborate this hypothesis, I sumoylated PARP-1’s DBD in vitro in the presence of a 
plasmid and then purified the modified protein as shown in Figure 6.2A. This SUMO 
conjugate was trypsinized in solution and analyzed by the Protein Analysis and 
Proteomics team of the London Research Institute on a ThermoScientific LTQ Orbitrap 
XL/ETD mass spectrometer coupled to a Waters NanoACQUITY UPLC system (LC 
MS). From this analysis, only one triply charged ion peptide bearing a SUMO1-specific 
mass signature was identified, which corresponded to sumoylated K203 (Figure 6.2C). 
Figure 6.1D indicates that properties other than supercoiling must enable a plasmid to 
enhance the sumoylation of PARP-1’s DBD. I therefore analyzed how three additional 
features of a plasmid influenced this modification phenomenon. Firstly, I asked whether 
the sequence of the template mattered because PARP-1 is able to recognize DNA in a 
sequence-specific and/or sequence-selective manner (see 1.5.2.2). I compared how 
well three plasmids of similar sizes, but carrying little sequence identity, stimulated the 
sumoylation of PARP-1’s DBD. Figure 6.3A shows that this modification event was 
enhanced equally well by all three templates. Secondly, I realized that since the 
plasmids I used for the reactions shown above were isolated from a common E. coli 
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Figure 6.2 - PARP-1’s DBD is sumoylated at K203. A) Scheme for the purification of 
sumoylated PARP-1’s DBD.  B) PARP-1’s DBD (6.75 nmol) was sumoylated in vitro in a final 
volume of 45 mL in the presence of a supercoiled plasmid (330 µg) and then purified as shown 
in A) and described in 2.17.1.1. A sample of the purified SUMO conjugate was resolved by 
SDS-PAGE and visualized by SYPRO Ruby staining. C) The purified DBD-SUMO1 conjugate 
was trypsinized in solution and analyzed by mass spectrometry. The graph reports the 
identification of a triply charged ion with an average mass-to-charge ratio (m/z) of  1060.5. This 
value matches the molecular weight (Mr), based on the average isotopic masses of the 
occurring amino acids, of large branched peptide that would be generated by trypsinization 
(scissors) of SUMO1-modified K203 (3180.46/3 = 1060.15). 
 
 
strain, they must have been methylated at the N6 position of the adenine and C5 
position of the cytosine that are found within certain sequences (Marinus and Morris, 
1973). In mammals DNA is also modified at the C5 position of a cytosine, but only 
within a CpG (Siegfried and Cedar, 1997). PARP-1 can influence the patterns of DNA 
methylation in mammalian cells (Caiafa et al., 2009), but how it behaves towards 
methylated DNA has never been addressed. These considerations raised the 
possibility that the methylation state of DNA may control PARP-1 sumoylation. 
Accordingly, I evaluated the ability of methylated and non-methylated plasmids to 
A B
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Figure 6.3 - The sumoylation of PARP-1’s DBD is stimulated by a plasmid probably due to 
its size rather than because it carries certain sequences or it is methylated. PARP-1’s 
DBD (3 pmol) was sumoylated in vitro in the presence of: A) three different plasmids (240 ng of 
pHU2020, 4.8 kbp, pHU1338, 5.3 kbp, or pHU1916, 5.5 kbp), B) an E. coli, i.e. Dam and Dcm, 
methylated or a non-methylated version of pHU2020 (240 ng), or D) dsDNA molecules of 
increasing lengths generated by PCR using pHU1771 as a template and oHU1374 together with 
oHU1411 (994 bp, 53 ng), oHU1413 (1969 bp, 105 ng), oHU1415 (2940 bp, 157 ng), oHU1416 
(3896 bp, 208 ng) or oHU1375 (4300 bp, 229 ng). The products of these PCR amplifications 
were resolved by agarose gel electrophoresis, visualized with SYBER Green (2.12.7), extracted 
from the gel and then used in sumoylation reactions. The reaction products were analyzed by 
western blotting against PARP-1. 
 
 
stimulate the modification of PARP-1’s DBD. Figure 6.3B shows that this domain was 
sumoylated to a similar extent in the presence of either type of plasmid. Lastly, I 
analyzed whether the length of the DNA influenced the sumoylation of PARP-1’s DBD. 
In order to do so, I sumoylated the protein in the presence of progressively longer 
dsDNA fragments (Figure 6.3C). Since these DNA duplexes were linear and therefore 
bore free ends, which PARP-1’s DBD is able to recognize (Pion et al., 2003), I used the 
same number of molecules in each reaction to maintain the number of DSBs constant. 
Figure 6.3D shows that the sumoylation of PARP-1’s DBD was progressively 
enhanced as the size of the DNA incubated with it increased. 
 
 
A B
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Figure 6.4 - Sumoylation of PARP-1’s DBD is inhibited in the presence of nicked DNA. A) 
Structure of the nicked dumbbell. B) A sample of the nicked and ligated dumbbells (see 2.19.3) 
was resolved by denaturing PAGE (2.11.3) and visualized with ethidium bromide (2.12.7). C) 
PARP-1’s DBD (3 pmol) was sumoylated in vitro in the presence of a supercoiled plasmid (240 
ng) and increasing amounts (0.6, 1.5, 3 and 6 pmol) of the nicked dumbbell. The products of 
these reactions were analyzed by western blotting against PARP-1. 
 
 
These data indicate that PARP-1’s DBD is sumoylated at K203 in the presence of a 
plasmid, not because it contains certain sequences or is methylated but probably 
because it is a rather long piece of DNA. 
6.2.3 PARP-1’s DBD cannot be sumoylated in the presence of nicked 
DNA 
The finding that introducing nicks in a plasmid reduced its ability to stimulate the 
sumoylation of PARP-1’s DBD (Figure 6.1D) put forward the possibility that when this 
domain is bound to nicked DNA it cannot be sumoylated. To address this problem, I 
studied how the plasmid-stimulated modification of PARP-1’s DBD was affected by 
adding increasing amounts of SSBs to the reaction. The nicked DNA consisted of a 44 
nt long oligonucleotide that folds onto itself to form 18 bp of double-stranded DNA with 
a nick in the middle and a tight hairpin at either end so that no DSBs are exposed 
(“dumbbell”, Figure 6.4A). Ligating this molecule produces an “intact” piece of DNA 
(Figure 6.4B). Figure 6.4C shows that the sumoylation of PARP-1’s DBD was 
progressively inhibited by increasing amounts of the nicked dumbbell, hence indicating 
that nicked DNA specifically inhibits the modification of this domain of PARP-1. 
B 
A
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6.2.4 Sumoylation of PARP-1’s DBD relies upon its second zinc finger  
PARP-1 recognizes SSBs in the DNA mainly through its second zinc finger (Gradwohl 
et al., 1990; Ikejima et al., 1990). I was therefore curious to determine whether the 
inhibitory action of nicked DNA on the modification of PARP-1’s DBD  depended on the 
second zinc finger of the protein. To address this hypothesis, I initially examined how 
well a construct that consisted of only the second zinc finger of PARP-1, including 
K203, was sumoylated in the presence of a plasmid, nicked DNA or DNA duplexes of 
increasing lengths. Figure 6.5A, left panel, and Figure 6.5B show that the sumoylation 
of such a protein was also enhanced by a plasmid or DNA molecules of increasing 
lengths and inhibited by DNA carrying a SSB (Figure 6.5C). Introducing a point 
mutation (R122I) in the second zinc finger of PARP-1 that impairs its ability to bind 
DNA but preserves its natural fold (Sebastian Eustermann, personal communication) 
completely abolished its ability to be preferentially sumoylated in the presence of DNA 
(Figure 6.5A, right panel). Interestingly, the extent to which PARP-1’s second zinc 
finger was sumoylated under the conditions described in Figure 6.1 was similar to that 
observed for equivalent experiments where the “full” DBD was used instead (Figure 
6.5A).  
Figure 6.5 - The second zinc finger of PARP-1’s DBD is necessary and sufficient for DNA-
stimulated sumoylation. A) A wild type or mutant (R122I) construct of the second zinc finger of 
PARP-1 (aa 103-214, 3 pmol) was subjected to in vitro sumoylation in the presence of: A) a 
supercoiled plasmid (240 ng), B) dsDNA molecules of increasing sizes as described in Figure 
6.3D, or C) a supercoiled plasmid (240 ng) and two amounts of the nicked dumbbell (3 and 6 
pmol). The products of these reactions were analyzed by western blotting against PARP-1. 
A 
B C
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Altogether these observations show that the DNA-dependent sumoylation of PARP-1’s 
DBD is mainly mediated through its second zinc finger.  
6.2.5 Sumoylation does not significantly affect the structure of PARP-1’s 
DBD or its ability to recognize nicked DNA  
The evidence provided here that DNA affects the sumoylation of PARP-1’s DBD 
persuaded us to find out whether the reverse may be also happening: does the 
attachment of SUMO to this domain of PARP-1 change its structure and thereby alter 
its ability to recognize DNA? We decided to address this question by comparing the 
tertiary structure of the unmodified DBD to that of the sumoylated form. For this part of 
my research I collaborated with Sebastian Eustermann, who had extensive experience 
in studying the solution structure of PARP-1’s DBD by NMR. Towards this end, I 
modified and purified an 15N- and 13C-labelled version of the DBD with a non-labelled 
His6-SUMO1 using an analogous strategy to that I already described in the caption of 
Figure 6.2. Figure 6.6A shows a sample of PARP-1’s DBD before and after being 
sumoylated and purified. Sebastian Eustermann measured the chemical shifts 
produced by the backbone NH groups of the DBD conjugated to SUMO1 by 1H 15N 
heteronuclear single quantum coherence NMR and compared them to those of the 
unmodified domain. If the SUMO1 moiety that was attached to the DBD affected the 
overall structure of this domain by interacting non-covalently with some of its residues, 
then we expected the chemical shifts produced by these amino acids to differ between 
the unmodified and sumoylated proteins, because they would be in different local 
magnetic field environments. For this experiment, the SUMO1 conjugated to PARP-1’s 
DBD was not labelled to avoid the appearance of SUMO1-specific chemical shifts in 
the NMR spectrum, which would have significantly complicated its analysis.  
Figure 6.6B shows the changes in the chemical shift for each amino acid within PARP-
1’s DBD between its unmodified and sumoylated forms. We observed the highest 
degree of chemical shift perturbations around K203, which was expected given that 
SUMO is conjugated to such residue. Besides this obvious difference, sumoylation 
caused only small changes in the chemical shifts of only a few other residues of PARP-
1’s DBD, suggesting that SUMO1 does not significantly contact any residues in PARP-
1’s DBD nor changes its structure. As a matter of fact, the data favour a “bead on a 
string” model where PARP-1’s DBD and SUMO1 move more or less freely with respect 
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Figure 6.6 - The structure of PARP-1’s DBD or its ability to recognize nicked DNA. A) 
A15N- and 13C-labelled version of PARP-1’s DBD (200 nmol) was sumoylated in vitro under 
standard conditions in the presence of a supercoiled plasmid (10 mg) in a total volume of 1.4 
L. After 6 h the sumoylated DBD was purified essentially as described in Figure 6.2A and Figure 
6.2B. Approximately  1 µg of unmodified and sumoylated PARP-1’s DBD were resolved by 
SDS-PAGE and stained with Coomassie. Although the two proteins samples were resolved on 
the same gel, they are shown separately for presentation purposes only. B) The SUMO1-DBD 
conjugate obtained in A) was subjected to 1H 15N heteronuclear single quantum coherence 
NMR to measure the chemical shifts produced by the backbone amide groups of its DBD 
moiety. These chemical shifts were compared against those yielded by the unmodified PARP-
1’s DBD to determine the extent of chemical shift perturbation (Y axis) that sumoylating such a 
domain induced at each one of its amino acids (X axis), as described in 2.22. 
 
 
to each other. Yet, we noticed some small differences in the chemical shifts around 
L110, which indicates that SUMO1 may have some preference in the way it positions 
itself with respect to the second zinc finger of PARP-1. To corroborate these structural 
data, Sebastian Eustermann assayed the affinity of the unmodified and sumoylated 
DBDs for the nicked dumbbell (Figure 6.3A) by electrophoretic mobility shift analysis. 
The DBD of PARP-1 and the nicked dumbbell were mixed together at various molar 
ratios, incubated and loaded onto an poly-acrylamide gel. After electrophoresis, the 
DNA was visualized with ethidium bromide. Sebastian Eustermann observed that the 
unmodified and sumoylated DBDs associated with the nicked dumbbell at similar 
protein:DNA molar ratios (personal communication).  
These data indicate that the conjugation of SUMO1 to K203 of PARP-1’s DBD does not 
significantly affect its structure or ability to recognize nicked DNA. 
A B 
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6.2.6 DNA enhances the sumoylation of the full-length PARP-1 at K203 
and K486 
The finding that DNA stimulated the sumoylation of K203 within PARP-1’s DBD raised 
the question of whether this phenomenon was specific for such a domain or a similar 
effect also occurred at sites located elsewhere in PARP-1. This is a relevant issue 
because, in the presence of DNA damage, the DBD of PARP-1 is able to interact with 
and activate its catalytic domain even when these two regions are physically separated 
from each other (Altmeyer et al., 2009). These results therefore suggest that DNA may 
bring about changes in PARP-1 that go beyond its DBD. The identification of a second 
sumoylation site in PARP-1 provided a means to address the above-mentioned 
problem because it is located in its auto-modification domain (485VKAE488, Figure 5.3, 
Martin et al., 2009; Messner et al., 2009) and it falls within a sumoylation consensus 
motif, which meant that it should be recognized by UBC9 alone in vitro. Purified full-
length wild type His6-PARP-1 was sumoylated in the absence or presence of a 
supercoiled plasmid and analyzed by western blotting analysis. Figure 6.7A shows that 
His6-PARP-1 was completely converted into multiple slow-migrating forms in the 
presence of DNA, which must represent SUMO1-modified species because they are 
recognized by an anti-SUMO1 antibody. This effect was independent of supercoiling 
because the polymerase was modified equally well by non-saturating amounts of 
relaxed and supercoiled plasmids (Figure 6.7B). In contrast, in the absence of DNA I 
barely detected any sumoylation of the polymerase. Although I cannot exclude that a 
few of the PARP-1-SUMO1 species shown in Figure 6.7A represented SUMO chains 
conjugated to K203, their number and electrophoretic mobilities strongly suggested that 
DNA enhanced the modification of the full-length PARP-1 at more than one lysine 
residue. To test this hypothesis, I created mutants of the full-length His6-PARP-1 where 
its two known sites of sumoylation, i.e. K203 and K486, were individually changed to 
arginines and then I sumoylated them in the absence or presence of a plasmid. Figure 
6.7C confirms that His6-PARP-1 was sumoylated at the relevant sites in the in vitro 
reactions described here and it shows that DNA stimulated not only the modification of 
K203 but also that of K486. Surprisingly, a K203/486R mutant of His6-PARP-1 was also 
efficiently sumoylated in the presence of DNA (Figure 6.7C), which means that in vitro 
a third lysine of PARP-1 can be sumoylated. Since the data reported elsewhere in this 
thesis (Figure 5.3) and by Martin et al. (2009) indicate that in vivo there may be a third 
sumoylation site in PARP-1, I sumoylated His6-PARP-1 in vitro in the presence
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Figure 6.7 - PARP-1 is sumoylated at K203 and K486 in the presence of DNA. A) His6-
PARP-1 (3 pmol) was sumoylated in vitro in the presence of A) a supercoiled plasmid (240 ng) 
or B) a supercoiled or a relaxed plasmid (20 ng). C) Wild type, K203R, K486R, or K203/486R 
His6-PARP-1 (3 pmol) were sumoylated in vitro in the presence of a supercoiled plasmid (240 
ng). D) His6-PARP-1 (3 pmol) was subjected to in vitro sumoylation in the presence of a 
supercoiled plasmid (240 ng) and equivalent amounts of either wild type SUMO1 or SUMO1 
T95R. The reaction products were analyzed by western blotting against PARP-1. E) His6-PARP-
1 (200 pmol) was modified in a 1.3 mL sumoylation reaction supplemented with an untagged 
version of the SUMO1 E1 enzyme, SUMO1 T95R and a supercoiled plasmid (15.6 µg) and 
purified as described in 2.17.1.2. The isolated protein was dialyzed against 100 mM ammonium 
acetate before being vacuum concentrated to approximately 50 µL, trypsinized in solution and 
then analyzed by mass spectrometry. The graph shows the mass-to-charge ratio (m/z) 
distribution of the b- (red and green) and y-series (blue) ions generated by fragmenting a 
precursor peptide that included K512 of PARP-1 and showed a 114 Da mass signature, which 
corresponds to the addition of GG “tag” to the peptide. 
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of a plasmid and SUMO-1 T95R. This mutant of SUMO-1 facilitates the identification of 
sumoylated residues by mass spectrometry because, after trypsinization, the peptides 
conjugated to it would bear a smaller and more easily detectable mass addition (a GG 
“tag”) than those attached to the wild type modifier (Knuesel et al., 2005). Sumoylated 
His6-PARP-1 was captured by metal affinity chromatography, as described in more 
detail in the caption of Figure 6.7E, and analyzed by the Protein Analysis and 
Proteomics team of the London Research Institute on a ThermoScientific LTQ Orbitrap 
XL/ETD mass spectrometer coupled to a Waters NanoACQUITY UPLC system (LC 
MS/MS). Sumoylating His6-PARP-1 in the presence of wild type SUMO1 or the T95R 
mutant resulted in essentially identical modification patterns (Figure 6.7D), indicating 
that this mutation in SUMO1 does not appreciably distort the in vitro modification of the 
polymerase. Mass spectrometric analysis of the sumoylated His6-PARP-1 identified 
and sequenced two unique peptides that bore a di-glycine mass signature, which 
corresponded to sumoylated K486 and K512 (Figure 6.7E). These data therefore 
suggest that when K203 and K486 are mutated in PARP-1, the sumoylation machinery 
may preferentially target K512 in vitro. Since K512 does not appear to be a relevant 
modification site of PARP-1 in vivo (Figure 5.3), I decided not to confirm this result by 
mutagenesis because K512 was probably modified in vitro by virtue of the fact that it 
falls within a sumoylation consensus motif (511VKEE514). 
Altogether these findings show that the ability of DNA to stimulate the sumoylation of 
PARP-1 is not limited to the modification of its DBD but it also happens at sites located 
elsewhere in the polymerase, and even on sites that may not be physiologically 
relevant.  
6.2.7 A minimal DNA substrate stimulates the sumoylation of the full-
length PARP-1 through the second zinc finger 
Having observed that a plasmid stimulated the sumoylation of the full-length PARP-1, I 
wondered whether the second zinc finger of this protein and nicked DNA also played a 
role in such a modification event, as I showed for the DBD alone. For the experiments 
described in this paragraph I used the intact dumbbell to enhance the sumoylation of 
PARP-1 because, unlike the DBD alone, this minimal DNA substrate was sufficiently 
long to trigger the modification of the full-length polymerase and it did not bear free 
ends (Figure 6.8A). In order to address the above-described question, I tested how the 
nicked and intact dumbbells affected the sumoylation of wild type His6-PARP-1 or that 
of a mutant carrying a defective second zinc finger (R122/138I). Figure 6.8A, top
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Figure 6.8 - Sumoylation of PARP-1 in the presence of a minimal DNA substrate depends 
on its second zinc finger. A) His6-PARP-1 (wild type or R122/138I, 3 pmol) were subjected to 
in vitro sumoylation in the presence of increasing amounts of the intact dumbbell (1.5, 3 or 6 
pmol) or the nicked one (6 pmol). B) His6-PARP-1 was sumoylated in vitro in the presence of 
the intact dumbbell (3 pmol) and increasing amounts of the nicked one (0.38, 0.75, 1.5, 3 or 6 
pmol). The reaction products were analyzed by western blotting against PARP-1. 
 
 
panel, shows that the intact dumbbell stimulated the sumoylation of the wild type His6-
PARP-1 in a dose-dependent manner. The nicked substrate did not afford such an 
effect; on the contrary, it counteracted the ability of the intact dumbbell to enhance 
PARP-1 sumoylation (Figure 6.8B). Mutating the second zinc finger of the polymerase 
completely abolished these DNA-dependent effects (Figure 6.8A, bottom panel). 
Altogether the results presented here show that a short intact DNA molecule stimulates 
the sumoylation of the full-length PARP-1 by means of its second zinc finger, but one 
that carries a SSB has instead the opposite effect. 
6.2.8 DNA length defines two types of PARP-1 sumoylation  
Although the data described in the previous paragraph show that nicked DNA can 
inhibit PARP-1 sumoylation, I found that this phenomenon did not happen when the 
modification of the polymerase was brought about by a plasmid (Figure 6.9A), instead 
of the intact dumbbell. This was the case even if I used an amount of plasmid that was 
equivalent, with respect to the number of nucleotides, to the quantity of intact dumbbell 
employed for the experiments shown in Figure 6.8A. Such an unusual observation 
made me think about the differences that exist between a plasmid and the intact 
dumbbell, which could explain it. The different lengths of these DNA molecules could 
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have been the determining factor. To explore this hypothesis, I compared the ability of 
the nicked dumbbell to inhibit the enhancement of PARP-1 sumoylation triggered by 
short or long dsDNA oligonucleotides. The shorter DNA molecule was 15 bp long, 
which is the smallest DNA substrate that can stimulate the sumoylation of PARP-1 
(Figure 6.9A and Figure 6.9F), while the longer one was 61 bp long. Figure 6.9B 
shows that the nicked dumbbell hindered the capacity of the 15 bp long 
oligonucleotide, but not that of the 61 bp long one, to stimulate the sumoylation of His6-
PARP-1. This difference could have stemmed from the different amounts of DNA 
present in the two sets of reactions, as both the 15 and 61 bp long oligonucleotides 
were used at a protein:DNA molar ratio of 1:1, but one is four times as long as the 
other. I therefore tested the inhibitory activity of the nicked dumbbell on PARP-1 
sumoylation in reactions supplemented with the 61 bp long oligonucleotide at a 
protein:DNA molar ratio of 1:0.25. Figure 6.9B shows that even under these conditions 
the nicked DNA did not significantly inhibit the modification of PARP-1. 
The ability of nicked DNA to inhibit PARP-1 sumoylation was not the only property of 
this modification event that was affected by length of the DNA used to stimulate it. I 
found that while the sumoylation of the wild type polymerase was enhanced by a 
dsDNA as short as 15 bp, that of the R122/138I mutant happened only in the presence 
of the 61 bp long oligonucleotide (Figure 6.9C). Titrating increasing amounts of either 
the 15 or 61 bp long oligonucleotide in sumoylation reactions containing the wild type 
His6-PARP-1 showed that, at equivalent molar amount, the longer DNA stimulated the 
sumoylation of this protein more efficiently than the shorter one (Figure 6.9D). 
Additionally, I found that the extent to which PARP-1 sumoylation grew with increasing 
amounts of the 61 bp long DNA did not change significantly between the wild type His6-
PARP-1 and the R122/138I mutant (Figure 6.9D). Likewise, these two versions of the 
polymerase were modified equally well and with similar kinetics in the presence of a 
non-saturating amount of a plasmid (Figure 6.9E).  
The possibility that the phenomena described above were simply the consequence of 
adding any double-stranded oligonucleotide to PARP-1 can be excluded because the 
sumoylation of the polymerase could not be stimulated by either 15-25 nt long single-
stranded DNA molecules (Figure 6.9F) or a 21 bp long dsRNA (Figure 6.9G). Figure 
6.9F did however show that a 61 nt long oligonucleotide could actually stimulate the 
modification of PARP-1, which probably occurred because this DNA substrate was long 
enough to form double-stranded DNA secondary structures. 
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Figure 6.9 - DNA length defines two types of PARP-1 sumoylation. His6-PARP-1 (3 pmol) 
was sumoylated in vitro in the presence of increasing amounts of the nicked dumbbell (0.38, 
0.75, 1.5, 3 or 6 pmol) and a constant amount of either A) a plasmid DNA (20 ng) or B) dsDNA 
oligonucleotides of different lengths (15 bp long dsDNA, 3 pmol; 61 bp long dsDNA, 3 or 0.75 
pmol). C) His6-PARP-1 (wild type or R122/138I, 3 pmol) was subjected to in vitro sumoylation in 
the presence of C) 8, 15, 25 and 61 bp long oligonucleotides (3 pmol), D) 0.38, 0.75, 1.5, 3 or 6 
pmol of either the 15 or the 61 bp long dsDNAs, or E) 20 ng of supercoiled plasmid for the 
indicated lengths of time. His6-PARP-1 (3 pmol) was sumoylated in vitro in the presence of F) 3 
pmol of the indicated double-stranded or single-stranded DNA oligonucleotides or G) 1 pmol of 
either the 25 bp long dsDNA or a 21 bp long dsRNA. 
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These data, together with those presented in the previous paragraph, demonstrate that 
the length of the DNA used to stimulate PARP-1 sumoylation determines how sensitive 
this modification event is to SSBs and inactivating the second zinc finger of the 
polymerase. These two factors can in fact inhibit the modification of the polymerase 
only when it is brought about by DNA substrates of a minimal length, but not longer 
ones. 
6.2.9 The third zinc finger is not important for the DNA-dependent 
sumoylation of PARP-1 
In addition to showing that the second zinc finger of PARP-1 is essential for triggering 
the sumoylation of this protein in the presence of short DNA molecules, the data 
presented above suggested that when the length of DNA is not limiting other features 
within the polymerase become relevant in stimulating its modification. Thus, I set out to 
explore whether the other two zinc fingers located within the N-terminal DNA-binding 
domain of PARP-1 also played a role in such a phenomenon. Even though I had 
already shown that deleting the first zinc finger from PARP-1’s DBD did not significantly 
affect its sumoylation (Figure 6.5), I decided to study the consequences of inactivating 
it in the full-length protein. In fact, in such a context the first zinc finger of PARP-1 could 
have possibly played a role in stimulating its sumoylation by, for instance, interacting 
with regions located outside the DBD. Additionally, I was curious to establish whether 
the third zinc finger of PARP-1 played a role in its modification because although it 
does not seem to bind DNA on its own (Tao et al., 2008), it has been shown that 
features C-terminal to the first two zinc fingers of PARP-1 are important for binding to 
intact DNA (Ikejima et al., 1990). In order to address the question described above, I 
created His6-PARP-1 mutants where either the first (C21G) or the third (C298A) zinc 
finger was inactivated. Unfortunately, although I was able to purify the His6-PARP-1 
C21G mutant through several chromatographic steps, it eluted from a gel filtration 
column in the void volume (data not shown), which suggested that it was heavily 
aggregated and it was therefore unusable. The His6-PARP-1 C298A mutant also had a 
slight tendency to aggregate; yet, I recovered a significant amount of it that had the 
same elution profile as that of the wild type His6-PARP-1 over gel filtration (data not 
shown). These observations are consistent with Langelier et al. (2008), who on such 
basis proposed that the C298A mutation destabilizes the structure of PARP-1 only 
locally. Since the His6-PARP-1 C298A mutant appeared to be well behaved, I 
examined how efficiently it was sumoylated in the presence of a plasmid, the intact
Chapter 6. Results IV 
232 
Figure 6.10 - The third zinc finger does not play a significant role in the DNA-dependent 
sumoylation of PARP-1. All the reactions shown in this figure were carried out under the same 
experimental conditions as the equivalent ones shown in Figures 6.7 and Figure 6.8, but in this 
case using His6-PARP-1 C298A instead. The reaction products were analyzed by western 
blotting against PARP-1. 
 
 
dumbbell or oligonucleotides of different lengths. In addition, I also studied the extent to 
which the nicked DNA inhibited the enhancement of His6-PARP-1 C298A modification 
triggered by the intact dumbbell, the 15 and 61 bp long dsDNAs or the plasmid DNA. 
Figure 6.10A-E show that the His6-PARP-1 C298A mutant behaved similarly to the wild 
type protein (Figure 6.10 and Figure 6.9) with respect to the way it was sumoylated 
under the conditions tested here. In fact, the only difference between the two proteins 
was that the mutant seemed to be sumoylated somewhat more efficiently than the wild 
type protein.  
Altogether these data show that the third zinc finger of PARP-1 does not play a 
significant role in the DNA-dependent sumoylation of this protein, at least when it is 
individually mutated. 
B A C 
D E 
Chapter 6. Results IV 
233 
6.2.10 Small changes in salt concentration considerably affect plasmid-
stimulated PARP-1 sumoylation 
As I mentioned above, Ikejima et al. (1990) showed that the first two zinc fingers of 
PARP-1 and unknown features C-terminal to them are important for the binding of this 
protein to an intact supercoiled plasmid. This interaction was detected at a very low salt 
concentration, i.e. 2 mM magnesium acetate, and it was found to be fairly weak 
because it was significantly, but not completely, reduced in the presence of as little as 
100 mM KCl (Ikejima et al., 1990). Conversely, PARP-1, or at least its DBD 
encompassing all three zinc fingers, can bind to single- or double-stranded breaks at 
much higher salt concentrations (Lilyestrom et al., 2010). By taking into account these 
observations and the evidence provided here that intact DNA stimulates the 
sumoylation of PARP-1, I hypothesized that this modification phenomenon should be 
sensitive to small changes in the salt concentrations used for the sumoylation 
reactions. Thus, I set out to test how well a plasmid enhanced the modification of His6-
PARP-1 in the presence of increasing concentrations of different salts. The in vitro 
sumoylation reactions described in this part of my thesis were routinely carried out in a 
buffered solution containing 110 mM potassium acetate as a source of salt, which in 
terms of ionic strength corresponds to a 50-60 mM NaCl/KCl solution. I therefore chose 
to examine the extent of PARP-1 sumoylation in reaction mixtures containing 110, 180 
and 230 mM potassium acetate or 50, 100 and 150 mM NaCl/KCl because they have 
corresponding ionic strengths. Importantly, since the intrinsic activities of the SUMO 
activating and conjugating enzymes are only mildly affected across this range of salt 
concentrations (Figure 6.11, lower panel), it follows that any major changes in the 
plasmid-stimulated sumoylation of PARP-1 under these conditions should stem from 
alterations in the interaction between the polymerase and DNA or, perhaps less likely, 
between the polymerase and UBC9. Figure 6.11, upper panel, shows that, for all of the 
three salts used, the DNA-induced sumoylation of His6-PARP-1 was almost complete 
at the lowest concentrations, it was reduced to half of that amount at the intermediate 
ones and it was nearly abolished at the highest.  
These results suggest that the interaction between a plasmid and PARP-1 that must 
happen to trigger its sumoylation is weak and it is similar to the strength of binding that 
PARP-1 exhibits towards a supercoiled plasmid (Ikejima et al., 1990). 
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Figure 6.11 - The plasmid-triggered sumoylation of PARP-1 is inhibited by small changes 
in salt concentration. His6-PARP-1 (3 pmol) was sumoylated in vitro in the presence of a 
supercoiled plasmid (240 ng) and a reaction solution in which the type and concentration of salt 
it normally contained, i.e. 110 mM potassium acetate, were varied as indicated in the figure 
itself. The solutions supplemented with potassium acetate also contained 2 mM magnesium 
acetate, while those prepared with NaCl or KCl also included 2 mM MgCl2. The reaction 
products were analyzed by western blotting against PARP-1. 
 
6.2.11 DNA packaged into chromatin can stimulate PARP-1 sumoylation 
For many of the reactions shown in this part of my thesis I used a recombinant plasmid, 
or some other form of naked DNA, to stimulate the sumoylation of PARP-1. However, 
this protein may never see DNA in this form in a eukaryotic cell because there DNA is 
packaged into chromatin. In addition, PARP-1 itself has a role in chromatin compaction 
both in vivo and in vitro (Kraus, 2008). Thus, I wondered whether PARP-1 sumoylation 
also occurred in the context of chromatin. To address this question I examined how 
well PARP-1’s DBD and the full-length protein were sumoylated in the presence of a 
chromatin mimic. This mimic consisted of a freshly reconstituted nucleosomal array 
that contained 60 nucleosomes evenly spaced along an 11 kbp DNA molecule (a gift 
from Daniela Rhodes). It consisted of a tandemly repeated high affinity histone octamer 
binding sequence that was 187 bp long (Lowary and Widom, 1998). 
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Figure 6.12 - Chromatin-packaged DNA can stimulate the sumoylation of PARP-1. Full-
length His6-PARP-1 or PARP-1’s DBD (3 pmol) were subjected to in vitro sumoylation reactions 
in the absence of any DNA or in the presence of 240 ng of intact plasmid or 240 ng of an 11 
kbp DNA molecule consisting of sixty tandemly repeated high affinity histone octamer binding 
sequences. The latter DNA substrate was used either naked or in a complex with histones. The 
products of these reactions were analyzed by western blotting against PARP-1. 
 
 
Figure 6.12 shows that the nucleosome array was able to stimulate the sumoylation of 
the full-length His6-PARP-1, perhaps to a slightly lesser extent than the naked 11 kbp 
DNA, which was used as a control. Conversely, neither the chromatin mimic nor the 
control substrate enhanced the sumoylation of PARP-1’s DBD. 
These results strongly suggest that even when DNA is packaged in the form of 
chromatin it can stimulate the sumoylation of the full-length PARP-1. 
6.3 Discussion 
The main finding of this part of my research is that in vitro DNA regulates the 
sumoylation of PARP-1 in at least two different ways, which will be discussed below. 
6.3.1 Intact DNA stimulates PARP-1 sumoylation 
Classic B-form DNA appeared to stimulate PARP-1 modification, regardless of its 
sequence. In fact, in the presence of a supercoiled intact plasmid the modification of 
both the full-length PARP-1 and its DBD alone were specifically enhanced (Figure 6.1 
and Figure 6.7). Relaxing the plasmid did not affect this stimulatory phenomenon, thus 
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indicating that it cannot have been triggered by unusual supercoiling-induced DNA 
structures such as hairpins, cruciforms, bent DNA and base unpaired regions, to which 
PARP-1 can specifically bind (Jorgensen et al., 2009; Lonskaya et al., 2005; Potaman 
et al., 2005; Sastry and Kun, 1990; Soldatenkov et al., 2008). The latter observation 
also argues against the possibility that the plasmid-induced sumoylation of PARP-1 
may have stemmed from its ability to recognize non-covalent DNA crossovers 
(Chasovskikh et al., 2005). Although PARP-1 apparently does so on both supercoiled 
and relaxed plasmids (Chasovskikh et al., 2005), the former should contain more of 
these structures, as it carries supercoiling nodes, than the latter, where such structures 
probably occur only stochastically. In addition, these considerations also suggest that 
the ability of the intact dumbbell to enhance the sumoylation of the full-length PARP-1 
was not mediated through the hairpins that this DNA substrate carried but rather by the 
intact stretch of DNA found between them. In order to undoubtedly prove this point it 
will be useful to show that another type of short intact DNA molecule, such as a double-
stranded oligonucleotide whose free ends have been occluded with streptavidin, 
stimulates the modification of like the intact dumbbell does.  
6.3.1.1 Can PARP-1 bind intact DNA? 
The above-discussed observations provide strong evidence that intact DNA stimulates 
PARP-1 sumoylation. Yet, they do not prove that it does so by productively binding to 
the polymerase. This is an issue that I did not directly examine but which could be 
addressed to undoubtedly confirm the validity of such a stimulatory phenomenon, 
especially in the light that it is still unclear whether PARP-1 can recognize, at least in a 
physiologically relevant manner, intact B-form DNA (see 1.5.2.2). The data reported by 
Ikejima et al. (1990) indicate that the apparent binding of PARP-1 to unbroken DNA 
was actually the major interaction they detected in their assays. Deleting the first two 
zinc fingers of PARP-1 did not affect this generalized affinity for intact DNA, except for 
making it weaker. Consistent with these data suggesting that PARP-1 binds intact DNA 
weakly, I found that the ability of a plasmid to stimulate PARP-1 sumoylation was 
significantly affected by small changes in salt concentration (Figure 6.11). 
If PARP-1 cannot normally bind intact DNA, how/why would it stimulate the 
sumoylation of this protein? In the reactions presented above PARP-1 was sumoylated 
under relatively low ionic conditions (110 mM KOAc ~ 50 mM NaCl), which could 
however be defined as “standard” given that they have been commonly used 
elsewhere for this type of assay (Werner et al., 2009). There is therefore the chance 
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that at this low salt concentration, PARP-1’s recognized affinity for broken or unusual 
forms of DNA may have been enhanced enough to allow it to associate with intact DNA 
as well, probably in an abnormal manner. Such a non-physiological type of DNA 
binding might have destabilized the polymerase, causing it to amass into large 
complexes, which could be better substrates for sumoylation. In fact, a similar 
mechanism has been shown to underlie the increased sumoylation that PML 
experiences in response to arsenic trioxide (Zhang et al., 2010). This drug can directly 
bind PML, causing it to forms oligomers that are recognized by UBC9 better than the 
monomeric PML (Zhang et al., 2010). The apparent susceptibility of a fragment of 
PARP-1, spanning from its N-terminus to the BRCT domain, to form high molecular 
weight complexes in the presence of DNA under particular, sub-optimal, conditions 
would argue in favour of this model (Lilyestrom et al., 2010).  
6.3.2 Single-stranded breaks inhibit PARP-1 sumoylation 
Unlike intact DNA, SSBs inhibited the sumoylation of both the full-length PARP-1 and 
its DBD alone in vitro (Figure 6.3 and Figure 6.8). Such a phenomenon is more easily 
explainable than the one described above because it is well established that PARP-1 
recognizes and is activated by this type of DNA breaks (D'Silva et al., 1999; Gradwohl 
et al., 1990; Ikejima et al., 1990; Pion et al., 2005). Yet, PARP-1 sumoylation was not 
appreciably inhibited in vivo by exposing cells to drugs, such as MMS or H2O2, which 
introduce SSBs in their DNA (Figure 5.2). It is unlikely that this incongruence may have 
arisen from an insufficient number of SSBs in the cells because the employed amounts 
of, and length of exposure to, the relevant drugs should have produced enough lesions 
to outnumber the quantity of PARP-1 molecules found in a nucleus. An alternative 
scenario to explain the incongruence described above could be envisioned on the 
basis of the proposed model that PARP-1 binds to damaged DNA very dynamically, 
through rapid cycles of biding to DNA lesions, auto-parylation, disassociation from the 
DNA, de-parylation and re-binding to the damaged DNA (Haince et al., 2008; 
Woodhouse and Dianov, 2008). This model therefore suggests that in vivo the binding 
of PARP-1 to DNA nicks may be too transient to produce a visible drop in its 
sumoylation levels. Consistent with this idea, both Rajvee Shah and I found that even 
PARP-1 auto-parylation, an event that is directly coupled to the polymerase 
recognizing damaged DNA, could not be easily detected and, even when it was, it was 
very transitory.  
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6.3.2.1 Stoichiometric vs. non-stoichiometric effects of nicked DNA 
on PARP-1 sumoylation 
Although it is evident that SSBs negatively affect the in vitro sumoylation of PARP-1, 
two observations presented here suggest that the mechanisms underlying this 
phenomenon may not be as simple as a nick-induced change in the conformation of 
the polymerase.  
Firstly, it still remains unclear why the nicks carried within the dumbbell substrate 
inhibited the plasmid-induced sumoylation of PARP-1’s DBD at roughly stoichiometric 
ratios (Figure 6.4), while those present in the plasmid DNA afforded a higher inhibitory 
effect than expected, that is, about 50% even though the ratio of SSBs to DBD 
molecules present in the reaction was only 1:6. Since the full-length PARP-1 can 
impart considerable changes on the structure of DNA (Chasovskikh et al., 2005), it is 
possible that when its DBD binds to SSBs within a plasmid it could alter the properties 
of the intact DNA flanking them enough to make it unable to stimulate sumoylation. In 
this way, a nick would inhibit the sumoylation of PARP-1’s DBD not only by directly 
binding to it but also by prevent it from interacting with the intact DNA surrounding such 
SSBs. Alternatively, this phenomenon could be explained by assuming that PARP-1’s 
DBD binds long intact DNA cooperatively (see 6.3.5.1) and that introducing nicks in it 
disrupts this mode of binding locally to the site of lesion. This situation could occur if 
PARP-1’s DBD adopted different conformations when bound to different types of DNA, 
which in fact seems to be the case (Lilyestrom et al., 2010). Conversely, the nicked 
dumbbell might have inhibited the sumoylation of PARP-1’s DBD in a stoichiometric 
manner because these two molecules can form a 1:1 complex (Sebastian Eustermann, 
personal communication), which, in addition to being refractory to sumoylation, would 
also be distinct and independent from the plasmid and its ability to stimulate the 
modification of PARP-1’s DBD.  
Secondly, I observed that the nicked dumbbell could hinder the sumoylation of the full-
length PARP-1 only when short DNA molecules were used to stimulate this 
modification event in the first place. As a matter of fact, it seems that DNA size can 
affect various other aspects of the in vitro sumoylation of PARP-1, which will be 
discussed in more detail below (see 6.3.5).  
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6.3.3 A role for the second zinc finger of PARP-1 in its sumoylation 
The evidence that SSBs can inhibit PARP-1 sumoylation in vitro suggested that this 
phenomenon relied upon its second zinc finger motif because it directly recognizes this 
type of DNA lesion (Gradwohl et al., 1990). Unfortunately I could not directly prove this 
hypothesis because mutating such a domain completely abrogated the ability of the 
intact dumbbell or a plasmid to stimulate the sumoylation of the full-length protein or its 
DBD alone, respectively (Figure 6.4 and Figure 6.8). These stimulatory events had in 
fact to occur in the first place in order to detect the inhibitory effect that SSBs exert on 
PARP-1 sumoylation. That said, I believe that nicked DNA does indeed inhibit the 
modification of PARP-1 through its second zinc finger because such a type of DNA 
lesion hindered the plasmid-induced modification of a fragment of the polymerase 
encompassing just this domain (Figure 6.4). For lack of evidence proving otherwise, I 
cannot however categorically exclude that other domains of PARP-1 may also be 
involved in this process (see 6.3.4).  
The fact that mutating the second zinc finger of PARP-1 abolished its ability to become 
sumoylated in the presence of intact DNA indicated that this finger motif must also be 
involved in recognizing intact DNA. This observation was interesting because such a 
domain had been generally viewed as a nick sensor. Yet, it was not completely 
unexpected provided that in at least one other instance, i.e. Ligase III, a PARP-type 
zinc finger that was thought to specifically bind nicked DNA was also found to bind 
intact DNA, albeit at relatively low salt concentrations (Cotner-Gohara et al., 2008). 
Consistent with the idea that the second zinc finger of PARP-1 may also bind intact 
DNA, Ikejima et al. (1990) showed that deleting the DBD from this protein led to a 
significant weakening of the pervasive binding to intact DNA that the full-length 
polymerase demonstrated in their assays.  
6.3.4 A role for other domains of PARP-1 in its sumoylation 
Interestingly, except for its inability to be sumoylated in the presence of the intact 
dumbbell, or other short DNA molecules (Figure 6.8 and Figure 6.9), the finger II 
mutant of the full-length PARP-1’s behaved identically to the wild type protein in all of 
the presented assays. Instead, mutating such a domain in PARP-1’s DBD completely 
abolished its plasmid-induced sumoylation (Figure 6.5). It therefore seems likely that in 
addition to the second zinc finger other motifs within the full-length PARP-1 must be 
involved in stimulating the sumoylation of this protein in the presence of DNA.  
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The fact that the roles of such unknown determinants in the modification of PARP-1 is 
detectable only on long DNA molecules suggests that only these DNA substrates 
provide enough surface for binding to such structures, probably together with the finger 
II motif. If this scenario were true, it would explain why the second zinc finger of PARP-
1 played a role in its sumoylation only in the presence of very short DNA substrates. 
Since the enhancement of PARP-1 sumoylation afforded by the finger II domain of the 
polymerase appeared to be much less pronounced than that mediated through the 
unknown determinants, it is possible that the former event could have become 
detectable only when the latter was prevented. This situation could have happened if, 
for instance, the finger II motif of PARP-1, but not the other unknown determinants, 
were able to recognize the very short DNA substrates used to stimulate the 
modification of the polymerase. Such a hypothesis would predict that the second zinc 
finger of PARP-1 should be able to bind relatively short DNA substrates, like the 
dumbbell (18 bp), on its own without leaving too much unexposed DNA. In fact, it has 
been shown that, at least on nicked DNA, PARP-1 protects 7 bp pairs of DNA on both 
sides of a SSB, apparently through its second zinc finger (Gradwohl et al., 1990; Le 
Cam et al., 1994).  
Although it is clear that the second zinc finger of PARP-1 plays a role in the DNA-
dependent sumoylation of the polymerase, the identity of the other domains that are 
likely to be involved in such a modification event remains an open question. I will, 
however, propose two possibilities.  
6.3.4.1 The first and third zinc fingers of PARP-1 
The first scenario envisions that the first and third zinc fingers of PARP-1 could be the 
answer to the question mentioned above. I partly addressed this issue by examining 
the consequence of individually mutating these motifs on PARP-1 sumoylation.  
As far as the first zinc finger was concerned, my attempt to inactive it by mutating one 
of its zinc-coordinating residues (C21) led to the heavy aggregation of the resulting 
mutant protein (data not shown), thus rendering it unusable. Although this finding was 
rather disappointing, it is an important one because it questions the validity of those 
functions that have been ascribed to the first zinc finger of PARP-1 by means of 
mutating its C21 residue (Hassa et al., 2005; Mortusewicz et al., 2007; Trucco et al., 
1996; Wacker et al., 2007). The authors of these studies assumed that such a mutation 
specifically inactivated the first zinc finger of PARP-1, without affecting the overall 
integrity of the protein, which I have shown it is not the case. Despite these practical 
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limitations, the evidence that the DNA-stimulated sumoylation of PARP-1’s DBD (finger 
I + finger II) was not significantly affected by deleting its finger I domain indicates that 
such a motif is not likely to be involved in this modification event (compare Figure 6.3 
with Figure 6.5).  
The third zinc finger of PARP-1 is unique in comparison to its finger I and II motifs 
because it does not seem to bind DNA, at least on its own (Tao et al., 2008), but 
instead it appears to relay the conformational changes that the DBD undergoes when it 
binds DNA to the catalytic domain, thereby activating it (Altmeyer et al., 2009; Langelier 
et al., 2010; Langelier et al., 2008; Tao et al., 2008). On the one side, this information 
argues against the possibility that the finger III motif of PARP-1 would be involved in 
stimulating its sumoylation, at least by directly recognizing DNA. On the other hand, it 
suggests that such a domain could have mediated the enhancement of modification 
that PARP-1 experiences in the presence of DNA at K486, which is located far away 
from the DBD. This scenario would be consistent with the evidence that some of the 
pervasive binding to intact DNA that PARP-1 exhibits in the assays reported by Ikejima 
et al. (1990) depends on features C-terminal to its first two finger domains. I however 
found that the sumoylation patterns of a PARP-1 mutant carrying an inactive finger III 
domain were essentially undistinguishable from those of the wild type protein (Figure 
6.10), thus indicating that such a motif does not play a major role in this modification 
event.  
The observations discussed above provide compelling evidence that neither the first 
nor the third zinc finger of PARP-1 play a major role in the DNA-stimulated sumoylation 
that this protein undergoes in vitro. This conclusion could be, however, somewhat 
flawed because it was reached by studying the consequences of inactivating such 
motifs individually. It has been shown that neighbouring zinc fingers, like those found in 
PARP-1, can collaborate with each other to bring about a common function, so that 
when only one of them is inactivated a specific phenotype may not be readily 
detectable (Green et al., 1988). Although it is not known whether this phenomenon 
actually applies to PARP-1’s zinc fingers, it is a possibility that would explain why 
individually mutating such motifs did not noticeably affect its sumoylation. Thus, it will 
be important to examine how inactivating combinations of such domains impinges on 
the modification of the polymerase. In order to carry out these experiments, it will be 
necessary to isolate mutations that specifically abolish the functions of PARP-1’s zinc 
fingers without affecting their structures or that of the polymerase itself. One such type 
of mutant has already been identified for the finger II motif of PARP-1, and has been 
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used in this thesis, while another has been recently reported for the finger III domain 
(Langelier et al., 2010).  
6.3.4.2 Other domains of PARP-1 
The second scenario envisages that domains of the full-length PARP-1 other than its 
finger I, II or III motifs may contribute to its DNA-dependent sumoylation. There is some 
evidence in favour of this hypothesis as it has been shown that a fragment of PARP-1 
including its third zinc finger and AD domains can still bind DNA, although in a length-
dependent manner. In addition fusing this polypeptide to the C-terminal portion of 
PARP-1 containing its WGR and catalytic domains increased its affinity for DNA 
(Thibodeau et al., 1993). Interestingly, the WRG motif has been proposed to bind 
nucleic acids (Nagashima et al., 2005). 
6.3.5 The effects of DNA length on PARP-1 sumoylation 
One of the most surprising features about the in vitro sumoylation of PARP-1 presented 
here was that it was affected by the length of the DNA molecules used as stimulating 
cofactors. Another was that the way in which DNA length affected the modification of 
the full-length PARP-1 and that of its DBD alone differed. At present I do not have a 
definitive answer to the questions of why or how these phenomena took place. I will 
nevertheless propose possible explanations on the basis of the presented data as well 
as published work.  
6.3.5.1 The effects of DNA length on the stimulation of PARP-1 
sumoylation 
I observed that PARP-1’s DBD was efficiently sumoylated only in the presence of very 
long DNA molecules (Figure 6.3). Since linear DNA duplexes were used to carry out 
this experiment, I decided to supplement each reaction with the same number of DNA 
molecules, regardless of their lengths. This is an important experimental detail because 
it ensured that all of the reactions contained the same number of free DNA ends. 
Conversely, if I used the same amount of DNA in each reaction, then they would have 
not only contained molecules of different lengths but also different amounts of DSBs. 
Since PARP-1’s DBD recognizes such a type of break (Pion et al., 2003), it follows that 
any phenotype observed under the latter experimental conditions could have been 
triggered by a change in either the number of DNA breaks or the length of the 
molecules present in the reactions, thus making it inconclusive. Keeping the number of 
DNA molecules constant in all reactions ensured that they carried the same number of 
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DSBs, yet, it also meant that the reactions supplemented with the longer DNA 
molecules contained a greater total amount of DNA than those containing the shorter 
DNA duplexes. It is therefore possible that PARP-1’s DBD might have been 
preferentially sumoylated in the reactions supplemented with the longer DNA 
substrates simply because they contained more DNA. This option seems, however, 
very unlikely because the sumoylation of PARP-1’s DBD was not enhanced the least in 
the presence of an amount of intact dumbbell that in the case of a plasmid would 
greatly stimulate it (data not shown). Thus, in order to substantiate these speculations it 
will be useful to show that PARP-1’s DBD is also preferentially modified in sumoylation 
reactions supplemented with the same amount of increasingly long DNA substrates 
whose ends have been occluded, for instance, with streptavidin.  
Should these experiments confirm that PARP-1’s DBD indeed requires long DNA 
molecules to be efficiently sumoylated, they would not, however, answer the question 
of why such a phenomenon occured. This is an important issue because the fact that 
long stretches of naked DNA do not probably exist in vivo would question the 
physiological validity of this observation. I believe that PARP-1’s DBD required long 
DNA duplexes to be proficiently sumoylated simply because it was a sub-optimal 
substrate for this type of modification event. It is in fact possible that such a domain, 
being only a small portion of the full-length PARP-1, lacked structures important for 
allowing it to be sumoylated in the presence of more biologically relevant DNA 
cofactors (see 6.3.4). Consistently, I found that the full-length PARP-1 was efficiently 
modified also in the presence of short DNA duplexes (15 bp dsDNA and intact 
dumbbell, Figure 6.8 and Figure 6.9).  
If it was indeed specific motifs within the full-length PARP-1 that enabled this protein, 
as opposed to its DBD alone, to be sumoylated in the presence of short DNA 
molecules, how did such structures bring about this difference? Two likely scenarios 
can be envisioned. Firstly, it is possible that the second zinc finger of PARP-1 may 
actually require the help of these unknown determinants to efficiently promote 
sumoylation. Consequently, in their absence, i.e. as in PARP-1’s DBD, the 
sumoylation-potential of such a finger could have been reduced to such an extent that 
it made it necessary to use very long DNA molecule to promote its modification. This 
hypothesis is consistent with the evidence that although both the full-length PARP-1 
and its DBD alone contained the finger II motif, only in the context of the former protein 
was this domain able/necessary to stimulate sumoylation in the presence of short DNA 
molecules (Figure 6.5 and Figure 6.8). Secondly, it is possible that PARP-1 may need 
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to dimerize on DNA and/or cooperatively bind to it to be efficiently sumoylated, and that 
these molecular events preferentially occur in the context of the full-length PARP-1. It 
has in fact been reported for at least three targets of sumoylation that dimerization is an 
essential pre-requisite for their modification (Kim et al., 2005; Kirsh et al., 2002; Mascle 
et al., 2007). There is also some evidence in favour of PARP-1 being able to dimerize 
specifically on DNA  (Altmeyer et al., 2009; Mendoza-Alvarez and Alvarez-Gonzalez, 
1993; Pion et al., 2003; Pion et al., 2005). The catalytic domain of PARP-1 alone can 
also form dimers in a DNA-independent manner (Mendoza-Alvarez and Alvarez-
Gonzalez, 2004). Finally, PARP-1 has also been proposed to bind DNA cooperatively, 
yet, this property has not been observed in all studies (Lilyestrom et al., 2010; Pion et 
al., 2003; Pion et al., 2005).  
6.3.5.2 The effects of DNA length on the inhibition of PARP-1 
sumoylation 
The inhibitory activity that SSBs had on the sumoylation of the full-length PARP-1 could 
only be detected when this modification event was stimulated by a short DNA substrate 
(15 bp dsDNA or the intact dumbbell, Figure 6.8 and Figure 6.9), but not a longer one 
(61 bp dsDNA or plasmid, Figure 6.9). This observation is strikingly similar to how 
inactivating the second finger of the polymerase abolished its DNA-dependent 
sumoylation only on a minimal DNA substrate.  Earlier, I proposed that the latter of 
these two phenomena occurred probably because in the presence of short DNA 
duplexes the DNA-stimulated sumoylation of PARP-1 is exclusively dependent on the 
activity of its second zinc finger, while on longer duplexes other motifs may come into 
play. A similar model could have explained a partial reduction in the ability of nicked 
DNA to inhibit the PARP-1 sumoylation stimulated by short vs. long DNA substrates; 
yet, a complete loss of this ability is much harder to rationalize. At present, I cannot 
propose any hypothetical, yet realistic, explanations for this phenomenon because I 
was unable to study in more detail the interplay between PARP-1 and DNA. This 
process remains in fact to date poorly understood. Once its underlying properties are 
uncovered, examining how they impinge on the DNA-dependent sumoylation of PARP-
1 should shed light on the causes of the observations described above.  
6.3.6 The effects of free DNA ends on PARP-1 sumoylation 
The data reported in Figure 6.8 and Figure 6.9 indicated that the intact dumbbell 
stimulated the sumoylation of the full-length PARP-1 less efficiently than a DNA 
Chapter 6. Results IV 
245 
substrate of equivalent length but bearing free ends (15 bp dsDNA). The simplest 
explanation for this phenomenon is that the enhancement of PARP-1 sumoylation 
afforded by intact DNA is further increased in the presence of DSBs. PARP-1 directly 
binds to this type of DNA lesion, thus in their presence the polymerase may adopt a 
conformation that makes it an even better substrate for sumoylation than that it 
acquires when it is bound to intact DNA. That said, I cannot find a reason for why the 
modification of PARP-1’s DBD, unlike that of the full-length protein, was not stimulated 
by DSBs, given that both proteins can recognize DSBs (Ikejima et al., 1990; Lilyestrom 
et al., 2010). Such a discrepancy could be potentially explained by the same models I 
proposed earlier to rationalize the other differences in sumoylation behaviour between 
the full-length PARP-1 and its DBD alone (see 6.3.4 and 6.3.5).  
Since DSBs seemed to enhance the sumoylation of the full-length PARP-1 in vitro, I 
would have expected them to be able to trigger a similar effect in vivo. On the contrary, 
the levels of sumoylated PARP-1 did not significantly change when this kind of DNA 
lesion was introduced in cells by exposing them to γ-rays (Figure 5.2). This 
phenomenon is reminiscent of how nicked DNA inhibited PARP-1 sumoylation in vitro 
but did not apparently do so in vivo. It is therefore reasonable to propose that both 
phenomena could have been underlain by the same molecular mechanisms, which I 
discussed in 6.3.1.  
In the future, in order to undoubtedly prove that DSBs do indeed stimulate the 
sumoylation of the full-length PARP-1, it will be necessary to show that occluding the 
ends of linear DNA molecules with streptavidin reduces the ability of these DNA 
substrates to stimulate the modification of the polymerase. A partial, but not complete, 
loss of such stimulatory effect would also further corroborate the conclusion that PARP-
1 sumoylation is also triggered by intact DNA. A positive finding from these 
experiments would open new research avenues; yet, it would also add an extra layer of 
complexity to a biological process, the interplay between PARP-1 sumoylation and 
DNA, that is already quite complex. In particular, such a finding would make it quite 
challenging to explain why both intact DNA and a DSBs can stimulate PARP-1 
sumoylation, while another form of DNA damage, i.e. SSBs, would inhibit it. I will 
present a tentative model to rationalize all these events in Chapter 7.  
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Chapter 7. Conclusions and future directions 
The work presented in this thesis aimed at uncovering mechanisms by which 
sumoylation interplays with DNA to regulate processes important for DNA metabolism, 
in the hope to ultimately provide insight on how SUMO helps maintaining genome 
stability. 
Provided that when I started working on this project only a few proteins with a role in 
DNA metabolism had been shown to be sumoylated, I initially used frog egg extracts, 
mass spectrometry and western blotting to systematically identify proteins conjugated 
to SUMO that associated with chromatin during unperturbed or disrupted DNA 
replication (Chapter 3), because under these conditions such cellular fraction should be 
enriched for factors with a role in DNA metabolism. This analysis, in fact, identified only 
a few hypothetical SUMO substrates that did not have DNA-related roles, while the 
majority were involved in DNA replication, repair and recombination as well as 
chromatin remodelling and gene transcription. It also indicated that SUMO2-modified 
species were probably more abundant than those conjugated to SUMO1, at least on 
replicating frog sperm chromatin, and that their abundance was not affected by DNA 
damage but required progression through S phase. Amongst the new targets of 
sumoylation I identified, the modification of a few of them was confirmed by western 
blotting in Xenopus egg extracts, and it was also shown to occur for the corresponding 
orthologous proteins in S. cerevisiae. The observation that some of the sumoylation 
events reported here are conserved in yeast and frogs, and possibly also in human 
cells (Golebiowski et al., 2009), puts forward the possibility that they play evolutionarily 
conserved, and therefore possibly important, roles. Since many of them concern 
proteins that are involved in the maintenance of genome stability and Helle Ulrich is 
interested in understanding how sumoylation impinges on this biological process, she 
is keen on exploring further their possible functions.  
Amongst the conserved targets of sumoylation that I identified in the screen described 
in Chapter 3, I investigated in more detail the modification of the largest subunit of the 
six-membered origin recognition complex, ORC1 (Chapter 4). In S. cerevisiae, I found 
that all of the six subunits of this complex were sumoylated in a Siz1- and Siz2-
dependent manner. Golebiowski et al. (2009) also recently showed that ORC is 
sumoylated in human cells, hence indicating that this modification event is probably 
evolutionary conserved in all eukaryotes. In frog egg extracts, the sumoylation of ORC1 
appeared to occur specifically on chromatin, yet the modification of a recombinant 
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yeast ORC was not significantly affected by origin DNA in vitro, which suggests that 
other determinants may be involved in this phenomenon. In both Xenopus egg extracts 
and yeast cells, ORC sumoylation seemed to disappear following the initiation of DNA 
replication, until the start of the G2 phase. This observation suggested that such a 
modification event probably played a role during S phase, which would have been 
consistent with the recognized functions of ORC. That said, I found that altering the 
general levels of sumoylation in both experimental systems did not appreciably affect 
the efficiency of DNA replication, hence implying that SUMO does not significantly 
affect the essential roles of ORC in such a process. It has been proposed for other 
protein complexes in which all or most of their components are sumoylated that these 
modification events may work as a molecular glue during their biogenesis or to keep 
the complexes together (Matunis et al., 2006). This is unlikely to be the case for the 
sumoylation of ORC because this complex can be recombinantly produced in a variety 
of different systems, apparently in the absence of SUMO. Although the ways in which 
sumoylation impinges on the properties of ORC remain unknown, it is likely that, if this 
modification event actually has a role, it probably concerns a function that this complex 
performs as a whole, rather than one that is specifically carried out by ORC sub-
complexes or even by some of its subunits on their own. Thus, in order to gain insight 
in the roles of ORC sumoylation it will be necessary to create, and study the 
phenotypes of, an unsumoylatable mutant of the complex. Since this task may not be 
technically or biologically feasible at present, an alternative could be to study the 
consequences of hyper-sumoylating ORC in vivo by UBC9 fusion-dependent 
sumoylation (UFDS, Niedenthal, 2009) and/or how sumoylating ORC in vitro affects its 
roles in pre-replication complex formation, which has been recently reconstituted in a 
test-tube (Remus et al., 2009).  
Having appreciated that exploring the functions of ORC sumoylation was probably too 
challenging of a project for the tools I had available, I decided to focus my attention to 
the modification of another protein that was identified in Chapter 3, i.e. PARP-1. Not 
only was this protein known to play important roles in DNA metabolism but also 
preliminary data indicated that a digested plasmid could stimulate the sumoylation of its 
DBD. Further analysis revealed that the modification of PARP-1’s DBD 1) was not 
affected by whether a plasmid contained DSBs or specific DNA sequences, was 
supercoiled or methylated but 2) it instead occurred in the presence of DNA molecules 
that carried a relatively long stretch of intact DNA and 3) in a manner that depended on 
the second zinc finger of this protein being functional (Chapter 6). The sumoylation of 
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the full-length PARP-1 was also stimulated by an intact plasmid; yet, DNA molecules of 
minimal length could trigger this modification phenomenon as well. It is therefore 
possible that PARP-1’s DBD was efficiently sumoylated only in the presence of long 
DNA molecules because it lacked features, instead present in the full-length PARP-1, 
which should have allowed it to recognize short DNA substrates. The participation of at 
least two regions within the full-length PARP-1 in its DNA-dependent sumoylation, i.e. 
the second zinc finger and other unknown determinants, could also explain why 
inactivating the former one of these two domains abolished the modification of the full-
length polymerase only by DNA substrates of minimal length, but not longer ones. 
These results have two important implications for the PARP-1 field. Firstly, not only do 
they imply that PARP-1 can recognize intact B-form DNA, which is an event that 
remains poorly understood and rather controversial (see 1.5.2), but they also assign a 
functional consequence to it, that is, the stimulation of PARP-1 sumoylation. Secondly, 
these results imply that the polymerase recognizes intact DNA, at least partly, through 
its second zinc finger, which is a domain that has been generally considered as a DNA 
nick sensor (see 1.5) That said, the ability of such a domain to recognize nicked DNA 
probably underlies the ability of SSBs to inhibit PARP-1 sumoylation. It therefore 
appears that DNA structures that normally trigger the catalytic activity of PARP-1, e.g. 
DNA nicks, inhibit its sumoylation, while those that normally activate the polymerase, 
e.g. intact DNA, actually stimulate its conjugation to SUMO. 
In order to place the rather mechanistic results described above in a more functional 
context, after having identified PARP-1 as a preferential target of SUMO3 and mapped 
its two main modification sites (K203 and K486), I investigated the possible roles of 
PARP-1 sumoylation in vivo (Chapter 5). Towards this end I used an unsumoylatable 
PARP-1 mutant, an in vitro sumoylated PARP-1 and/or PARP-1-SUMO fusion, to 
mimic a constitutively sumoylated polymerase. I found that SUMO did not affect PARP-
1’s catalytic activity, localization, association with intact chromatin or binding to nicked 
DNA. Conversely, mutating the sumoylation sites of the polymerase increased PARP-
1’s half-life in a proteasome-dependent manner under normal growth conditions, hence 
indicating that SUMO probably targets PARP-1 for proteasomal degradation. This 
process is likely to occur through a poly-sumoylation-triggered poly-ubiquitylation event 
because the PARP-1-SUMO fusions were found to be specifically poly-sumoylated 
under normal growth conditions, as was the endogenous PARP-1 following specific 
environmental signals. In addition, both types of sumoylated proteins were converted 
into high molecular weight ubiquitylated species upon proteasomal inhibition. At 
Chapter 7. Conclusions and future directions 
249 
present, I cannot however explain why even though the PARP-1-SUMO constructs 
were poly-sumoylated and poly-ubiquitylated, they apparently were as stable as the 
unsumoylatable PARP-1 mutant.  
These observations are consistent with the results that have been meanwhile reported 
by Martin et al. (2009), which suggest that PARP-1 could be a substrate of the SUMO-
targeted ubiquitin ligase RNF4. They proposed that RNF4 could mediate the 
degradation of the poly-sumoylated PARP-1 that is produced upon heat shock, hence 
allowing its removal from the HSP70.1 promoter under such stressful conditions (Martin 
et al., 2009). This phenomenon is likely to be linked to the activation of the HSP70.1 
gene itself because an unsumoylatable PARP-1 mutant failed to trigger the expression 
of such a gene following heat shock as well as the wild type protein (Martin et al., 
2009). A role for PARP-1 sumoylation in controlling transcription is, however, unlikely to 
be specific for heat shock and heat shock-responsive genes because I found that other 
environmental cues, which like heat shock can boost the general levels of sumoylation 
in a cell, also up-regulated the modification of PARP-1. Additionally, the modification of 
PARP-1 also affects the activation of hypoxia-responsive genes after hypoxia, which 
can enhance general sumoylation levels as well (Messner et al., 2009).  
In the light of the results described above and the current knowledge concerning 
sumoylation and PARP-1, I will put forward a tentative model for how the modification 
of the polymerase could work (Figure 7.1). I propose that sumoylation is used as a 
means of differentially labelling two functionally-distinct populations of PARP-1. The 
first one is engaged in DNA repair, e.g. PARP-1 bound to nicked DNA, and therefore 
should not be sumoylated and degraded because this could compromise cell survival. 
The other population is involved in some other aspect of PARP-1 biology, such as 
transcription regulation, where the removal of the polymerase from certain regions of 
intact DNA, through sumoylation and subsequent degradation, may be important to 
trigger specific downstream events. This phenomenon must occur under normal growth 
conditions because inhibiting the sumoylation of PARP-1 affects its stability even under 
undisturbed growth (Chapter 5). PARP-1 could instead be removed from specific 
genomic regions under particular conditions by the increased sumoylation it undergoes 
in response to certain environmental signals, possibly also in cooperation with its DNA-
stimulated modification. 
An issue that has been puzzling scientists working on PARP-1 is how this protein can 
function in both DNA sensing/repair and transcription regulation. More and more 
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evidence suggests that this functional duality probably depends on PARP-1’s ability to 
control chromatin structure, yet, how this dichotomy is controlled remains unclear. The 
model described above suggests that sumoylation may be involved in this process. 
Such a model is however clearly incomplete because, for instance, it would not be able 
to explain the likely stimulatory role of DSBs on PARP-1 sumoylation (Chapter 6). Thus 
further work will be necessary to fine-tune it. Firstly, it will be important to show that 
PARP-1 bound to nicked DNA cannot be not sumoylated in vivo because this result will 
confirm that 1) sumoylation is used to differentiate between two populations of the 
polymerase and 2) SSBs are inhibitory to PARP-1 sumoylation also in a cell. Being 
able to capture PARP-1 molecules that are associated with a DNA nick is technically 
challenging in vivo because this enzyme turns over DNA breaks extremely quickly. I 
reasoned, however, that since PARP-1 is the main acceptor of PAR in a cell and SSBs 
induce its auto-modification, then sumoylated PARP-1 should not be parylated, if the 
polymerase bound to nicked DNA cannot be sumoylated. All my attempts to determine 
whether this prediction were true were unfortunately hindered by the fact that I could 
never reliably detect PARP-1 auto-parylation following DNA damage, in the cells I 
employed. These experiments are now being trialled by our collaborator Jacob Seeler. 
Secondly, it will be useful to confirm that sumoylation plays a more general role in 
clearing promoters, or possibly other DNA regions, from PARP-1 under normal growth 
conditions and/or specifically in response to environmental cues. This issue could be 
addressed by comparing the distribution of PARP-1 along the entire genome between 
cells that produce wild type PARP-1, an unsumoylatable PARP-1 mutant or the PARP-
1-SUMO fusions, during unperturbed growth and in response to specific stimuli. These 
results could be then used to explore how sumoylation-dependent changes in the 
occupancy by PARP-1 of a specific DNA region impinges on the expression of the 
relevant genes, if such a region corresponds to a promoter, or other biological 
processes, if it corresponds to other functional DNA sequence, e.g. centromeres, 
telomeres, introns vs. exons etc. 
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Figure 7.1 - A possible model for how the sumoylation of PARP-1 could function. See 
main text for details. FII = PARP-1’s second zinc finger, ? = unanswered questions, Pa = PAR, S 
= SUMO, U = ubiquitin. 
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